WorldWideScience

Sample records for demencia tipo alzheimer

  1. Demencia tipo Alzheimer, deterioro cognitivo y toma de decisiones

    Directory of Open Access Journals (Sweden)

    Aurora Moreno

    2011-04-01

    Full Text Available El objetivo de este trabajo es el de conocer cómo es la toma de decisiones en la Demencia Tipo Alzheimer (DTA en situaciones de incertidumbre, si se manifiesta la tendencia al riesgo o no, y la relación que guarda la ejecución con el status cognitivo en cada una de las áreas evaluadas por los test de cribado del deterioro cognitivo propios de las demencias. Participaron 10 pacientes con DTA, y comparados con 10 sujetos controles. Se utilizó la Prueba Cartas (basada en la Iowa Gambling Task, donde los sujetos deben elegir entre varias opciones que entrañan más o menos riesgo, y una batería de cribado del deterioro cognitivo. Los resultados reflejaron que los sujetos con DTA en etapas iniciales presentan cierta tendencia al riesgo en las decisiones que toman y no desarrollan patrones estratégicos de elección. Parece que el deterioro cognitivo y el grado de afectación en las distintas áreas se relaciona con la forma en que toman decisiones.

  2. Heterogeneidad clínica de la demencia y severidad de la apraxia en pacientes con demencia tipo Alzheimer

    Directory of Open Access Journals (Sweden)

    Daniel G. Politis

    2013-11-01

    Full Text Available La evolución clínica de la Enfermedad de Alzheimer presenta gran heterogeneidad clínica. Se han descripto diferentes subtipos clínicos, entre ellos Mayeux et al. (1985 reportan la existencia de 4, que presentan diferentes niveles de severidad cognitiva y funcional. La diversidad clínica de estos no ha sido claramente investigada.La evolución clínica de la Enfermedad de Alzheimer presenta gran heterogeneidad clínica. Se han descripto diferentes subtipos clínicos, entre ellos Mayeux et al. (1985 reportan la existencia de 4, que presentan diferentes niveles de severidad cognitiva y funcional. La diversidad clínica de estos no ha sido claramente investigada.Objetivos: estudiar la severidad de demencia, la severidad de la apraxia y el deterioro funcional en relación con los subtipos clínicos de Mayeux en pacientes con Demencia tipo Alzheimer (DTA. Se evaluaron 49 pacientes con diagnóstico de DTA. Se encontraron correlaciones estadísticamente significativas entre la clasificación de Mayeux con la severidad de la demencia, la severidad de la apraxia y el deterioro funcional.La severidad de demencia, de la apraxia y el deterioro funcional parece acompañar los diferentes subtipos clínicos descriptos por Mayeux, por lo cual la evaluación y detección de las mismas podrían contribuir a la clasificación clínica y pronóstico de la DTA.

  3. Sobrecarga, afrontamiento y salud en cuidadoras de pacientes con demencia tipo Alzheimer

    Directory of Open Access Journals (Sweden)

    Leticia Guarino

    2012-12-01

    Full Text Available El presente estudio relacionó las variables sobrecarga del cuidador y los estilos de afrontamiento con la saludgeneral percibida en 300 cuidadoras de personas con demencia tipo Alzheimer en estadio II, divididas en220 cuidadoras informales y 80 cuidadoras formales no profesionales, evaluadas en la sede nacional de laFundación Alzheimer de Venezuela, ubicada en la ciudad de Caracas - Venezuela. Entre los resultados másrelevantes destaca que las cuidadoras informales presentan mayores niveles de sobrecarga, en comparacióncon las cuidadoras formales no profesionales. Esto se asoció a un mayor compromiso en la salud percibidade aquellas, que específicamente presentaron mayores síntomas somáticos y de ansiedad. En cuanto a los estilosde afrontamiento, se encontró que las cuidadoras informales usan significativamente más afrontamientoemocional y menos afrontamiento racional y por desapego, que las cuidadoras formales no profesionales, loque lleva a comprometer más la salud de las primeras. Finalmente, los indicadores de salud están directamenterelacionados con mayor sobrecarga, de tal forma que a mayor sobrecarga, mayor deterioro, lo que se observacon mayor magnitud en las cuidadoras informales.

  4. El proceso de Toma de Decisiones en pacientes con Demencia tipo Alzheimer

    Directory of Open Access Journals (Sweden)

    Jose R. Alameda

    2012-04-01

    Full Text Available Tomar decisiones es algo común en nuestra vida y contribuye a la adaptación al medio en que vivimos, por ello es relevante conocer cómo es el proceso de toma de decisiones y las posibles disfunciones que puedan darse a causa de su deterioro. En el caso de los pacientes con demencia tipo Alzheimer, los problemas en la toma de decisiones parecen incluso ya en fases leves, lo que dificulta la correcta interacción con el entorno, especialmente en situaciones de incertidumbre. Este proceso ha sido analizado desde varios enfoques, siendo la hipótesis del marcador somático y la tarea de la Iowa Gambling Task (IGT uno de los más utilizados. El objetivo de este trabajo es el de analizar la toma de decisiones en pacientes con DTA frente a un grupo de sujetos control, y analizar el tipo de elecciones de ambos grupos en situaciones de incertidumbre mediante la una versión modificada de la IGT, observar si son tendentes al riesgo o no, y la relación que guarda su ejecución con el status cognitivo en cada una de las áreas evaluadas por los tests. Además de la IGT, utilizaremos como test de cribado en demencias el Miniexamen Cognoscitivo de Lobo, Test del Reloj a la Orden y Copia y Test de Fluidez Verbal de Isaacs. En nuestros resultados, los sujetos con DTA presentan una ejecución deficitaria en la IGT, tanto en el cómputo global como en su análisis por bloques, con una estrategia de elección de cartas aleatoria, por lo que podríamos considerar ciertas tendencias al riesgo, si bien su ejecución muestra cierta capacidad de aprendizaje a lo largo de los bloques. Por último, el deterioro cognitivo y el grado de afectación en las distintas áreas analizadas se relacionan con la forma en que toman decisiones los pacientes con DTA.

  5. RELACIÓN ENTRE DEPRESIÓN Y SOBRECARGA EN CUIDADORES DE PACIENTES CON DEMENCIA TIPO ALZHEIMER

    OpenAIRE

    Mayra Juliana Galvis; Ara Mercedes Cerquera Córdoba

    2016-01-01

    El Alzheimer es el tipo de demencia más frecuente. Debido al deterioro progresivo que produce, los pacientes requieren de cuidado permanente. Las personas que asumen el rol de cuidadores de estos pacientes pueden sufrir efectos adversos a nivel psicológico, físico y social. Se realizó un estudio no experimental, transversal correlacional, con el objetivo de establecer la relación entre los niveles de depresión y sobrecarga en una muestra de 84 cuidadores formales y 92 informales de pacientes ...

  6. Diferencias en el apoyo social percibido entre cuidadores informales y formales de pacientes con demencia tipo Alzheimer

    Directory of Open Access Journals (Sweden)

    Daysy Katherine Pabón Poches

    2014-01-01

    Full Text Available Este estudio de tipo no experimental transversal comparativo tuvo como objetivo identificar las diferencias de apoyo social percibido entre cuidadores informales y formales de la ciudad de Bucaramanga (Colombia y su área metropolitana. Se evaluaron 53 informales y 62 cuidadores formales de pacientes con demencia tipo Alzheimer por medio del cuestionario MOS de apoyo social percibido. Se logró determinar que existe una diferencia estadísticamente significativa entre interacción social (p=0,03; apoyo afectivo (p=0,032 y apoyo global (p=0,037 de los grupos de cuidadores formales e informarles; los cuidadores formales presentan mayor puntuación, lo que denota una mejor percepción del apoyo social que reciben.

  7. RELACIÓN ENTRE DEPRESIÓN Y SOBRECARGA EN CUIDADORES DE PACIENTES CON DEMENCIA TIPO ALZHEIMER

    Directory of Open Access Journals (Sweden)

    Mayra Juliana Galvis

    2016-01-01

    Full Text Available El Alzheimer es el tipo de demencia más frecuente. Debido al deterioro progresivo que produce, los pacientes requieren de cuidado permanente. Las personas que asumen el rol de cuidadores de estos pacientes pueden sufrir efectos adversos a nivel psicológico, físico y social. Se realizó un estudio no experimental, transversal correlacional, con el objetivo de establecer la relación entre los niveles de depresión y sobrecarga en una muestra de 84 cuidadores formales y 92 informales de pacientes con esta enfermedad de la ciudad de Bucaramanga, Colombia., utilizando el inventario de depresión estado-rasgo (IDER, y la escala de sobrecarga de Zarit (versión para cuidadores informales y versión ajustada para cuidadores formales. Se se encontró correlación a nivel de p<.01 entre sobrecarga y depresión (estado y rasgo en los cuidadores informales, pero no en los formales. Resulta importante profundizar en la relación entre el afecto negativo y la sobrecarga, así como estudiar las variables contextuales que podrían incrementar el malestar de ambos grupos de cuidadores.

  8. DISOCIACIONES EN EL RENDIMIENTO PRÁXICO EN PACIENTES CON DEMENCIA TIPO ALZHEIMER: IMITACIÓN DE GESTOS TRANSITIVOS, INTRANSITIVOS Y NO FAMILIARES

    Directory of Open Access Journals (Sweden)

    PABLO GUILLERMO GÓMEZ

    2011-01-01

    Full Text Available En el contexto de evaluación de praxias, los gestos pueden clasificarse en tres categorías: transitivos, intransitivos y no familiares. Si bien ha sido reportada la disociación entre los distintos tipos de gestos, es usual que en la evaluación de praxias o en el análisis del desempeño de los pacientes no se consideren por separado estas tres categorías de gestos, o se varíe la definición de ellas. El objetivo del estudio que se informa fue eva luar si en un mismo grupo de pacientes con demencia tipo Alzheimer se encuentran disociaciones entre gestos transitivos, intransitivos y no familiares, previamente descriptas en el rendimiento práxico de pacientes con lesiones focales (González Rothi, Mack, Verfaellie, Brown & Heilman, 1988; Negri et al., 2007. Se evaluaron 50 pacientes con diagnóstico de demencia tipo Alzheimer probable en imitación de praxias (gestos transitivos, gestos intransitivos y gestos no familiares y uso de objetos. Los estímulos fueron tomados de la batería cognitiva de evaluación de praxias (Politis, 2003. Los gestos eran inicialmente realizados por el examinador, quien mantenía su ejecución durante la imitación del paciente. El grupo con diagnóstico de demencia tipo Alzheimer rindió significativamente peor que el grupo de los controles sanos. En el grupo de pacientes, las cuatro pruebas de praxias correlacionaron entre si. Sin embargo, se hallaron disociaciones en el rendimiento individual de cada paciente en esas mismas pruebas. La disociación entre gestos transitivos, intransitivos y no familiares apoya la posibilidad de que estos diferentes tipos de gestos involucren sistemas de procesamiento distintos.

  9. Mecanismos cognitivos en la toma de decisiones en situaciones de incertidumbre. Un estudio con pacientes con demencia tipo Alzheimer

    Directory of Open Access Journals (Sweden)

    Aurora Moreno

    2012-08-01

    Full Text Available Los pacientes con demencia tipo Alzheimer (DTA suelen presentar problemas en la toma de decisiones (TD, incluso ya en fase leve. Diversos estudios han analizado el funcionamiento de los mecanismos cognitivos en los procesos de TD, especialmente en situaciones de incertidumbre. Una de estas aproximaciones es la hipótesis del marcador somático a través de la Iowa Gambling Task (IGT y el índice Gambling (IG. Uno de los problemas es la inespecificidad de los indicadores de la IGT, por ello se han propuesto modelos explicativos para solventar estas carencias, como el Prospective Valence Learning (PVL. En este trabajo, aplicamos la IGT a 10 pacientes y 10 controles. Analizamos los parámetros del PVL: aversión a las pérdidas (λ regla de utilidad (α, recencia (A y consistencia (c, y la evolución de la tarea en función de las elecciones ventajosas. Nuestros resultados muestran que el rendimiento de los controles es mejor que el de pacientes DTA, aunque en las fases iniciales no hay diferencias, estas se ciñen a los dos bloques finales. En los parámetros del PVL se obtienen diferencias en α y c y en menor medida en λ. A partir de los parámetros del PVL podemos caracterizar el proceso de toma de decisiones de los pacientes DTA, como sensibles a las pérdidas, más influenciados por las elecciones inmediatas y un nivel de consistencia muy bajo, que indica estrategias de elección aleatoria.

  10. Diagnóstico del estado nutricional de los pacientes con demencia tipo Alzheimer registrados en el Grupo de Neurociencias, Medellín, 2004.

    Directory of Open Access Journals (Sweden)

    Angélica María Muñoz

    2006-03-01

    Full Text Available Introducción. Los pacientes con demencia tipo Alzheimer presentan riesgo de deterioro del estado nutricional por cambios fisiológicos, socioeconómicos y psicológicos relacionados con la enfermedad, lo que se suma al proceso de envejecimiento. Objetivo. Describir el estado nutricional de los pacientes con demencia tipo Alzheimer del Grupo de Neurociencias de la Universidad de Antioquia según el estadio de evolución. Materiales y métodos. Estudio descriptivo transversal. Cada paciente fue evaluado para obtener información general, de salud, composición corporal, alimentaria, signos clínicos y aspectos psicosociales. Resultados. Se evaluaron 77 pacientes con edad promedio de 65,5±12,8 años, 48 de ellos con antecedentes familiares de la enfermedad y 39 con más de 60 meses de diagnóstico; el estadio más frecuente fue el moderado y el tipo de demencia más común, la familiar precoz; la enfermedad se diagnosticó antes de los 50 años en 26 pacientes. Hubo diferencias estadísticamente significativas en el índice de masa corporal, el área grasa braquial y el área magra braquial por estadio, y mayor compromiso en el estadio grave (p=0,001, p=0,000 y p=0,000; en todos los estadios se presentó compromiso de la reserva energética y muscular. El calcio y los folatos fueron los nutrientes más comprometidos en el consumo. Conclusión. Aun en el estadio inicial, los pacientes presentaron compromiso del estado nutricional, evidenciado por déficit en la reserva energética y muscular, signos clínicos y consumo inadecuado de calcio y folatos. A medida que avanza la enfermedad, el compromiso de los indicadores nutricionales es mayor. Lo anterior evidencia la necesidad del cuidado nutricional individual de acuerdo con el estadio de la enfermedad.

  11. Relación entre ansiedad, depresión, estrés y sobrecarga en cuidadores familiares de personas con demencia tipo alzheimer por mutación e280a en presenilina 1

    OpenAIRE

    Luis Méndez; Oscar Giraldo; Daniel Aguirre-Acevedo; Francisco Lopera

    2010-01-01

    Introducción: El deterioro cognitivo y funcional de la Enfermedad de Alzheimer (EA) produce un impacto significativo en el Cuidador Principal. Trastornos de ansiedad y afectivos son mayores en cuidadores familiares de personas con Alzheimer que en la población general. Objetivo: Describir la relación entre Ansiedad, Depresión, Estrés y Sobrecarga en Cuidadores Familiares de personas con demencia tipo Alzheimer por mutación E280A en Presenilina 1. Sujetos y Método: Seleccionamos 14 cuidadores ...

  12. Nivel de depresión experimentada por una muestra de cuidadores informales de pacientes con demencia tipo Alzheimer

    Directory of Open Access Journals (Sweden)

    Ara Mercedes Cerquera Córdoba

    2012-01-01

    Full Text Available Estudio transversal descriptivo, tipo cuantitativo, cuyo objetivo fue identificar el nivel de depresión en una muestra de cuidadores informales de pacientes con Alzheimer, compuesta por 52 sujetos. Se tuvo en cuenta los siguientes criterios de inclusión: ser cuidador informal principal, tener mínimo 3 meses cuidando al enfermo, no recibir ningún tipo de remuneración económica y cuidar pacientes no institucionalizados. Se aplicó el Inventario de Depresión Estado/ Rasgo (IDER. Los resultados arrojados indican en la escala total de estado 46,2% y en la subescala de eutimia estado 51,9%, lo cual evidencia una alta presencia de depresión. En la escala total de rasgo se encuentra un total de ausencia de 76,9% y en la subescala de distimia rasgo una ausencia de 88,5%, lo cual indica que no hay relevancia en cuanto el nivel de depresión como rasgo.

  13. ADAPTACIÓN DE LA BATERÍA DE EVALUACIÓN DE LA MEMORIA SEMÁNTICA EN LA DEMENCIA DE TIPO ALZHEIMER (EMSDA A LA POBLACIÓN DE LA CIUDAD DE BUENOS AIRES

    Directory of Open Access Journals (Sweden)

    LINA GRASSO

    2011-01-01

    Full Text Available Se llevó a cabo la adaptación de la Batería pa ra la Evaluación de la Memoria Semántica en Demencia de tipo Alzheimer (Peraita, González Labra, Sánchez Bernardos & Galeote Moreno, 20001 para su aplicación en la Ciudad de Buenos Aires (República Argentina. Esta batería permite evaluar mediante pruebasde modalidad visual, verbal y auditiva, el deterioro del conocimiento de seis categorías semánticas de seres vivientes y no vivientes. Ha sido desarrollada para población de habla hispana con la finalidad de evaluar el deterioro semántico en la Demencia de tipo Alzheimer. Su valor radica en que complementa la evaluación neuropsicológica, donde los aspectos de la memoria semántica por lo general están poco representados, otorgándole valor predictivo al posibilitar la detección temprana de determinadas patologías en las que se encuentra afectado ese sistema de la memoria. Se administró la batería a 30 sujetos sin deterioro cognitivo que tenían entre 61 y 88 años de edad y un promedio de 12 años de escolaridad. Los participantes fueron cuidadosamente seleccionados y se excluyeron a quienes pudieran presentar indicadores de deterioro cognitivo. La evaluación de los ítemes se realizó en base a la frecuencia de las respuestas correctas. Se tomó este criterio considerando que se trata de variables categóricas y el tamaño de la muestra. Se estimó la proporción de respuestas correctas en las seis categorías y dominios de seres vivientes y seres no vivientes. Los nue vos ítemes fueron seleccionados respetando la estructura de la batería y considerando su correlación entre las distintas pruebas.

  14. Demencia en la enfermedad de Alzheimer: un enfoque integral Dementia in Alzheimer's disease: a comprehensive approach

    Directory of Open Access Journals (Sweden)

    Víctor T. Pérez Martínez

    2005-08-01

    Full Text Available El substrato patológico de la principal de las demencias, lo constituyen las siguientes lesiones: la degeneración neurofibrilar abundante y difusa, las placas neuríticas y el depósito anormal de sustancia amiloide en el cerebro, causante de la toxicidad cerebral. La demencia en la enfermedad de Alzheimer cumple con un patrón clínico-topográfico de tipo cortical característico. Su diagnóstico definitivo es anatomopatológico, pero se puede establecer un diagnóstico probable basado en la clínica y en la evaluación neuropsicológica. No existe tratamiento efectivo concluyente para el deterioro cognitivo de la enfermedad de Alzheimer.The pathological substrate of the main dementia is composed of the following lesions: the diffuse and abundant neurofibrillar degeneration, the neuritic plaques and the abnormal deposit of amyloid substance in the brain, causing cerebral toxicity. Dementia in Alzheimer's disease accomplishes a clinicotopographic pattern of characteristic cortical type. Its definitive diagnosis is anatomopathological, but a probable diagnosis based on the clinic and the neuropsychological evaluation can be established. There is no a concluding effective treatment for the cognitive deterioration of Alzheimer's disease.

  15. Plan de estudio del paciente con demencia y diagnóstico diferencial con el Alzheimer Study plan for dementia patients and differential diagnosis with Alzheimer's disease

    Directory of Open Access Journals (Sweden)

    Francisco Lopera Restrepo

    1997-03-01

    Full Text Available La demencia es un síndrome con múltiples etiologías. Antes de iniciar el estudio de un paciente con demencia debe trazarse un plan que se elabora con base en la anamnesis y el examen físico y neurológico. La primera deberá ser dirigida hacia la búsqueda de datos clave para el diagnóstico diferencial en la historia de la enfermedad o en la personal y familiar del individuo demente. Aunque la demencia tipo Alzheimer es la más frecuente su diagnóstico sólo debe establecerse cuando se han descartado todas las otras formas de demencia. En este artículo se exponen los pasos a seguir en la clínica para llegar de manera racional a un diagnóstico etiológico y hacer el diagnóstico diferencial. Dementia is a disorder with multiple etiologies. A diagnostic plan must be established before starting the study of a dementia patient, including clinical history, and physical and neurological exams. Key data should be searched through the history on the development of the disease and the familiar background of dementia. Even though Alzheimer's dementia (AD is the most frequent one, the diagnosis of this disorder should only be established when other causes have been ruled out. This paper proposes a sequential and stepwise program in order to get a proper diagnosis.

  16. Impacto fisiológico de la musicoterapia en la depresión, ansiedad, y bienestar del paciente con demencia tipo Alzheimer. Valoración de la utilización de cuestionarios para cuantificarlo

    Directory of Open Access Journals (Sweden)

    José Enrique de la Rubia Ortí

    2014-08-01

    Full Text Available La enfermedad de Alzheimer se ha convertido en una de las dolencias más prevalentes y que más preocupa en nuestra sociedad por el impacto que genera tanto en el paciente como en familiares y cuidadores. Debido en gran medida a que los tratamientos farmacológicos no son a día de hoy curativos de esta demencia, nos planteamos terapias alternativas que mejoren todos los parámetros de la enfermedad. En este sentido, se conoce la relación directa entre el estrés crónico que sufre el individuo en los últimos años de su vida, y la aparición de los primeros síntomas de la enfermedad destacando la depresión, ansiedad y tristeza. Y al pensar en los extraordinarios beneficios que tiene la música, nos planteamos valorar el impacto que tendría la musicoterapia en estos síntomas. Para ello, realizamos una intervención corta aplicando un protocolo estandarizado por nosotros. Paralelamente, realizamos cuestionarios estandarizados que miden la depresión y la ansiedad relacionadas con el estrés, y la felicidad relacionada con el bienestar, antes y después de la intervención, pudiendo valorar si hay mejoría, y si el empleo de los cuestionarios es adecuado para cuantificarla. Los resultados obtenidos muestran una gran mejora en los pacientes en relación a estos síntomas, pudiendo considerar por tanto a la musicoterapia como una herramienta terapéutica muy eficaz para disminuir el estrés de estos pacientes.

  17. Implementación de un programa de estimulación cognitiva en personas con demencia tipo Alzheimer: un estudio piloto en chilenos de la tercera edad / Implementation of a Cognitive Stimulation Program for People with Alzheimer Disease: A Pilot Study in a Chilean Elderly Sample

    Directory of Open Access Journals (Sweden)

    Claudia Miranda Castillo

    2013-06-01

    Full Text Available La Terapia de Estimulación Cognitiva (TEC es una intervención psicosocial para personas con demencia que ha obtenido buenos resultados en población anglosajona. El objetivo de este estudio fue evaluar la eficacia de la TEC en una muestra de personas chilenas. Participaron 22 pacientes con diagnóstico de Enfermedad de Alzheimer (EA en fase leve a moderada, pertenecientes a un centro asistencial de la ciudad de Quillota, Chile. Para determinar la eficacia del programa, se definió un diseño experimental mixto 2x2 de medidas repetidas, asignándose aleatoriamente la muestra a dos grupos: intervención (GI y control (GC. Se establecieron tres dimensiones para evaluar: cognición, calidad de vida y capacidad funcional de la persona con demencia. Posterior a la intervención, el GI presentó una mejoría significativa en sus indicadores de deterioro cognitivo y calidad de vida; por el contrario, el GC no evidenció cambios positivos en ninguna dimensión, empeorando el declive cognitivo. Ninguno de los grupos experimentó cambios significativos en la capacidad funcional. Si bien en la comparación intergrupo no existieron diferencias significativas en ninguna variable, el GI presentó una mejoría sustancial de la función cognitiva, en comparación con el aumento en la progresión del deterioro cognitivo en el GC. Se recomienda que futuras investigaciones contrasten dichos resultados utilizando una muestra más grande de personas con EA.

  18. Funciones Orbitofrontales en pacientes con Demencia tipo Alzheimer

    OpenAIRE

    Solórzano Jiménez, Luis Mariano

    2016-01-01

    [ES] La DTA se caracteriza por el deterioro progresivo de la memoria y de otras áreas de la función cognitiva, tal es el caso de las funciones ejecutivas (FE), propias de la corteza prefrontal (CPF) y relacionadas con la autorregulación del comportamiento. De esta forma, los procesos asociados a las FE pueden ser de índole cognitivo (memoria de trabajo, razonamiento, resolución de problemas, planificación, secuenciación, atención sostenida, resistencia a la interferencia, utilización de feedb...

  19. Daño nuclear en neuronas de cerebros de pacientes con enfermedad de Alzheimer y otras demencias

    Directory of Open Access Journals (Sweden)

    Francisco Lopera

    2000-02-01

    Full Text Available

    Introducción: La enfermedad de Alzheimer (EA es una entidad neurodegenerativa y es la causa más común de demencia. Recientemente se reportó en Antioquia (Colombia un grupo familiar con una mutación puntual en el codon 280 de la Presenilina 1 denominada E280A (sustitución de un ácido glutámico por una alanina, la cual produce un incremento en el acúmulo de b-Amiloide (bA de 42-43 aminoácidos y una patología cerebral severa. Durante los últimos años se ha propuesto que la muerte celular es uno de los factores principales de pérdida neuronal en la EA. Hasta el presente no se ha establecido el tipo de muerte celular implicadas en la pérdida neuronal. Por lo tanto el objetivo de esta investigación es establecer el tipo de muerte celular que ocurre en la EA y otras demencias tales como la Demencia Fronto Temporal (DFT, Huntington y Demencia Cerebro Vascular, con base en los siguientes criterios: 1. Fragmentación del ADN. 2. Cambios morfológicos nucleares. 3. Cambios citoplasmáticos y 4. Expresión de ciertas proteínas asociadas a muerte celular. Los resultados de esta investigación permitirán establecer una correlación entre los parámetros morfológicos e histoquímicos antes mencionados, entre placas de bA y ovillos neurofibrilares en la EA y con ovillos neurofibrilares en la DFT adicionalmente. Este trabajo nos permitirá determinar si existe un mecanismo común de muerte celular en las enfermedades neurodegenerativas con demencia.

    Neuropsicología de la demencia semántica

    OpenAIRE

    Andrade Quintero, Luz Helena

    2012-01-01

    La Demencia Semántica causa alteraciones en la capacidad para recordar el significado de las palabras, rostros y objetos, producto de atrofia asimétrica o bilateral de los lóbulos temporales anteriores. Clínicamente se han observado múltiples síndromes clínicos superpuestos con otras enfermedades degenerativas como la Afasia Primaria Progresiva y la Demencia tipo Alzheimer. El propósito de este estudio fue identificar alteraciones lingüísticas y semánticas en un grupo de pacientes con Demenci...

  1. CALIDAD DE LAS GUIAS DE PRACTICA CLÍNICA ESPAÑOLAS SOBRE LA ENFERMEDAD DE ALZHEIMER Y OTRAS DEMENCIAS

    Directory of Open Access Journals (Sweden)

    Laura Parra-Anguita

    2016-01-01

    Full Text Available Fundamento: La atención a pacientes con enfermedad de Alzheimer y otras demencias se ha convertido en un objetivo prioritario de los sistemas sanitarios. Así lo demuestra el aumento del número de guías de práctica clínica (GPC elaboradas en nuestro país para ayudar a los profesionales en la toma de decisiones sanitarias. El objetivo de nuestro estudio fue evaluar la calidad de las GPC españolas sobre enfermedad de Alzheimer y otras demencias a través de la metodología de evaluación Appraisal of guidelines research and evaluation (AGREE II. Método: Se seleccionaron nueve GPC españolas con los criterios de inclusión: guías completas, dirigidas a personal sanitario, publicadas entre 2002-2013. Dos revisores evaluaron independientemente la calidad de las guías a través del instrumento AGREE II para la evaluación del rigor metodológico y la transparencia de las GPC. Resultados: El 88,8% de las guías obtuvieron una calificación de muy baja calidad con respecto a la Independencia editorial. En cuanto al rigor en la elaboración y la claridad en la presentación el 77,7% también obtuvieron muy baja calidad. Hay una guía que destaca por obtener una puntuación por encima del 50% en todos los dominios del instrumento. Conclusiones: El dominio peor valorado es la independencia editorial seguido de los dominios de rigor en la elaboración y aplicabilidad. Los dominios mejor valorados son alcance y objetivos y claridad en la presentación. La guía del Ministerio de Sanidad, Servicios Sociales e Igualdad destaca obteniendo una valoración por encima del 50% en todos los dominios. La calidad global de las 9 guías evaluadas es baja o muy baja, sólo dos obtienen una puntuación global de buena calidad.

  2. Influencia de un programa de ejercicio físico sobre la marcha y el equilibrio en personas con demencia

    OpenAIRE

    López García, Ana

    2012-01-01

    Objetivos: Analizar cómo varían los efectos del ejercicio físico sobre la marcha y el equilibrio de enfermos con demencia que asisten a un centro de día según sexo, edad, tipo de demencia, grado de deterioro, nivel de dependencia y tiempo desde diagnóstico. Material y método: Se han valorado 25 (6 varones; edad media 76,44 DE 8,81) sujetos con demencia (76% Alzheimer) cada seis meses en un año durante el cuál realizaron cinco sesiones semanales de ejercicio físico dirigido de 45 minutos. ...

  3. Deterioro cognitivo leve: ¿dónde termina el envejecimiento normal y empieza la demencia?

    Directory of Open Access Journals (Sweden)

    Nilton Custodio

    2012-10-01

    Full Text Available Con el aumento de la prevalencia de demencia en el mundo, debemos poner especial atención a la evaluación diagnóstica de estadios previos a la demencia. El deterioro cognitivo leve (DCL podría ser considerado un estadio precoz de demencia, en especial de la enfermedad de Alzheimer (AD; por lo que consideramos importante un diagnóstico adecuado, mediante la utilización de instrumentos y técnicas fiables y sensibles, que permitan discriminar entre sujetos con envejecimiento normal y patológico. Los estudios epidemiológicos muestran una elevada prevalencia de DCL en la población general. Asimismo, se ha documentado la progresión de DCL a demencia y EA, sobre todo en sujetos con DCL del tipo amnésico. La edad, el estado de portador del APOE-ε4, la atrofia del hipocampo en resonancia magnética y la presencia de algunos biomarcadores en líquido cefalorraquídeo parecen influir en la conversión. Se sugiere que el estudio de pacientes con sospecha de DCL sea el mismo que se emplea en la sospecha de demencia y EA. La evaluación neuropsicológica es la única prueba que permite confirmar el diagnóstico y nos ayuda a realizar una adecuada clasificación de los subtipos de DCL: amnésico, multidominio y monodominio no amnésico.

  4. Prevalencia de demencia en una población urbana de Lima-Perú: estudio puerta a puerta

    Directory of Open Access Journals (Sweden)

    Nilton Custodio

    2008-12-01

    Full Text Available Objetivos: Calcular la prevalencia y tipos de demencia en una población de una comunidad urbana de Lima. Diseño: Muestreo por conglomerados bietápico. Instituciones: Instituciones de salud privadas. Pacientes: Individuos mayores de 65 años. Intervenciones: En el distrito de Cercado del Lima, 1 532 individuos mayores de 65 años, seleccionados aleatoriamente, fueron sometidos a evaluaciones neuropsicológicas breves, que incluyeron el Mini Mental State Examination (MMSE, la prueba del dibujo del reloj (PDR y el cuestionario de actividades funcionales de Pfeffer (PFAQ. Según los resultados obtenidos luego de la aplicación del MMSE, PDR y PFAQ, los individuos fueron clasificados como seleccionados y no seleccionados, siendo el grupo de seleccionados aquellos que presentaban deterioro cognitivo luego de la aplicación de dichas pruebas. El grupo de personas seleccionadas fueron sometidas a evaluaciones neurológicas, neuropsicológicas, exámenes de laboratorio y tomografía computada (TC cerebral. Principales medidas de resultados: Prevalencia de demencia. Resultados: Encontramos 105 casos de demencia, lo que corresponde a una prevalencia de 6,85%, siendo la enfermedad de Alzheimer el diagnóstico más frecuente (56,2%; dicha prevalencia se incrementó con la edad y tuvo predominio en el sexo femenino. El análisis de regresión logística mostró que la edad, género femenino y nivel educativo bajo se encontraban correlacionados con la prevalencia alta de demencia. Conclusiones: La prevalencia de demencia en esta población peruana fue 6,85% y la enfermedad de Alzheimer, el diagnóstico más frecuente; la edad, el género femenino y el nivel educativo bajo fueron los factores correlacionados con esta prevalencia alta.

  5. Demencia en el ámbito de los cuidados paliativos del Hospicio de Seychelles

    Directory of Open Access Journals (Sweden)

    Kleydis Blanco Torres

    2011-12-01

    Full Text Available

    Fundamento: La demencia tiene una alta prevalencia tanto en países desarrollados como en aquellos en vía de desarrollo, y constituye una de las principales causas de estadio terminal por enfermedad no oncológica.
    Objetivo
    : Determinar el comportamiento de algunas variables biológicas en pacientes con demencia en estadio terminal. Métodos: Estudio descriptivo en 16 pacientes con diagnóstico de demencia en estadio terminal, ingresados en el Hospicio de Seychelles entre febrero de 2010 y febrero de 2011. Se analizó el comportamiento de la demencia en relación con las variables: edad, tipo de demencia, respuesta al mini examen cognitivo de Folstein y a los Índices de Charlson y Barthel, presencia de enfermedades crónicas no transmisibles y escenario de salud responsable de la remisión.
    Resultados: El 31,3 % de los pacientes ingresados en el Hospicio presentaban una demencia. El grupo de edad con mayor número de casos fue el de 75 a 84 años. La demencia vascular y Alzheimer tuvieron igual número de casos con un 37,5 % cada una. El 56 % de los pacientes fallecieron durante los primeros 15 días del ingreso y solo el 12,5 % después de los 6 meses. La hipertensión arterial y la enfermedad cerebrovascular fueron las enfermedades crónicas no transmisibles más frecuentes. El 56 % de los casos fue remitido desde el escenario hospitalario.
    Conclusiones: La demencia en estadio terminal muestra un comportamiento que permite anticipar una adecuada estrategia de cuidados paliativos a nivel del Hospicio.

    Dementia in Palliative Care in the Seychelles´ Hospice

    Background
    : Dementia presents a high prevalence both in developed and developing countries. It is one of the main causes of terminal stage for a non oncological illness. Objective: To determine the behaviour of

  6. Musicoterapia en personas con demencia: intervenciones no farmacológicas. Guía de orientación

    OpenAIRE

    García Valverde, Esther

    2014-01-01

    Esta guía pretende ofrecer una visión integral de la musicoterapia especializada en personas con demencia, proporcionando estrategias de intervención basadas en la evidencia científica y en la práctica profesional. Va dirigida a musicoterapeutas que intervienen en el ámbito de la enfermedad de Alzheimer y otras demencias.

  7. COORDINACIÓN SOCIOSANITARIA Y EVALUACIÓN INTEGRAL EN DEMENCIAS: EL ROL DE LAS ASOCIACIONES DE FAMILIARES DE ENFERMOS DE ALZHEIMER

    Directory of Open Access Journals (Sweden)

    María Eugenia Domínguez Orozco

    2013-05-01

    Full Text Available La coordinación de servicios sociales y sanitarios en España es una labor que recientemente ha comenzado a desarrollarse. La adecuación de las demencias en la valoración de la dependencia es una de las cuestiones que se analiza en este artículo, donde se reflexiona sobre la aportación de las asociaciones de familiares en el proceso diagnóstico, la atención asistencial y la provisión de servicios y/o recursos. Se presenta un protocolo de evaluación general para el diagnóstico de demencia y analizaremos la relevancia de la detección temprana de estadios iniciales como el deterioro cognitivo leve. Los profesionales psicólogos podrían ser considerados como agentes facilitadores para los “gestores de casos” en el proceso de las valoraciones y la adjudicación de los servicios.

  8. Envejecimiento y Alzheimer. Terapias asistidas con animales domésticos

    OpenAIRE

    Herrera García, Tamara

    2015-01-01

    Este trabajo pretende dar a conocer, las diferentes teorías en cuanto al envejecimiento, una revisión teórica en cuanto a la enfermedad del Alzheimer, sus fases y los diferentes tipos de demencias, y por último las terapias asistidas con animales domésticos como medio de mejorar la autonomía en personas enfermas de Alzheimer. Los profesionales dedicados a ello tienen la tarea de prestarles una atención individualizada, puesto que son un colectivo de personas no homogéneo. Es importante destac...

  9. Tratamiento farmacológico específico en la Enfermedad de Alzheimer

    OpenAIRE

    Simón Marrodán, Roberto

    2016-01-01

    La Enfermedad de Alzheimer es un proceso neurodegenerativo que conlleva un deterioro progresivo de la memoria y de otras funciones superiores. Es el tipo de demencia más común. En el 95% de los casos afecta a personas mayores de 65 años. Se ha realizado una revisión bibliográfica narrativa utilizando bases de datos, buscadores y páginas web, con el objetivo de conocer cuál es el tratamiento farmacológico específico en la Enfermedad de Alzheimer. Las palabras clave utiliza...

  10. DIABETES MELLITUS COMO FACTOR DE RIESGO DE DEMENCIA EN LA POBLACIÓN ADULTA MAYOR MEXICANA

    Science.gov (United States)

    Silvia, Mejía-Arango; Clemente, y Zúñiga-Gil

    2012-01-01

    Introduccion La diabetes mellitus y las demencias constituyen dos problemas crecientes de salud entre la población adulta mayor del mundo y en particular de los paises en desarrollo. Hacen falta estudios longitudinales sobre el papel de la diabetes como factor de riesgo para demencia. Objetivo Determinar el riesgo de demencia en sujetos Mexicanos con diabetes mellitus tipo 2. Materiales y Metodos Los sujetos diabéticos libres de demencia pertenecientes al Estudio Nacional de Salud y Envejecimiento en México fueron evaluados a los dos años de la línea de base. Se estudió el papel de los factores sociodemográficos, de otras comorbilidades y del tipo de tratamiento en la conversión a demencia. Resultados Durante la línea de base 749 sujetos (13.8%) tuvieron diabetes. El riesgo de desarrollar demencia en estos individuos fue el doble (RR, 2.08 IC 95%, 1.59–2.73). Se encontró un riesgo mayor en individuos de 80 años y más (RR 2.44 IC 95%, 1.46–4.08), en los hombres (RR, 2.25 IC 95%, 1.46–3.49) y en sujetos con nivel educativo menor de 7 años. El estar bajo tratamiento con insulina incrementó el riesgo de demencia (RR, 2.83, IC 95%, 1.58–5.06). Las otras comorbilidades que aumentaron el riesgo de demencia en los pacientes diabéticos fueron la hipertensión (RR, 2.75, IC 95%, 1.86–4.06) y la depresión (RR, 3.78, 95% IC 2.37–6.04). Conclusión Los sujetos con diabetes mellitus tienen un riesgo mayor de desarrollar demencia, La baja escolaridad y otras comorbilidades altamente prevalentes en la población Mexicana contribuyen a la asociación diabetes-demencia. PMID:21948010

  11. PLAN NACIONAL DE DEMENCIAS: ANTECEDENTES GLOBALES Y SÍNTESIS DE LA ESTRATEGIA CHILENA

    Directory of Open Access Journals (Sweden)

    Jean Gajardo J.

    2016-05-01

    Full Text Available La demencia constituye una condición prioritaria para la salud pública. El creciente número de personas con algún tipo de demencia y los insuficientes recursos sociosanitarios para su abordaje, hacen necesario desarrollar estrategias específicas para enfrentarla. La Organización Mundial de la Salud ha indicado la urgencia de contar con planes o estrategias biopsicosociales para el abordaje de la demencia en cada país. Este manuscrito realiza una revisión del contexto político en salud que se observa en Chile y los intentos existentes en el país para desarrollar recomendaciones y planes de acción, en el marco de los acontecimientos internacionales que se están desarrollando en la actualidad. Se enfatiza la demencia como un problema sociosanitario complejo, que requiere un abordaje coordinado de diferentes sectores, y cuyos principales objetivos se orientan a la prevención y el logro de la mejor calidad de vida posible en las personas que viven con demencia y sus entornos de apoyo.

  12. Factores de riesgo y personalidad premórbida en la enfermedad de Alzheimer

    OpenAIRE

    Conde Sala, Josep Lluís

    1999-01-01

    Los objetivos de la investigación fueron: a) explorar e identificar de factores de riesgo no- biológicos para las demencias, b) plantear probables perfiles de riesgo bio - psico - sociales de forma específica para la enfermedad de Alzheimer y c) sugerir elementos de prevención para un posible desarrollo de políticas de salud pública. La hipótesis subyacente hacía referencia a la existencia de unos factores de riesgo de tipo psicosocial y de personalidad, presentes anteriormente al desarrollo ...

  13. Efeitos de um programa de atividade física sobre os sintomas depressivos e a qualidade de vida de idosos com demência de Alzheimer Efectos de un programa de actividad física en los síntomas depressivos y la calidad de vida del ancianos con demencia de Alzheimer Effects of a physical activity program on depressive symptoms and quality of life of elderly with Alzheimer's dementia

    Directory of Open Access Journals (Sweden)

    Heloisa Schievano Groppo

    2012-12-01

    Full Text Available O objetivo do estudo foi analisar os efeitos de um programa de exercícios físicos sobre os sintomas depressivos e a percepção da Qualidade de vida (QV de pacientes com Doença de Alzheimer (DA e de seus cuidadores. Seis idosas realizaram um programa de exercícios físicos durante seis meses, outras seis compuseram o grupo controle. O Mini-Exame do Estado Mental, a Escala de Qualidade de Vida e a Escala de Depressão em Geriatria foram aplicados para avaliação das variáveis. Os dados foram analisados através de uma ANOVA "two-way" e correlação de Pearson, com nível de significância de 5% (p El objetivo del estudio fue analizar los efectos de un programa de ejercicios en los síntomas depresivos y la percepción de calidad de vida (CV de los pacientes con Demencia de Alzheimer (DA y sus cuidadores. Seis personas ancianas realizaran un programa de ejercicio físico por un periodo del seis meses, otro grupo estaba formado por el grupo de control. El Mini Examen del Estado Mental, la Escala de Calidad de Vida y la Escala de Depresión Geriátrica fueran utilizados para evaluar las variables. Los datos fueron analizados por análisis de varianza de dos entradas (ANOVA de dos vías y la correlación de Pearson, con un nivel de significancia de 5% (p The aim of the study was to analyze the effects of a physical exercises' program on depressive symptoms and quality of life (QL in elderly with Alzheimer's Disease (AD and QL of their caregivers. Six elderly women performed a physical exercises' program with six months of duration, and the other six composed the control group. The Mini-Mental State Examination, the Quality of Life Scale and the Geriatric Depression Scale were applied to evaluate the variables. Data were analyzed by Analyze of Variance (Two-way and Pearson's correlations. The level of significance was set at 5% (p < 0.05. The results showed that the physical exercises' program proposed could aid on the reduction of depressive

  14. Masoterapia en las alteraciones conductuales de ancianos con demencia

    OpenAIRE

    Carolina Barquilla Ávila; Juan Rodríguez-Mansilla

    2015-01-01

    Objetivo: Conocer la eficacia del masaje terapéutico sobre las alteraciones conductuales de ancianos con demencia. Diseño: Revisión de la literatura científica. Fuente de datos: La búsqueda de las publicaciones se llevó a cabo en 6 bases de datos científicas: PubMed, Cochrane Library Plus, PEDro, Dialnet, Scopus y CSIC, entre 1983 y 2013. Los términos de búsqueda incluyeron la combinación de las palabras clave «massage», «dementia», «therapy», «behavior disorders» y «Alzheimer». Sele...

  15. Análisis de las prestaciones sociosanitarias en los cuidadores familiares de enfermos de Alzheimer

    Directory of Open Access Journals (Sweden)

    María Dolores Ruiz Fernández

    2014-08-01

    Full Text Available La demencia tipo Alzheimer constituye uno de los principales problemas de salud, debido a la discapacidad y dependencia que produce. Con la implementación de la ley 39/2006, se intenta dar respuesta a las necesidades, mediante un catálogo de servicios y recursos sociosanitarios de apoyo a los enfermos y a sus familiares. Para conocer el perfil de los beneficiarios de esas ayudas, teniendo en cuenta el conocimiento de los cuidadores, la fase y el nivel de dependencia, se realizó un estudio con 255 cuidadores/as familiares de personas diagnosticadas con demencia tipo Alzheimer. Los resultados muestran que, los cuidadores con conocimiento de la enfermedad y las personas que se encuentran en una fase más avanzada, son los que más recursos utilizan. En concreto, los cuidadores con conocimientos, utilizaron en mayor medida el respiro familiar, y los cuidadores en fase leve de la enfermedad son los que disfrutan mayoritariamente de los servicios de voluntariado y de ayuda a domicilio, mientras que en fases más avanzadas son beneficiarios del centro de día y de la prestación económica a cargo del familiar. Finalmente, destacar que el servicio de voluntariado se utiliza por los sujetos con menor nivel de dependencia, mientras que los más dependientes son los que más usan la prestación económica

  16. Demencia y dolor Dementia and pain

    OpenAIRE

    J. Alaba; E. Arriola; A. Navarro; M. F. González; C. Buiza; C. Hernández; A. Zulaica

    2011-01-01

    El interés de los investigadores por el dolor, su evaluación e intervención en personas con demencia es creciente. Dada la tendencia demográfica a un incremento del envejecimiento poblacional, aumentando las patologías que presentan dolor y el avance en los conocimientos en el campo de las demencias, se identifican cambios que se producen en diferentes áreas cerebrales implicadas en el control del dolor. La presente revisión se centra en las modificaciones que se producen en la percepción del...

  17. Perfis Diferenciais de Perda de Memória entre a Demência Frontotemporal e a do Tipo Alzheimer

    Directory of Open Access Journals (Sweden)

    Allegri Ricardo F.

    2001-01-01

    Full Text Available Os estados iniciais da demência tipo Alzheimer (DTA caracterizam-se classicamente por deterioração da memória enquanto que as mudanças de conduta e de personalidade aparecem nas etapas iniciais da demência frontotemporal (DFT. Entretanto, na prática clínica, o diagnóstico diferencial é difícil. O objetivo do presente trabalho foi estudar o rendimento da memória de pacientes com DTA (n= 20 e com DFT (n= 20 comparando-o com um grupo de controles (n = 20. Os pacientes, emparelhados por idade e escolaridade, foram avaliados com uma bateria neuropsicológica exaustiva. Para a avaliação da memória, examinou-se a "queixa subjetiva" de perda de memória (memória subjetiva, a aprendizagem de uma lista de palavras (memória episódica e o desempenho no teste de denominação de Boston (memória semântica. As pontuações de ambos os grupos de pacientes, na grande maioria das provas, foram significativamente inferiores às dos controles. Os pacientes com DTA mostraram uma deterioração global da memória episódica (tipo amnésia e semântica com um alto nível de queixa subjetiva. Os sujeitos com DFT, por outro lado, apresentaram um déficit de memória importante na recuperação da informação, mas com melhores capacidades de registro da informação, apesar das dificuldades de reconhecimento do seu distúrbio.

  18. Auditoría clínica de la administración de fármacos en una residencia de personas mayores enfermas de Alzheimer y otras demencias neurodegenerativas Clinical audit regarding the administration of drugs in a residence for elderly people with Alzheimer’s disease and other neurodegenerative dementias

    Directory of Open Access Journals (Sweden)

    Mar Prado Somalo

    2006-03-01

    Full Text Available El equipo de enfermería de la Residencia El Sol observó cómo la administración de fármacos a los residentes conllevaba ciertos riesgos inherentes a la demencia. A partir de este hecho nos planteamos realizar una auditoría clínica para establecer qué tipo de incidencias se producía y determinar qué medidas tomar para minimizarlas. El estudio ha durado 12 meses y ha servido para identificar a los residentes con mayor riesgo, las incidencias de mayor frecuencia y buscar estrategias desde el equipo de enfermería que sean eficaces en la reducción del número de incidencias con la colaboración del resto del personal de la residencia.The Nursing Staff at the Residencia El Sol noticed there were significant risks associated to the administration of drugs to the residents given their condition of dementia sufferers. This was the starting point for a Clinical Audit whose aims are to determine what kind of incidents take place whilst administering medication and what measures can be implemented in order to minimize their incidence. The study lasted 12 months and has served different purposes such as identifying the residents at a highest risk, determining the most frequent incidents and helping the Nursing Team develop startegies with a view to reduce the number of those incidents in close collaboration with the rest of the staff at the Residencia El Sol.

  19. INTIMIDAD, SEXUALIDAD, DEMENCIAS. ESTRATEGIAS AFECTIVAS Y APROPIACIÓN DEL TRABAJO DE CUIDADO EN CONTEXTOS DESESTABILIZANTES

    OpenAIRE

    Natacha Borgeaud-Garciandía

    2016-01-01

    El presente artículo se centra en el trabajo de cuidado domiciliario en contextos que suponen la confrontación de las cuidadoras con elementos perturbadores y potencialmente desestabilizantes: la intimidad, la sexualidad y la demencia senil de adultos mayores muy dependientes. Proviene de una investigación en sociología cualitativa en la cual se llevaron a cabo entrevistas biográficas de tipo “historias de vida”con cuidadoras. Apoyándonos en las nociones d...

  20. Intervenciones cognitivas en demencias: la musicoterapia

    OpenAIRE

    Pastor Vilar, T.; Navarro Pardo, Esperanza; Díaz Dho Brodksy, R.; Moret Tatay, Carmen; Vázquez-Martínez, A.

    2011-01-01

    El aumento de envejecimiento de la población tiene múltiples repercusiones, una de ellas es la preocupación por las enfermedades asociadas a las edades avanzadas y los tratamientos a utilizar. Aunque la demencia no es una consecuencia natural del envejecimiento, constituye el trastorno neurológico más frecuente en edades avanzadas. En la actualidad no existe cura para esta patología, sólo tratamientos que intentan demorarla. Las intervenciones cognitivas junto con los fármacos son el tratamie...

  1. NEUROPATOLOGÿA DE LAS DEMENCIAS NEURODEGENERATIVAS

    Directory of Open Access Journals (Sweden)

    Dra. Paulina Arriagada B.

    2016-05-01

    Full Text Available Las demencias neurodegenerativas se caracterizan por la pérdida selectiva y progresiva de poblaciones neuronales vulnerables, lo que determina la presentación clínica de éstas. La misma población neuronal puede comprometerse en diferentes enfermedades. Dado que la presentación clínica refleja las neuronas vulnerables del proceso patológico subyacente, es claro que más de una enfermedad puede dar cuenta de un síndrome clínico determinado. Estas enfermedades comparten como mecanismo patogénico la acumulación de agregados proteicos, a menudo asociado con toxicidad y una falla del clearence por vías de degradación celular. Para el propósito de esta breve revisión, se presentan los aspectos neuropatológicos más relevantes de las demencias degenerativas, de acuerdo a la clasificación clínica y la patología molecular subyacente.

  2. Marcadores lingüísticos y mnésicos en el diagnóstico diferencial de la depresión y la demencia: un estudio con seguimiento

    OpenAIRE

    Calvo Piernagorda, Cristóbal Manuel

    2011-01-01

    El diagnóstico de la Enfermedad de Alzheimer (EA) se lleva a cabo por exclusión. A menudo, los primeros síntomas de la enfermedad van acompañados de síntomas depresivos que son clínicamente significativos, lo que hace más difícil el diagnóstico diferencial; algunas veces, un trastorno diagnosticado como depresión puede ser en realidad una demencia (pseudodepresión); sin embargo, en otras ocasiones, un cuadro que inicialmente tiene el aspecto de una demencia puede ser en realidad un trastorno ...

  3. DETERIORO Y DEMENCIA. Orientación para médicos no especialistas.

    Directory of Open Access Journals (Sweden)

    Archibaldo Donoso Sepúlveda

    2007-01-01

    Full Text Available La enfermedad de Alzheimer (EA, que se expresa com o una pérdida progresiva de las funciones cognitivas comenzando por la memor ia, es la más importante de las afecciones degenerativas del SNC y una de las p rincipales causas de invalidez en los adultos. El deterioro cognitivo leve (DCL es una entidad qu e se define porque existe una pérdida discreta de la memoria y a veces otras capa cidades, pero sin que exista una limitación en las actividades habituales de la persona, o sea sin que exista una demencia. Sin embargo, es muy posible que pocos años después se haga evidente una EA. En esta revisión se comentan algunos conceptos bási cos sobre las demencias; su clasificación etiológica, sus manifestaciones clíni cas, y su manejo. Se hace especial hincapié en el apoyo psicosocial que requieren los pacientes y sus familias.

  4. Intimidad, sexualidad, demencias. La relación subjetiva con el trabajo de cuidado en contextos desestabilizantes

    OpenAIRE

    Natacha Borgeaud-Garciandía

    2016-01-01

    El presente artículo se centra en el trabajo de cuidado domiciliario en contextos que suponen la confrontación de las cuidadoras con elementos perturbadores y potencialmente desestabilizantes: la intimidad, la sexualidad y la demencia senil de adultos mayores muy dependientes. Proviene de una investigación en sociología cualitativa en la cual se llevaron a cabo entrevistas biográficas de tipo “historias de vida” con cuidadoras. Apoyándonos en las nociones de “trabajo sucio”, “trabajo emociona...

  5. Rendimiento en pruebas cognitivas breves, de adultos mayores con demencia en estadios avanzados, residentes de una comunidad urbana de Lima, Perú

    Directory of Open Access Journals (Sweden)

    Nilton Custodio

    Full Text Available Objetivos. Evaluar el rendimiento de la prueba de dibujo de reloj en versión de Manos (PDR-M y Mini Mental State Examination (MMSE en su versión peruana, para detectar demencia de cualquier tipo en adultos mayores residentes de una comunidad urbana de Lima, Perú. Materiales y métodos. Análisis secundario de base de datos, de tipo observacional, analítico y transversal; con diseño de prueba diagnóstica, teniendo como prueba estándar a las evaluaciones clínica y neuropsicológica en conjunto. Se evaluó el rendimiento de las pruebas individualmente, así como de forma combinada. Resultados. El rendimiento de MMSE para la evaluación de pacientes con demencia de cualquier tipo presentó sensibilidad de 64,1%, especificidad de 84,1%, VPP de 24,4%, VPN de 96,7%, LR (+ de 4,03 y LR (- de 0,43. La PDR-M presentó sensibilidad de 89,3%, especificidad de 98,1%, VPP de 79,3%, VPN de 99,1%, LR (+ de 47,79 y LR (- de 0,11. Cuando se aplicaron ambas pruebas, y al menos una de ellas fue positiva, presentaron sensibilidad de 98,1%, especificidad de 84,1%, VPP de 33,1%, VPN de 99,8%, LR (+ de 6,17 y LR (- de 0,02. Al realizar el análisis, por separado, de demencia tipo alzhéimer y no alzhéimer, los valores de los parámetros no se diferencian sustancialmente de los obtenidos para demencias de cualquier tipo. Conclusiones. La combinación de MMSE y PDR-M demuestran un buen rendimiento para detectar demencia en estadios moderado y severo en población residente de una comunidad urbana de Lima.

  6. Estigma hacia la demencia: una revisión

    OpenAIRE

    Mascayano, F.

    2015-01-01

    La demencia, hoy denominada trastorno neurocognitivo mayor en el DSM-V, es una prioridad para la salud pública debido a su creciente prevalencia y alto impacto individual social. El estigma, es decir, la devaluación y exclusión social que vive un individuo producto de una característica, atributo o comportamiento; es un fenómeno colectivo vinculado a esta condición, el cual impacta en la calidad de vida de las personas con demencia y sus entornos familiares que usualmente brindan apoyo, y ha ...

  7. OCUPACIÓN LABORAL Y RIESGO DE DETERIORO COGNITIVO Y DEMENCIA EN PERSONAS MAYORES DE 55 AÑOS: UNA REVISIÓN SISTEMÁTICA

    Directory of Open Access Journals (Sweden)

    Ana Cristina Gracia Rebled

    2016-01-01

    Full Text Available Fundamentos: El deterioro cognitivo y la demencia son dos problemas de salud con elevada prevalencia en población mayor. Es importante identificar los factores de riesgo potencialmente modificables asociados. La ocupación laboral podría ser un factor que influye en la demencia. El objetivo fue analizar la asociación entre la ocupación principal desarrollada a lo largo de la vida con el deterioro cognitivo y la demencia en personas mayores. Métodos: Revisión sistemática de la literatura desde 1990 y marzo de 2014 para identificar la asociación entre ocupación y deterioro cognitivo evaluado por el Mini Mental Status Examination (MMSE. La búsqueda se realizó en las bases de datos Web of Knowledge, Pubmed, Medline, ISI Web of Science, Science Direct, CocINDEX with Full Text, SPORTDiscus with Full Text, Dialnet Plus, Education Resources Information Center, GreenFile, Journal Storage y The Cochrane Library. Criterios de inclusión: artículos publicados entre 1990 y marzo de 2014 que utilizaran el MMSE para valorar el rendimiento cognitivo en población mayor de 55 años y que incluyeran la ocupación como variable de estudio así como la existencia de deterioro cognitivo o demencia, escritos en castellano, inglés o francés. Resultados: Se seleccionaron 18 artículos. Cinco estudios transversales y seis longitudinales analizaron la asociación entre ocupación y deterioro cognitivo; dos transversales y ocho longitudinales estudiaron la asociación entre demencia y ocupación. El 67% identificaron que había relación entre el tipo de trabajo y el rendimiento cognitivo en la edad adulta. Conclusiones: Las personas con una actividad laboral predominantemente manual a lo largo de la vida tienen mayor riesgo de padecer deterioro cognitivo y/o demencia que aquellas que tienen ocupaciones con mayor requerimiento intelectual.

  8. IDOSOS COM ALZHEIMER: UM ESTUDO DESCRITIVO

    Directory of Open Access Journals (Sweden)

    Ítala Thaise Aguiar Holanda

    2012-01-01

    Full Text Available Estudio exploratório y descriptivo cujo objetivo fue clasificar el grado de demencia en ancianos afectados por la enfermedad de Alzheimer mediante el Clinical Dementia Rating y describir el perfil de estos a partir de informaciones del cuidador familiar. El Clinical Dementia Rating fue aplicado a 30 pacientes durante visita domiciliaria y sus miembros cuidadores integrantes de la Asociación de Alzheimer de Fortaleza, Ceará, Brasil, en 2009. Los resultados señalaron que los pacientes eran en su mayoría mujeres, casadas, de bajo nivel de educación y com grado de demencia grave. Se entiende la importancia de implementar programas multiprofesionales para pacientes y famílias, así como establecer acciones específicas de educación en salud y aplicación del Clinical Dementia Rating en la evaluación de estos.

  9. APOE epsilon4 and Alzheimer's disease: positive association in a Colombian clinical series and review of the Latin-American studies Asociación positiva entre APOE épsilon4 y demencia de Alzheimer en una serie clinica en Bogotá (Colombia y revision de los estudios latinoamericanos

    Directory of Open Access Journals (Sweden)

    Martine Jacquier

    2001-03-01

    Full Text Available OBJECTIVE: As the strength of the association between the APOE epsilon4 allele and Alzheimer's disease (AD varies across ethnic groups, we studied if there was such an association in Colombian patients. METHOD: We performed apolipoprotein E (APOE genotyping in a clinical sample of 83 unrelated AD patients, predominantly late-onset (>65 yrs including familial ( n =30 and sporadic AD cases (n= 53 diagnosed according to NINCDS-ADRDA criteria and assessed by a multi-disciplinary team. Control subjects (n = 44 had no significant cognitive impairment by medical interview and neuro-psychological testing. RESULTS: We found a high association (OR= 5.1 95%CI 1.9 -13.6 between APOE epsilon4 and AD, in this series with predominantly late-onset cases with familial aggregation in 24 cases (28.9%. A significant negative association was found between epsilon2 and AD (OR= 0.2 95% CI 0.05-0.75. CONCLUSION: Further population-based surveys in Colombia are warranted to precise a possible dose effect of APOE epsilon4.OBJETIVO: Como la fortaleza de la asociación entre el alelo épsilon4 del gen APOE y la enfermedad de Alzheimer (EA difiere entre grupos étnicos, quisimos evaluar si esta asociación existe en pacientes colombianos. MÉTODOS: Realizamos una genotipificación para el gen de la apolipoproteina E (APOE en una muestra clínica de 83 pacientes con EA no relacionados, de inicio predominantemente tardío (> 65 años, incluyendo casos familiares (n=30 y esporádicos (n=53 diagnosticados según los criterios del NINCDS-ADRDA y evaluados por un equipo multi-disciplinario. Los sujetos control (n= 44 no presentaban deterioro cognoscitivo de acuerdo con la entrevista médica y la evaluación neuropsicológica. RESULTADOS: Hallamos una alta asociación (OR= 5.1; IC95% 1.9- 13.6 entre APOE épsilon4 y EA en la serie de casos de inicio tardío y con agregación familiar en 24 sujetos (28.9%. Una asociación negativa, estadísticamente significativa, fue encontrada

  10. Actitudes, dudas y conocimientos de los colectivos implicados en la atención del paciente con Alzheimer: resultados de la encuesta del proyecto kNOW Alzheimer

    Directory of Open Access Journals (Sweden)

    Pablo Martínez-Lage Álvarez

    2016-03-01

    Full Text Available Introducción: La enfermedad de Alzheimer (EA involucra a colectivos diversos de profesionales y cuidadores. Las actitudes y necesidades de formación en diagnóstico temprano, tratamiento, síntomas conductuales, recursos sociosanitarios y aspectos legales o éticos son desconocidas. Métodos: Estudio observacional transversal tipo encuesta dentro del proyecto kNOW Alzheimer, iniciativa de la SEN, SEGG, SEMERGEN, SEFAC y CEAFA mediante cuestionarios específicos. Cada sociedad invitó a todos sus miembros a cumplimentarlos a través de www.knowalzheimer.com. Resultados: Participaron 114 neurólogos, 113 geriatras, 275 médicos de atención primaria, 328 farmacéuticos y 858 cuidadores. Los retrasos en el diagnóstico se originan en pacientes y cuidadores, el sistema y en los profesionales, que carecen de medios o malinterpretan síntomas tempranos. Persiste el uso del término “demencia senil”. Profesionales y cuidadores perciben buena eficacia del tratamiento. Se apuesta por el diagnóstico y tratamiento en fase pre-demencia. Hay déficit de formación en el manejo de la conducta. Los profesionales afirman que informan pero los cuidadores se sienten desinformados. Los cuidadores desean conocer cuanto antes si ellos o un familiar padecen Alzheimer. Los síntomas conductuales y la necesidad de restringir actividades son fuentes de sobrecarga. Los farmacéuticos pueden contribuir a la detección y manejo, pero precisan de formación amplia. Hay necesidad de formación en aspectos legales, bioéticos, recursos y acceso a la investigación. Conclusiones: Este proyecto ha permitido obtener información sobre actitudes y dudas de los colectivos involucrados en la atención a la EA, necesidades de formación y puntos de mejora.

  11. INTIMIDAD, SEXUALIDAD, DEMENCIAS. ESTRATEGIAS AFECTIVAS Y APROPIACIÓN DEL TRABAJO DE CUIDADO EN CONTEXTOS DESESTABILIZANTES

    Directory of Open Access Journals (Sweden)

    Natacha Borgeaud-Garciandía

    2016-01-01

    Full Text Available El presente artículo se centra en el trabajo de cuidado domiciliario en contextos que suponen la confrontación de las cuidadoras con elementos perturbadores y potencialmente desestabilizantes: la intimidad, la sexualidad y la demencia senil de adultos mayores muy dependientes. Proviene de una investigación en sociología cualitativa en la cual se llevaron a cabo entrevistas biográficas de tipo “historias de vida”con cuidadoras. Apoyándonos en las nociones de “trabajo sucio”, “trabajo emocional”y “defensas”, se analiza cómo estas trabajadoras se protegen y resignifican su trabajo ante la amenaza de sufrimiento que conlleva tal confrontación, lo cual puede resultar aún más difícil cuando los familiares rechazan el declive de su mayor. A la vez, la convivenciaprolongada les permite a las cuidadoras desarrollar un trabajo de cuidado integral, que pueden apreciar y repatriar en su buen cuidado. A través de sus estrategias emocionales, las cuidadoras resignifican el trabajo sucio a la vez que buscan preservar su identidad de “buena cuidadora”, socialmente valorada.

  12. Factores de riesgo asociados a la demencia degenerativa en pacientes geriátricos

    Directory of Open Access Journals (Sweden)

    Alejandro Rodríguez Constantín

    2003-04-01

    Full Text Available Se realizó un estudio analítico de tipo caso-control, para determinar factores de riesgo asociados a la aparición de demencia degenerativa en pacientes geriátricos pertenecientes al Consejo Popular "Los Maceo", del Policlínico Docente "Carlos J. Finlay", de la ciudad de Santiago de Cuba, desde septiembre a diciembre del año 2000. La muestra se constituyó con 22 casos identificados previamente como dementes degenerativos por el Equipo Multidisciplinario Gerontológico y 66 controles. Se aplicó una encuesta y se realizó el análisis de los resultados obtenidos. Se calcularon los odds radio (OR correspondientes a cada variable. El bajo nivel de escolaridad (OR=3,99, y el antecedente patológico familiar de demencia (OR=3,01 fueron identificados como factores de riesgo. No presentaron asociación causal las variables sexo (OR=1,46; modificaciones intensas del tono emocional (OR=1 y cambio brusco repetitivo del entorno habitacional (OR=1. La ejercitación de la capacidad intelectual después de los 60 años (OR=0,8 se consideró factor protector.A case control-type analytical study was made to determine the risk factors associated to the occurrence of degenerative dementia in old patients living in the people´s council "Los Maceo", whose population is taken care of by "Carlos J. Finlay" teaching polyclinics in Santiago de Cuba City. The sample was made up of 22 cases previously diagnosed as degenerative dements by the Multidisciplinary Gerontology Team and 66 controls. A survey was administered and the results achieved were analyzed. Odd ratios of each variable were estimated. Low educational level (OR=3,99 and the pathological family history of dementia (OR = 3.01 were identified as risk factors. No causal relation was observed among sex, intensive changes in emotional state and sudden repetitive change of the living environment (0R=1. The exercising of intellectual abilities after 60 years of age was considered to be a protective factor.

  13. Modelo de intervención psicológica en resiliencia para cuidadores informales de pacientes con Alzheimer

    Directory of Open Access Journals (Sweden)

    Ara Mercedes Cerquera Córdoba

    2015-01-01

    Full Text Available El objetivo del presente estudio es diseñar un modelo de intervenció psicológica en resiliencia, con enfoque cognitivo conductual, para cuidadores informales de pacientes con demencia tipo Alzheimer. Se tienen en cuenta las variables depresión, carga, resiliencia, apoyo social y estrategias de afrontamiento, consideradas en la literatura como influyentes en el rol del cuidador. Para realizar el diseño se tiene en cuenta la propuesta metodológica de Mori (2008, y para la evaluación del modelo en su estructura y proceso, la propuesta de evaluación de calidad del servicio de Donabedian (2005. Se concluye que el diseño de programas de intervención para cuidadores informales de pacientes con Alzheimer aparece como una alternativa necesaria para contrarrestar los efectos del cuidado. Este modelo brinda información necesaria para facilitar la réplica en otros contextos, y aporta los elementos requeri dos para su implementación.

  14. Retos, perspectivas y consideraciones éticas en torno a la evaluación del lenguaje en la persona con demencia Challenges, perspectives and ethics considerations over the language assessment of the person with dementia

    OpenAIRE

    Beatriz Valles González

    2008-01-01

    El presente ensayo plantea una reflexión en torno a los retos, perspectivas y dilemas éticos que se presentan al evaluar el lenguaje de las personas con demencia. Esta se hizo desde dos perspectivas, una de tipo epistemológica-ontológica, dirigida a estudiar el concepto de trastorno del lenguaje y su relación con el envejecimiento. La otra, metodológica, relacionada con el análisis de las técnicas de evaluación lingüística utilizadas en el diagnóstico de las alteraciones lingüísticas de esta ...

  15. Relações entre controle executivo e memória episódica verbal no comprometimento cognitivo leve e na demência tipo Alzheimer Relationships between executive control and verbal episodic memory in the mild cognitive impairment and the Alzheimer-type dementia

    Directory of Open Access Journals (Sweden)

    Amer Cavalheiro Hamdan

    2005-04-01

    Full Text Available Este estudo comparou e relacionou o desempenho de idosos com Comprometimento Cognitivo Leve e Demência Tipo Alzheimer em testes de controle executivo e de memória episódica verbal. Para a avaliação da memória episódica verbal utilizamos a Tarefa de Recordação de Palavras Imediata e a Tarefa de Recordação de Palavras com Intervalo. Na avaliação do controle executivo foram utilizados, os seguintes testes: Random Number Generation, Trail Making Test, Fluência Verbal semântica e fonológica, Wisconsin Card Sorting Test, Reading Span Test e Brow-Peterson Test. Treze idosos do grupo controle foram equiparados quanto à idade e escolaridade com nove idosos com Comprometimento Cognitivo Leve e oito idosos com Demência Tipo Alzheimer. Foram encontradas diferenças e associações estatisticamente significantes em relação aos testes de controle executivo entre os grupos investigados. Apesar da presença de associações significativas entre a memória episódica verbal e o controle executivo, não foram evidenciados déficits do controle executivo nos idosos com Comprometimento Cognitivo Leve.This study compared and related the performance of older people with Mild Cognitive Impairment and Alzheimer-type dementia in tests of executive control and of verbal episodic memory. In the evaluation of the verbal episodic memory we used the Task of Immediate Word Recall and the Task of Delayed Word Recall. In the evaluation of executive control we used the following tests: Random Number Generation, Trail Making Test, Semantic and Phonological Verbal Fluency, Wisconsin Card Sorting Test, Reading Span Test, and Brow-Peterson Test. Thirteen elders of the control group were compared by age and education with nine elders with Mild Cognitive Impairment and eight elders with Alzheimer-type dementia. Differences and significant statistical associations were found in relation to the tests of executive control with the groups investigated. Despite the

  16. Demencia: estados preclínicos y mortalidad en cohortes suecas

    OpenAIRE

    García Ptacek, Sara

    2016-01-01

    El aumento de la esperanza de vida de la población ha elevado exponencialmente la prevalencia de las demencias. Los estadios preclínicos de las enfermedades neurodegenerativas pueden durar años y la supervivencia tras el diagnóstico es variable. El objetivo de esta tesis es doble, primero, contribuir a la caracterización de los pacientes con deterioro cognitivo ligero (DCL) y quejas cognitivas subjetivas (QCS) que podrían estar en un estadio pre-demencia de la EA. Segundo, identificar qué fac...

  17. Demencia por déficit de vitamina B12: reporte de caso

    OpenAIRE

    Junco Bonet, Miguel Damián

    2014-01-01

    Fundamento: la deficiencia de vitamina B12 (cianocobalamina) puede producir varios desórdenes neurológicos, incluida la neuropatía periférica, degeneración subaguda combinada de la médula espinal, neuropatía óptica y alteraciones cognitivas que van desde la confusión leve hasta la demencia o la psicosis. La causa más frecuente de deficiencia de vitamina B12 es la anemia perniciosa. Objetivo: presentar un caso clínico de demencia por déficit de vitamina B12. Caso clínico: paciente masculino de...

  18. Intimidad, sexualidad, demencias. La relación subjetiva con el trabajo de cuidado en contextos desestabilizantes

    Directory of Open Access Journals (Sweden)

    Natacha Borgeaud-Garciandía

    2016-03-01

    Full Text Available El presente artículo se centra en el trabajo de cuidado domiciliario en contextos que suponen la confrontación de las cuidadoras con elementos perturbadores y potencialmente desestabilizantes: la intimidad, la sexualidad y la demencia senil de adultos mayores muy dependientes. Proviene de una investigación en sociología cualitativa en la cual se llevaron a cabo entrevistas biográficas de tipo “historias de vida” con cuidadoras. Apoyándonos en las nociones de “trabajo sucio”, “trabajo emocional” y “defensas”, se analiza cómo estas trabajadoras se protegen y resignifican su trabajo ante la amenaza de sufrimiento que conlleva tal confrontación, lo cual puede resultar aún más difícil cuando los familiares rechazan el declive de su mayor. A la vez, la convivencia prolongada les permite a las cuidadoras desarrollar un trabajo de cuidado integral, que pueden apreciar y repatriar en su buen cuidado. A través de sus estrategias emocionales, las cuidadoras resignifican el trabajo sucio a la vez que buscan preservar su identidad de “buena cuidadora”, socialmente valorada.

  19. Inventario de Sobrecarga en Cuidadores Familiares sin Formación Especializada de Enfermos de Alzheimer

    Directory of Open Access Journals (Sweden)

    María del Carmen Pérez-Fuentes

    2017-01-01

    Full Text Available Antecedentes/Objetivo: La demencia tipo Alzheimer es una de las causas más frecuentes de dependencia en población mayor, a lo que se une, la considerable demanda de cuidados. Además, cuando el cuidador es un familiar o una persona sin formación especializada, el cuidado tiene un impacto sobre su salud. Para conocer las necesidades de estos cuidadores y evaluar el nivel de sobrecarga o malestar del cuidador, se realiza la propuesta del Inventario de Sobrecarga en Cuidadores Familiares sin Formación Especializada de Enfermos de Alzheimer (IPSO-CA24. Método: En base a las respuestas de 255 cuidadores, se analizaron las propiedades psicométricas del cuestionario, mediante análisis de fiabilidad, análisis factoriales exploratorios y confirmatorios. Resultados: Los análisis factoriales informan de una estructura de seis factores relacionados (Reacción ante el diagnóstico, Salud física, Sintomatología psicológica (cuidador, Sintomatología conductual (enfermo, Conocimientos de la enfermedad y Nivel de dependencia, con una fiabilidad entre 0,75 y 0,93, que explican el 66,52% de la varianza total. También se obtiene apoyo para su validez convergente. Conclusiones: El IPSO-CA24 viene a dar respuesta a la necesidad de un instrumento que permita una valoración multidimensional de la sobrecarga del cuidador familiar sin formación especializada. © 2017 Asociación Española de Psicología Conductual. Published by Elsevier España, S.L.U. This is an open access article under the CC BY−NC−ND license (http://creativecommons. org/licenses/by−nc−nd/4.0/.

  20. Estudio descriptivo sobre el perfil de los cuidadores de personas con demencia: la feminización del cuidado

    Directory of Open Access Journals (Sweden)

    Rocío Lago Urbano

    2012-01-01

    Full Text Available Abstract The aim of this research is to understand the typical caregivers of persons suffering from Alzheimer’s disease and other forms of dementias in the city of Huelva. The sample was taken from caregivers of differing sex, age, social class, family and profession. A questionnaire was developed in order to collect the relevant data in order to establish a profile of the caregivers. The results show that the caregiver profile is characterized by female between 50 and 55 years old, married, who has been caring for the sickly for 6 or 7 years, sharing the same home with the ill person with a lack of relief from family rotation. These caregivers often have little time for leisure and have, at times, had to leave their working life to cope with care. Resumen El objetivo de esta investigación consistió en conocer el perfil de los cuidadores de los enfermos de Alzheimer y otras demencias en la ciudad de Huelva. La muestra fue conformada por cuidadores de enfermos de Alzheimer de diferente sexo, edad, y condiciones sociales, familiares y laborales. Para la recogida de datos se elaboró un cuestionario que proporcionó la información necesaria. Los resultados indican que el perfil del cuidador comprende en lo fundamental características como: ser mujer de entre 50 y 55 años, estar casada, estar cuidando al enfermo entre 6 o 7 años, compartir el mismo domicilio con la persona enferma y no gozar de rotación familiar. Estas cuidadoras suelen tener poco tiempo para el ocio y en ocasiones han abandonado su vida laboral para asumir los cuidados.

  1. Papel de la fisioterapia en la enfermedad de Alzheimer

    OpenAIRE

    Lallana Jiménez, Lucía

    2013-01-01

    La enfermedad de Alzheimer es una enfermedad neurodegenerativa que representa entre el 50% y el 60% de las demencias. Se caracteriza por déficits cognitivos, desorientación espacio-temporal y pérdida de memoria a corto plazo, lo cual da lugar a una dificultad en la realización de las tareas cotidianas por parte del enfermo. La enfermedad evoluciona a los largo de cuatro estadios: -Fase 1: se caracteriza por perdidas de memoria a corto plazo pero el paciente es todavía relativamente independie...

  2. ESTIMULACIÓN BASADA EN MINDFULNESS PARA PERSONAS MAYORES CON ENFERMEDAD DE ALZHEIMER U OTRAS DEMENCIAS

    Directory of Open Access Journals (Sweden)

    Domingo Jesús Quintana Hernández

    2015-09-01

    Full Text Available Los tratamientos psicológicos son una práctica habitual en el contexto sociosanitario de atención a personas mayores dependientes. En los últimos años se está introduciendo la práctica de mindfulness para personas mayores. Sin embargo, estas prácticas presentan dificultades para su aplicación en residencias y centros de día por el deterioro cognitivo que presentan los usuarios de estos servicios. En este artículo se muestra cómo se desarrollo un programa de estimulación basado en mindfulness en el entrenamiento de las actividades de vida diaria (AVD. Esta intervención se fundamenta en el entrenamiento del personal auxiliar y/o cuidador de forma simultánea con los usuarios de los servicios para, posteriormente en la rutina del centro, realizar un entrenamiento de la presencia consciente en la acción durante las AVD. El objetivo final de esta intervención es potenciar la coherencia funcional y la integración personal mediante prácticas de mindfulness en acción en actividades básicas, instrumentales o avanzadas.

  3. Alzheimer's Association

    Science.gov (United States)

    ... will not share your information. * Required. View archives. Alzheimer's impact is growing Alzheimer's disease is the sixth- ... Last Updated: Our vision is a world without Alzheimer's Formed in 1980, the Alzheimer's Association advances research ...

  4. EL RESPETO A LA AUTONOMÍA EN EL MANEJO DE ANCIANOS CON DEMENCIA

    Directory of Open Access Journals (Sweden)

    Tirso Zúñiga S.

    2017-12-01

    Full Text Available En la actualidad es de suma importancia conocer el proceso de envejecimiento para el diseño de acciones eficaces de política pública desde una perspectiva amplia, es decir, incluyendo los aspectos ético-filosóficos, socio-culturales, económicos y de salud. Respecto al problema de la demencia en ancianos, hay que decir que esta enfermedad neurodegenerativa crece a partir de los 65 años y se duplica cada 5 años, como consecuencia principal del envejecimiento de la población mundial, particularmente en los países de bajo y mediano ingreso América Latina y el Caribe. Entre un 4% y un 6% de los ancianos han sufrido alguna forma de maltrato. Los tratados de Geriatría abordan el problema de la vejez y la demencia desde la perspectiva médica, pero, tratándose de un asunto de calidad de vida se requiere del enfoque ético. El respeto a la autonomía es uno de los principios éticos más mencionados en la bioética que se ve lesionado con mucha frecuencia en el anciano con demencia. Respetar la autonomía de una persona es reconocer con la debida atención su capacidad cognitiva y preferencias, incluyendo su derecho a sostener ciertos puntos de vista, realizar determinadas elecciones y seguir ciertas acciones basadas en los propios valores y creencias. Por tanto, es muy importante el diagnóstico en etapa temprana de la enfermedad de una persona que sufre de alguna demencia, ya que conserva mayor estado de lucidez para informarle sobre los documentos de voluntades anticipadas y la designación de un representante legal o tutor de su confianza. La autonomía de los ancianos con demencia es reducida en estadios avanzados de la enfermedad, pero no nula y especialmente si se refiere al campo de su cuidado.

  5. Enfoque, diagnóstico y tratamiento a un paciente con demencia en la atención primaria de salud Approach, diagnosis and treatment of a patient with dementia in primary health care

    Directory of Open Access Journals (Sweden)

    Juan Carlos LLibre Guerra

    2008-06-01

    Full Text Available Las demencias y la enfermedad de Alzheimer constituyen un serio y creciente problema de salud en países con una alta expectativa de vida como el nuestro. A pesar de su creciente importancia, la demencia es una enfermedad frecuentemente infradiagnosticada e infravalorada. El papel del médico de atención primaria es clave en el diagnóstico del síndrome demencial. El diagnóstico de demencia es fundamentalmente clínico, su secuencia diagnóstica a nivel de la Atención Primaria de Salud incluye una evaluación clínica, una evaluación neuropsicológica mínima, la evaluación funcional y la evaluación al familiar, lo que se complementa con la realización de exámenes complementarios. El médico de atención primaria debe estar capacitado para el adecuado diagnóstico y seguimiento de los pacientes en el marco de su comunidad, lo que evitaría el gasto de recursos e incomodidades para el paciente y la familia, al contar en la propia área de salud con un profesional preparado y conocedor de sus problemas en su entorno familiar y social, capaz de prestarle un adecuado seguimiento y un oportuno asesoramiento y apoyo a la familia.Dementias and Alzheimer's disease are a serious and increasing health problem in countries with a high life expectancy at birth as ours. In spite of its increasing importance, dementia is frequently underdiagnosed and underestimated. The role of the doctor in primary health care level is essential in the diagnosis of demential syndrome. The diagnosis of dementia is mainly clinical. Its diagnostic sequence at the primary health care level includes a clinical evaluation, a minimal neuropsychological assesment, a functional evaluation, an evaluation to the relative and complementary tests. The primary care physician should be qualified for an adequate diagnosis and follow-up of the patients in the community, which would avoid the expense of resources and the inconveniences for the patient and his family, on having in

  6. Relación entre el burnout y la calidad de vida del cuidador de personas con demencia

    Directory of Open Access Journals (Sweden)

    Josep Deví Bastida

    Full Text Available Objetivos: Determinar el efecto burnout en la calidad de vida del cuidador de personas con demencia. Metodología: Revisión sistemática de artículos científicos que aportan información sobre la calidad de vida y el burnout de los cuidadores de personas con demencia. Las fuentes de datos usadas en el presente trabajo son PsycInfo, Web of Knowledge, Scopus, PubMed y Google Schoolar. Se han seleccionado 10 artículos siguiendo los criterios de selección y calidad marcados en la tabla 1, y sus características principales se muestran en la tabla 2. Resultados: Se han agrupado en función de los estadísticos usados en cada estudio; las variables analizadas son aquellas que recogen la relación entre la carga del cuidador y la calidad de vida del cuidador de personas con demencia. Existe una correlación negativa y estadísticamente significativa entre el burnout y la calidad de vida. La calidad de vida depende de los niveles de carga, que a su vez está relacionada con el tiempo que tienen los cuidadores para ellos mismos, el soporte social, los problemas de comportamiento del enfermo con demencia, la autoestima del cuidador y las finanzas. La calidad de vida relacionada con la salud está inversamente relacionada con los niveles de dependencia de la persona con demencia y con la edad del cuidador. Conclusiones: Una mayor percepción de carga conlleva una peor calidad de vida. Así pues, para mejorar la calidad de vida de los cuidadores de una persona con demencia debemos incidir en las variables que influyen la carga del cuidador.

  7. PREJUÍZOS COGNITIVOS EM IDOSOS COM DIABETES MELLITUS TIPO 2

    Directory of Open Access Journals (Sweden)

    Regina Maria Fernandes Lopes

    2009-01-01

    Full Text Available El avance en las condiciones de salud propicia el progresivo aumento de la esperanza de vida. Estudios han identificado la existencia de una conexión entre la Diabetes Mellitus (DM y demencia. La hiperglicemia podría ser un factor importante en la incidencia de la enfermedad de Azheimer, la cual puede ser una causa secundaria de demencia. La diabetes mellitus tipo 2 (DM2 está asociada con déficits cognitivos y funcionales, y el WCST es una de las herramientas que puede ser utilizada para evaluar funcionamiento ejecutivo. El objetivo de este estudio fue evaluar los déficits cognitivos de ancianos con diabetes mellitus tipo 2. Los participantes fueron 254 ancianos de ambos sexos, mayores de 60 años; 44 de ellos diagnosticados de DM2 y 210 en un grupo control de población general. El diseño fue un estudio cuantitativo transversal. Los instrumentos utilizados fueron: datos sociodemográficos, WCST, MMSE, BDI, BAI, GD, junto a las Sub pruebas de: Vocabulario, códigos, números y Cubos del WAIS-III. Los resultados mostraron una diferencia significativa en el desempeño de los ancianos con diabetes tipo 2 en comparación con el grupo control en cuatro descriptores de WCST que indicaban un deterioro. Igualmente los ancianos con diabetes tipo 2 mostraron una intensidad de síntomas depresivos y de ansiedad estadísticamente mayor que el grupo control

  8. Personas mayores con demencia institucionalizadas : efectos de la musicoterapia versus los talleres de reminiscencia-recreación

    OpenAIRE

    Solé Resano, Carme; Mercadal-Brotons, Melissa; Castro, Mónica de; Asensio, Francisca María

    2017-01-01

    Las personas afectadas de demencia continúan creciendo cada año.. Dentro del marco de la Psicología Positiva, vamos a estudiar los efectos positivos de la musicoterapia en la calidad de vida de las personas con demencia. El objetivo principal es analizar y comparar los efectos de un programa de musicoterapia (grupo experimental), y un programa de reminiscencia/recreación (grupo control) en personas mayores institucionalizadas. Se analiza el impacto: cognitivo, estado anímico y participación-i...

  9. Problemas en el proceso de adaptación a los cambios en personas cuidadoras familiares de mayores con demencia

    Directory of Open Access Journals (Sweden)

    Sara Moreno-Cámara

    2016-05-01

    Conclusiones: La escasez de apoyo formal y el infradiagnóstico de la demencia dificultan la adaptación de la persona cuidadora al cuidado de una persona afectada por demencia. El proceso de adaptación podría mejorar reforzando el apoyo formal en las primeras fases del cuidado para reducir el estrés del proceso de aprendizaje autodidacta de las familias cuidadoras, así como adaptando las intervenciones a cada fase de la evolución del rol cuidador.

  10. Evaluación de la prueba del reloj en el tamizaje de enfermedad de Alzheimer

    Directory of Open Access Journals (Sweden)

    Teodoro Oscanoa

    2004-03-01

    Full Text Available Objetivo: Examinar la capacidad discriminativa de la prueba del reloj con 10 puntos en el tamizaje de trastorno cognoscitivo por enfermedad de Alzheimer. Material y Métodos: Evaluación de una prueba diagnóstica mediante estudio de pacientes con y sin enfermedad de Alzheimer, provenientes del Consultorio Externo del Servicio de Geriatría del Hospital Almenara, Lima, Perú. Participaron 31 pacientes (10 varones y 21 mujeres con enfermedad de Alzheimer y 31 pacientes sin esta enfermedad (21 varones y 10 mujeres. A ambos grupos se les realizó el prueba del reloj. No hubo diferencia significativa entre la edad y grado de instrucción de ambos grupos. La gravedad de la demencia según el Clinical Dementia Ratio de Hughes fue leve en 10 (32,3%, moderada 12 (38,7% y severa en 9 (29%. Resultados: Considerando como punto de corte un valor de 6 en la prueba del reloj, se encontró una sensibilidad de 83,9%, especificidad 93,5%, valor predictivo positivo 92,9 y valor predictivo negativo 85,3%. Conclusión: La prueba del reloj parece ser un examen simple y efectivo para la evaluación inicial de trastornos cognitivos en pacientes adultos mayores con sospecha de demencia por enfermedad de Alzheimer.

  11. Rasgos distintivos de la comorbilidad y funcionalidad en ancianos institucionalizados con deterioro cognitivo y demencia

    Directory of Open Access Journals (Sweden)

    Armando Carlos Roca Socarras

    2013-07-01

    Full Text Available Fundamento: altos niveles de comorbilidad y el declinar funcional están estrechamente relacionados con la mortalidad a corto plazo y la pobre calidad de vida de las personas mayores institucionalizadas. Objetivo: determinar la asociación del deterioro cognitivo con la alta comorbilidad y el declinar funcional en personas mayores institucionalizadas. Métodos: estudio descriptivo de 156 pacientes ingresados en un hogar de ancianos ubicado en Mahé, Seychelles, entre el 2010 y el 2012. Se analizó el comportamiento de los adultos mayores en relación con: presencia de deterioro cognitivo y demencia, edad, sexo, enfermedades crónicas no transmisibles, niveles de comorbilidad, declinar funcional, filtrado glomerular estimado, polifarmacia, y años de escolaridad. En la evaluación de la comorbilidad se utilizó el Índice de Charlson en su versión abreviada y en la valoración funcional el Índice de Barthel. Resultados: el 57,7 % de los residentes presentaron deterioro cognitivo o demencia, de ellos el 66,7 % pertenecieron al sexo masculino. Los pacientes con deterioro cognitivo y demencia analizados en el estudio tuvieron una mayor probabilidad de padecer alta comorbilidad (OR: 5,88; intervalo de confianza del 95% [IC95]: 5,42-6,33 y peor desempeño funcional (OR: 20,53; IC95%: 19,54-21,29 que los casos institucionalizados sin estas entidades. Otras variables estudiadas en los casos con deterioro cognitivo como la edad, presencia de polifarmacia, filtrado glomerular estimado y años de escolaridad mostraron diferencias significativas en comparación con los adultos mayores sin deterioro cognitivo. Conclusiones: los pacientes con deterioro cognitivo tienen una comorbilidad y deterioro funcional superior a los casos sin deterioro cognitivo. Se constata asociación del deterioro cognitivo con la alta comorbilidad y un peor desempeño funcional.

  12. Alteraciones emocionales en la enfermedad de Parkinson idiopático sin demencia

    OpenAIRE

    Hurtado González, Carlos Alberto

    2014-01-01

    [ES]Actualmente la enfermedad de Parkinson ha comenzado a ser considerada como una patología de carácter neuroconductual cognitivo que se encuentra relacionada con alteraciones emocionales como la depresión, ansiedad y apatía que contribuyen a desmejorar la calidad de vida de los pacientes que padecen esta enfermedad. El objetivo de este trabajo tiene como propósito estudiar y analizar las alteraciones emocionales (depresión, ansiedad y apatía) en pacientes con EP sin demencia en est...

  13. Patogenia y tratamientos actuales de la enfermedad de Alzheimer

    Directory of Open Access Journals (Sweden)

    Marco J Albert Cabrera

    Full Text Available El Alzheimer es una enfermedad neurodegenerativa que se manifiesta como deterioro cognitivo y trastornos conductuales. En Cuba, junto a la demencia, ocupa el lugar número 6 en el cuadro de principales causas de muerte. No hay tratamiento eficaz para detener la progresión del Alzheimer. Sin embargo, algunas terapias detienen o ralentizan temporalmente el deterioro cognitivo, funcional y conductual de la enfermedad. En el trabajo se presenta una revisión actualizada a partir de la base de datos MEDLINE (2008-2013 sobre los mecanismos patológicos y los medicamentos usados en el tratamiento de los pacientes con la referida afección.

  14. Alzheimer's Myths

    Science.gov (United States)

    ... home. Myth 3: Only older people can get Alzheimer's Reality: Alzheimer's can strike people in their 30s, ... Myth 7: Silver dental fillings increase risk of Alzheimer's disease Reality: According to the best available scientific ...

  15. Repercusión de la demencia en los cuidadores primordiales del policlínico "Ana Betancourt" Repercussion of dementia in the fundamental carers of "Ana Betancourt" Polyclinic

    Directory of Open Access Journals (Sweden)

    Víctor T. Pérez Martínez

    2010-06-01

    Full Text Available Introducción: la demencia senil es reconocida actualmente como una entidad mayor en el orden socioeconómico, geriátrico, psiquiátrico y epidemiológico. Su atención representa un elevado costo emocional y económico para el paciente, la familia y el cuidador primordial. Objetivos: describir la repercusión psicosocial del síndrome demencial en los cuidadores primordiales del policlínico "Ana Betancourt". Métodos: se realizó un estudio descriptivo de corte transversal, durante el primer cuatrimestre del año 2009, en el policlínico "Ana Betancourt" del municipio Playa. Incluyó a 36 cuidadores de igual número de pacientes diagnosticados con demencia y enfermedad de Alzheimer, escogidos mediante muestreo por criterios. Resultados: los cuidadores primordiales eran en su mayoría féminas, hijas del paciente, en la quinta década de la vida, amas de casa, divorciadas y con un nivel de escolaridad de preuniversitario. El principal motivo de consulta de los cuidadores fue solicitar ayuda profesional para controlar los síntomas no cognitivos de la enfermedad. El cuidador dedica alrededor de 13 h diarias al cuidado del paciente que sufre de demencia, la mayor parte en la supervisión y vigilancia. Se encontró marcada afectación psicológica en el 64 % de los cuidadores. El nivel de sobrecarga o estrés en la población de cuidadores estudiada resultó elevado. Conclusiones: el cuidado del paciente que sufre de demencia se asocia a una sobrecarga y estrés relevantes que se expresa en la elevada morbilidad psicológica constatada en los cuidadores primordiales. Se recomienda diseñar un plan de intervención educativa dirigido a estos cuidadores para reducir la sobrecarga o estrés crónico que sufren.Introduction: senile dementia is nowadays recognized as a major entity in socioeconomic, geriatric, psychiatric and epidemiologic order. Its care represents a high emotional and economic cost for patient, family and fundamental carer

  16. Ludopatía y epilepsia en demencia frontotemporal: Reporte de dos casos

    Directory of Open Access Journals (Sweden)

    Sheila Castro-Suarez

    Full Text Available RESUMEN La demencia frontotemporal es un trastorno neurodegenerativo cuyo subtipo más común es la variante conductual. Es considerada la causa de demencia más frecuente en menores de 60 años. Se presentan dos casos no emparentados cuyos síntomas típicos fueron: deterioro progresivo de la cognición, del comportamiento, alteraciones psiquiátricas como desinhibición, actos impulsivos, apatía, falta de empatía, estereotipias y cambios en los hábitos de alimentación. La resonancia magnética cerebral, en ambos casos, mostró atrofia frontotemporal a predominio izquierdo; en la evaluación neuropsicológica se evidenció alteraciones de las funciones ejecutivas. El primer caso cursó con ludopatía como síntoma inicial, motivo por el cual permaneció por un año en un centro psiquiátrico, siendo el segundo en Latinoamérica y uno de los pocos casos reportados en el mundo. El segundo caso presentó crisis epilépticas en su evolución.

  17. DEMENCIA FRONTOTEMPORAL, CÓMO HA RESURGIDO SU DIAGNÓSTICO

    Directory of Open Access Journals (Sweden)

    Patricia Lillo Z, MD, PhD

    2016-05-01

    Full Text Available Desde la descripción inicial efectuada por Pick hace más de un siglo atrás, el interés por las demencias frontotemporales ha tenido un gran crecimiento. Gracias a los avances de las neuroimágenes y el desarrollo de biomarcadores, el progreso en este campo ha generado nuevos conocimientos en torno a la categorización clínica, correlatos neuronales de las funciones cerebrales superiores y mecanismos de neurodegeneración. Paradójicamente, estos avances han traído consigo cierta controversia y desafíos, los cuales han motivado la creación de nuevos criterios diagnósticos. Esta breve revisión muestra la evolución histórica de estas condiciones y describe los criterios diagnósticos actuales para la variante conductual y las afasias progresivas primarias, que son las dos formas clínicas de las demencias frontotemporales.

  18. Personalidad y demencia: aproximación al perfil diferencial del cuidador

    Directory of Open Access Journals (Sweden)

    Elena de Andrés-Jiménez

    2011-12-01

    Full Text Available El objetivo de este estudio es determinar la existencia de un perfil de personalidad característico de los cuidadores y cuidadoras familiares de personas con demencia. El adecuado conocimiento y manejo de las variables psicológicas que afectan de alguna manera al cuidador, ayuda a promover las acciones oportunas destinadas a atenuar el impacto del cuidado y mejorar la calidad de vida del cuidador y la persona cuidada. La población objeto de estudio está formada por 69 cuidadores familiares de personas con demencia, miembros de distintas asociaciones y centros de día. Los resultados obtenidos permiten identificar un perfil de personalidad característico para estos cuidadores, revelador de un funcionamiento psicológico específico en esta muestra, que si bien no podemos relacionar directamente con las tareas propias del cuidado de una persona con esta enfermedad, si nos proporciona información muy relevante para atender de forma más precisa a las necesidades de este colectivo. Asimismo, el análisis de los estilos de personalidad en función del sexo muestra una vez más que la mujer se encuentra en este ámbito en una situación de mayor vulnerabilidad.

  19. HABILIDADES PARA EL CUIDADO Y DEPRESIÓN EN CUIDADORES DE PACIENTES CON DEMENCIA

    Directory of Open Access Journals (Sweden)

    José Hernando Ávila-Toscano

    2010-01-01

    Full Text Available El objetivo de este estudio fue identificar relaciones entre lashabilidades para el cuidado (conocimiento, valor y pacienciay depresión en cuidadores de pacientes con demencia. Seevaluaron 32 cuidadores a quienes se les aplicó el Inventariode depresión de Beck y el Caring Ability Inventory. Los datosse analizaron con SPSS 18.0 Statistics empleando el coeficientede correlación de Pearson y un modelo de regresiónlineal de pasos sucesivos. Se obtuvieron promedios elevadosde conocimientos, paciencia y valor, lo cual indica un buenrendimiento de las habilidades para cuidar, mientras que lapresencia de manifestaciones depresivas se halló en el 46.9%de la muestra. Finalmente, se establece que la depresión seasoció más a los cuidadores noveles con poca formación educativay con buen nivel de conocimientos.

  20. Understanding Alzheimer's

    Science.gov (United States)

    ... Navigation Bar Home Current Issue Past Issues Understanding Alzheimer's Past Issues / Fall 2007 Table of Contents For ... and brain scans. No treatment so far stops Alzheimer's. However, for some in the disease's early and ...

  1. Calidad del registro del diagnóstico de demencia en atención primaria. La situación en España en el periodo 2002-2011

    Directory of Open Access Journals (Sweden)

    María del Canto de Hoyos-Alonso

    2016-01-01

    Conclusiones: Casi la mitad de los pacientes con anticolinesterásicos o memantina no tienen registrado diagnóstico de demencia en su HCE-AP. El registro mejora al aumentar el tiempo de seguimiento. Se requieren mejoras de la HCE-AP, coordinación asistencial adecuada y actitud activa para aumentar la calidad del registro de demencia.

  2. The role of high-fat diet in an APP/PS1 model of familial Alzheimer disease = Efecto de una dieta rica en grasas en ratones APP/PS1, modelo familiar de la enfermedad de Alzheimer

    OpenAIRE

    Petrov, Dmitry

    2015-01-01

    La obesidad es una pandemia mundial, la cual según estudios recientes afecta a más de 2.000 millones de personas en todo el mundo y conlleva una fuerte presión de los sistemas sanitarios globales. El problema se ve aumentado no sólo por los costes directos asociados al sobrepeso, sino también por las comorbilidades relacionadas, entre ellas el incremento del riesgo de desarrollo de enfermedades neurodegenerativas, como por ejemplo la enfermedad de Alzheimer (EA), principal causa de demencia s...

  3. Depressive symptoms associated with hereditary Alzheimer's disease: a case description.

    Science.gov (United States)

    Contreras, Mónica Yicette Sánchez; Vargas, Paula Alejandra Osorio; Ramos, Lucero Rengifo; Velandia, Rafael Alarcón

    The authors describe a family group studied by the Centro de Biología Molecular y Biotecnología, and the Clínica de la Memoria, las Demencias y el Envejecimiento (Universidad Tecnológica de Pereira, Colombia), and evaluate the association of depressive symptoms with Alzheimer's disease (AD). This family presented a hereditary pattern for AD characterized by an early onset of dementia symptoms, a long preclinical depressive course, and, once the first symptoms of dementia appeared, a rapid progression to severe cognitive function impairment. The authors found a high prevalence of depressive symptoms in this family and propose that the symptoms could be an important risk factor for developing AD in the presence of other risk factors such as the APOE E4 allele.

  4. Demencias: su enfoque diagnóstico Dementias: their diagnostic approach

    Directory of Open Access Journals (Sweden)

    Víctor T. Pérez Martínez

    2006-12-01

    Full Text Available La reducción de la capacidad cognitiva es esencial para el diagnóstico de demencia. La secuencia diagnóstica incluye la evaluación clínica (neurológica y psicopatológica, la evaluación neuropsicológica y la evaluación familiar. El equipo de salud debe estar capacitado para abordar la demencia, desde su diagnóstico precoz, hasta el plan de actuación individualizado para cada paciente y cuidador. La mayor influencia en el diagnóstico temprano dependerá de la preparación y actualización del equipo de Atención Primaria de Salud. La implicación real de la Atención Primaria en la detección y tratamiento efectivo de los problemas cognitivos en general es escasa, pero es innegable que las crecientes necesidades de la población que envejece le otorgan un papel de vanguardia a este nivel asistencial. En nuestro medio la exploración del estado mental no constituye una práctica sistemática, y persiste un grado no despreciable de subregistro para dicho diagnóstico.The reduction of the cognitive capacity is essential for the diagnosis of dementia. The diagnostic sequence includes the cllinical evaluation (neurological and psychopathological, the neuropsychological assessment and the family evaluation. The health team should be trained to deal with dementia from its early diagnosis to the action plan individualized for each patient and health care provider. The highest influence on the early diagnosis will depend on the training and updating of the Primary Health Care team. The real involvement of Primary Care in the detection and effective treatment of the cognitive problems in general is scarce, but it is undeniable that the growing needs of the aging population grant a role of avanguard to this health care level. In our context, the exploration of the mental state is not a systematic practice, and there is a degree of subregister for this diagnosis that should not be discarded.

  5. TIPOS DE DISCURSO

    OpenAIRE

    Garcia, Afrânio; UERJ

    2012-01-01

    O professor Adilson Citelli, em seu excelente livro Linguageme persuasão, apresenta cinco tipos de discurso:§ discurso dominante§ discurso autorizado§ discurso polêmico,§ discurso lúdico§ discurso autoritário.

  6. Desintegración de las praxias en la enfermedad de Alzheimer

    Directory of Open Access Journals (Sweden)

    Carlos A. Bardeci

    1972-03-01

    Full Text Available Se describe la sintomatologia clínica, los resultados de métodos auxiliares y de la punción biopsia cerebral de una paciente con enfermedad de Alzheimer. Se analizan los diversos aspectos clínicos, sosteniendose como posible determinar la individualidad clínica de la enfermedad de Alzheimer, dentro del capítulo de las demencias preseniles y su diagnóstico en vida. Las formas de apraxia presentes en esta observación confirman la correlación estrecha que existe entre los distintos niveles de su desintegración, à su relación con las perturbaciones del espacio al cual están genéticamente vinculadas; el espacio euclidiano para la apraxia constructiva, el espacio centrado en el propio cuerpo para la ideomotora y el concreto de manipulación de objetos para la ideatoria.

  7. Literatura e medicina: reflexões sobre a perda de memória na demência de tipo Alzheimer em geral, e na de alguém caro em particular.

    Directory of Open Access Journals (Sweden)

    Gérard Danou

    2016-01-01

    Full Text Available Os problemas da memória ligadas quer à velhice quer às diversas demências colocam importantes problemas à sociedade, aos médicos e aos neurobiologistas. Se as pes-quisas fundamentais exploram fi namente as lesões celulares cerebrais, a questão dos cuidados (zelar por de cada doente em particular permanece intacta, e é necessário aprender na cronicidade a inventar, sem cessar, para manter os vínculos e os farrapos de subjetividade. Afi rmar a vida, contra as forças da morte. O escritor Pierre Pachet oferece-nos uma verda-deira celebração das línguas, permanecendo o mais próximo possível de sua mãe, e a fi lósofa Catherine Malabou tenta colocar em evidência em que sentido uma certa destrutividade pode às vezes ser criadora de outra realidade.RÉSUMÉ Les troubles de la mémoire liés soit au grand âge soit aux diverses démences dont la maladie d’Alzheimer, posent d’importants problèmes de société donc aux médecins et aux neurobiologistes. Si les recherches fondamentales explorent fi nement les lésions cellulaires cérébrales, la question des soins (prendre soin de chaque malade singulier reste entière, et il faut apprendre dans la chronicité, à inventer sans cesse pour maintenir du lien et des lambeaux de subjectivité.  Affi r-mer la vie encore, contre les forces de mort. Pierre Pachet en écrivain nous offre une véritable célébration des langues, en restant au plus près de sa mère, et Catherine Malabou philosophe, tente de mettre en évidence en quoi une certaine destructivité peut parfois être créatrice d’autre chose.

  8. LITERATURA E MEDICINA: REFLEXÕES SOBRE A PERDA DE MEMÓRIA NA DEMÊNCIA DE TIPO ALZHEIMER EM GERAL, E NA DE ALGUÉM CARO EM PARTICULAR.

    Directory of Open Access Journals (Sweden)

    Gérard Danou

    2016-01-01

    Full Text Available Os problemas da memória ligadas quer à velhice quer às diversas demências colocam importantes problemas à sociedade, aos médicos e aos neurobiologistas. Se as pes-quisas fundamentais exploram fi namente as lesões celulares cerebrais, a questão dos cuidados (zelar por de cada doente em particular permanece intacta, e é necessário aprender na cronicidade a inventar, sem cessar, para manter os vínculos e os farrapos de subjetividade. Afi rmar a vida, contra as forças da morte. O escritor Pierre Pachet oferece-nos uma verda-deira celebração das línguas, permanecendo o mais próximo possível de sua mãe, e a fi lósofa Catherine Malabou tenta colocar em evidência em que sentido uma certa destrutividade pode às vezes ser criadora de outra realidade. RÉSUMÉ  Les troubles de la mémoire liés soit au grand âge soit aux diverses démences dont la maladie d’Alzheimer, posent d’importants problèmes de société donc aux médecins et aux neurobiologistes. Si les recherches fondamentales explorent fi nement les lésions cellulaires cérébrales, la question des soins (prendre soin de chaque malade singulier reste entière, et il faut apprendre dans la chronicité, à inventer sans cesse pour maintenir du lien et des lambeaux de subjectivité.  Affi r-mer la vie encore, contre les forces de mort. Pierre Pachet en écrivain nous offre une véritable célébration des langues, en restant au plus près de sa mère, et Catherine Malabou philosophe, tente de mettre en évidence en quoi une certaine destructivité peut parfois être créatrice d’autre chose.

  9. Dolor y demencia en las personas que viven en una unidad de larga estancia

    Directory of Open Access Journals (Sweden)

    Margarida Sotto Mayor

    2015-03-01

    Full Text Available El dolor es prevalente, infradiagnosticado e infratratado en las personas con diagnóstico de demencia u otros trastornos mentales. Objetivo: identificar la prevalencia del dolor y su relación con las variables sociodemográficas, clínicas y funcionales de las 80 personas residentes en una unidad de larga estancia (ULE del centro de Francia. Métodos: elaboración de un guion orientador para la recogida de datos de variables sociodemográficas, clínicas y funcionales. Registro de dolor. Resultados: El dolor tiene una prevalencia del 70% en los residentes de la ULE. Conclusión: población envejecida, sobre todo del sexo femenino, polimedicada, con pluripatología, dolor y menor conciencia de sí misma. Son necesarias medidas formativas que ayuden a los cuidadores formales e informales a identificar el dolor en las personas que no lo verbalizan y a comprender las alteraciones de comportamiento resultantes del dolor en las personas con deterioro cognitivo.

  10. Cambios en la composición corporal en función del grado de demencia en un grupo de ancianos institucionalizados

    OpenAIRE

    Camina Martín, M. A.; Mateo Silleras, Beatriz de; Carreño Enciso, L.; Cruz Marcos, S. de la; Miján de la Torre, A.; Redondo del Río, María Paz

    2013-01-01

    Objetivo: Valorar el estado nutricional de un grupo de ancianos institucionalizados con demencia, analizando los cambios en la composición corporal en función de su estadio evolutivo. Método: Se ha realizado un estudio transversal en el que se valoró el estado nutricional y la composición corporal (antropometría, MNA, y bioimpedancia) en 63 ancianos institucionalizados con diagnóstico de demencia en estadios evolutivos 5, 6 y 7 de las escalas GDS (Global Deterioration Scale) y FAST (Functiona...

  11. El modelo de la atención centrada en la persona : análisis descriptivo de una muestra de personas mayores con demencia en centros residenciales

    OpenAIRE

    Vila-Miravent, Josep; Villar, Feliciano; Celdrán, Montserrat; Fernández, Elena

    2012-01-01

    Este análisis descriptivo tiene el objetivo de evaluar la calidad asistencial de una muestra de personas con demencia institucionalizadas usando el Dementia Care Mapping (DCM) como metodología de observación sistemática y de examinar la presencia de pautas asociadas a la psicología social maligna en las residencias observadas. Participaron en el estudio 73 personas con demencia ingresadas en residencias a largo plazo. Los resultados más relevantes apuntan a la presencia de una cultura de cuid...

  12. Instrumentos para la evaluación de la sobrecarga del cuidador familiar de personas con demencia

    Directory of Open Access Journals (Sweden)

    África Martos Martínez

    2015-08-01

    Full Text Available El envejecimiento poblacional en los países desarrollados es una realidad que ha dado paso al aumento de las enfermedades degenerativas, entre ellas la demencia. Los cambios que se producen en la demencia, suponen una perdida funcional que vuelve a la persona afectada más dependiente de los demás para el desempeño de las actividades, por lo que estas pasan a ser una función asumida por el cuidador. El proceso de convertirse en cuidador supone la aparición, en muchos casos de sobrecarga, esto es, la percepción que el cuidador tiene acerca de la influencia que el cuidado tiene sobre su salud, su vida social, personal y económica. La cuantificación del riesgo de agotamiento, debería ser un procedimiento común. Por ello, este estudio pretende realizar una revisión de los instrumentos de evaluación de la sobrecarga del cuidador familiar de la persona con demencia. El método que se siguió fue la recisión sistemática de las bases de datos Lilacs, ProQuest, PsycARTICLES y Dialnet Plus, tras la cual, se pasó a buscar la fuente primaria de los instrumentos utilizados en los estudios hallados. Así, se encontraron 4 instrumentos distintos y 6 versiones de estos. En 34 de los 42 estudios, fue utilizado como instrumento de evaluación de la sobrecarga la escala de Zarit (Zarit Caregiver Burden Interview o una versión o adaptación del mismo. Estos resultados indican que la preferencia por esta escala para la evaluación de la sobrecarga en los cuidadores, es un continuo que no ha variado desde los años 90.

  13. [Cognitive plasticity in Alzheimer's disease patients receiving cognitive stimulation programs].

    Science.gov (United States)

    Zamarrón Cassinello, Ma Dolores; Tárraga Mestre, Luis; Fernández-Ballesteros, Rocío

    2008-08-01

    The main purpose of this article is to examine whether cognitive plasticity increases after cognitive training in Alzheimer's disease patients. Twenty six patients participated in this study, all of them diagnosed with mild Alzheimer's disease, 17 of them received a cognitive training program during 6 months, and the other 9 were assigned to the control group. Participants were assigned to experimental or control conditions for clinical reasons. In order to assess cognitive plasticity, all patients were assessed before and after treatment with three subtests from the "Bateria de Evaluación de Potencial de Aprendizaje en Demencias" [Assessment Battery of Learning Potential in Dementia] (BEPAD). After treatment, Alzheimer's disease patients improved their performance in all the tasks assessing cognitive plasticity: viso-spatial memory, audio-verbal memory and verbal fluency. However, the cognitive plasticity scores of the patients in the control group decreased. In conclusion, this study showed that cognitive stimulation programs can improve cognitive functioning in mildly demented patients, and patients who do not receive any cognitive interventions may reduce their cognitive functioning.

  14. Demencia secundaria a infarto talámico bilateral (Síndrome de Percheron): Reporte de un caso

    OpenAIRE

    Villafuerte-Espinoza, Mirla; Neyra-Ontaneda, Diego; Vizarreta, José Hernandez; Gamarra, Marco Zúñiga

    2015-01-01

    La parte más anterior y medial del tálamo está conectada con el lóbulo frontal, es así que un infarto bi-talámico puede producir demencia secundaria por desconexión de los circuitos tálamo-corticales. Presentamos elcaso de un paciente de 65 años con el síndrome de Percheron, entidad poco frecuente que cursó con la triada de trastorno del nivel de conciencia, alteraciones oculo-motoras y trastornoscognitivo conductuales. En la angio-tomografía cerebral se evidenció una hipodensidad medial-ante...

  15. Calidad de vida y estado de salud en personas mayores de 60 años con demencia institucionalizadas

    Directory of Open Access Journals (Sweden)

    Carmen Rodríguez-Blázquez

    2015-01-01

    Full Text Available Es necesario profundizar en los distintos aspectos que componen la calidad de vida (CdV en las personas con demencia que viven en residencias. El objetivo de este estudio fue describir la CdV e identificar los factores relacionados con ella. Métodos: Muestra compuesta por 525 personas con demencia mayo¬res de 60 años en 14 residencias de España. La CdV se evaluó mediante el EQ-5D (índice y escala visual analógica, EQ-EVA y Quality of Life in Alzheimer’s Disease (QoL-AD versiones residente y cuidador. También se utilizaron Clinical Dementia Rating Scale (CDR, el índice de Barthel, la escala Cornell de depresión en demencia (CSDD, una versión adaptada de la Cumulative Illness Rating Scale for Geriatrics (CIRS-G, Short Porta¬ble Mental Status Questionnaire (SPMSQ y el Mini Examen Cognoscitivo (MEC. Para determinar la asociación entre variables se utilizó el coeficiente de correlación de Pearson y la prueba t de Student. Resultados: Las escalas presentaron entre ellas correlaciones de 0,17 a 0,50. La puntuación QoL-AD cuidador fue mejor en varones con menos discapacidad y depresión (28,94±4,91, 29,91±4,74 y 28,44±4,94, respecti¬vamente; (p<0,01 y correlacionó con el índice de Barthel 0,45 y con la CSDD -0,36. El QoL-AD residente fue mejor en ausencia de depresión (29,29±6,03. El índice EQ-5D fue mayor en varones (0,19±0,33 con me¬nos discapacidad (0,42±0,32 y su coeficiente de correlación con el índice de Barthel fue de 0,79. Conclusiones: En personas mayores con demencia institucionalizadas en residencias la calidad de vida se relaciona con el estado funcional y la depresión

  16. Retos, perspectivas y consideraciones éticas en torno a la evaluación del lenguaje en la persona con demencia Challenges, perspectives and ethics considerations over the language assessment of the person with dementia

    Directory of Open Access Journals (Sweden)

    Beatriz Valles González

    2008-03-01

    Full Text Available El presente ensayo plantea una reflexión en torno a los retos, perspectivas y dilemas éticos que se presentan al evaluar el lenguaje de las personas con demencia. Esta se hizo desde dos perspectivas, una de tipo epistemológica-ontológica, dirigida a estudiar el concepto de trastorno del lenguaje y su relación con el envejecimiento. La otra, metodológica, relacionada con el análisis de las técnicas de evaluación lingüística utilizadas en el diagnóstico de las alteraciones lingüísticas de esta población. A partir de ella se proponen diferentes alternativas como: revisar el concepto de trastorno, redefinir el objetivo de la evaluación del lenguaje y profundizar en el conocimiento del funcionamiento lingüístico del adulto mayor sano como paso previo para el uso del análisis del discurso como herramienta válida para valorar la eficiencia lingüística de las personas que padecen demencia. Todas estas acciones pueden garantizar una atención ética y ajustada a las necesidades lingüísticas reales de este colectivo y de su familia.The purpose of the present study is to reflect on the challenges, perspectives and ethical dilemmas that are present when we assess language of people with dementia. This thought followed two perspectives: an epistemological and ontological one, addressed to study the concept of language disorder and its relation with aging. The other perspective, methodological, related to the analysis of the linguistic assessment techniques used in the diagnosis of the linguistic deficits of this population. Based on these perspectives, we propose useful alternatives, such as to review the concept of disorder, to redefine the objective of language evaluation and to deepen the knowledge of the linguistic functioning of healthy elderly people as a previous step for the use of the discourse analysis as a valid tool to evaluate the linguistic efficiency and to plan the intervention for people with dementia. These actions

  17. Envejecimiento activo en personas con enfermedad de Alzheimer en la Residencia Nicolás Rodríguez de Olmedo (Valladolid)

    OpenAIRE

    Callejo Casquete, Amanda

    2014-01-01

    Debido al aumento considerable de la población anciana en la actualidad y a su vinculación con las diferentes demencias, y en especial con la enfermedad del Alzheimer, el presente trabajo de fin de grado pretende que la sociedad tome conciencia de la importancia del envejecimiento activo, proyectando una imagen positiva de las personas mayores. El presente trabajo, haciendo hincapié en la importancia que conlleva desarrollar unos hábitos de vida saludable tanto física como mentalmente, plante...

  18. EL ROL DE LA EVALUACIÓN NEUROPSICOLÓGICA EN EL DIAGNÓSTICO Y EN EL SEGUIMIENTO DE LAS DEMENCIAS

    Directory of Open Access Journals (Sweden)

    Matías Molina D.

    2016-05-01

    Full Text Available El aumento progresivo de la esperanza de vida ha impuesto nuevos desafíos en el abordaje de las patologías que sufren los adultos mayores. Las demencias son unas de las patologías más frecuentes en este grupo etario, causando la pérdida de autonomía de los pacientes y afectando la salud y calidad de vida de sus cuidadores. En conjunto con otros exámenes, la evaluación neuropsicológica cumple un rol fundamental en el proceso de diagnóstico de las demencias, objetivando el Deterioro Cognitivo, entregando información sobre la autonomía de los pacientes y cumpliendo un rol indispensable en el seguimiento de estas enfermedades. La siguiente revisión presentará la problemática y los primeros estudios cognitivos de las demencias, finalizando con una síntesis de las investigaciones que han contribuido a establecer los perfiles neuropsicológicos de las demencias con mayor incidencia en la población.

  19. Aplicación del modelo Balance of Care en la toma de decisiones acerca del mejor cuidado para las personas con demencia

    Directory of Open Access Journals (Sweden)

    Ester Risco

    2017-11-01

    Discusión: El modelo Balance of Care permite evaluar de manera sistemática, objetiva y mediante un equipo multidisciplinario el emplazamiento más adecuado para las personas con demencia. Se deberían incluir otras intervenciones coste-eficientes para mejorar la situación domiciliaria de estas personas.

  20. Resiliencia, Personalidad Resistente y Crecimiento en Cuidadores de Personas con Demencia en el Entorno Familiar: Una Revisión

    Directory of Open Access Journals (Sweden)

    Violeta Fernández-Lansac

    2011-01-01

    Full Text Available La investigación en torno al cuidado no profesional de mayores con demencia ha proliferado a lo largo de los últimos años, constatando muchos autores que, del mismo modo en que el cuidado se asocia a un buen número de consecuencias negativas, diversos efectos positivos pueden derivarse de esta experiencia. Sin embargo, y a pesar del impacto de la corriente positiva en la actualidad, son muy escasos los estudios que valoran la personalidad resistente (hardiness, la resiliencia y el crecimiento personal en cuidadores. El presente artículo hace una revisión sistemática de las contribuciones más relevantes a este campo, a partir del análisis de nueve publicaciones. Todos estos trabajos evalúan, de un modo cuantitativo, la resiliencia, el hardiness o el crecimiento en familiares de personas con demencia. Las características y resultados de dichos trabajos serán valoradas, teniendo en consideración sus implicaciones para el estudio y la atención a los cuidadores

  1. Demencia frontotemporal no familiar y epilepsia generalizada Frontotemporal dementia non familial and generalized epilepsy

    Directory of Open Access Journals (Sweden)

    Patricio Fuentes

    2005-12-01

    Full Text Available Se presenta un paciente de 62 años, sin antecedentes familiares de demencia, que a los 45 años debuta con crisis súbitas de disnea, visión borrosa, caída al suelo y movimientos repetitivos de brazos. Tratado por epilepsia con fenitoína y ácido valproico, repite esporádicamente crisis semejantes. Hace 4 años sus familiares notan cambios de personalidad, irritabilidad y conductas obsesivas. Hace 2 años aparecen episodios de desorientación de días de duración, algunos con alucinaciones auditivas y también fenómenos convulsivos. Ultimamente presenta crisis polimorfas, algunas con prolongada alteración de conciencia, estados catatoniformes y relajación esfinteriana. Examen físico y neurológico sin anormalidades. Evaluación neuropsicológica evidenció consistentes defectos en funciones frontales. EEG mostraron lentitud generalizada y actividad irritativa esporádica en regiones frontotemporales. Atrofia cortical de predominio anterior en CT scan e hipoperfusión fronto-temporal bilateral en SPECT. Exámenes de laboratorio y LCR normales. CONCLUSIÓN: La asociación de DFT con epilepsia, en forma no familiar, sugiere un síndrome neurodegenerativo cortical diferente.A 62 year-old patient is presented, without family antecedents of dementia who begins with 45 years of age with sudden crisis of dyspnea, blurred vision, fall to the floor and repetitive jerks of arms. Tried by epilepsy with phenytoin and valproate repeats similar crisis sporadically. Four years ago their relatives began to notice changes of personality, irritability and obsessive behaviors. Later on, are added episodes of disorientation of days of duration, some with auditory hallucinations and also convulsive manifestations. Finally appear polymorphic crisis, some with continue alteration of consciousness, catatonic states and sphincteric incontinence. Physical and neurological examination without abnormalities. Neuropsychological evaluation evidenced consistent

  2. MELLITUS TIPO 1

    Directory of Open Access Journals (Sweden)

    Luciana Vládia Carvalhêdo Fragoso

    2010-01-01

    Full Text Available Investigación de carácter cualitativo, con el objetivo de comprender las experiencias cotidianas de los adolescentes con diabetes tipo 1. Los sujetos del estudio son 14 adolescentes atendidos en una clínica para la diabetes en Fortaleza, Ceará, Brasil, de junio a octubre de 2008. La recolección de los datos se hizo a través de entrevistas semi-estructuradas y se organizaron de acuerdo al análisis de contenido de Morse y Field. Se observó que el descubrimiento de la diabetes fue un momento difícil para los adolescentes debido a los cambios que tuvieron que hacer como el control terapéutico. Hacer una dieta adecuada es muy difícil como consecuencia de estímulos internos y externos a que están sometidos y a las dificultades financieras. Los adolescentes tienen el apoyo de la familia y amigos para su tratamiento diario. Además, les gusta el servicio realizado por los profesionales de salud de la clínica. Sin embargo, hay mucho que mejorar como enfermeras en la valorización de las experiencias de la vida de los adolescentes con diabetes, como la identificación de factores que interfieren en el control metabólico.

  3. Estar ahí, al cuidado de un paciente con demencia Being there, ever caring for a patient with dementia

    Directory of Open Access Journals (Sweden)

    Margarita María Gómez Gómez

    2007-03-01

    Full Text Available Por causa de las pérdidas orgánicas, la persona con demencia se reduce cada vez más hasta la total invalidez, y si no encuentra quién se ocupe de ella, se degradará hasta la completa indigencia. Objetivo: Comprender las razones que tiene el cuidador de un familiar con demencia para estar ahí, a su lado, y las acciones que realiza para mantenerse en el cuidado. Metodología: El estudio se realizó en Medellín, Colombia, desde enero de 2002 hasta junio de 2004 con los lineamientos propuestos por la Teoría Fundada; se entrevistaron 22 individuos, cuya característica común era llevar mínimo tres años al cuidado de una persona con demencia. Los participantes se contactaron a través del Programa de Cuidadores del Grupo de Neurociencias de la Universidad de Antioquia y del programa Adulto Mayor, del Instituto de Seguros Sociales; el análisis se hizo manualmente. Resultados: "Estar ahí" es una decisión que toman los cuidadores, motivada por la relación filial o familiar con la persona cuidada, y que está sustentada en cuatro asuntos culturales: función socio-económica del grupo, tradición, reciprocidad y religión. Se constataron, además, los sentimientos de desgaste que viven los cuidadores para mantenerse en el cuidado y su necesidad de información, aprender de la experiencia, reflexión, programar otras actividades y apoyo. Conclusión: El cuidador de un paciente con demencia reconoce que "solo no puede", por lo que urge crear ambientes y espacios de apoyo a los cuidadores, para contribuir a su bienestar y salud.Due to their organic losses demented patients evolve towards total invalidity. If they do not find caring people absolute destitution awaits them. Objective: To understand caregiver reasons for "being there" to a patient with dementia and what are his actions to remain giving care. Methodology: This grounded study was carried in Medellín from January 2002 to June 2004. Twenty-two people with a minimum three years

  4. Demencia secundaria a infarto talámico bilateral (Síndrome de Percheron): Reporte de un caso

    OpenAIRE

    Villafuerte-Espinoza, Mirla; Neyra-Ontaneda, Diego; Hernandez Vizarreta, José; Zúñiga Gamarra, Marco

    2015-01-01

    La parte más anterior y medial del tálamo está conectada con el lóbulo frontal, es así que un infarto bi-talámico puede producir demencia secundaria por desconexión de los circuitos tálamo-corticales. Presentamos el caso de un paciente de 65 años con el síndrome de Percheron, entidad poco frecuente que cursó con la triada de trastorno del nivel de conciencia, alteraciones oculo-motoras y trastornos cognitivo conductuales. En la angio-tomografía cerebral se evidenció una hipodensidad medial-an...

  5. Estrógenos, envejecimiento y enfermedad de Alzheimer Estrogens, aging and Alzheimer's dosiase

    Directory of Open Access Journals (Sweden)

    Fabio Sánchez E.

    1999-03-01

    Full Text Available El posible papel protector que ejercen los estrógenos en el envejecimiento y en la prevención de la enfermedad de Alzheimer es un tema de mucho interés y de investigación hoy en día. Existen evidencias de que la merma en la producción de estrógenos después de la menopausia está asociada con deterioro cognitivo que puede subsanarse o prevenirse con el uso de terapia de sustitución hormonal. Algunos estudios han concluido, además, que la terapia de sustitución hormonal con estrógenos se relaciona con disminución del riesgo de desarrollar enfermedad de Alzheimer o, por lo menos, con un retardo en su inicio. Otros estudios clínicos evidencian, aunque de manera preliminar, que los estrógenos pueden mejorar las funciones cognitivas en mujeres con enfermedad de Alzheimer. Sin embargo, estas evidencias no son suficientes aún para recomendar el uso indiscriminado de estrógenos en todas las mujeres postmenopáusicas ni en las afectadas por demencia. Habrá que esperar los resultados del estudio prospectivo WHI-MS que analizará los efectos de la terapia de sustitución hormonal sobre el desarrollo de la demencia en una gran población femenina. Este estudio los definirá a más tardar en unos 7 años. Ante una enfermedad incurable como la de Alzheimer, cualquier terapia que ofrezca un retardo en la edad de aparición, que reduzca su severidad o la velocidad de progresión o produzca mejoría en la calidad de vida, se convierte de hecho en asunto de interés para todos los afectados y para la comunidad científica que estudia este trastorno. The possible protective role of estrogens in aging and Alzheimer‘s disease, is presently a subject of considerable interest and research. There are evidences that decreased estrogen production after menopause is associated with cognitive deterioration that can be prevented or corrected with hormonal substitution therapy (HST. Some studies have concluded that HST with estrogens is related with a

  6. mellitus tipo 2

    Directory of Open Access Journals (Sweden)

    Margarita Lazcano-Ortiz

    2008-01-01

    Full Text Available Objetivo: valorar las propiedades psicométricas de la escala de afrontamiento y proceso de adaptación de Roy en población mexicana. Materiales y métodos: la escala se aplicó a 200 participantes con diabetes mellitus tipo 2. Para validar el constructo se realizó la extracción de factores con componentes principales y rotación Varimax, con Eigenvalores por arriba de 1 y cargas de factor mayores a ,30. Resultados: seis reactivos fueron eliminados del análisis por mostrar correlación negativa con la correlación total de la escala. El análisis de componentes principales inicial reveló nueve factores con una variación explicada de 65,29%. Sin embargo, no se consideraron tres factores por contener cada uno de ellos solamente un reactivo. Por tanto, la escala final se acepta con 38 reactivos. El coeficiente de confiabilidad Alfa de Cronbach fue de, 93. Discusión: el análisis reveló seis factores, uno más de lo reportado por Roy, y con mayor variación explicada. Algunos reactivos parecen no ser bien comprendidos por los participantes. Conclusiones: este artículo aporta una aproximación metodológica para explorar la adecuación de un instrumento a una población diferente para la que originalmente fue diseñado. Se concluye que la escala tiene consistencia interna y validez de constructo incipiente, los datos reportados en este estudio deben tomarse en cuenta con cautela. Es conveniente revisar de nuevo los reactivos y adecuarlos a la cultura particular, y probar la escala de nuevo con pacientes con enfermedades crónicas degenerativas a fin de contar con instrumentos culturalmente equivalentes.

  7. Alzheimer's: Glossary

    Science.gov (United States)

    ... as a nursing home. Learn more: Residential Care Working with Care Providers Adult day centers Adult day centers offer people with Alzheimer's and other dementias the opportunity to be social and to participate in activities in a safe environment. Learn more: Adult Day Centers Advance directive An ...

  8. Alzheimers sygdom

    DEFF Research Database (Denmark)

    Høgh, Peter

    2017-01-01

    Alzheimer's disease is a neurodegenerative disorder with insidious onset and slow progression. Prevalence is increasing, although not as fast as previously believed. The clinical diagnosis may be difficult, but diagnostic methods have been introduced and proven to be accurate in supporting...

  9. Asociación de familiares de enfermos de Alzheimer cubriendo un vacío

    Directory of Open Access Journals (Sweden)

    María de Perosanz Calleja

    Full Text Available RESUMEN Introducción: Existe una alta prevalencia de adultos mayores diagnosticados de demencia que generan una importante demanda de cuidados y recursos sociosanitarios. Los centros de día atienden a las personas en situaciones de dependencia y facilitan la integración familiar. Nuestras preguntas iniciales son acerca de las asociaciones de enfermos y familiares. ¿Cómo surgen y se organizan? ¿Qué servicios ofrecen? ¿Qué competencias desarrollan los profesionales de enfermería? Objetivo: Analizar la percepción que tienen los miembros del equipo de una asociación de familiares de enfermos de Alzheimer y otras demencias sobre el funcionamiento y el servicio que ofrecen a la sociedad. Material y métodos: Estudio cualitativo descriptivo, realizado en una asociación de familiares de enfermos de Alzheimer. Se realizan tres entrevistas semiestructuradas respetando las consideraciones éticas establecidas para los trabajos de investigación con personas. Resultados: Surgen tres categorías en el análisis de los relatos, la historia de la asociación, la estructura y organización del equipo interdisciplinar, destacando las competencias del profesional de enfermería y la oferta de servicios que ha desarrollado. Conclusiones: La asociación surge ante las necesidades de atención sentidas por parte de las familias y que no obtienen respuesta en otras instituciones. Se ha consolidado como un recurso imprescindible cuyo objetivo es mantener a la persona dependiente en su medio habitual y proporcionar apoyo a sus cuidadores. Atiende desde un equipo interdisciplinar que contribuye al desarrollo de unos fines comunes, donde la enfermería desarrolla las competencias propias de la profesión.

  10. Quiz: Alzheimer's Disease

    Science.gov (United States)

    ... of this page please turn JavaScript on. Feature: Alzheimer's Disease Quiz: Alzheimer's Disease Past Issues / Winter 2015 Table of Contents ... How many Americans over age 65 may have Alzheimer's disease? as many as 5 million as many ...

  11. Latin-America, a road to prevention of cognitive impairment [Editorial

    Directory of Open Access Journals (Sweden)

    Ricardo F. Allegri

    2016-07-01

    Full Text Available Las demencias se caracterizan por un deterioro adquirido y persistente de una o más capacidades cognitivas, generalmente asociado a alteraciones conductuales y de severidad suficiente para llevar a una pérdida de la autonomía. Las principales causas de demencias son la enfermedad de Alzheimer, las cerebrovasculares y otros tipos de demencias. La demencia es la tercera causa de carga de enfermedad para discapacidad y muerte en personas mayores de 65 años. El envejecimiento poblacional viene aumentando sostenidamente en los últimos años, siendo esta problemática mayor en los países en vías de desarrollo como sucede en Latinoamérica.

  12. Cuidados de enfermagem ao idoso com Demência que apresenta sintomas comportamentais La atención de enfermería a los ancianos con Demencia y con síntomas comportamentales Nursing care for the aged with Dementia and with behavioral symptoms

    Directory of Open Access Journals (Sweden)

    Luana Cardoso Pestana

    2009-08-01

    Full Text Available No curso das demências, os transtornos comportamentais são altamente prevalentes e estão freqüentemente associados ao stress dos cuidadores. Este estudo tem como objetivo identificar na literatura os tipos de demências que apresentam sintomas comportamentais e psicológicos associados; descrever o manejo não farmacológico destes distúrbios e descrever a atuação da enfermagem neste contexto. Foi pesquisada a literatura nas áreas de geriatria e enfermagem. Tornou-se evidente que a assistência de enfermagem prestada ao idoso demenciado vai muito além dos cuidados básicos e depende da participação ativa da família. A identificação de estratégias para minimizar e manejar os sintomas comportamentais é uma importante contribuição que a enfermagem pode dar para a geriatria.En el curso de la demencia, los trastornos de comportamiento son muy prevalentes y se asocian frecuentemente con el estrés de los cuidadores. Este estudio tiene como objetivo identificar en la literatura científica los tipos de demencias asociadas a los trastornos de comportamiento y síntomas psicológicos, describir el manejo no-farmacológico de estas alteraciones y describir las intervenciones de enfermería en este contexto. La Literatura en los campos de la geriatría y de enfermería fue investigada. Se hizo evidente que los cuidados de enfermería prestados a las personas mayores con demencia va más allá de la atención básica y depende de la participación activa de la familia. La identificación de estrategias para minimizar y manejar los síntomas de comportamiento es una importante contribución que la enfermería puede ofrecer a la geriatría.In the course of dementia, behavioral disorders are highly prevalent and are frequently associated with the stress of caregivers. This study aims to identify in scientific literature the types of dementia associated with behavioral and psychological symptoms (BPSD; describe the non

  13. Enfermedad de Alzheimer

    OpenAIRE

    Serrano Reyes, Carlos Daniel; Fundación Valle de Lili

    2001-01-01

    ¿Cuáles son las manifestaciones de la enfermedad de Alzheimer?/ Signos de alarma de la enfermedad de Alzheimer/ ¿Cómo se diagnostica la enfermedad?/ ¿Cómo se trata la enfermedad de Alzheimer?/ ¿Qué se está investigando sobre la enfermedad?/ ¿Qué otras enfermedades se parecen al Alzheimer?

  14. Crescimento de genótipos de frangos tipo caipira

    Directory of Open Access Journals (Sweden)

    R. C. Veloso

    2015-10-01

    Full Text Available RESUMOObjetivou-se com este trabalho comparar o padrão de crescimento, mediante ajustes das respectivas curvas de crescimento por modelos não lineares, bem como estudar o desenvolvimento de cortes de carcaça em relação ao peso da carcaça em diferentes genótipos de frangos tipo caipira. Foram utilizados 840 pintos de um dia, machos, distribuídos em delineamento inteiramente ao acaso, dos seguintes genótipos da linhagem Redbro: Caboclo, Carijó, Colorpak, Gigante Negro, Pesadão Vermelho, Pescoço Pelado e Tricolor. As aves foram alojadas em 28 boxes, sendo 30 aves/boxe, em galpão de alvenaria com acesso a um piquete de 45m², com quatro repetições. O peso corporal individual dos frangos foi medido ao nascer, aos 14, 28, 42, 56, 70 e 84 dias de idade. Para a determinação das curvas de crescimento do peso corporal das aves, os dados coletados foram avaliados por meio dos modelos não lineares: Brody, Gompertz, Logístico, Richards e von Bertalanffy. Foi empregado o PROC NLIN do SAS, utilizando-se o método interativo de Gauss-Newton. Os critérios usados para escolha do modelo de melhor ajuste da curva de crescimento foram o coeficiente de determinação, o desvio padrão assintótico, o desvio médio absoluto dos resíduos e o índice assintótico. As análises para obtenção dos coeficientes alométricos foram realizadas por meio do PROC GLM do SAS para os genótipos Carijó, Colorpak, Pesadão Vermelho, Pescoço Pelado e Tricolor. Foram avaliados os pesos da carcaça, do peito, das coxas, das sobrecoxas, das pernas e das asas das aves abatidas aos 85 dias de idade. Apenas as equações propostas por Gompertz, von Bertalanffy e Logístico atingiram a convergência, e o modelo proposto por von Bertalanffy foi o mais adequado para descrever o crescimento dos genótipos de frangos caipiras. Todos os cortes avaliados apresentaram crescimento tardio em relação ao peso da carcaça em genótipos de frangos tipo caipira.

  15. [Map of Alzheimer's disease and other dementias in Spain. MapEA Project].

    Science.gov (United States)

    Martínez-Lage, Pablo; Martín-Carrasco, Manuel; Arrieta, Enrique; Rodrigo, Jesús; Formiga, Francesc

    In the current context of increased life expectancy and progressive aging of the population a very significant increase in the number of people with cognitive impairment and dementia is expected. Consequently, Spain will face an enormous social and health problem in the next decades. The Mapa de la enfermedad de Alzheimer y otras demencias en España project aims to analyse plans, prevention and early diagnosis activities, process of care and resources available across the 17 Spanish regions for the management of cognitive impairment and dementia in order to identify improvement areas, as well as to provide a list of recommendations. The working group consisted of an Advisory Committee of 5 national experts and a Committee of Experts from each region made up of professionals in the field of Neurology, Geriatrics, Psychiatry, and Primary Care, as well as representatives of Family Associations of People with Alzheimer's and other dementias. The Expert Committee of each region held meetings in which the current situation of care was reviewed. Plans available in Spain for dementia management are mostly obsolete or have not been implemented. Prevention and early detection activities are generally not carried out. There is great variability of care process that patients must follow for the diagnosis, treatment, and follow-up of the disease, and not all diagnostic test are available in different regions. In general, resources are considered scarce and unknown. The Mapa de la enfermedad de Alzheimer y otras demencias en España study has been able to detect the main points that require changing n the management, organisation, and coordination of resources, such as information and training of the personnel involved. Furthermore, the study has revealed that, in Spain, the necessary conditions are in place in Spain, such as the availability and capacity of professionals involved, as well as there being the potential diagnostic and health care resources to address this room

  16. Evaluación psicológica en adultos mayores con factores de riesgo para la enfermedad de Alzheimer

    Directory of Open Access Journals (Sweden)

    Juana Adela Fong Estrada

    2013-12-01

    Full Text Available Se efectuó un estudio descriptivo y transversal de 100 adultos mayores que acudieron a la consulta de Geriatría del Policlínico de Especialidades "Saturnino Lora Torres" de Santiago de Cuba, durante el trimestre enero-marzo del 2012, a fin de evaluar psicológicamente a los ancianos con factores de riesgo de enfermedad de Alzheimer. Para determinar si existían signos de demencia se emplearon los tests de Hachinski, Mini-Mental y Hasegawa. En la serie prevalecieron la ingestión de alcohol, seguido del antecedente familiar de la enfermedad y el deterioro moderado. Se concluyó que en las consultas de Geriatría es de vital importancia la determinación de los factores de riesgo de la citada afección y la realización de los tests para detectar precozmente el deterioro cognitivo en los gerontes.

  17. Estudio sobre efectos del programa SADL (Stimulation Activities of Daily Living) de terapia ocupacional sobre el nivel de autonomía en las actividades de la vida diaria de personas con demencia institucionalizados

    OpenAIRE

    Jiménez Palomares, María

    2014-01-01

    La demencia afecta las habilidades cognitivas, altera la conducta y produce una pérdida progresiva de la funcionalidad. El deterioro cognitivo se expresa normalmente en una disminución de las habilidades requeridas para un correcto desempeño de las actividades de la vida diaria. Hemos llevado a cabo un ensayo clínico con 58 ancianos diagnosticados de demencia leve-moderado, ingresados en centros Residenciales de Extremadura y aprobado por el Comité de Bioética de la Universidad de Extr...

  18. Arte y salud: diseño e implementación de talleres y contenidos digitales de ámbito cultural para pacientes con Alzhéimer y otras demencias

    OpenAIRE

    López Méndez, Lorena

    2016-01-01

    Esta tesis doctoral se presenta como una tesis fundamentalmente práctica, en el marco multidisciplinar que engloba la Educación Artística, el ámbito de la Tercera Edad, las Demencias, las Artes Plásticas y Visuales y el Arte Contemporáneo. La tesis está vinculada al Proyecto AR.S: ARTE Y SALUD, diseño y desarrollo de materiales y actividades creativas y artísticas para personas con Alzhéimer y otras Demencias y cuidadores-familiares, como al programa de becas predoctorales de Personal Invest...

  19. Neuroimagen en la enfermedad de Alzheimer: nuevas perspectivas

    Science.gov (United States)

    Becker, James T.

    2012-01-01

    Introducción y desarrollo En los próximos 50 años vamos a presenciar un incremento significativo de la población mayor de 65 años y por lo tanto va a aumentar, considerablemente, el número de individuos con riesgo de desarrollar demencias neurodegenerativas, especialmente la enfermedad de Alzheimer (EA). Las estrategias actuales de tratamiento farmacológico y no farmacológico se han centrado en las fases sintomáticas de esta enfermedad y, gradualmente, vamos teniendo una mayor comprensión de los posibles factores de riesgo del síndrome clínico. Conclusiones Los estudios de neuroimagen han sido muy útiles para mostrar los cambios estructurales del envejecimiento normal y patológico, así como también los factores de riesgo para la EA. Los tratamientos apropiados de los factores de riesgo y su posible combinación con tratamientos específicos para la EA podrían prolongar el período presintomático de la EA y, por tanto, mejorar la calidad de vida y disminuir la carga para el paciente, la familia y la sociedad. PMID:20517866

  20. Incidencia de las demencias en hemodiálisis: Apoyo al cuidador principal Incidence of dementia in haemodialysis: Support for the main carer

    Directory of Open Access Journals (Sweden)

    Mª Ángeles Sánchez Lamolda

    2013-03-01

    Full Text Available Las demencias, aparecen cada día con más frecuencia en pacientes con tratamiento de hemodiálisis; la edad de entrada al tratamiento dialítico ha aumentado en los últimos años, influenciada por el aumento de la esperanza de vida. El deterioro en el estilo de vida del paciente afecta tanto a familiares como cuidadores, presentándose una situación compleja y difícil de manejar. En la actualidad, constituye un serio problema de salud con una repercusión social y económica a gran escala, por la pérdida de independencia del paciente y la carga física y psicológica que sufre la familia. Objetivo: Conocer la incidencia de las demencias y su relación con la edad, sexo, nivel de estudios, patologías asociadas. Material y método: Estudio descriptivo y transversal. Para conocer la incidencia de las demencias utilizamos el cuestionario: (short portable mental status questionarire Pfeiffer. Variables: sexo, edad, nivel de estudios, Convivencia, Hipertensión arterial, Diabetes. Resultados: el 28% de los pacientes presentan demencia, 36% se encuentra entre 75-79 años, afectando considerablemente al sexo femenino. El 58% no han terminado los estudios primarios. Hipertensión arterial no es estadísticamente significativa, Diabetes Mellitus aparece en el 48% de los pacientes que presentan demencia. Conclusión: La edad de los pacientes en hemodiálisis ha aumentado considerablemente, dando lugar a la aparición de las demencias, de ahí la necesidad de establecer las intervenciones de enfermería adecuadas para mejorar la calidad asistencial, ofrecer la información adecuada a familiares y cuidadores sobre las medidas a tener en cuenta en cada situación.Dementia appears with increasing frequency in patients undergoing haemodialysis: the age of starting dialysis treatment has increased in recent years, influenced by the increase in life expectancy. The deterioration in the patient's lifestyle affects both relatives and carers, creating a

  1. The Alzheimer's Project

    Science.gov (United States)

    ... Navigation Bar Home Current Issue Past Issues The Alzheimer's Project Past Issues / Spring 2009 Table of Contents ... of this page please turn Javascript on. The Alzheimer's Project A 4-Part Documentary Series Starting May ...

  2. Duelo y muerte en cuidadores familiares y profesionales de enfermos de Alzheimer Mourning and death in informal and professional caregivers of Alzheimer's disease patients

    Directory of Open Access Journals (Sweden)

    Enrique Pérez-Godoy Díaz

    2007-06-01

    Full Text Available Como en cualquier proceso crónico y degenerativo abocado a la muerte, la enfermedad de Alzheimer y las demencias provocan en sus cuidadores familiares y profesionales diversos sentimientos, procesos y duelos tanto ante la muerte real como la muerte psíquica. Utilizando una metodología cualitativa analizamos diversos casos de cuidadores de enfermos de Alzheimer institucionalizados en un centro sociosanitario de donde concluimos que no sólo la muerte real puede provocar un duelo en los cuidadores sino también la pérdida inexorable de capacidades, y en último término su muerte psíquica. Esta muerte afecta también a cuidadores profesionales posiblemente porque les muestra su propia vulnerabilidad como seres humanos, recordándoles su propia muerte y lo que podría percibirse como más cruel: la posibilidad de una muerte en vida.Alzheimer's disease and other dementias can cause in caregivers diverse feelings, processes and mournings, which are lived in different ways. This occurs both in psychological and actual death. By using a methodology of a qualitative research, we look through some different cases of caregivers whose relatives are living in an institution. We conclude that not only the actual death can cause a sense of mourning in caregivers of dementia patients, but also the inexorable loss of capacities and eventually their "psychological" death. This death also possibly affects the professional caregivers because it shows them their vulnerability as human beings. This type of death makes them to think about the possibility of a death in life.

  3. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... on the latest news and advances in Alzheimer's treatments, care and research. Get tips for living with ... dementia What is Alzheimer's 7 stages of Alzheimer's Treatments Contact us 24/7 Helpline: 1-800-272- ...

  4. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... c)(3) organization. Copyright © 2018 Alzheimer's Association ® . All rights reserved. Our vision is a world without Alzheimer's Formed in 1980, the Alzheimer's Association is the world's leading voluntary health ...

  5. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... is Alzheimer's 7 stages of Alzheimer's Treatments Contact us 24/7 Helpline: 1-800-272-3900 Find ... Walk to End Alzheimer's Become an advocate About Us | News | Events | Press | About this Site | Privacy Policy | ...

  6. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... In My Area | Alzheimer's & Dementia | Life with ALZ | Research | Professionals | We Can Help | Join the Cause alz. ... news and advances in Alzheimer's treatments, care and research. Get tips for living with Alzheimer's as well ...

  7. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... Home Text size: A A A 2018 Alzheimer's Disease Facts and Figures Download the full report: Download ... about memory loss? KNOW THE 10 SIGNS Alzheimer's Disease Facts in Each State The 2018 Alzheimer's Disease ...

  8. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... is a not-for-profit 501(c)(3) organization. Copyright © 2018 Alzheimer's Association ® . All rights reserved. Our ... Alzheimer's Association is the world's leading voluntary health organization in Alzheimer's care, support and research.

  9. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... 501(c)(3) organization. Copyright © 2018 Alzheimer's Association ® . All rights reserved. Our vision is a world without Alzheimer's Formed in 1980, the Alzheimer's Association ...

  10. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... a rate twice as high. Invest in a world without Alzheimer's. Donate Caregivers Eighty-three percent of ... Association ® . All rights reserved. Our vision is a world without Alzheimer's Formed in 1980, the Alzheimer's Association ...

  11. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... health and long-term care costs. worried about memory loss? KNOW THE 10 SIGNS Alzheimer's Disease Facts ... Copyright © 2018 Alzheimer's Association ® . All rights reserved. Our vision is a world without Alzheimer's Formed in 1980, ...

  12. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... your chapter: search by state In My Area | Alzheimer's & Dementia | Life with ALZ | Research | Professionals | We Can Help | Join the Cause alz.org >> Alzheimer's & Dementia >> Home Text size: A A A 2018 Alzheimer's ...

  13. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... Dementia >> Home Text size: A A A 2018 Alzheimer's Disease Facts and Figures Download the full report: Download ... worried about memory loss? KNOW THE 10 SIGNS Alzheimer's Disease Facts in Each State The 2018 Alzheimer's Disease ...

  14. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... Alzheimer's & Dementia | Life with ALZ | Research | Professionals | We Can Help | Join the Cause alz.org >> Alzheimer's & Dementia >> ... as well as simple ideas on how you can support the fight to end Alzheimer's. First name: ...

  15. Genetics Home Reference: Alzheimer disease

    Science.gov (United States)

    ... Email Facebook Twitter Home Health Conditions Alzheimer disease Alzheimer disease Printable PDF Open All Close All Enable Javascript to view the expand/collapse boxes. Description Alzheimer disease is a degenerative disease of the brain ...

  16. Alzheimer\\'s Disease: Yesterday, Today, Tomorrow

    Directory of Open Access Journals (Sweden)

    Farid Fadaei

    2007-04-01

    Full Text Available Alzheimer's disease is the most common and well - known cause of dementia, as a progressive, irreversible brain disorder that affects cognitive function, personality, thought, perception and behaviour. Alzheimer's disease is the fourth leading cause of death in western countries. Interesting to know that this disease was unknown in medical community till 100 years ago and had no name. Dr. Alois Alzheimer, a German psychiatrist was the person who suspected the presence of this new illness and by succinct clinical, neuroanatomic, and neuropathologic examination of some cases; including the first known case of this disease- a woman named Auguste Deter- documented it. In further Emil Kraepe1inby knowing about the cases that Dr. Alzheimer reported, and another reports of this disease that were published in the first decade of the twentieth century, set the name of Alzbeimer on this new disease. Descriptions of Dr. Alzheimer and Kraepelin are the same as the present day descriptions of this disease. Electron microscopy, quantitative morphology and modem biochemistry emerging in the second half of the twentieth century opened a new era in dementia research with description of the ultra structure and biochemistry of senileplaques and neuronfibrillary tangles, the major disease markers of Alzheimer's disease. Basic research gave insight into the molecular genetics and pathophysiology of Alzheimers disease and based on the biochemical findings, new pharmacological treatment options were opened. The future attempts will probably be concentrated on the prevention of this disease. Oxidative stress, excessive transition metal ions, and misfolded / aggregated proteins and inflammation are among the probable causes of Alzheimer's disease and the future research will focus on their better understanding and prevention of their occurrence. As the last word, stem cells grafts that in animals have led to remarkable improvement of brain function may also be a

  17. Técnicas de rehabilitación neuropsicológica en demencias: hacia la ciber-rehabilitación neuropsicológica

    Directory of Open Access Journals (Sweden)

    Eva Mª Arroyo-Anlló

    2012-01-01

    Full Text Available Las técnicas de rehabilitación neuropsicológica están destinadas a paliar el deterioro cognitivo de pacientes que sufren una demencia de severidad leve, sin el uso de psicofármacos. Actualmente, la mayoría de estos programas de intervención cognitiva en demencias está siendo mejorada, a través de la incorporación de los avances en el campo de la Tecnología de la Información y Comunicación (TIC. El objetivo del presente trabajo es la revisión de los avances más recientes en este campo. Describiremos las técnicas de rehabilitación neuropsicológica desde las más clásicas (Terapia de Orientación a la Realidad y la Terapia de Reminiscencias, pasando por las más actuales, como las técnicas para la facilitación de la re-codificación, las técnicas de acondicionamiento del entorno y para el aprendizaje de nueva información (Recuperación Espaciada, Difuminación de los Indicios de Recuperación, Aprendizaje sin Errores y Procedimentalización de Tareas. Esta revisión finaliza con las técnicas ciber-neuropsicológicas, las cuales aplican las últimas novedades de las TIC como la realidad virtual a la rehabilitación neuropsicológica.

  18. Desintegración de las praxias en la enfermedad de Alzheimer Disintegration of praxias in Alzheimer's disease: a case report

    Directory of Open Access Journals (Sweden)

    Carlos A. Bardeci

    1972-03-01

    Full Text Available Se describe la sintomatologia clínica, los resultados de métodos auxiliares y de la punción biopsia cerebral de una paciente con enfermedad de Alzheimer. Se analizan los diversos aspectos clínicos, sosteniendose como posible determinar la individualidad clínica de la enfermedad de Alzheimer, dentro del capítulo de las demencias preseniles y su diagnóstico en vida. Las formas de apraxia presentes en esta observación confirman la correlación estrecha que existe entre los distintos niveles de su desintegración, à su relación con las perturbaciones del espacio al cual están genéticamente vinculadas; el espacio euclidiano para la apraxia constructiva, el espacio centrado en el propio cuerpo para la ideomotora y el concreto de manipulación de objetos para la ideatoria.The case of a patient with Alzheimer's disease is reported and some considerations about the clinical individuality of the disease and the characteristics shown by the disintegration of behavior are made. In the study, the following methods were used: neurological examinations focused especially on movement disturbances, ecoencephalography, electroencephalography, cerebral cintilography, right carotid arteriography and cerebral biopsy. The clinical aspects of the disease, just as the correlation of the data obtained by the auxiliary methods allow the formulation of the diagnosis, confirmed by right frontal cerebral puncture. The patient's clinical context shows the basic syndromes: 1 frontal with fixative amnesia, lack of interest, deterioration of the consciousness of situation and of the intellectual level, bilateral apprehension reflex; 2 parieto-temporo-occipital with indifference for the left hemibody, for the visual hemifield and for the space of this side. In addition, there arises a serious complication of motor behavior (praxias with the disintegration of all functional levels: instrumental (melokinesic apraxia, space linked to the body (ideomotor, Euclidean space

  19. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... people without Alzheimer's — a rate twice as high. Invest in a world without Alzheimer's. Donate Caregivers Eighty- ... IL 60601 Alzheimer's Association is a not-for-profit 501(c)(3) organization. Copyright © 2018 Alzheimer's Association ® . ...

  20. Neuroimaging of Alzheimer's disease

    International Nuclear Information System (INIS)

    Matsuda, Hiroshi

    2005-01-01

    Main purposes of neuroimaging in Alzheimer's disease have been moved from diagnosis of advanced Alzheimer's disease to diagnosis of very early Alzheimer's disease at a prodromal stage of mild cognitive impairment, prediction of conversion from mild cognitive impairment to Alzheimer's disease, and differential diagnosis from other diseases causing dementia. Structural MRI studies and functional studies using fluorodeoxyglucose (FDG)-PET and brain perfusion SPECT are widely used in diagnosis of Alzheimer's disease. Outstanding progress in diagnostic accuracy of these neuroimaging modalities has been obtained using statistical analysis on a voxel-by-voxel basis after spatial normalization of individual scans to a standardized brain-volume template instead of visual inspection or a conventional region of interest technique. In a very early stage of Alzheimer's disease, this statistical approach revealed gray matter loss in the entorhinal and hippocampal areas and hypometabolism or hypoperfusion in the posterior cingulate cortex. These two findings might be related in view of anatomical knowledge that the regions are linked through the circuit of Papez. This statistical approach also offers accurate evaluation of therapeutical effects on brain metabolism or perfusion. The latest development in functional imaging relates to the final pathological hallmark of Alzheimer's disease-amyloid plaques. Amyloid imaging might be an important surrogate marker for trials of disease-modifying agents. (author)

  1. Neuroinflammation in Alzheimer's disease

    DEFF Research Database (Denmark)

    Heneka, Michael T; Carson, Monica J; Khoury, Joseph El

    2015-01-01

    Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment, but includes strong interactions with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to pattern recognition receptors on microglia and astroglia......, and trigger an innate immune response characterised by release of inflammatory mediators, which contribute to disease progression and severity. Genome-wide analysis suggests that several genes that increase the risk for sporadic Alzheimer's disease encode factors that regulate glial clearance of misfolded...... therapeutic or preventive strategies for Alzheimer's disease....

  2. Terapias asistidas con animales: síntomas y funcionalidad en trastornos del espectro autista y demencia senil

    OpenAIRE

    González Rosauro, Belén

    2012-01-01

    En este trabajo se realiza un recorrido teórico acerca de los principales aspectos que engloba la terapia asistida con animales, una modalidad terapéutica con una base histórica sólida que actualmente goza de una popularidad en creciente desarrollo. Los numerosos estudios realizados han sido capaces de verificar las grandes ventajas que supone realizar una terapia de este tipo como complemento a otros tratamientos principales, además de los cuantiosos beneficios de los animales para el ser hu...

  3. Posición y perspectivas de los médicos sobre las directivas anticipadas en pacientes con demencia incipiente

    Directory of Open Access Journals (Sweden)

    Mercedes Mattiussi

    2012-08-01

    Full Text Available La demencia es una enfermedad progresiva que compromete la capacidad de tomar decisiones. Las directivas anticipadas (DA permitirían a los pacientes expresar tempranamente sus voluntades sobre cuidados a recibir en estadios finales. Los médicos de cabecera (MC están en una situación privilegiada para indagar acerca de las DA. El objetivo del presente estudio fue conocer las perspectivas de los MC sobre las DA en pacientes con demencia. Se llevó a cabo una investigación cualitativa por grupos focales y entrevistas individuales a MC de ancianos del Hospital Italiano de Buenos Aires. Se realizó muestreo intencional, conformándose grupos homogéneos según edad y jerarquía. La discusión se estimuló con una viñeta. Se realizó análisis de contenido temático en equipo interdisciplinario. Participaron 12 MC de hasta 30 años; 32 de edad intermedia y 8 mayores de 45 años. Entre los jóvenes las DA tuvieron mayor aceptación. Los mayores consideran que la familia toma las decisiones y que nuestra sociedad está inmadura para estas discusiones. Otros condicionantes para la discusión fueron: dificultades prácticas para implementar las DA, el lapso temporal entre la formulación y su implementación, dificultad para predecir la evolución de los pacientes, falta de legislación y de políticas institucionales específicas. Los jóvenes manifestaron falta de capacitación para dialogar sobre DA con sus pacientes. Como conclusión, se observó que los facilitadores y barreras para la discusión sobre DA difieren según la edad de los MC. Las intervenciones que se orienten a favorecer su utilización deberían adaptarse a los médicos a quienes van dirigidas.

  4. Neuroinflammation in Alzheimer's disease

    NARCIS (Netherlands)

    Heneka, Michael T.; Carson, Monica J.; El Khoury, Joseph; Landreth, Gary E.; Brosseron, Frederic; Feinstein, Douglas L.; Jacobs, Andreas H.; Wyss-Coray, Tony; Vitorica, Javier; Ransohoff, Richard M.; Herrup, Karl; Frautschy, Sally A.; Finsen, Bente; Brown, Guy C.; Verkhratsky, Alexei; Yamanaka, Koji; Koistinaho, Jari; Latz, Eicke; Halle, Annett; Petzold, Gabor C.; Town, Terrence; Morgan, Dave; Shinohara, Mari L.; Perry, V. Hugh; Holmes, Clive; Bazan, Nicolas G.; Brooks, David J.; Hunot, Stephane; Joseph, Bertrand; Deigendesch, Nikolaus; Garaschuk, Olga; Boddeke, Erik; Dinarello, Charles A.; Breitner, John C.; Cole, Greg M.; Golenbock, Douglas T.; Kummer, Markus P.

    Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment, but includes strong interactions with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to pattern recognition receptors on microglia and astroglia, and

  5. Neuroinflammation in Alzheimer's disease

    NARCIS (Netherlands)

    Heneka, M.T.; Carson, M.J.; Khoury, J. El; Landreth, G.E.; Brosseron, F.; Feinstein, D.L.; Jacobs, A.H.; Wyss-Coray, T.; Vitorica, J.; Ransohoff, R.M.; Herrup, K.; Frautschy, S.A.; Finsen, B.; Brown, G.C.; Verkhratsky, A.; Yamanaka, K.; Koistinaho, J.; Latz, E.; Halle, A.; Petzold, G.C.; Town, T.; Morgan, D.; Shinohara, M.L.; Perry, V.H.; Holmes, C.; Bazan, N.G.; Brooks, D.J.; Hunot, S.; Joseph, B.; Deigendesch, N.; Garaschuk, O.; Boddeke, E.; Dinarello, C.A.; Breitner, J.C.; Cole, G.M.; Golenbock, D.T.; Kummer, M.P.

    2015-01-01

    Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment, but includes strong interactions with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to pattern recognition receptors on microglia and astroglia, and

  6. Seven Stages of Alzheimer's

    Science.gov (United States)

    ... Disease > Stages Overview What Is Dementia? What Is Alzheimer's? Younger/Early Onset Facts and Figures Know the 10 Signs Stages Inside the Brain: An Interactive Tour Risk Factors Diagnosis Treatments Myths Clinical Studies Research Brain Donation ...

  7. Communication and Alzheimer's

    Science.gov (United States)

    ... We will not sell or share your name. Communication and Alzheimer's Tweet Bookmark this page | Email | Print ... stage Communication in the late stage Changes in communication In addition to changes in the brain caused ...

  8. EVALUACIÓN NEUROPSICOLÓGICA EN LA ENFERMEDAD DE ALZHEIMER: MEMORIA EPISÓDICA Y SEMÁNTICA.

    Directory of Open Access Journals (Sweden)

    Ana Comesaña

    2009-01-01

    Full Text Available Este trabajo tiene como objetivo realizar una revisión del proceso de evaluación neuropsicológica en pacientes con Alzheimer (EA, específicamente la referida a la memoria episódica y semántica. La enfermedad de Alzheimer es la principal forma de demencia. Es uno de los problemas sanitarios, sociales y culturales más importantes en actualidad. El diagnóstico y la diferenciación entre el envejecimiento normal y patológico son dificultosos en los primeros momentos, por lo tanto, la evaluación neuropsicológica cumple un papel fundamental. Los criterios utilizados actualmente son los del DSM IV (American Psychiatric Association, 1994 y los del NINCDS-ADRDA (Instituto Nacional para los Desórdenes Neurológicos, de la Comunicación y el Accidente Cerebro Vascular y la Asociación para la Enfermedad de Alzheimer y Desórdenes Relacionados (McKhann G, Drachman D, Folstein M, y col., 1984, y exigen que el diagnóstico de EA probable se corrobore por evaluación neuropsicológica, además de la evaluación clínica y otros estudios. A partir de la división de la memoria a largo plazo en semántica y episódica, se crearon pruebas específicas para su evaluación neuropsicológica en distintas patologías, incluyendo la EA. De esta manera, se realizó una importante contribución a la detección temprana del deterioro de la memoria que es característico de la enfermedad.

  9. Treatment of Alzheimer disease.

    Science.gov (United States)

    Winslow, Bradford T; Onysko, Mary K; Stob, Christian M; Hazlewood, Kathleen A

    2011-06-15

    Alzheimer disease is the most common form of dementia, affecting nearly one-half [corrected] of Americans older than 85 years. It is characterized by progressive memory loss and cognitive decline. Amyloid plaque accumulation, neurofibrillary tau tangles, and depletion of acetylcholine are among the pathologic manifestations of Alzheimer disease. Although there are no proven modalities for preventing Alzheimer disease, hypertension treatment, omega-3 fatty acid supplementation, physical activity, and cognitive engagement demonstrate modest potential. Acetylcholinesterase inhibitors are first-line medications for the treatment of Alzheimer disease, and are associated with mild improvements in cognitive function, behavior, and activities of daily living; however, the clinical relevance of these effects is unclear. The most common adverse effects of acetylcholinesterase inhibitors are nausea, vomiting, diarrhea, dizziness, confusion, and cardiac arrhythmias. Short-term use of the N-methyl-D-aspartate receptor antagonist memantine can modestly improve measures of cognition, behavior, and activities of daily living in patients with moderate to severe Alzheimer disease. Memantine can also be used in combination with acetylcholinesterase inhibitors. Memantine is generally well tolerated, but whether its benefits produce clinically meaningful improvement is controversial. Although N-methyl-D-aspartate receptor antagonists and acetylcholinesterase inhibitors can slow the progression of Alzheimer disease, no pharmacologic agents can reverse the progression. Atypical antipsychotics can improve some behavioral symptoms, but have been associated with increased mortality rates in older patients with dementia. There is conflicting evidence about the benefit of selegiline, testosterone, and ginkgo for the treatment of Alzheimer disease. There is no evidence supporting the beneficial effects of vitamin E, estrogen, or nonsteroidal anti-inflammatory drug therapy.

  10. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... were diagnosed in the mild cognitive impairment (MCI) stage — before dementia — it would collectively save $7 trillion ... symptoms What is dementia What is Alzheimer's 7 stages of Alzheimer's Treatments Contact us 24/7 Helpline: ...

  11. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... of Alzheimer's. Today, someone in the United States develops Alzheimer's every 65 seconds. By mid-century, someone in the United States will develop the disease every 33 seconds. GET INVOLVED. Join ...

  12. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... secrets of Alzheimer's disease: exploring the brain - Duration: 6:27. Fondation Vaincre Alzheimer 348,442 views 6:27 Loading more suggestions... Show more Language: English ...

  13. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... and privacy policy . Plan ahead Get help and support I have Alzheimer's I am a caregiver I ... world's leading voluntary health organization in Alzheimer's care, support and research.

  14. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... and social benefits and facilitating participation in important clinical trials, early diagnosis enables ... in Alzheimer's treatments, care and research. Get tips for living with Alzheimer's as well ...

  15. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... age 65 and older and approximately 200,000 individuals under age 65 who have younger-onset Alzheimer's. ... of health care and long-term care for individuals with Alzheimer's or other dementias are substantial. Dementia ...

  16. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... state. Read past editions . Sign up for our e-newsletter Stay up-to-date on the latest ... Alzheimer's. First name: Last name: *Email: *Zip: Weekly E-Newsletter Breaking Research Updates The Alzheimer's Association does ...

  17. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... SPECIAL REPORT: FINANCIAL AND PERSONAL BENEFITS OF EARLY DIAGNOSIS Early diagnosis of Alzheimer's provides a number of ... is a not-for-profit 501(c)(3) organization. Copyright © 2018 Alzheimer's Association ® . All rights reserved. Our ...

  18. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... ACTION > Read past editions . Sign up for our e-newsletter Stay up-to-date on the latest ... Alzheimer's. First name: Last name: *Email: *Zip: Weekly E-Newsletter Breaking Research Updates The Alzheimer's Association does ...

  19. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... This number includes an estimated 5.5 million people age 65 and older and approximately 200,000 ... who have younger-onset Alzheimer's. One in 10 people age 65 and older (10 percent) has Alzheimer's ...

  20. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... Join the Cause alz.org >> Alzheimer's & Dementia >> Home Text size: A A A 2018 Alzheimer's Disease Facts and Figures Download the full report: Download the Infographic: English Spanish Share the ...

  1. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... care. Caring for someone with Alzheimer's? Get Resources Cost to Nation Alzheimer's places a huge burden on the health care system, with annual costs exceeding a quarter of a trillion dollars. In ...

  2. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... SPECIAL REPORT: FINANCIAL AND PERSONAL BENEFITS OF EARLY DIAGNOSIS Early diagnosis of Alzheimer's provides a number of important benefits ... to detect Alzheimer's disease and provide an accurate diagnosis earlier than at any other time in history. ...

  3. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... of death among those age 65 and older. It also is a leading cause of disability and ... development of biomarkers for Alzheimer's disease is making it possible to detect Alzheimer's disease and provide an ...

  4. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... THE 10 SIGNS Alzheimer's Disease Facts in Each State The 2018 Alzheimer's Disease Facts and Figures report ... on the impact of this disease in every state across the nation. Click below to see the ...

  5. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... 272.3900 Donate Alzheimer's & Dementia What Is Alzheimer's? Brain Tour Younger/Early Onset Risk Factors Genetics Myths ... Dementia Korsakoff Syndrome Related Conditions CTE MCI Traumatic Brain Injury Facts and Figures Know the 10 Signs ...

  6. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... Share the facts: Quick Facts Prevalence Mortality Caregivers Cost Special Report Alzheimer's in each state Quick Facts Share the facts: Prevalence The number of Americans living with Alzheimer's is growing — and growing fast. An ...

  7. Alzheimer's Disease Facts and Figures

    Science.gov (United States)

    ... Dementia >> Home Text size: A A A 2018 Alzheimer's Disease Facts and Figures Download the full report: ... twice as high. Invest in a world without Alzheimer's. Donate Caregivers Eighty-three percent of the help ...

  8. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... Dementia >> Home Text size: A A A 2018 Alzheimer's Disease Facts and Figures Download the full report: ... twice as high. Invest in a world without Alzheimer's. Donate Caregivers Eighty-three percent of the help ...

  9. African-Americans and Alzheimer's

    Science.gov (United States)

    ... Share Plus on Google Plus African-Americans and Alzheimer's alz.org | IHaveAlz Introduction 10 Warning Signs Brain ... African-Americans are at a higher risk for Alzheimer's disease. Many Americans dismiss the warning signs of ...

  10. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... Help | Join the Cause alz.org >> Alzheimer's & Dementia >> Home Text size: A A A 2018 Alzheimer's Disease ... people who receive adult day services and nursing home care. Take action. Become an advocate SPECIAL REPORT: ...

  11. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... existing cases of Alzheimer's. Today, someone in the United States develops Alzheimer's every 65 seconds. By mid-century, someone in the United States will develop the disease every 33 seconds. GET ...

  12. Down Syndrome and Alzheimer's Disease

    Science.gov (United States)

    ... A A A Share Plus on Google Plus Alzheimer's & Dementia alz.org | IHaveAlz Overview What Is Dementia ... chapter Join our online community Down Syndrome and Alzheimer's Disease As they age, those affected by Down ...

  13. Catarata e diabetes mellitus tipo 1

    OpenAIRE

    Pizzol,Melissa Manfroi Dal; Esteves,Jorge Freita; Sccoco,Caio Augusto; Roggia,Murilo Felix; Rosa,Carolina Maurente da; Lambert,José Humberto Franco; Canani,Luís Henrique

    2008-01-01

    OBJETIVO: Avaliar a prevalência de catarata e seus fatores de risco em uma população portadora de diabetes mellitus tipo 1 (DM1). MÉTODOS: Estudo de casos e controles de um banco de dados de 181 pacientes (362 olhos) com diagnóstico de diabetes mellitus tipo 1. Os pacientes foram classificados como casos quando apresentavam diagnóstico de catarata. As variáveis estudadas foram a presença ou não de retinopatia diabética, tratamento com panfotocoagulação, presença de hipertensão arterial sistêm...

  14. Neuropsychiatric symptoms of the elderly with Alzheimer's disease and the family caregivers' distress.

    Science.gov (United States)

    Storti, Luana Baldin; Quintino, Débora Teles; Silva, Natália Michelato; Kusumota, Luciana; Marques, Sueli

    2016-08-15

    to analyze the relationship between the distress of the family caregiver and the presence of neuropsychiatric symptoms in elderly patients with Alzheimer's disease or mixed dementia. a descriptive, cross-sectional study conducted in the Geriatric and Dementias Clinic of a general tertiary hospital, with 96 elderly people with Alzheimer's disease or mixed dementia and their family caregivers. Questionnaires to characterize the elderly and caregivers, and the Neuropsychiatric Inventory were used. Descriptive statistics and Pearson correlation test were performed. 68.7% of the elderly were women, average age 80.8 years, 56.2% had Alzheimer's disease and 43.7%, mixed dementia. Among caregivers, 90.6% were women, average age 56, 70.8% took care of parents and 64.6% lived with the elderly. There was a strong (r = 0.82) and significant (p Inventario Neuropsiquiátrico. Se realizaron estadísticas descriptivas y prueba de correlación de Pearson. el 68,7% de los ancianos eran mujeres, con una edad promedio de 80,8 años, el 56,2% tenían enfermedad de Alzheimer y el 43,7%, demencia mixta. Entre los cuidadores, el 90,6% eran mujeres, con una media de 56 años, el 70,8% se hacía cargo del padre / madre y el 64,6% vivía con los ancianos. Hubo una fuerte (r = 0,82) y significativa (p Inventario Neuropsiquiátrico y la puntuación total en el Inventario Neuropsiquiátrico-Desgaste y fuerte correlación (r = 0,80) y significativa (p Inventario Neuropsiquiátrico-Desgaste y el número de síntomas neuropsiquiátricos, es decir, cuanto mayor sea el número, la frecuencia y la severidad de estos síntomas en los ancianos, mayor es el desgaste del cuidador. la presencia de síntomas neuropsiquiátricos en los ancianos estaban relacionados con un mayor desgaste en los cuidadores.

  15. Síndrome de Down y enfermedad de Alzheimer: factores de riesgo, evaluación e intervención

    Directory of Open Access Journals (Sweden)

    Elvira Díaz Pérez

    2016-06-01

    Full Text Available Existe una estrecha relación entre el síndrome de Down y la enfermedad de Alzheimer. Diversos factores de riesgo influyen en esta relación, en la que la evaluación de la demencia es difícil debido a la falta de instrumentos y tratamientos específicos. Se realizó una búsqueda de los años comprendidos entre 2005-2015 en diferentes bases de datos. Se identificaron diversos factores de riesgo (genéticos, ambientales, cognitivos y se encontraron varios instrumentos de evaluación, poco adecuados y/o con debilidades psicométricas. Los tratamientos existentes son escasos y, casi exclusivamente, farmacológicos. Se discute acerca de la importancia de llevar a cabo estudios sistemáticos sobre los factores de riesgo para la prevención de la enfermedad de Alzheimer en personas con síndrome de Down, así como la necesidad de un protocolo de evaluación específico y adaptado que permita implementar tratamientos más específicos y efectivos.

  16. [Biomarkers of Alzheimer disease].

    Science.gov (United States)

    Rachel, Wojciech; Grela, Agatha; Zyss, Tomasz; Zieba, Andrzej; Piekoszewski, Wojciech

    2014-01-01

    Cognitive impairment is one of the most abundant age-related psychiatric disorders. The outcome of cognitive impairment in Alzheimer's disease has both individual (the patients and their families) and socio-economic effects. The prevalence of Alzheimer's disease doubles after the age of 65 years, every 4.5 years. An etiologically heterogenic group of disorders related to aging as well as genetic and environmental interactions probably underlie the impairment in Alzheimer's disease. Those factors cause the degeneration of brain tissue which leads to significant cognitive dysfunction. There are two main hypotheses that are linked to the process of neurodegeneration: (i) amyloid cascade and (ii) the role of secretases and dysfunction of mitochondria. From the therapeutic standpoint it is crucial to get an early diagnosis and start with an adequate treatment. The undeniable progress in the field of biomarker research should lead to a better understanding of the early stages of the disorder. So far, the best recognised and described biomarkers of Alzheimer's disease, which can be detected in both cerebrospinal fluid and blood, are: beta-amyloid, tau-protein and phosphorylated tau-protein (phospho-tau). The article discusses the usefulness of the known biomarkers of Alzheimer's disease in early diagnosis.

  17. [How to define Alzheimer's disease].

    Science.gov (United States)

    Poncet, Michel

    2011-09-01

    Alzheimer's disease, which was considered to be a rare disease in subjects aged under 65 until the seventies/eighties, has become a very common disease affecting mostly older subjects. Many consider that it is important to review the meaning of the eponym "Alzheimer's disease", and a revolution, quite literally, is likely to occur. The role of vascular lesions in the onset of dementias among older subjects is widely acknowledged; considering those dementias as Alzheimer's disease may have negative consequences for patient management. Indeed, vascular lesions can be prevented and treated, while Alzheimer's lesions cannot. It may be justified to use "Alzheimer syndrome" instead of "Alzheimer's disease" when vascular risk factors and, all the more so, vascular lesions are present. Significant progress has been made in the understanding of the pathological proteins involved in Alzheimer's disease, as well as their effects on neurons and synapses. However, the etiology of the disease is still unknown, except in the rare hereditary cases, and there is no cure for Alzheimer's disease at present. Clinical research is progressing, and diagnostic criteria for the pre-dementia stage of Alzheimer's disease were suggested. In France, the outstanding Alzheimer plan 2008-2012 should play an important role in enhancing the understanding of Alzheimer's disease, Alzheimer's syndromes and related disorders.

  18. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... Get YouTube Red. Working... Not now Try it free Find out why Close How Alzheimer's Changes the ... 4:22 Your Amazing Brain - Dementia Explained - Alzheimer's Research UK - Duration: 4:58. AlzheimersResearch UK 16,695 ...

  19. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... date on the latest news and advances in Alzheimer's treatments, care and research. Get tips for living with ... is dementia What is Alzheimer's 7 stages of Alzheimer's Treatments Contact us 24/7 Helpline: 1-800-272- ...

  20. Demência fronto-temporal: aspectos clínicos e terapêuticos Demencia frontotemporal: aspectos clínicos y terapéuticos Frontotemporal dementia: clinical and therapeutic features

    Directory of Open Access Journals (Sweden)

    Antônio Lúcio Teixeira-Jr

    2006-04-01

    Full Text Available A demência fronto-temporal é uma importante causa de demência no período pré-senil. Caracteriza-se por significativas modificações do comportamento e da personalidade, enquanto o funcionamento cognitivo avaliado por testes psicométricos tradicionais encontra-se relativamente preservado. Muitos pacientes buscam o psiquiatra em virtude dos sintomas comportamentais proeminentes, como apatia, desinibição e comportamentos perseverativos ou estereotipados. O tratamento racional da demência fronto-temporal é atualmente limitado. Os sintomas comportamentais são controlados principalmente por inibidores seletivos da recaptação de serotonina.La demencia frontotemporal es una importante causa de demencia en el período presenil de la vida. Se caracteriza por alteraciones significativas en el comportamiento y en la personalidad, mientras la función cognitiva evaluada por pruebas psicométricas convencionales resulta relativamente preservada. Muchos pacientes recurren al psiquiatra en función de síntomas comportamentales sobresalientes como apatía, desinhibición y comportamientos perseverantes o estereotipados. El tratamiento racional de la demencia frontotemporal aún se encuentra bastante limitado. Los síntomas comportamentales se controlan principalmente con inhibidores selectivos de la recaptación de serotonina.Frontotemporal dementia is a major cause of dementia in the presenium. It is characterized by significant changes in behavior and personality, while cognitive functioning as assessed by traditional psychometric tests is relatively preserved. Thus, many patients present to the psychiatrist because of the prominence of behavioral symptoms, such as apathy, disinhibition, perseverative or stereotyped behaviors. Rational treatment for frontotemporal dementia is currently limited. The behavioral symptoms are controlled mainly with selective serotonin reuptake inhibitors.

  1. Coping in aged people with Alzheimer's disease Coping en ancianos con la enfermedad de Alzheimer Coping em idosos com doença de Alzheimer

    Directory of Open Access Journals (Sweden)

    Juliana Nery de Souza

    2007-02-01

    Full Text Available The intensity of stress experiences and elaboration of coping essentially depend on individuals' cognitive assessment. Considering the cognitive impairment of elderly persons with Alzheimer's disease (DA, this study aimed to identify their coping style. The Jalowiec Coping Inventory was applied to 60 elderly, 30 in the control group and 30 in the DA group. The results demonstrated a predominance of emotion-focused coping in the DA group and problem-focused coping in the control group, but the difference was not statistically significant (p=0.124. In addition, it was observed that individuals with better cognitive development in the DA group selected problem-focused coping strategies (p=0.0074. Thus, it seems there is a tendency to select evasive and emotional control strategies in demented elderly with worsened cognitive performance, rather than attempting to solve the problem or minimize its consequences.La elaboración de estrategias de ataque a las situaciones estresantes depende de la evaluación cognitiva hecha por el individuo. Considerando el déficit cognitivo de los ancianos con la enfermedad de Alzheimer (DA, este estudio tuvo por objetivo verificar el estilo de coping predominantemente utilizado por ellos. Para esto, fue aplicado el inventario de Coping de Jalowiec en 60 ancianos, de los cuales 30 individuos eran cognitivamente saludables (grupo control y 30 individuos con DA. Se observó un predominio del coping enfocado en la emoción en el grupo DA y enfocado en el problema en el grupo control, aunque no hubo una diferencia significativa. Así, parece haber una tendencia, en los ancianos con demencia, a elegir estrategias evasivas y de control emocional, en detrimento de la tentativa de solucionar el problema o minimizar sus consecuencias.A intensidade da experiência do estresse e a elaboração do coping dependem, fundamentalmente, da avaliação cognitiva feita pelo indivíduo. Considerando o déficit cognitivo de idosos com

  2. Epidemiology of Alzheimer disease.

    Science.gov (United States)

    Mayeux, Richard; Stern, Yaakov

    2012-08-01

    The global prevalence of dementia has been estimated to be as high as 24 million, and is predicted to double every 20 years until at least 2040. As the population worldwide continues to age, the number of individuals at risk will also increase, particularly among the very old. Alzheimer disease is the leading cause of dementia beginning with impaired memory. The neuropathological hallmarks of Alzheimer disease include diffuse and neuritic extracellular amyloid plaques in brain that are frequently surrounded by dystrophic neurites and intraneuronal neurofibrillary tangles. The etiology of Alzheimer disease remains unclear, but it is likely to be the result of both genetic and environmental factors. In this review we discuss the prevalence and incidence rates, the established environmental risk factors, and the protective factors, and briefly review genetic variants predisposing to disease.

  3. Neuroinflammation in Alzheimer's Disease

    Science.gov (United States)

    Heneka, Michael T.; Carson, Monica J.; El Khoury, Joseph; Landreth, Gary E.; Brosseron, Frederik; Feinstein, Douglas L.; Jacobs, Andreas H.; Wyss-Coray, Tony; Vitorica, Javier; Ransohoff, Richard M.; Herrup, Karl; Frautschy, Sally A.; Finsen, Bente; Brown, Guy C.; Verkhratsky, Alexei; Yamanaka, Koji; Koistinaho, Jari; Latz, Eicke; Halle, Annett; Petzold, Gabor C.; Town, Terrence; Morgan, Dave; Shinohara, Mari L.; Perry, V. Hugh; Holmes, Clive; Bazan, Nicolas G.; Brooks, David J.; Hunot, Stephane; Joseph, Bertrand; Deigendesch, Nikolaus; Garaschuk, Olga; Boddeke, Erik; Dinarello, Charles A.; Breitner, John C.; Cole, Greg M.; Golenbock, Douglas T.; Kummer, Markus P.

    2018-01-01

    Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment but strongly interacts with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to pattern recognition receptors on micro- and astroglia and trigger an innate immune response, characterized by the release of inflammatory mediators, which contribute to disease progression and severity. Genome wide analysis suggests that several genes, which increase the risk for sporadic Alzheimer's disease en-code for factors that regulate glial clearance of misfolded proteins and the inflammatory reaction. External factors, including systemic inflammation and obesity are likely to interfere with the immunological processes of the brain and further promote disease progression. This re-view provides an overview on the current knowledge and focuses on the most recent and exciting findings. Modulation of risk factors and intervention with the described immune mechanisms are likely to lead to future preventive or therapeutic strategies for Alzheimer's disease. PMID:25792098

  4. Epidemiology of Alzheimer Disease

    Science.gov (United States)

    Mayeux, Richard; Stern, Yaakov

    2012-01-01

    The global prevalence of dementia has been estimated to be as high as 24 million, and is predicted to double every 20 years until at least 2040. As the population worldwide continues to age, the number of individuals at risk will also increase, particularly among the very old. Alzheimer disease is the leading cause of dementia beginning with impaired memory. The neuropathological hallmarks of Alzheimer disease include diffuse and neuritic extracellular amyloid plaques in brain that are frequently surrounded by dystrophic neurites and intraneuronal neurofibrillary tangles. The etiology of Alzheimer disease remains unclear, but it is likely to be the result of both genetic and environmental factors. In this review we discuss the prevalence and incidence rates, the established environmental risk factors, and the protective factors, and briefly review genetic variants predisposing to disease. PMID:22908189

  5. Regional differences in astrocyte activation in HIV-associated dementia Diferencias regionales en la activación astrocitaria en demencia asociada a HIV

    Directory of Open Access Journals (Sweden)

    María C. Vanzani

    2006-04-01

    Full Text Available Since astrogliosis is a histological marker usually observed in HIV-associated dementia (HIV-D, we decided to investigate the potential relationship between the expression of glial fibrillary acidic protein (GFAP and the regional distribution of cells positive (+ for this specific marker of astrocyte activation. Histological sections of brain tissues obtained at necropsy from 5 HIV-D patients and 5 age-matched controls without history of neuropsychiatric illness were immunostained with peroxidase. Mean numbers of GFAP(+ astrocytes were significantly increased in entorhinal cortex, hippocampus and subcortical white matter of patients, but values in frontal cortex and basal ganglia were similar to those of controls. In contrast, surface density of immunoreactive GFAP was significantly increased in all tested brain areas from all patients, including unusually affected regions such as entorhinal cortex and hippocampus. Therefore, such consistent finding of hypertrophic astrocytes, ranging from highest cell percentajes in subcortical white matter to lowest in basal ganglia indicates that quantification of surface density in GFAP (+ cells appears to be a more reliable approach to score gliosis than the counting of their cell nuclei. Because astrocyte activation involves both protective and detrimental effects on adjacent neuronal subsets, the evidence of regional differences in this reactive potential highlights the importance of accurately defining their contribution to the neuropathogenesis not only of HIV-D, but of a wide range of neurodegenerative disorders.Siendo la astrogliosis un signo histológico habitualmente presente en demencia asociada a HIV, se investigó la eventual relación entre expresión de proteína gliofibrilar ácida (GFAP y localización regional de células positivas para ese marcador específico de la activación astrocitaria. Por inmunoperoxidasa, se procesaron cortes histológicos de tejidos cerebrales obtenidos por

  6. "Una vida que no es normal": el contexto de los cuidados familiares en la demencia "A life that is not normal": the context of family care in dementia

    Directory of Open Access Journals (Sweden)

    Carmen de la Cuesta-Benjumea

    2011-06-01

    Full Text Available El grupo mayoritario de los cuidadores lo conforman mujeres que viven en situación de vulnerabilidad y cuentan con poco apoyo formal. Mientras que la bibliografía destaca los estudios sobre la carga del cuidado y cómo aliviarla, hay pocas investigaciones que describan las circunstancias donde se desarrollan estos cuidados. El propósito de este estudio cualitativo es describir el contexto en el que se desenvuelven los cuidados de familiares con demencia avanzada. Para las cuidadoras, su vida no es normal. Llevar una vida restringida y sin vida propia son categorías que describen el contexto de la vida de las cuidadoras. A esta clase de vida, las cuidadoras se han acostumbrado. Las enfermeras pueden mejorar esta situación, pueden aconsejar a los cuidadores para que reserven parcelas de vida propia, son además una voz autorizada para sensibilizar y fomentar prácticas equitativas en el cuidado familiar.The largest group of caregivers are women who live in situation of vulnerability and have little formal support. While research literature emphasises the burden of care and the relief of that burden, there are few studies that describe the context where this care takes place. The purpose of this qualitative study is to describe the context of dementia family care giving. For participants their life is not normal. Having a restricted life and without a proper life are the categories that describe care givers context. To this kind of life they are accustomed.Nurses can improve this situation. They can advice caregivers to reserve parcels of their persona life. Nurses are also authorized voices to promote and sensitize equitable family care practices.

  7. Inflammation and Alzheimer's disease

    NARCIS (Netherlands)

    Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G. M.; Cooper, N. R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B. L.; Finch, C. E.; Frautschy, S.; Griffin, W. S.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.; Mrak, R.; Mackenzie, I. R.; McGeer, P. L.; O'Banion, M. K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; van Muiswinkel, F. L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Wyss-Coray, T.

    2000-01-01

    Inflammation clearly occurs in pathologically vulnerable regions of the Alzheimer's disease (AD) brain, and it does so with the full complexity of local peripheral inflammatory responses. In the periphery, degenerating tissue and the deposition of highly insoluble abnormal materials are classical

  8. Mitophagy and Alzheimer's Disease

    DEFF Research Database (Denmark)

    Kerr, Jesse S.; Adriaanse, Bryan A.; Greig, Nigel H.

    2017-01-01

    Neurons affected in Alzheimer's disease (AD) experience mitochondrial dysfunction and a bioenergetic deficit that occurs early and promotes the disease-defining amyloid beta peptide (Aβ) and Tau pathologies. Emerging findings suggest that the autophagy/lysosome pathway that removes damaged...

  9. Immunterapi mod Alzheimers sygdom

    DEFF Research Database (Denmark)

    Falkentoft, Alexander Christian; Hasselbalch, Steen Gregers

    2016-01-01

    Passive anti-beta-amyloid (Aß) immunotherapy has been shown to clear brain Aß deposits. Results from phase III clinical trials in mild-to-moderate Alzheimer's disease (AD) patients with two monoclonal antibodies bapineuzumab and solanezumab and intravenous immunoglobulin have been disappointing...

  10. Updating the Diagnosis and Management of Dementia. Practical Contributions in our Context Actualización en diagnóstico y manejo de las demencias. Aportes prácticos en nuestro contexto

    Directory of Open Access Journals (Sweden)

    Eduardo Fernández Casteleiro

    2012-03-01

    Full Text Available Considering as our main goal to expose the state of the art in diagnosis and treatment of dementia insisting in its latest advances and suggesting practical contributions for its management in our context, we offer a panoramical view of dementia as an important health problem and expose the essentials for its diagnosis and management including cognitive impairment diagnosis, variants, etiologic diagnosis, the diagnosis of demential syndrome, the importance of neuropsychiatric assessment and the treatment options. We emphasize in the need to provide appropriate orientation to families and those who take care of the elderly.Con el objetivo de exponer el estado del arte sobre el diagnóstico y tratamiento de las demencias insistiendo en los últimos avances, y sugerir aportes prácticos para su manejo en este contexto, se brinda una panorámica acerca de la importancia de las demencias como problema de salud. Se plantean los elementos imprescindibles para el diagnóstico y abordaje de esta afección, que incluye el diagnóstico del deterioro cognitivo, sus variantes, el diagnóstico etiológico, el diagnóstico del síndrome demencial, la importancia de la valoración neuropsiquiátrica y las opciones del tratamiento. Se resalta la necesidad de la orientación adecuada de la familia y el cuidador.

  11. El cuidado informal en enfermos de Alzheimer: evaluación a partir de un modelo teórico Alzheimer's disease caregivers. Assessment from a theoretical model

    Directory of Open Access Journals (Sweden)

    Ronald Gallardo Vargas

    2012-02-01

    Full Text Available La enfermedad de Alzheimer, dado su curso progresivo, obliga al acompañamiento de estas personas. Quienes fungen como cuidadores informales presentan quejas por malestares asociados a la situación de cuidar. Para la comprensión de esta problemática se realizó un estudio descriptivo y transversal cuyo objetivo general fue caracterizar el cuidado informal de personas con demencia en la enfermedad de Alzheimer, a partir de las dimensiones comunes de los modelos de estrés y afrontamiento adaptado a las situaciones de cuidado. Se seleccionó una muestra intencional de quince cuidadores informales e igual número de familiares enfermos, pertenecientes a la ciudad de Pinar del Río. Para el cumplimiento del objetivo se utilizaron las técnicas: entrevista semiestructurada, el Inventario de ansiedad de Beck, la Escala de Depresión del Centro para Estudios Epidemiológicos, el Cuestionario de carga del cuidador de Zarit, el test Listado de problemas de memoria y de conducta, el Cuestionario de apoyo social y la Escala de modos de afrontamientos. Entre los principales resultados estuvo la presencia de estresores relativos a la cantidad de horas y actividades de cuidado. Predominaron los comportamientos problemáticos con presentación muy frecuente en la mayoría de los enfermos, refiriéndose en los cuidadores sentimientos negativos asociados a los mismos. Predominó la percepción de sobrecarga intensa, así como ansiedad y depresión. La estrategia de afrontamiento más utilizada fue la aceptación de la responsabilidad, seguida del autocontrol. La mayoría de los cuidadores perciben un bajo apoyo social. Se declara repercusión del cuidado en las áreas laboral, socioeconómica y de descanso.Alzheimer's disease, due to its gradual progression, compels accompanying persons for these patients. Caregivers complain of discomforts associated with the care of Alzheimer's patients. To be aware of this problem a descriptive and cross-sectional study

  12. Ataxia espinocerebelar tipo 6: relato de caso

    Directory of Open Access Journals (Sweden)

    Bianca Simone Zeigelboim

    2014-10-01

    Full Text Available O objetivo deste estudo foi verificar as alterações vestibulococleares observadas em um caso de ataxia espinocerebelar tipo 6. O caso foi encaminhado do Hospital de Clínicas para o Laboratório de Otoneurologia de uma Instituição de Ensino e foi submetido aos seguintes procedimentos: anamnese, inspeção otológica, avaliações audiológica e vestibular. O caso retrata uma paciente com diagnóstico genético de ataxia espinocerebelar tipo 6, do sexo feminino, com 57 anos de idade, que referiu desequilíbrio à marcha com tendência a queda para a esquerda, disartria e disfonia. Na avaliação audiológica apresentou configuração audiométrica descendente a partir da frequência de 4kHz e curva timpanométrica do tipo "A" com presença dos reflexos estapedianos bilateralmente. No exame vestibular observou-se na pesquisa da vertigem posicional presença de nistagmo vertical inferior e oblíquo, espontâneo e semiespontâneo múltiplo com características centrais (ausência de latência, paroxismo, fatigabilidade e vertigem, nistagmooptocinético abolido e hiporreflexia à prova calórica. Constataram-se alterações labirínticas que indicaram afecção do sistema vestibular central evidenciando-se a importância dessa avaliação. A existência da possível relação entre os achados com os sintomas vestibulares apresentados pela paciente apontou a relevância do exame labiríntico neste tipo de ataxia uma vez que a presença do nistagmo vertical inferior demonstrou ser frequente neste tipo de patologia.

  13. Alzheimer's and Dementia Testing for Earlier Diagnosis

    Science.gov (United States)

    ... for Earlier Diagnosis What if we could diagnose Alzheimer's before symptoms started? The hope is, future treatments ... diagnosis is among the most active areas in Alzheimer's science, and funding from the Alzheimer's Association has ...

  14. Alzheimer's or Depression: Could It Be Both?

    Science.gov (United States)

    Alzheimer's or depression: Could it be both? Alzheimer's and depression have some similar symptoms. Proper treatment improves quality of life. By Mayo Clinic Staff Early Alzheimer's disease and depression share many ...

  15. What Do We Know About Preventing Alzheimer's?

    Science.gov (United States)

    ... Signs of Alzheimer's Disease? / Preventing Alzheimer's Disease / Quiz: Alzheimer's Disease / Treatment Winter 2015 Issue: Volume 9 Number 4 Page 11 MedlinePlus | Subscribe | Magazine Information | Contact Us | Viewers & Players Friends of the National Library of Medicine (FNLM)

  16. Divergência genética entre genótipos de frangos tipo caipira

    Directory of Open Access Journals (Sweden)

    R. C. Veloso

    2015-10-01

    Full Text Available RESUMOObjetivou-se com este trabalho verificar a divergência genética entre sete genótipos de frangos tipo caipira da linhagem Redbro utilizando as características de desempenho por meio de técnicas de análise multivariada. Foram utilizados 840 pintos de um dia, machos, distribuídos em delineamento inteiramente ao acaso, dos seguintes genótipos: Caboclo, Carijó, Colorpak, Gigante Negro, Pesadão Vermelho, Pescoço Pelado e Tricolor. Após a consistência dos dados, foram avaliadas as seguintes variáveis: ganho em peso médio diário, consumo de ração médio diário e conversão alimentar, para os períodos: 1 a 28, 1 a 56, 1 a 70 e 1 a 84 dias de idade; peso corporal ao nascimento, aos 28, 56, 70 e aos 84 dias de idade. O desempenho dos genótipos foi avaliado por meio da análise de variância multivariada e da função discriminante linear de Fisher, usando os testes do maior autovalor de Roy e da união-interseção de Roy para as comparações múltiplas. O estudo da divergência genética foi feito por meio da análise por variáveis canônicas e pelo método de otimização de Tocher. Os genótipos Caboclo e Gigante Negro apresentaram médias canônicas diferentes dos demais genótipos. As duas primeiras variáveis canônicas explicaram 97,41% da variação entre os genótipos. A divergência genética entre os genótipos avaliados permitiu a formação de quatro grupos com os seguintes genótipos: grupo 1 - Colorpak; grupo 2 - Pesadão Vermelho e Pescoço Pelado; grupo 3 - Carijó e Tricolor; e grupo 4 - Caboclo e Gigante Negro.

  17. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... How Alzheimer's Changes the Brain National Institute On Aging Loading... Unsubscribe from National Institute On Aging? Cancel Unsubscribe Working... Subscribe Subscribed Unsubscribe 7K Loading... ...

  18. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... mail addresses with third parties. Please read our security and privacy policy . Plan ahead ... | Contact Us National Headquarters Alzheimer's Association National Office, 225 N. Michigan ...

  19. [Calcium hypothesis of Alzheimer disease].

    Science.gov (United States)

    Riazantseva, M A; Mozhaeva, G N; Kaznacheeva, E V

    2012-01-01

    Alzheimer's disease is the most common neurodegenerative disorder characterized by progressive memory and cognitive abilities loss. The etiology of Alzheimer's disease is poorly understood. In this regard, there is no effective treatment for the disease. Various hypotheses to explain the nature of the pathology of Alzheimer's disease led to the development of appropriate therapeutics. Despite of decades of research and clinical trials available therapeutics, at best, can only slow down the progression of the disease, but cannot cure it. This review dedicated to the one of modern hypotheses of Alzheimer's disease pathogenesis implied the impairment of calcium homeostasis as a key event for the development of neurodegenerative processes.

  20. O oraloma da diabetes melitos tipo 1 vs diabetes melitos tipo 2 - um estudo comparativo

    OpenAIRE

    Brás, Vítor Daniel Moreira

    2013-01-01

    A Diabetes Melitos é uma doença de grande prevalência a nível mundial e os seus mecanismos fisiopatológicos não são ainda totalmente conhecidos. Actualmente, a terapêutica seguida em casos de Diabetes Melitos é eminentemente sintomática consistindo na administração de insulina nos casos de Diabetes Melitos tipo 1 ou quando se verifica a falência das células beta do pâncreas de pacientes com Diabetes Melitos tipo 2, ou no controlo da glicemia nos casos de Diabetes Melitos ...

  1. Relación entre la memoria auditiva y el rendimiento neuropsicológico en pacientes de la tercera edad atendidos en el Centro Geriátrico y Gerontológico de la FAP

    OpenAIRE

    Infantes Portilla, Igor Edmundo Martín

    2017-01-01

    Determina la relación entre la memoria auditiva y el rendimiento neuropsicológico en pacientes de la tercera edad atendidos en el Centro Geriátrico y Gerontológico de la FAP. La investigación es de tipo correlacional, con diseño descriptivo correlacional. La muestra de estudio quedó constituida por 212 historias clínicas de pacientes adultos mayores que fueron evaluados y diagnosticados como pacientes sin alteración cognitiva y con demencia: tipo Alzheimer, vascular y mixta, entre los años 20...

  2. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... FightingAlzheimers 597,278 views 9:37 Reversing Alzheimer’s Disease- Dr. Dale Bredesen, MD - Duration: 1:13:27. Silicon ... 5:15 5 Signs You'll Get Alzheimer's Disease - Dr. Russell Blaylock Offers Crucial Advice. - Duration: 33:27. ...

  3. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... to prevent Alzheimer's | Lisa Genova - Duration: 13:57. TED 721,752 views 13:57 Alzheimer's Disease, How ... scans | Daniel Amen | TEDxOrangeCoast - Duration: 14:37. TEDx Talks 5,407,641 views 14:37 5 Signs ...

  4. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... Mortality Alzheimer's disease is the only top 10 cause of death in the United States that cannot be prevented, ... even slowed. Alzheimer's disease is the sixth-leading cause of death in the United States, and the fifth-leading ...

  5. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... get Alzheimer's disease were diagnosed in the mild cognitive impairment (MCI) stage — before dementia — it would collectively save $7 trillion to $7.9 trillion in health and long-term care costs. worried about memory loss? KNOW THE 10 SIGNS Alzheimer's Disease Facts ...

  6. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... ideas to treat and prevent the disease. Category Science & Technology License Standard YouTube License Show more Show ... 9:37. FightingAlzheimers 593,181 views 9:37 Kids Meet a Woman with Alzheimer's | Cut - Duration: 5: ...

  7. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... to treat and prevent the disease. Category Science & Technology License Standard YouTube License Show more Show less ... Mystery of Alzheimer's Disease - Duration: 4:22. Knoxville News Sentinel 34,722 views 4:22 Alzheimer's and ...

  8. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... Disease, How I Stopped and Reversed It - Duration: 9:37. FightingAlzheimers 593,181 views 9:37 Kids Meet a Woman with Alzheimer's | Cut - ... Oil: Ian Blair Hamilton and Cassie Bond - Duration: 9:57. AlkaWay 379,787 views 9:57 Tracking ...

  9. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... ideas to treat and prevent the disease. Category Science & Technology License Standard YouTube License Show more Show ... 1:36 Your Amazing Brain - Dementia Explained - Alzheimer's Research UK - Duration: 4:58. AlzheimersResearch UK 17,154 ...

  10. Asbestos exposure and Alzheimer disease

    Energy Technology Data Exchange (ETDEWEB)

    Bianchi, C; Bittesini, L; Brollo, A

    1986-02-01

    10 cases in which an asbestos-related disease (malignant pleural mesothelioma or asbestosis) was associated with severe Alzheimer type lesions in the brain are reported. The patients, all males aged between 67 and 78 years, had been occupationally exposed to asbestos in the shipbuilding industry. The hypothesis that asbestos is a favoring factor in the genesis of Alzheimer disease is discussed.

  11. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... suggested video will automatically play next. Up next What you can do to prevent Alzheimer's | Lisa Genova - Duration: 13:57. TED 759,201 views 13:57 The 7 Stages of Alzheimer's Disease Through a Caregiver's Eyes - Duration: 54:55. Toni Wombaker 966,865 ...

  12. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... and support I have Alzheimer's I am a caregiver I am a care professional I am a physician I am a researcher Message boards Get the facts 10 warning signs & symptoms What is dementia What is Alzheimer's 7 stages of ...

  13. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... ideas to treat and prevent the disease. Category Science & Technology License Standard YouTube License Show more Show ... 5:15 Your Amazing Brain - Dementia Explained - Alzheimer's Research UK - Duration: 4:58. AlzheimersResearch UK 16,695 ...

  14. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... are women. Older African-Americans are about twice as likely to have Alzheimer's or other dementias as older whites. Hispanics are about one and one-half times as likely to have Alzheimer's or other dementias as ...

  15. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... 702,464 views 13:57 2-Minute Neuroscience: Alzheimer's Disease - Duration: 2:01. Neuroscientifically Challenged 23,314 views 2:01 The 7 Stages of Alzheimer's Disease Through a Caregiver's Eyes - Duration: 54:55. Toni ...

  16. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... 342 views 2:01 Alzheimer's Disease, How I Stopped and Reversed It - Duration: 9:37. FightingAlzheimers 610, ... Old Man In Nursing Home Reacts To Hearing Music From His Era - Duration: 6:30. Mahmoud Abdul- ...

  17. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... health and long-term care costs. worried about memory loss? KNOW THE 10 SIGNS Alzheimer's Disease Facts ... is a not-for-profit 501(c)(3) organization. Copyright © 2018 Alzheimer's Association ® . All rights reserved. Our ...

  18. Inflammatory mechanisms in Alzheimer's disease

    NARCIS (Netherlands)

    Eikelenboom, P.; Zhan, S. S.; van Gool, W. A.; Allsop, D.

    1994-01-01

    Alzheimer's disease is aetiologically heterogeneous, but the pathogenesis is often considered to be initiated by the deposition of amyloid fibrils, followed by neuritic tau pathology and neuronal death. A variety of inflammatory proteins has been identified in the brains of patients with Alzheimer's

  19. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... The 7 Stages of Alzheimer's Disease Through a Caregiver's Eyes - Duration: 54:55. Toni Wombaker 965,067 ... 07 Day in the Life of an Alzheimer's Caregiver: Heartbreaking - Duration: 4:39. DavidNazarNews 35,452 views ...

  20. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... 632,620 views 13:57 2-Minute Neuroscience: Alzheimer's Disease - Duration: 2:01. Neuroscientifically Challenged 21,392 views 2:01 The 7 Stages of Alzheimer's Disease Through a Caregiver's Eyes - Duration: 54:55. Toni ...

  1. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... automatically play next. Up next 2-Minute Neuroscience: Alzheimer's Disease - Duration: 2:01. Neuroscientifically Challenged 22,187 views ... 130 views 13:57 The 7 Stages of Alzheimer's Disease Through a Caregiver's Eyes - Duration: 54:55. Toni ...

  2. Advancing frontiers in Alzheimer's disease research

    International Nuclear Information System (INIS)

    Glenner, G.G.; Wurtman, R.J.

    1987-01-01

    This book contain 16 chapters. Some of the titles are: Transmitter Alterations in Alzheimer's Disease: Relation to Cortical Dysfunction as Suggested by Positron Emission Tomography; Single-Photon Emission Computed Tomography in the Clinical Evaluation of Dementia; Clinical Diagnosis of Alzheimer's Disease; Down's Syndrome and Alzheimer's Disease: What is the Relationship; and Beta Protein: A Possible Marker for Alzheimer's Disease

  3. The biological substrates of Alzheimer's disease

    International Nuclear Information System (INIS)

    Scheibel, A.B.; Wechsler, A.F.; Brazier, M.A.B.

    1986-01-01

    This book contains 21 selections. Some of the titles are: Dementia of the Alzheimer Type: Genetic Aspects; Determination of Cerebral Metabolic Patterns in Dementia Using Positron Emission Tomography; Pathology of the Basal Forebrain in Alzheimer's Disease and Other Dementias; Characterization of Neurofibrillary Tangles with Monoclonal Antibodies Raised Against Alzheimer Neurofibrillary Tangles; and HLA Associations in Alzheimer's Disease

  4. Immunterapi mod Alzheimers sygdom

    DEFF Research Database (Denmark)

    Falkentoft, Alexander Christian; Hasselbalch, Steen Gregers

    2016-01-01

    Passive anti-beta-amyloid (Aß) immunotherapy has been shown to clear brain Aß deposits. Results from phase III clinical trials in mild-to-moderate Alzheimer's disease (AD) patients with two monoclonal antibodies bapineuzumab and solanezumab and intravenous immunoglobulin have been disappointing....... Subsequent analysis of pooled data from both phase III trials with solanezumab showed a reduction in cognitive decline in patients with mild AD. Solanezumab and new monoclonal antibodies are being tested in patients with prodromal and preclinical AD in search for a disease-modifying treatment....

  5. Diabetes tipo II e resolvinas D1

    OpenAIRE

    Silva, Isabel Alexandra Marques Batista da

    2015-01-01

    Dissertação para obtenção do grau de Mestre no Instituto Superior de Ciências da Saúde Egas Moniz A diabetes é um problema de saúde pública crescente com o envelhecimento da população, os maus hábitos alimentares e o sedentarismo. A obesidade poderá ser causa ou consequência da diabetes tipo II, sendo também um problema crescente de saúde pública. Esta monografia tem como objetivo estudar, com base no conhecimento atual, se as resolvinas D1 são uma alternativa viável na terapêutica da diab...

  6. 7 Warning Signs of Alzheimer's | Alzheimer's disease | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Alzheimer's Disease 7 Warning Signs of Alzheimer's Past Issues / Fall 2010 Table of Contents The ... Suncoast Gerontology Center, University of South Florida. How Alzheimer's Changes the Brain The only definite way to ...

  7. Quiz: Alzheimer's Disease Quiz | Alzheimer's disease | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Alzheimer's Disease Quiz: Alzheimer's Disease Quiz Past Issues / Fall 2010 Table of ... How many people in the United States have Alzheimer's disease? as many as 5.1 million as ...

  8. Estereótipos e mulheres na cultura marroquina

    OpenAIRE

    Sadiqi,Fatima

    2008-01-01

    Estereótipos sobre as mulheres no Marrocos podem ser caracterizados como crenças culturais incompletas e inexatas mantidas por algumas pessoas e que se encontram inscritos em expressões lingüísticas ou em discursos subliminares. A cultura popular marroquina emprega representações poderosas para transmitir e sustentar tais estereótipos. Embora existam alguns estereótipos positivos, a maioria dos estereótipos sobre as mulheres no Marrocos é negativa e reflete ditames patriarcais subliminares qu...

  9. leve a moderada

    Directory of Open Access Journals (Sweden)

    Luis Felipe Zapata

    2008-01-01

    Full Text Available La Demencia Tipo Alzheimer (DTA representa un 70% del total de demencias que afectan a las personas de edad avanzada. Es una enfermedad neurodegenerativa que ocasiona un significativo deterioro cognitivo en los pacientes e implica una incapacidad progresiva para el adecuado funcionamiento en la vida diaria. Los estudios han tenido como eje el deterioro cognitivo, principalmente los procesos de memoria que son los más dramáticos. Sólo en años recientes se ha empezado a investigar el deterioro que puede causar la enfermedad a otros niveles como en el reconocimiento de las expresiones faciales emocionales. El objetivo de la presente investigación es analizar el reconocimiento de la expresión facial emocional en pacientes con DTA frente a personas sanas y determinar si se presentan alteraciones en este tipo de reconocimiento en los pacientes con dicha demencia. PACIENTES Y MÉTODOS: se conformaron dos grupos. Uno de 22 pacientes con DTA leves y moderados y otro grupo de 22 personas sin demencia. Se aplicó el MMSE para el diagnóstico del grado de severidad de la demencia y la prueba de rostros Pofa Kit de Paul Ekman para la evaluación del reconocimiento de la expresión facial emocional. RESULTADOS: se encontraron diferencias significativas en el reconocimiento global entre el grupo control y el grupo de pacientes. La única emoción que permaneció reconocida fue la de felicidad aún en estados moderados de la enfermedad. La rabia y tristeza se vieron afectadas desde los estados leves y el reconocimiento de la expresión de miedo se alteró solo en los estados moderados de la enfermedad

  10. Economic considerations in the management of Alzheimer?s disease

    OpenAIRE

    Zhu, Carolyn W; Sano, Mary

    2006-01-01

    Alzheimer?s disease is a devastating chronic disease that significantly increases healthcare costs and affects the quality of life (QoL) of the afflicted patients and their caregivers. Population aging and other demographic changes may further increase the already staggering costs of this devastating disease. While few pharmacoeconomic studies have used a prospective health economics design to assess resource utilization, most studies showed beneficial treatment effects and suggested potentia...

  11. ESTUDIO DE MARCADORES BIOLOGICOS EN LA ENFERMEDAD DE ALZHEIMER

    Directory of Open Access Journals (Sweden)

    B. Calvo

    2006-02-01

    , siendo la causa mas frecuente de demencia en los paises occidentales. Su prevalencia va en aumento, debido al envejecimiento de la población. Por la edad de aparición la EA se puede clasificar en presenil ó de inicio temprano si aparece antes de los 60-65 años y senil o de inicio tardio si aparece después.En esta revisión se estudian los principales parámetros biológicos a utilizar en la enfermedad de Alzheimer e intentar diferenciarla de otras patologías degenerativas, ya que el diagnostico precoz de la EA es de gran importancia.El gen Apo E esta localizado en el cromosoma humano 19 y contiene 4 exones que codifica la apolipoproteina E de 299 aminoácidos. Las tres isoenzimas de la Apo E son la Apo E2, E3 y E4 y son productos de los tres alelos de cada locus génico. Tres fenotipos homozigoticos (apo E2/2, E3/3 y E4/4 y tres heterizigóticos (apo E3/2, E4/3 y E4/2 resultan de la expresión de cada uno de los tres alelos. La sustitución de los aminoácidos en los codones 112 y 158 conllevan a las diferencias entre apo E2, E3 y E4.Como la tau se trata de una proteína intracelular el nivel hallado en LCR es bajo. El desarrollo de una elevada afinidad por los anticuerpos monoclonales altamente específicos para la tau ha conducido al desarrollo de test para la detección de la tau en LCR y un número elevado de pacientes con Alhzeimer y controles han mostrado una elevada expresión de la tau en las células neuronales afectadas. Además los test basados en la determinación cuantitativa de la proteína tau en el LCR puede ser de gran ayuda en el diagnóstico de la EA.En la actualidad, el marcador en LCR que muestra mayor especificidad es fosfo-tau. No obstante la determinación conjunta de los tres marcadores tau, fosfo-tau y AB42 en LCR, aumenta la especificidad y sensibilidad respecto a su utilización individual.

  12. Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks

    Science.gov (United States)

    2017-05-11

    Alzheimer Disease, Early Onset; Alzheimer Disease; Alzheimer Disease, Late Onset; Dementia, Alzheimer Type; Logopenic Progressive Aphasia; Primary Progressive Aphasia; Visuospatial/Perceptual Abilities; Posterior Cortical Atrophy; Executive Dysfunction; Corticobasal Degeneration; Ideomotor Apraxia

  13. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... My Area | Alzheimer's & Dementia | Life with ALZ | Research | Professionals | We Can Help | Join the Cause alz.org >> ... I am a caregiver I am a care professional I am a physician I am a researcher ...

  14. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... Alzheimer's Live Well Taking Care of Yourself Reducing Stress Tips for Daily Life Helping Family and Friends ... Glossary Caregiver Health Be a Healthy Caregiver Caregiver Stress Caregiver Stress Check Caregiver Depression Changes to Your ...

  15. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... 2018 Alzheimer's Disease Facts and Figures report contains data on the impact of this disease in every ... with third parties. Please read our security and privacy policy . Plan ahead Get help and support I ...

  16. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... As the number of older Americans grows rapidly, so too will the numbers of new and existing ... caregivers who provide help to older adults do so for someone with Alzheimer's or another dementia. Who ...

  17. [Proceeding memory in Alzheimer's disease].

    Science.gov (United States)

    Arroyo-Anlló, Eva Ma; Chamorro-Sánchez, Jorge; Díaz-Marta, Juan Poveda; Gil, Roger

    2013-01-01

    Procedural learning can acquire or develop skills through performance and repetition of a task unconsciously or unintentionally. Procedural skills are considered as the cornerstone in the neuropsychological rehabilitation to promote the autonomy of patients with brain damage, as those with Alzheimer's disease. This review presents data about procedural skills in Alzheimer's disease. Over the past three decades, we have found 40 articles studying various procedural skills in the Alzheimer's disease: motor, perceptual-motor, cognitive, perceptual-cognitive and those developed through serial reaction-time paradigm. We analyzed every study evaluating a procedural skill, indicating the used task and preservation or no preservation of procedural learning. Overall, most of the papers published describe conservation of learning procedures or relatively conserved in Alzheimer's disease, which could be used to promote patient autonomy.

  18. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... Today, someone in the United States develops Alzheimer's every 65 seconds. By mid-century, someone in the United States will develop the disease every 33 seconds. GET INVOLVED. Join the cause Mortality ...

  19. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... 277 billion, including $186 billion in Medicare and Medicaid payments. Unless something is done, in 2050, Alzheimer's ... increases both in government spending under Medicare and Medicaid and in out-of-pocket spending. The costs ...

  20. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... dementias have twice as many hospital stays per year as other older people. Medicare beneficiaries with Alzheimer's ... and provide an accurate diagnosis earlier than at any other time in history. In addition to providing ...

  1. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... nursing home care. Take action. Become an advocate SPECIAL REPORT: FINANCIAL AND PERSONAL BENEFITS OF EARLY DIAGNOSIS ... across the nation. Click below to see the effect that Alzheimer's is having in your state. Read ...

  2. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... Argentina ADNI Amyloid Imaging Task Force Alzheimer’s Association Business Consortia (AABC) Biomarker Consortium GBSC Working Groups Global Alzheimer’s Association Interactive Network International Alzheimer's Disease Research ...

  3. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... Try it free Find out why Close How Alzheimer's Changes the Brain National Institute On Aging Loading... ... 23, 2017 This 4-minute video shows how Alzheimer’s affects the human brain and looks at promising ...

  4. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... three percent of the help provided to older adults in the United States comes from family members, ... of all caregivers who provide help to older adults do so for someone with Alzheimer's or another ...

  5. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... UK 17,154 views 4:58 2-Minute Neuroscience: Alzheimer's Disease - Duration: 2:01. Neuroscientifically Challenged 23, ... Language: English Location: United States Restricted Mode: Off History Help Loading... Loading... Loading... About Press Copyright Creators ...

  6. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... billion, including $186 billion in Medicare and Medicaid payments. Unless something is done, in 2050, Alzheimer's is ... people who receive adult day services and nursing home care. Take action. Become an advocate SPECIAL REPORT: FINANCIAL ...

  7. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... whites. Hispanics are about one and one-half times as likely to have Alzheimer's or other dementias ... an accurate diagnosis earlier than at any other time in history. In addition to providing significant medical, ...

  8. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... ALZHEIMER'S DISEASE IS THE 6TH LEADING CAUSE OF DEATH IN THE UNITED STATES. 16.1 MILLION AMERICANS ... AT OVER $323 BILLION. BETWEEN 2000 AND 2015 DEATHS FROM HEART DISEASE HAVE DECREASED 11% WHILE DEATHS ...

  9. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... Read past editions . Sign up for our e-newsletter Stay up-to-date on the latest news ... First name: Last name: *Email: *Zip: Weekly E-Newsletter Breaking Research Updates The Alzheimer's Association does not ...

  10. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... home care. Take action. Become an advocate SPECIAL REPORT: FINANCIAL AND PERSONAL BENEFITS OF EARLY DIAGNOSIS Early ... State The 2018 Alzheimer's Disease Facts and Figures report contains data on the impact of this disease ...

  11. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... search by state In My Area | Alzheimer's & Dementia | Life with ALZ | Research | Professionals | We Can Help | Join ... individuals to prepare legal, financial and end-of-life plans while they are still cognitively able to ...

  12. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... as many hospital stays per year as other older people. Medicare beneficiaries with Alzheimer's or other dementias are ... dementias make up a large proportion of all elderly people who receive adult day services and nursing ...

  13. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... disease is the only top 10 cause of death in the United States that cannot be prevented, ... Alzheimer's disease is the sixth-leading cause of death in the United States, and the fifth-leading ...

  14. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... Find out why Close How Alzheimer's Changes the Brain National Institute On Aging Loading... Unsubscribe from National ... minute video shows how Alzheimer’s affects the human brain and looks at promising ideas to treat and ...

  15. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... 323 BILLION. BETWEEN 2000 AND 2015 DEATHS FROM HEART DISEASE HAVE DECREASED 11% WHILE DEATHS FROM ALZHEIMER'S ... deaths from the number one cause of death (heart disease) decreased 11 percent. Among people age 70, ...

  16. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... Queue __count__/__total__ Find out why Close How Alzheimer's Changes the Brain National Institute On Aging Loading... ... 23, 2017 This 4-minute video shows how Alzheimer’s affects the human brain and looks at promising ...

  17. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... How Alzheimer's Changes the Brain National Institute On Aging Loading... Unsubscribe from National Institute On Aging? Cancel Unsubscribe Working... Subscribe Subscribed Unsubscribe 6.8K ...

  18. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... in the United States comes from family members, friends or other unpaid caregivers. Nearly half of all ... that they care not only for an aging parent, but also for children under age 18. Alzheimer's ...

  19. Alzheimer's: From Caring to Commitment

    Science.gov (United States)

    ... Current Issue Past Issues Home Current issue contents Alzheimer's: From Caring to Commitment From Caring to Commitment ... Caring to Commitment During her sister’s battle with Alzheimer’s, Anne Murphy stayed by her side and continues ...

  20. How Alzheimer's Changes the Brain

    Science.gov (United States)

    ... 3-months free Find out why Close How Alzheimer's Changes the Brain National Institute On Aging Loading... ... 23, 2017 This 4-minute video shows how Alzheimer’s affects the human brain and looks at promising ...

  1. How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... 3-months free Find out why Close How Alzheimer's Changes the Brain National Institute On Aging Loading... ... 23, 2017 This 4-minute video shows how Alzheimer’s affects the human brain and looks at promising ...

  2. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... Eighty-three percent of the help provided to older adults in the United States comes from family members, ... half of all caregivers who provide help to older adults do so for someone with Alzheimer's or another ...

  3. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... with third parties. Please read our security and privacy policy . Plan ahead Get help and support I ... About Us | News | Events | Press | About this Site | Privacy Policy | Copyrights & Reprints | Contact Us National Headquarters Alzheimer's ...

  4. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... Become an advocate SPECIAL REPORT: FINANCIAL AND PERSONAL BENEFITS OF EARLY DIAGNOSIS Early diagnosis of Alzheimer's provides a number of important benefits to diagnosed individuals, their caregivers and loved ones, ...

  5. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... as well as society as a whole. The development of biomarkers for Alzheimer's disease is making it ... I am a caregiver I am a care professional I am a physician I am a researcher ...

  6. Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available alz.org | Find Your Chapter 24/7 Helpline: 1.800.272.3900 Find your chapter: search by state In My Area | Alzheimer's & Dementia | Life with ALZ | Research | Professionals

  • Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... high. Invest in a world without Alzheimer's. Donate Caregivers Eighty-three percent of the help provided to ... comes from family members, friends or other unpaid caregivers. Nearly half of all caregivers who provide help ...

  • Alzheimer's Disease Facts and Figures

    Medline Plus

    Full Text Available ... with dementia indicate substantial emotional, financial and physical difficulties. Of the total lifetime cost of caring for ... up-to-date on the latest news and advances in Alzheimer's treatments, care and research. Get tips ...

  • How Alzheimer's Changes the Brain

    Medline Plus

    Full Text Available ... 5,433,357 views 14:37 After a year my dad remembered me! Alzheimer's, if you don' ... feedback! Yes No I'm not sure Language: English Location: United States Restricted Mode: Off History Help ...

  • Comprometimento medular por linfoma tipo Burkitt: relato de um caso

    Directory of Open Access Journals (Sweden)

    Murillo Côrtes Drummond

    1985-06-01

    Full Text Available Registro de caso de linfoma tipo Burkitt com comprometimento intrarraqueano em criança de três anos de idade. Considerações sobre esse tipo de tumor são feitas em função do caso observado e de dados da literatura.

  • Neurogenesis and Alzheimer's Disease

    Directory of Open Access Journals (Sweden)

    Philippe Taupin

    2006-01-01

    Full Text Available Alzheimer's disease (AD is a neurodegenerative disease, characterized in the brain by amyloid plaque deposits and neurofibrillary tangles. It is the most common form of dementia among older people. There is at present no cure for AD, and current treatments consist mainly in drug therapy. Potential therapies for AD involve gene and cellular therapy. The recent confirmation that neurogenesis occurs in the adult brain and neural stem cells (NSCs reside in the adult central nervous system (CNS provide new opportunities for cellular therapy in the CNS, particularly for AD, and to better understand brain physiopathology. Hence, researchers have aimed at characterizing neurogenesis in patients with AD. Studies show that neurogenesis is increased in these patients, and in animal models of AD. The effect of drugs used to treat AD on neurogenesis is currently being investigated, to identify whether neurogenesis contributes to their therapeutic activities.

  • The Danish Alzheimer intervention study

    DEFF Research Database (Denmark)

    Waldemar, G; Waldorff, F B; Buss, D V

    2011-01-01

    Background: There is a lack of appropriately designed trials investigating the efficacy of psychosocial interventions for patients with mild dementia and their family caregivers. This paper reports the rationale and design of the Danish Alzheimer Disease Intervention Study and baseline characteri......Background: There is a lack of appropriately designed trials investigating the efficacy of psychosocial interventions for patients with mild dementia and their family caregivers. This paper reports the rationale and design of the Danish Alzheimer Disease Intervention Study and baseline...

  • Unraveling Alzheimer?s: Making Sense of the Relationship between Diabetes and Alzheimer?s Disease 1

    OpenAIRE

    Schilling, Melissa A.

    2016-01-01

    Numerous studies have documented a strong association between diabetes and Alzheimer?s disease (AD). The nature of the relationship, however, has remained a puzzle, in part because of seemingly incongruent findings. For example, some studies have concluded that insulin deficiency is primarily at fault, suggesting that intranasal insulin or inhibiting the insulin-degrading enzyme (IDE) could be beneficial. Other research has concluded that hyperinsulinemia is to blame, which implies that intra...

  • Galantamine for Alzheimer's disease.

    Science.gov (United States)

    Olin, J; Schneider, L

    2001-01-01

    Galantamine (also called galanthamine, marketed as Reminyl (Janssen)) can be isolated from several plants, including daffodil bulbs, and now synthesized. Galantamine is a specific, competitive, and reversible acetylcholinesterase inhibitor. It is also an allosteric modulator at nicotinic cholinergic receptor sites potentiating cholinergic nicotinic neurotransmission. A small number of early studies showed mild cognitive and global benefits for patients with Alzheimer's disease, and recently several multicentre clinical trials have been published with positive findings. Galantamine has received regulatory approval in Sweden, is available in Austria, and awaits marketing approval in the United States, Europe, and other countries. The objective of this review is to assess the clinical effects of galantamine in patients with probable Alzheimer's disease, and to investigate potential moderators of an effect. The Cochrane Dementia Group specialized register of clinical trials was searched using the terms 'galantamine,' and 'galanthamine' (15 February 2000) as was the Cochrane Controlled Trials Register (2000, Issue 2). These terms were also used to search the following databases: EMBASE, MEDLINE, PsychLit; Combined Health Information Database, NRR (National Research Register), ADEAR (Alzheimer's Disease Education and Referral Centre clinical database, BIOMED (Biomedicine and Health), Glaxo-Wellcome Clinical Trials Register, National Institutes of Health Clinical Trials Databases, Current Controlled Trials, Dissertation Abstracts (mainly North American dissertations) 1961-1994, Index to UK Theses (British dissertations) 1970-1994. Published reviews were inspected for further sources. Additional information was collected from an unpublished investigational brochure for galantamine. Trials selected were randomized, double-blind, parallel-group, and unconfounded comparisons of galantamine with placebo for a treatment duration of greater than 4 weeks in people with Alzheimer

  • Lesao óssea em leucemias agudas linfoblásticas tipo T e TIPO nao T / nao B

    OpenAIRE

    Martins, Fernando Lopes

    2013-01-01

    Resumo: O AUTOR APRESENTA OS RESULTADOS DO ESTUDO RADIOLÓGICO DE ESQUELETO DE 61 PACIENTES PORTADORES DE LEUCEMIA AGUDA LINFOBLÁSTICA, CORRELACIONANDO A PRESENÇA OU NÃO DE Lesões ÓSSEAS COM A CLASSIFICAÇÃO IMUNOLÓGICA DE LAL TIPO T E TIPO não T / não B

  • Tipos especiales de niños

    Directory of Open Access Journals (Sweden)

    Mercedes Rodrigo Bellido

    1946-09-01

    Full Text Available En las tres últimas lecciones han sido expuestas algunas consideraciones referentes a niños y adolescentes desde el nacimiento hasta el dintel de la juventud. En todas ellas hemos procurado poner de relieve la necesidad de individualizar el conocimiento de cada niño para obtener mejores resultados en su adaptación a su futura vida de adultos, En todas ellas  nos hemos referido al llamado niño normal. Nos corresponde en la lección de hoy ocuparnos can la superficialidad característica de estas charlas tipo-muestrario, de otras categorías de niños muy dignos de interés.. quienes unas por exceso, otros por defecto, otros por dificultades de adaptación por diferentes causas, se desvían de la línea media de la normalidad. Consideramos que no está fuera del lugar, aquí, el tema de los niños excepcionales y por el contrario que es necesario intensificar el estudio de los trastornos de la vida mental y emocional de los niños en la preparación de los estudiantes de Medicina. Y no es nuestra solo esta opinión; no hace mucho tiempo en la Medical School de Ia Universidad de Minnessota hemos sabido que se ha hecho un intento de considerar y evaluar factores emocionales ambientales sobre las mismas bases que los descubrimientos fisiológicos.

  • Imagine stopping the progression of Alzheimer's

    Science.gov (United States)

    ... Issue Past Issues Imagine stopping the progression of Alzheimer's Past Issues / Fall 2006 Table of Contents For ... I have friends and loved ones suffering from Alzheimer's. But I can imagine… and hope for… a ...

  • Cuidando de idosos com Demência: um estudo a partir da prática ambulatorial de enfermagem Cuidando de ancianos con Demencia: pratica de enfermería en el ambulatorio Caring the elderly with Dementia: a study of the ambulatorial nursing practice

    Directory of Open Access Journals (Sweden)

    Rosimeire Ferreira Santana

    2005-02-01

    Full Text Available Investiga-se o cuidado realizado por cuidadores a idosos com demência, tendo como objetivos: Descrever as características de dezesseis idosos e seus cuidadores atendidos no ambulatório de neurogeriatria, do Rio de Janeiro, em 2004 ; Identificar diagnósticos de enfermagem e cuidados realizados por cuidadores, através de EDG, MEEM, AIVDs, AVDs aplicados na consulta de enfermagem. Aplicou-se o método quantitativo, descritivo, tipo estudo de caso, obtendo-se os resultados: No cliente - Desorientação, agressividade, pele seca, incontinência urinária, distúrbio no relacionamento familiar; No cuidador - Comunicação cuidador/ cliente ineficiente, desgaste físico, falta de conhecimento sobre cuidados; Cuidados realizados - alimentação, medicação e higiene. Conclui-se que são necessárias ações educativas de enfermagem visando à qualidade do cuidado ao idoso e seus familiares.Fue investigado la calidad del cuidado ejecutado por los cuidadores a los ancianos con demencia, teniendo como objetivos: - Describir el perfil de 16 ancianos y sus cuidadores acojidos en el ambulatorio de la neurogeriatria, del Rio de Janeiro, en el año 2004; Identificar diagnósticos de enfermería y cuidados ejecutados por los cuidadores, través de EDG, MEEM, AIVDs, AVDs que tuve aplicación en la consulta de enfermería. Fue aplicado el método de investigación de estudio de caso, obteniéndose los resultados: En el enfermo - Desorientación, agresividad, píele seca, disturbio urinario, disturbio en el reracionamiento familiar; En el cuidador - Comunicación cuidador/ enfermo ineficaz, desgaste, falta de conocimiento sobre cuidados; Cuidados ejecutados - alimentación, medicación y higiene. Se concluyó que son necesarias acciones educativas de enfermería con el objetivo de calificar el cuidado al anciano y sus familiares.The care provided by caregivers to elderly people with dementia is investigated having as objectives: to describe the

  • Calcium channel blockers and Alzheimer's disease★

    Science.gov (United States)

    Tan, Yi; Deng, Yulin; Qing, Hong

    2012-01-01

    Alzheimer's disease is characterized by two pathological hallmarks: amyloid plaques and neurofibrillary tangles. In addition, calcium homeostasis is disrupted in the course of human aging. Recent research shows that dense plaques can cause functional alteration of calcium signals in mice with Alzheimer's disease. Calcium channel blockers are effective therapeutics for treating Alzheimer's disease. This review provides an overview of the current research of calcium channel blockers involved in Alzheimer's disease therapy. PMID:25767489

  • Nuevo tipo de apoyos y articulaciones

    Directory of Open Access Journals (Sweden)

    Andrä, Fritz Leonhardt

    1963-11-01

    of theoretical and technical difficulties inherent in these bearings: they also express acknowledgement to German individuals and institutions, for their contribution to this investigation.Las tendencias actuales son funciones que dependen directamente de la presencia creciente y mejorada de los materiales de construcción que se ofrecen al comercio. En el campo de los materiales cabe una marcada subdivisión en naturales y preparados o sintéticos; estos últimos constituyen la preocupación de los autores para su aprovechamiento y adecuada aplicación. De entre ellos, las resinas sintéticas o caucho artificial, dentro de las distintas especies de la extensa familia han gozado de un lugar preferente en este estudio de nuevos tipos de apoyos que presentan los notables ingenieros alemanes Wolfhart Andrä y Fritz Leonhardt. En los ensayos de laboratorio y a escala natural, las variedades comerciales de estas resinas, conocidas con los nombres de «neopreno» y «Teflon», han sido elegidas por presentar, por lo menos actualmente, características marcadamente apropiadas a la finalidad perseguida en este estudio, del que se confía ulterior desarrollo y mejor acogida, por las importantes aplicaciones que de él se derivan en el campo de la ingeniería y construcción. Los autores estudian con detenimiento y sobrado rigor para las aplicaciones prácticas las deformaciones que de estos materiales se espera al someterlos a fuerzas de gran concentración. En los apoyos juega particular interés la distribución de la carga siempre concentrada en superficies relativamente pequeñas, lo que exige elevadas cargas unitarias y, con ello, la utilización de materiales extremadamente nobles para resistirlas con la resistencia que las deformaciones instantáneas requieren para recobrar rápidamente la posición de estabilidad perdida momentáneamente. La fatiga en el ciclo de deformaciones relaja los materiales, y ha de tenerse presente al considerar las características que los

    1. Alzheimer: sentidos, significados y cuidados desde una perspectiva transcultural Alzheimer: Significance, sense and care from a transcultural perspective

      Directory of Open Access Journals (Sweden)

      Mª Antonia Martorell-Poveda

      2010-09-01

      Full Text Available Objetivo principal: Explorar las vivencias, las representaciones y las prácticas sociales de los familiares de personas con Alzheimer en distintos contextos culturales. A la luz de tres casuísticas empíricas concretas, nuestro objetivo se centra en analizar cómo los cuidadores familiares identifican, denominan e interpretan el padecimiento y cómo establecen y desarrollan estrategias de cuidados. Con este fin, se comparan las experiencias de cuidadores familiares de la ciudad de Tarragona (España, de la Parroquia Santa Lucía, Municipio Maracaibo del Estado de Zulia (Venezuela y de Cuernavaca (México. Metodología: En base a una metodología cualitativa, centrada en el punto de vista del actor, los encuentros con los familiares cuidadores han permitido captar el sentido y el significado que adquiere para ellos la enfermedad y el cuidado circunscrito al ámbito doméstico. Como estrategias básicas para la recogida de información se utilizó la observación participante y la entrevista en profundidad. Además, para los casos de Tarragona y Cuernavaca, se realizaron sesiones de grupo focal. Resultados principales: Del análisis comparativo de los resultados se desprende un dominio de la influencia que el discurso biomédico hegemónico ejerce sobre los saberes de los familiares. Se han encontrado variados puntos de encuentro entre las vivencias, las representaciones y las prácticas sociales de los familiares de los tres contextos culturales, con escasos matices que nos permitan hablar de diferencias socioculturales en torno a las manifestaciones y percepciones sobre la demencia. Conclusión principal: Las similitudes encontradas nos hacen pensar en cómo se ha tendido a la globalización de un discurso sobre la que ha sido considerada "la epidemia del siglo XXI". La hegemonía del discurso biomédico influye en el hecho que los sentidos, los significados y los cuidados de cuidadores familiares de personas con Alzheimer en distintos

    2. Método de Montessori aplicado à demência: revisão da literatura Método Montessori aplicado a la demencia: revisión de la literatura Montessori Method applied to dementia: literature review

      Directory of Open Access Journals (Sweden)

      Daniela Filipa Soares Brandão

      2012-06-01

      Full Text Available O método de Montessori foi aplicado inicialmente às crianças, mas atualmente aplica-se a pessoas com demência. O objetivo deste trabalho é fazer uma revisão sistemática da investigação sobre a eficácia desse método, utilizando a Medical Literature Analysis and Retrieval System Online (Medline com as palavras-chave demência e método de Montessori. Foram selecionados 10 estudos, onde se verificam melhorias significativas na participação e no envolvimento construtivo e diminuição dos afectos negativos e do envolvimento passivo. Não obstante, as revisões da literatura acerca desta intervenção não farmacológica em demência classificam esse método como fraco, em termos de eficácia. Essa aparente discrepância pode explicar-se porque o método de Montessori pode ter, de fato, uma influência pouco significativa em dimensões como a dos problemas comportamentais ou porque não existe investigação acerca desse método com elevados níveis de controle como são a presença de vários grupos de controle ou o duplo-cego.El método Montessori se aplicó inicialmente a los niños, pero ahora se aplica a las personas con demencia. El propósito de este estudio es revisar de forma sistemática la investigación sobre la eficacia de este método, utilizando Medical Literature Analysis and Retrieval System Online (Medline con las palabras clave demencia y método Montessori. Se seleccionaron 10 estudios, que tienen mejoras significativas en la participación y en el compromiso constructivo, y la reducción de efectos negativos y de la participación pasiva. Sin embargo, la revisión de la literatura sobre esta intervención no farmacológica en la demencia clasifica este método como débil en términos de eficacia. Esta aparente discrepancia puede explicarse porque el método Montessori puede tener una influencia poco significativa en los problemas de conducta, o porque no hay investigación sobre este método con altos niveles de

    3. CT study in Alzheimer's disease

      Energy Technology Data Exchange (ETDEWEB)

      Arai, Heii; Kobayashi, Kazunari; Ikeda, Kenji; Nagao, Yoshiko; Ogihara, Ryuji; Kosaka, Kenji [Tokyo Metropolitan Matsuzawa Hospital (Japan)

      1983-01-01

      Cerebral atrophy on CT was studied in 18 patients with clinically diagnosed Alzheimer's disease and in 14 healthy age-matched subjects as the control. The patients with Alzheimer's disease were divided into three groups of Stages I, II and III, according to their clinical symptoms. The study of the measurement method disclosed that the computerized measurement involving calculation of the number of pixels contained within the range of the designated CT numbers is liable to produce errors for the determination of the subarachnoid spaces and the ventricles with calcified colloid plexus. Therefore, for the present study was the method adopted, in which the subarachnoid spaces and the ventricles are measured based on the number of pixels contained in the region of interest by tracing them on the display monitor. Then, both Subarachnoid Space Volume Index (SVI) and Ventricle Volume Index (VVI) were calculated as the indices for cortical atrophy and ventricular dilatation in a slice through the level of the foramen interventriculare Monroi and other three successive ones through upper regions. Cerebral atrophy observed on CT in Alzheimer patients is attributable to Alzheimer's disease processes, rather than to physiological aging of the brain. The degree of the atrophy increases in proportion to the clinical stage, and cortical atrophy is apparent even at Stage I, whereas ventricular dilatation becomes pronounced at later stage. CT is one of effective clinical tests for the diagnosis of Alzheimer's disease.

    4. Nutritional supplementation for Alzheimer's disease?

      Science.gov (United States)

      Shea, Thomas B; Remington, Ruth

      2015-03-01

      Evidence for the benefit of nutrition in Alzheimer's disease continues to accumulate. Many studies with individual vitamins or supplements show marginal, if any, benefit. However, new findings with combinatorial formulations demonstrate improvement in cognitive performance and behavioral difficulties that accompany Alzheimer's disease. Herein, we review some of the most recent clinical advances and summarize supportive preclinical studies. We present novel positive effects on Alzheimer's disease derived from diet, trace elements, vitamins and supplements. We discuss the inherent difficulty in conducting nutritional studies because of the variance in participants' nutritional history, versus pharmacological interventions in which participants are naive to the intervention. We examine the evidence that epigenetics play a role in Alzheimer's disease and how nutritional intervention can modify the key epigenetic events to maintain or improve cognitive performance. Overall consideration of the most recent collective evidence suggests that the optimal approach for Alzheimer's disease would seem to combine early, multicomponent nutritional approaches (a Mediterranean-style diet, multivitamins and key combinatorial supplements), along with lifestyle modifications such as social activity and mental and physical exercise, with ultimate addition of pharmacological agents when warranted.

    5. CT study in Alzheimer's disease

      International Nuclear Information System (INIS)

      Arai, Heii; Kobayashi, Kazunari; Ikeda, Kenji; Nagao, Yoshiko; Ogihara, Ryuji; Kosaka, Kenji

      1983-01-01

      Cerebral atrophy on CT was studied in 18 patients with clinically diagnosed Alzheimer's disease and in 14 healthy age-matched subjects as the control. The patients with Alzheimer's disease were divided into three groups of Stages I, Ii and III, according to their clinical symptoms. The study of the measurement method disclosed that the computerized measurement involving calculation of the number of pixels contained within the range of the designated CT numbers is liable to produce errors for the determination of the subarachnoid spaces and the ventricles with calcified colloid plexus. Therefor, for the present study was the method adopted, in which the subarachnoid spaces and the ventricles are measured based on the number of pixels contained in the region of interest by tracing them on the display monitor. Then, both Subarachnoid Space Volume Index (SVI) and Ventricle Volume Index (VVI) were calculated as the indices for cortical atrophy and ventricular dilatation in a slice through the level of the foramen interventriculare Monroi and other three successive ones through upper regions. Cerebral atrophy observed on CT in Alzheimer patients is attributable to Alzheimer's disease processes, rather than to physiological aging of the brain. The degree of the atrophy increases in proportion to the clinical stage, and cortical atrophy is apparent even at Stage I, whereas ventricular dilatation becomes pronounced at later stage. CT is one of effective clinical tests for the diagnosis of Alzheimer's disease. (J.P.N.)

    6. Insulin and Alzheimer disease: type 3 diabetes?

      Directory of Open Access Journals (Sweden)

      Andrés Jagua Gualdrón

      2007-01-01

      Full Text Available Alzheimer Disease is a neurodegenerative disease of central nervous system whose incidence will increase in next years. Recent investigations relate alzheimer with insulin signaling defects in neurons. Is alzheimer Disease a type 3 diabetes? In this communication write a brief article about evidences from this alzheimer‘s disease model.

    7. Alzheimer's disease: studies of diagnosis and therapy

      NARCIS (Netherlands)

      J.J. Claus (Jules Johan)

      1993-01-01

      textabstractDespite tremendous recent advances in the clinical neurology, neurobiology and epidemiology of Alzheimer's disease, the cause as well as its treatment remains as much a mystery today as when it was first described in 1907 by Alois Alzheimer.' Alzheimer's disease, the most common type

    8. Alzheimer disease and anesthesia.

      Science.gov (United States)

      Inan, Gözde; Özköse Satirlar, Zerrin

      2015-01-01

      Alzheimer disease (AD) is one of the most common neurodegenerative diseases and the most prevalent form of dementia. Some factors in the development of AD, age being the best-known one, have been suggested; however, no causes have been found yet. The pathophysiology of the disease is highly complex, current therapies are palliative, and a cure is still lacking. Adverse effects of anesthetics in the elderly have been reported since the 1950s; however, awareness of this old problem has recently gained inportance again. Whether exposure to surgery and general anesthesia (GA) is associated with the development of AD has been questioned. As the population is aging, many elderly patients will need to be anesthetized, and maybe some were already anesthetized before they were diagnosed. Exposure to anesthetics has been demonstrated to promote pathogenesis of AD in both in vitro and in vivo studies. However, to date, there have not been any clinical trials to address a link between exposure to GA and the development of AD in humans. Therefore, before making any conclusions we need further studies, but we should be aware of the potential risks and take cautions with vulnerable elderly patients.

    9. Alzheimer's disease and intelligence.

      Science.gov (United States)

      Yeo, R A; Arden, R; Jung, R E

      2011-06-01

      A significant body of evidence has accumulated suggesting that individual variation in intellectual ability, whether assessed directly by intelligence tests or indirectly through proxy measures, is related to risk of developing Alzheimer's disease (AD) in later life. Important questions remain unanswered, however, such as the specificity of risk for AD vs. other forms of dementia, and the specific links between premorbid intelligence and development of the neuropathology characteristic of AD. Lower premorbid intelligence has also emerged as a risk factor for greater mortality across myriad health and mental health diagnoses. Genetic covariance contributes importantly to these associations, and pleiotropic genetic effects may impact diverse organ systems through similar processes, including inefficient design and oxidative stress. Through such processes, the genetic underpinnings of intelligence, specifically, mutation load, may also increase the risk of developing AD. We discuss how specific neurobiologic features of relatively lower premorbid intelligence, including reduced metabolic efficiency, may facilitate the development of AD neuropathology. The cognitive reserve hypothesis, the most widely accepted account of the intelligence-AD association, is reviewed in the context of this larger literature.

    10. Serotonin 6 receptor controls alzheimer?s disease and depression

      OpenAIRE

      Yun, Hyung-Mun; Park, Kyung-Ran; Kim, Eun-Cheol; Kim, Sanghyeon; Hong, Jin Tae

      2015-01-01

      Alzheimer?s disease (AD) and depression in late life are one of the most severe health problems in the world disorders. Serotonin 6 receptor (5-HT6R) has caused much interest for potential roles in AD and depression. However, a causative role of perturbed 5-HT6R function between two diseases was poorly defined. In the present study, we found that a 5-HT6R antagonist, SB271036 rescued memory impairment by attenuating the generation of A? via the inhibition of ?-secretase activity and the inact...

    11. Actividad física y su relación con la incidencia de demencia y mortalidad en la cohorte NEDICES

      OpenAIRE

      Llamas Velasco, Sara

      2017-01-01

      La falta de actividad física es considerada uno de los principales factores de riesgo de las enfermedades no transmisibles, contribuyendo sustancialmente a la carga mundial de morbilidad, mortalidad y discapacidad. En este contexto la OMS ha realizado una serie de recomendaciones, siendo en el caso de los adultos mayores de 65 años recomendable dedicar al menos 150 minutos por semana a realizar actividades físicas moderadas aeróbicas, o bien algún tipo de actividad física vigorosa aeróbica du...

    12. EFEITOS DA CINESIOTERAPIA NOS DOENTES DE ALZHEIMER: ANÁLISE BIBLIOMÉTRICA

      Directory of Open Access Journals (Sweden)

      Geraedson Aristides da SILVA

      2015-12-01

      Full Text Available Etimologicamente a Cinesioterapia é definida como a arte de curar utilizando técnicas de movimentos. A mesma é empregada por fisioterapeutas com intuito de prevenir, manter e recuperar funções dos indivíduos antes que doenças alcancem um horizonte clínico irreversível. Objetivo: Revisar a literatura científica acerca da aplicabilidade de técnicas cinesioterapêuticas e seus respectivos efeitos da sobre pacientes portadores da doença de Alzheimer. Materiais e Métodos: Foi realizada pesquisa nas bases de dados LILACS, PuBmed e SciELO nas línguas portuguesa, inglesa e espanhola, sendo incluídos estudos a partir do ano de 1999. Como estratégia de busca utilizou-se as palavras: doença de Alzheimer, cinesioterapia e exercício físico, de forma combinada e isolada. Resultados: Dos 1.063 artigos encontrados foram selecionados apenas vinte um, ou seja, apenas aqueles que abordaram conceitos sobre a fisiopatologia do Alzheimer, que explicassem a cinesioterapia e o efeito deste tipo de terapêutica sobre a doença. Conclusão: Verifica-se a existência de uma lacuna sobre estudos que abordem a utilização da cinesioterapia de forma exclusiva no doente de Alzheimer.

    13. OTROS TIPOS ESPECÍFICOS DE DIABETES MELLITUS

      Directory of Open Access Journals (Sweden)

      DRA. M. Gabriela Sanzana G.

      2016-03-01

      En las “Diabetes Atípicas” (no incluidas en la clasificación ADA, se mencionan la DM tipo 2 en niños y adolescentes, favorecida por el aumento de la obesidad y del sedentarismo; la diabetes propensa a la cetosis, que debutan en cetoacidosis, con etiopatogenia y evolución de DM2; los Latent Autoinmune Diabetes of Adults (LADA, DM tipo 1 de lenta aparición y la diabetes postrasplante.

    14. Time trend in Alzheimer diagnoses and the association between distance to an Alzheimer clinic and Alzheimer diagnosis

      DEFF Research Database (Denmark)

      Jørgensen, Terese Sara Høj; Torp-Pedersen, Christian; Gislason, Gunnar H

      2015-01-01

      BACKGROUND: Centralization of specialized health care in Denmark has caused increased geographical distance to health-care providers, which may be a barrier for Alzheimer patients to seek health care. We examined the incidence of Alzheimer diagnosis in Denmark between 2000 and 2009 and investigated...... the association between patients' distance to Alzheimer clinics and Alzheimer diagnoses. METHODS: Data of all individuals aged 65+ years were collected from Danish national registers. Incidences of Alzheimer diagnoses were analysed with joinpoint regression and hazard ratios (HRs) for Alzheimer diagnoses were...... analysed with Cox regressions. RESULTS: The annual incidence of Alzheimer diagnoses increased with 32.5% [95% confidence interval (CI): 7.1-63.8] among individuals aged 65-74 years from 2000 to 2002 and with 29.1% (95% CI: 11.0-50.2) among individuals aged 75+ years from 2000 to 2003. For both groups...

    15. Pharmacologic management of Alzheimer disease.

      Science.gov (United States)

      Downey, Deborah

      2008-02-01

      Although the diagnosis of AD can be devastating, treatment options exist that can slow the disease's progression and allow patients to continue performing ADLs, thereby improving the quality of life for both patient and caregiver. Research is ongoing, and it is estimated by the Alzheimer's Association that finding a treatment that could delay onset by only 5 years could reduce the number of individuals with AD by nearly 50% over the next 50 years (Alzheimer's Association, 2007). Although pharmacotherapy is not yet a cure, it does remain an important part of a total approach to caring for patients and families affected by AD.

    16. beta. -Amyloid gene dosage in Alzheimer's disease

      Energy Technology Data Exchange (ETDEWEB)

      Murdoch, G H; Manuelidis, L; Kim, J H; Manuelidis, E E

      1988-01-11

      The 4-5 kd amyloid ..beta..-peptide is a major constituent of the characteristic amyloid plaque of Alzheimer's disease. It has been reported that some cases of sporatic Alzheimer's disease are associated with at least a partial duplication of chromosome 21 containing the gene corresponding to the 695 residue precursor of this peptide. To contribute to an understanding of the frequency to such a duplication event in the overall Alzheimer's population, the authors have determined the gene dosage of the ..beta..-amyloid gene in this collection of cases. All cases had a clinical diagnosis of Alzheimer's confirmed neuropathologically. Each Alzheimer's case had an apparent normal diploid ..beta..-amyloid gene dosage, while control Down's cases had the expected triploid dosage. Thus partial duplication of chromosome 21 may be a rare finding in Alzheimer's disease. Similar conclusions were just reported in several studies of the Harvard Alzheimer collection.

    17. Caracterización demográfica de cuidadores informales de ancianos con ictus y demencias en Santiago de Cuba / Demographic characterization of informal caretakers of ancient with ictus and dementias in Santiago de Cuba

      Directory of Open Access Journals (Sweden)

      Larissa Beatriz Turtós Carbonell

      2016-07-01

      Full Text Available La presente investigación se realizó para caracterizar demográficamente a una población de cuidadores informales de pacientes con ictus y demencia, e identificar la relación estadística entre características demográficas y patologías asociadas a la tarea de cuidador. Para ello se realizó un estudio descriptivo con 237 cuidadores. Se aplicó una Encuesta para obtener la información necesaria. El análisis de datos implicó estadística descriptiva y correlacional. El 71.7% de cuidadores fue mujer, el 28.3% hombre. La edad media es de 49.83 años, y el tiempo medio de dedicación a la tarea de 42.86 meses. El 49.4% de cuidadores son hijos o parejas del enfermo, el 50.6% tiene otros vínculos consanguíneos. El 53.2% es cuidador a tiempo completo, mientras 46.7% a tiempo parcial

    18. Atendiendo a las Variadas Problemáticas de los Cuidadores Familiares de Personas con Demencia: Aportaciones de la Terapia Cognitivo-Conductual y de la Terapia de Aceptación y Compromiso

      Directory of Open Access Journals (Sweden)

      Andrés Losada

      2015-01-01

      Full Text Available Cuidar a un familiar mayor con demencia se asocia con consecuencias emocionales negativas para los cuidadores. En este trabajo se describe una terapia cognitivo-conductual (TCC y otra de aceptación y compromiso (ACT que han sido diseñadas para reducir el malestar emocional de los cuidadores. El objetivo de la TTC es modificar creencias y pensamientos disfuncionales relacionados con el cuidado y entrenar a los cuidadores en el aumento de la frecuencia de actividades gratificantes. Incluye además entrenamiento en relajación y en habilidades para pedir ayuda. A través de la terapia ACT se trabaja la identificación del patrón personal de evitación experiencial y la alternativa de la aceptación de emociones, pensamientos y sensaciones, se ayuda al cuidador a identificar sus valores y las barreras para la acción coherente con ellos y se trabaja para incrementar la motivació del cuidador para comprometerse con sus valores y llevar a cabo acciones coherentes con dichos valores.

    19. How Alzheimer's Changes the Brain

      Medline Plus

      Full Text Available ... Sleep | Letting Go - Duration: 6:28:17. ZenLifeRelax 1,475,805 views 6:28:17 Alzheimer e a confusão na hora de dormir - Duration: 0:44. Meu caduquinho favorito 5,221 views 0: ...

    20. How Alzheimer's Changes the Brain

      Medline Plus

      Full Text Available ... ideas to treat and prevent the disease. Category Science & Technology License Standard YouTube License Show more Show ... 345,680 views 6:27 Kids Meet a Woman with Alzheimer's | Cut - Duration: 5:15. Cut 7, ...

    1. Alzheimer's Disease Facts and Figures

      Medline Plus

      Full Text Available ... caregivers are "sandwich generation" caregivers — meaning that they care not only for an aging parent, but also for children under age 18. Alzheimer's takes a devastating toll on caregivers. Compared with caregivers of people ... long-term care expenses or from the value of unpaid care. ...

    2. Alzheimer's Disease Facts and Figures

      Medline Plus

      Full Text Available ... Almost two-thirds of Americans with Alzheimer's are women. Older African-Americans are about twice as likely ... or older. Approximately two-thirds of caregivers are women; more specifically, over one-third of dementia caregivers ...

    3. How Alzheimer's Changes the Brain

      Medline Plus

      Full Text Available ... to treat and prevent the disease. Category Science & Technology License Standard YouTube License Show more Show less ... to a Cure: Combating Alzheimer's With New Compute Technology - Duration: 5:13. Great Big Story 455,862 ...

    4. Alzheimer's Disease Facts and Figures

      Medline Plus

      Full Text Available ... of all elderly people who receive adult day services and nursing home care. Take action. Become an advocate SPECIAL REPORT: FINANCIAL AND PERSONAL BENEFITS OF EARLY DIAGNOSIS Early diagnosis of Alzheimer's ... and long-term care costs. worried about memory ...

    5. How Alzheimer's Changes the Brain

      Medline Plus

      Full Text Available ... Wombaker 929,392 views 54:55 2-Minute Neuroscience: Alzheimer's Disease - Duration: 2:01. Neuroscientifically Challenged 21, ... disease - Duration: 41:57. The Florey Institute of Neuroscience and Mental Health 2,709 views 41:57 ...

    6. How Alzheimer's Changes the Brain

      Medline Plus

      Full Text Available ... 17. TEDx Talks 12,392 views 12:17 Alzheimer’s Is Not Normal Aging — And We Can Cure It | Samuel Cohen | TED Talks - Duration: 7:54. TED 286,506 views 7:54 Day in the Life of an Alzheimer's Caregiver: Heartbreaking - Duration: 4:39. DavidNazarNews 31,783 ...

    7. How Alzheimer's Changes the Brain

      Medline Plus

      Full Text Available ... 146 views 12:17 Alzheimer’s Is Not Normal Aging — And We Can Cure It | Samuel Cohen | TED Talks - Duration: 7:54. ... Alzheimer's Prevention Program: Keep Your Brain Healthy for the Rest of Your Life - Duration: 57: ...

    8. Genome instability in Alzheimer disease

      DEFF Research Database (Denmark)

      Hou, Yujun; Song, Hyundong; Croteau, Deborah L

      2017-01-01

      Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common form of dementia. Autosomal dominant, familial AD (fAD) is very rare and caused by mutations in amyloid precursor protein (APP), presenilin-1 (PSEN-1), and presenilin-2 (PSEN-2) genes. The pathogenesis...

    9. Head trauma and Alzheimer's disease

      NARCIS (Netherlands)

      Nandoe, Rishi D. S.; Scheltens, Philip; Eikelenboom, Piet

      2002-01-01

      The authors describe a case of a 55 year old woman who was diagnosed with Alzheimer's disease 1.5 years after a car accident in which she experienced a mild concussion. Extensive history taking disclosed no cognitive changes prior to the car accident. The case is discussed in view of the

    10. How Alzheimer's Changes the Brain

      Medline Plus

      Full Text Available ... to treat and prevent the disease. Category Science & Technology License Standard YouTube License Show more Show less ... Vsauce 4,618,939 views 15:02 Our story; Alzheimers' and Coconut Oil: Ian Blair Hamilton and ...

    11. How Alzheimer's Changes the Brain

      Medline Plus

      Full Text Available ... starting stop Loading... Watch Queue Queue __count__/__total__ It’s YouTube. Uninterrupted. Loading... Want music and videos with ... ads? Get YouTube Red. Working... Not now Try it free Find out why Close How Alzheimer's Changes ...

    12. How Alzheimer's Changes the Brain

      Medline Plus

      Full Text Available ... Disease - Duration: 42:07. All N One Home Health 102,543 views 42:07 Your Amazing Brain - ... Bredesen, MD - Duration: 1:13:27. Silicon Valley Health Institute 95,087 views 1:13:27 Alzheimer's ...

    13. Alzheimer's Disease Facts and Figures

      Medline Plus

      Full Text Available ... About one in three caregivers (34 percent) is age 65 or older. Approximately two-thirds of caregivers are women; more specifically, over one-third of dementia caregivers are daughters. Approximately one-quarter of ... under age 18. Alzheimer's takes a devastating toll on caregivers. ...

    14. Cerebral imaging revealing Alzheimer's disease

      International Nuclear Information System (INIS)

      2011-01-01

      Cerebral imaging is the only non-invasive means of examining the brain and is essential in studying Alzheimer's disease. As a tool for early diagnosis, evaluation and treatment monitoring, this technology is at the heart of the research being done to further improve its reliability and sensitivity. (authors)

    15. How Alzheimer's Changes the Brain

      Medline Plus

      Full Text Available ... ideas to treat and prevent the disease. Category Science & Technology License Standard YouTube License Show more Show less Loading... Autoplay When autoplay is enabled, a suggested video will automatically play next. Up next What you can do to prevent Alzheimer's | Lisa Genova - ...

    16. Galantamine for Alzheimer's disease.

      Science.gov (United States)

      Olin, J; Schneider, L

      2002-01-01

      Galantamine (also called galanthamine, marketed by Janssen as Reminyl) was originally isolated from several plants, including daffodil bulbs, but is now synthesized. Galantamine is a specific, competitive, and reversible acetylcholinesterase inhibitor. It is also an allosteric modulator at nicotinic cholinergic receptor sites potentiating cholinergic nicotinic neurotransmission. A small number of early studies showed mild cognitive and global benefits for patients with Alzheimer's disease (AD), and recently several multicentre clinical trials have been published with positive findings. Galantamine has received regulatory approval in 29 counties: Argentina, Australia, Canada, Czechia, the European Union (except for The Netherlands), Iceland, Korea, Mexico, Norway, Poland, Singapore, South Africa, Switzerland, Thailand, and the United States. The objective of this overview is to assess the clinical effects of galantamine in patients with probable AD, and to investigate potential moderators of an effect. The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 15 May 2002 using the terms galantamine and Reminyl. Published reviews were inspected for further sources. Additional information was collected from an unpublished investigational brochure for galantamine. Trials selected were randomized, double-blind, parallel-group, unconfounded comparisons of galantamine with placebo for a treatment duration of greater than 4 weeks for people with AD. Data were extracted independently by the reviewers and pooled where appropriate and possible. The pooled odds ratios (95%CI) or the average differences (95%CI) were estimated. Intention-to-treat and observed cases data were both reported, if the data were available. Outcomes of interest include the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), clinical global impression of change (CIBIC-plus or CGIC), Alzheimer's Disease Cooperative

    17. Método predictivo de volatilidad tipo cambio

      Directory of Open Access Journals (Sweden)

      Jeffrey Viales Abellán

      2011-01-01

      Full Text Available Las series temporales descritas por precios de ciertos activos financieros tales como el de las acciones y divisas presentan dos principales características, excesos de kurtosis y clustering de volatilidad. Para recoger estas características se han utilizado modelos no lineales tales como los modelos Garch o Volatilidad Condicionada y los modelos de Volatilidad Estocástica, ambos tipos de modelo son empleados para la gestión del riesgo cambiario a corto plazo; el primer tipo de modelos definen la volatilidad en función de la misma volatilidad rezagada y de los shocks (innovaciones de volatilidad; el segundo tipo de modelos son similares a los modelos Garch con la variante de que la volatilidad incluye por si misma un término aleatorio de tipo proceso Wienner2; estos modelos son empleados para simular caminatas aleatorias del tipo de cambio con volatilidades simuladas por las ecuación estocásticas de volatilidad.En el presente trabajo se analizará el desempeño del modelo Garch en comparación a las medidas de volatilidad utilizadas actualmente para la gestión del riesgo cambiario; sus implicaciones para la gestión de riesgos.

    18. Cognitive rehabilitation for elderly people with early-stage Alzheimer?s disease

      OpenAIRE

      Kim, Seyun

      2015-01-01

      [Purpose] The purpose of this study was to investigate the effect of cognitive rehabilitation including tasks of cognitive training on performance of everyday activities in elderly people with early-stage Alzheimer?s disease. [Subjects and Methods] Forty-three elderly people (15 men, 28 women) with a diagnosis of Alzheimer?s disease who had a Mini-Mental State Examination (MMSE) score of 18 or above were randomly assigned to two groups: the cognitive rehabilitation group (experimental) and co...

    19. La Planta única como tipo resistente a la escala

      OpenAIRE

      Colmenares Vilata, Silvia

      2014-01-01

      El sistema capitalista ha generado dos de los modelos espaciales de indiferencia funcional más extremos: por un lado, el espacio tecnificado y repetido del edificio de oficinas en altura, encarnado por la ?planta tipo? y, por otro, el espacio diáfano y extenso del gran contendor, que responde a la lógica de lo que llamaremos ?planta única?. En los edificios construidos para la industria automovilística y bélica americana se encuentra el germen de un tipo que servirá de modelo para los nuevos ...

    20. Efectos de inhibidores de colinesterasa en pacientes con enfermedad asociada a cuerpos de Lewy

      Directory of Open Access Journals (Sweden)

      Nilton Custodio

      2008-09-01

      Full Text Available Objetivos: Analizar los efectos de los inhibidores de colinesterasas (ICE donepezilo, rivastigmina y galantamina en el tratamiento de demencia con cuerpos de Lewy (DCL y demencia de la enfermedad de Parkinson (DEP. Diseño: Estudio tipo ensayo abierto. Lugar: Servicio de Neurología, Hospital Militar Central (HMC, y Unidad de Diagnóstico de Deterioro Cognitivo y Prevención de Demencia, Clínica Internacional. Participantes: Pacientes con demencia asociada a cuerpos de Lewy y demencia de la enfermedad de Parkinson. Intervenciones: Las mediciones de eficacia en 33 pacientes con diagnóstico de DCL y DEP se realizó con el Mini-Mental State Examination (MMSE, Alzheimer Disease Assessment Scale cognitive subscale (ADAS-cog, Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC, Alzheimer’s Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL, Neuro-Psychiatry Inventory (NPI, Prueba de dibujo de Reloj de Manos (PDR-M y la Unified Parkinson´s Disease Rating Scale-motor subscale (UPDRS-part III. Principales medidas de resultados: Síntomas cognitivos, funcionamiento global y actividades de vida diaria de los pacientes. Resultados: Diecisiete pacientes fueron tratados con rivastigmina, 9 con galantamina y 7 con donepezilo. Luego de 6 meses de tratamiento, los pacientes en tratamiento con rivastigmina mejoraron en 1,39 puntos en ADAS-cog respecto de su medición basal, mientras que los pacientes tratados con donepezilo y galantamina no mostraron cambios (cambios <0,2 puntos. Respecto al ADCS-ADL, los pacientes tratados con rivastigmina, donepezilo y galantamina demostraron disminución de 0,42, 0,58 y 0,75 puntos, respectivamente. En el MMSE, los pacientes tratados con rivastigmina y donepezilo no mostraron cambios y los pacientes tratados con galantamina tuvieron una disminución promedio de 1,19 puntos. No hubo diferencias significativas en la incidencia de síntomas parkinsonianos en los tres

    1. Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network.

      Science.gov (United States)

      Cummings, J; Aisen, P; Barton, R; Bork, J; Doody, R; Dwyer, J; Egan, J C; Feldman, H; Lappin, D; Truyen, L; Salloway, S; Sperling, R; Vradenburg, G

      2016-06-01

      Alzheimer's disease (AD) drug development is costly, time-consuming, and inefficient. Trial site functions, trial design, and patient recruitment for trials all require improvement. The Global Alzheimer Platform (GAP) was initiated in response to these challenges. Four GAP work streams evolved in the US to address different trial challenges: 1) registry-to-cohort web-based recruitment; 2) clinical trial site activation and site network construction (GAP-NET); 3) adaptive proof-of-concept clinical trial design; and 4) finance and fund raising. GAP-NET proposes to establish a standardized network of continuously funded trial sites that are highly qualified to perform trials (with established clinical, biomarker, imaging capability; certified raters; sophisticated management system. GAP-NET will conduct trials for academic and biopharma industry partners using standardized instrument versions and administration. Collaboration with the Innovative Medicines Initiative (IMI) European Prevention of Alzheimer's Disease (EPAD) program, the Canadian Consortium on Neurodegeneration in Aging (CCNA) and other similar international initiatives will allow conduct of global trials. GAP-NET aims to increase trial efficiency and quality, decrease trial redundancy, accelerate cohort development and trial recruitment, and decrease trial costs. The value proposition for sites includes stable funding and uniform training and trial execution; the value to trial sponsors is decreased trial costs, reduced time to execute trials, and enhanced data quality. The value for patients and society is the more rapid availability of new treatments for AD.

    2. Amyloid beta peptide immunotherapy in Alzheimer disease.

      Science.gov (United States)

      Delrieu, J; Ousset, P J; Voisin, T; Vellas, B

      2014-12-01

      Recent advances in the understanding of Alzheimer's disease pathogenesis have led to the development of numerous compounds that might modify the disease process. Amyloid β peptide represents an important molecular target for intervention in Alzheimer's disease. The main purpose of this work is to review immunotherapy studies in relation to the Alzheimer's disease. Several types of amyloid β peptide immunotherapy for Alzheimer's disease are under investigation, active immunization and passive administration with monoclonal antibodies directed against amyloid β peptide. Although immunotherapy approaches resulted in clearance of amyloid plaques in patients with Alzheimer's disease, this clearance did not show significant cognitive effect for the moment. Currently, several amyloid β peptide immunotherapy approaches are under investigation but also against tau pathology. Results from amyloid-based immunotherapy studies in clinical trials indicate that intervention appears to be more effective in early stages of amyloid accumulation in particular solanezumab with a potential impact at mild Alzheimer's disease, highlighting the importance of diagnosing Alzheimer's disease as early as possible and undertaking clinical trials at this stage. In both phase III solanezumab and bapineuzumab trials, PET imaging revealed that about a quarter of patients lacked fibrillar amyloid pathology at baseline, suggesting that they did not have Alzheimer's disease in the first place. So a new third phase 3 clinical trial for solanezumab, called Expedition 3, in patients with mild Alzheimer's disease and evidence of amyloid burden has been started. Thus, currently, amyloid intervention is realized at early stage of the Alzheimer's disease in clinical trials, at prodromal Alzheimer's disease, or at asymptomatic subjects or at risk to develop Alzheimer's disease and or at asymptomatic subjects with autosomal dominant mutation. Copyright © 2014 Elsevier Masson SAS. All rights reserved.

    3. Risk profiles of Alzheimer disease.

      Science.gov (United States)

      Bilbul, Melanie; Schipper, Hyman M

      2011-07-01

      Alzheimer disease (AD) is a dementing, neurodegenerative disorder that affects approximately 500,000 Canadians and its prevalence is expected to double over the next 30 years. Although several medications may temporarily augment cognitive abilities in AD, there presently exists no proven method to avoid the inevitable clinical deterioration in this devastating condition. The delineation of risk factors for the development of AD offers hope for the advent of effective prevention or interventions that might retard the onset of symptoms. In this article, we provide a comprehensive review of midlife risk factors implicated in the etiopathogenesis of sporadic AD. Although some risk factors are heritable and largely beyond our control, others are determined by lifestyle or environment and are potentially modifiable. In a companion paper, we introduce the concept of an Alzheimer Risk Assessment Clinic for ascertainment and mitigation of these and other putative dementia risk factors in middle-aged adults.

    4. Reação de resistência tipo I e tipo II a Giberela em cultivares de trigo

      Directory of Open Access Journals (Sweden)

      Rafael Hansen Alves

      2013-09-01

      Full Text Available O objetivo deste trabalho foi avaliar as reações de resistência tipo I e tipo II à giberela em 28 cultivares de trigo em casa de vegetação. A inoculação de Fusarium graminearum foi realizada no estádio de florescimento. Para a resistência tipo I, a avaliação foi feita 21 dias após a inoculação. Foi determinada a severidade no estádio de espiga seca e a porcentagem de grãos giberelados. A avaliação da severidade foi feita pela porcentagem de espiguetas infectadas, no estádio de espiga verde atribuindo-se uma nota em uma escala linear de zero (nenhuma infecção a 100 (100% de espiguetas infectadas. Para a resistência tipo II, as avaliações foram realizadas aos 7, 14 e 21 dias após a inoculação, contando-se as espiguetas com sintomas da doença, excluindo as duas espiguetas que foram inoculadas. As cultivares Frontana, BRS 177, BRS 179, BRS Umbu, BRS Camboim, Abalone, Ônix, Pampeano e Fundacep 30 apresentaram menor severidade da doença e menor porcentagem de grãos giberelados, demonstrando serem fontes de resistência tipo I. As cultivares BRS Guamirim, CD 120, Onix, Rubi, Fundacep 50, BRS 179, Pampeano, Abalone, CD 114, IPR 85, Safira, BRS Louro, CD 117, CDF 2002116, CD 115, BRS 177, CD 0529 e BRS Camboim apresentaram a menor área abaixo da curva de progresso da doença, demonstrando a presença da resistência do tipo II.

    5. Tipos de pasteurização e agentes coagulantes na fabricação do queijo tipo prato

      OpenAIRE

      Ramos, Thaís de Melo

      2013-01-01

      O presente trabalho foi realizado com os objetivos de avaliar a influência do tipo de pasteurização pelos sistemas de aquecimento indireto high temperature short time, ou HTST, e injeção direta de vapor (IDV), e avaliar a influência de duas diferentes enzimas coagulantes na fabricação do queijo tipo prato. O delineamento experimental utilizado neste experimento foi um fatorial 2 x 2 x 5 inteiramente casualizado, sendo dois sistemas de pasteurização (HTST e IDV), duas enzimas coagulantes e cin...

    6. Diabetes mellitus tipo 2 y osteoartritis primaria de rodilla

      Directory of Open Access Journals (Sweden)

      Rubén Daniel Arellano-Pérez Vertti

      2017-07-01

      Full Text Available Señor editor: Es nuestro interés dar a conocer los resultados del estudio sobre la asociación entre diabetes tipo 2 y osteoartritis primaria de rodilla en una población del norte de México.

    7. CARACTERIZAÇÃO PÓS-COLHEITA E SENSORIAL DE GENÓTIPOS DE BANANEIRAS TIPO PRATA

      Directory of Open Access Journals (Sweden)

      ARIANE CASTRICINI

      2015-03-01

      Full Text Available RESUMO O norte de Minas Gerais é grande produtor de banana ‘Prata-Anã’ irrigada, cultura altamente suscetível ao Mal-do-Panamá. O uso de genótipos resistentes é uma alternativa, mas os frutos devem apresentar características pós-colheita o mais próximo possível da ‘Prata-Anã’, para melhor aceitação pelos consumidores. O objetivo do trabalho foi caracterizar frutos em pós-colheita, identificar a preferência e a intenção de compra de diferentes genótipos de bananeira tipo Prata. Os genótipos Prata-Anã, BRS Platina e Fhia-18. foram caracterizados no ponto de colheita (verdes e maduros (estádio seis de maturação, por avaliações químicas, físicas e sensoriais. Quando verde, ‘BRS Platina’ apresentou maior massa fresca e tamanho que ‘Fhia-18’ e ‘Prata-Anã’. ‘Fhia-18.’ teve a tonalidade verde da casca mais intensa que a dos demais genótipos. Madura, ‘BRS Platina’ foi mais firme, mas com a mesma resistência ao despencamento que ‘Fhia-18’ e superior à ‘Prata-Anã’. ‘Fhia-18’ apresentou cor da casca com amarelo mais clara e tão brilhante quanto da ‘Prata-Anã’, mas ‘BRS Platina’ teve a tonalidade de amarelo mais intensa. Bananas ‘Fhia-18’ foram mais ácidas, ‘BRS Platina’, com menor acidez titulável, e ‘Prata-Anã’, o maior teor de sólidos solúveis. Os genótipos Prata-Anã e BRS Platina tiveram maior preferência e intenção de compra pelos consumidores, sendo as bananas ‘Prata-Anã’ em dedos e ‘BRS Platina’ e ‘Fhia-18’ em dedos, buquê e penca, as mais preferidas. Entretanto, a maioria compraria bananas ‘Prata-Anã’ em buquê e ‘BRS Platina’ e ‘Fhia-18’ em penca. Enquanto verdes, os genótipos foram semelhantes à ‘Prata-Anã’, e maiores diferenças químicas e físicas ocorreram quando maduros.

    8. Parâmetros de desempenho e carcaça de genótipos de frangos tipo caipira

      Directory of Open Access Journals (Sweden)

      R.C. Veloso

      2014-08-01

      Full Text Available Objetivou-se com este trabalho avaliar as características de desempenho e de carcaça de sete genótipos de frangos tipo caipira da linhagem Redbro. Foram utilizados 840 pintos de um dia, machos, distribuídos em delineamento inteiramente ao acaso, dos seguintes genótipos: Caboclo, Carijó, Colorpak, Gigante Negro, Pesadão Vermelho, Pescoço Pelado e Tricolor. Os frangos foram alojados em 28 boxes, sendo 30 frangos por boxe, em galpão de alvenaria com acesso a um piquete de 45m², em quatro repetições. As características de desempenho (conversão alimentar, ganho em peso médio diário, consumo de ração médio diário foram avaliadas nos períodos: um a 28, um a 56, um a 70 e um a 84 dias de idade. O peso corporal foi avaliado aos 28, 56, 70 e 84 dias de idade. As características de carcaça (peso e rendimento de carcaça, peito e pernas foram obtidas a partir do abate de dois frangos por boxe, aos 85 dias de idade. As análises estatísticas foram realizadas utilizando-se o "proc glm" do SAS. Verificou-se que, em todos os períodos, os frangos do genótipo Colorpak apresentaram maior peso corporal, consumo de ração médio diário, ganho em peso médio diário e melhor conversão alimentar. Entretanto, os genótipos Caboclo e Gigante Negro apresentaram menores consumo de ração médio diário, ganho de peso médio diário e pior conversão alimentar. Quanto ao rendimento de cortes, observou-se que os genótipos Caboclo e Gigante Negro apresentaram os menores valores, e o Carijó, Colorpak, Pesadão Vermelho, Pescoço Pelado e Tricolor obtiveram os melhores rendimentos de pernas. Para o rendimento de peito, o Carijó e o Pesadão Vermelho obtiveram os maiores valores. A escolha do genótipo deve ser feita de acordo com o interesse do mercado, pois há diferenças no desempenho e no rendimento de carcaça e dos cortes.

    9. Estrogen and early-onset Alzheimer's disease

      NARCIS (Netherlands)

      A.J.C. Slooter (Arjen); J.B. Bronzova (Juliana); A. Hofman (Albert); C. van Broeckhoven (Christine); C.M. van Duijn (Cornelia); J.C.M. Witteman (Jacqueline)

      1999-01-01

      textabstractEstrogen use may be protective for Alzheimer's disease with late onset. However, the effects on early onset Alzheimer's disease are unclear. This issue was studied in a population based setting. For each female patient, a female control was matched on age (within 5 years) and place of

    10. Harmonized diagnostic criteria for Alzheimer's disease

      DEFF Research Database (Denmark)

      Morris, J C; Blennow, K; Froelich, L

      2014-01-01

      BACKGROUND: Two major sets of criteria for the clinical diagnosis of Alzheimer's disease (AD) recently have been published, one from an International Working Group (IWG) and the other from working groups convened by the National Institute on Aging (NIA) and the Alzheimer's Association (AA...

    11. Gaps in Alzheimer's Knowledge among College Students

      Science.gov (United States)

      Eshbaugh, Elaine M.

      2014-01-01

      Despite the prevalence of the disease, it appears that there may be a need for increased education for formal and family caregivers of those with Alzheimer's disease and related dementias. Today's college students will be asked to fill both of these roles in the future. This study examined the level of knowledge of Alzheimer's disease among…

    12. Turning principles into practice in Alzheimer's disease

      NARCIS (Netherlands)

      Lindesay, J.; Bullock, R.; Daniels, H.; Emre, M.; Foerstl, H.; Froelich, L.; Gabryelewicz, T.; Martinez-Lage, P.; Monsch, A. U.; Tsolaki, M.; van Laar, T.

      P>The prevalence of dementia is reaching epidemic proportions globally, but there remain a number of issues that prevent people with dementia, their families and caregivers, from taking control of their condition. In 2008, Alzheimer's Disease International (ADI) launched a Global Alzheimer's Disease

    13. Fatty acids, lipid metabolism and Alzheimer pathology.

      NARCIS (Netherlands)

      Hooijmans, C.R.; Kiliaan, A.J.

      2008-01-01

      Alzheimer's disease is the most common form of dementia in the elderly. The cause of Alzheimer's disease is still unknown and there is no cure for the disease yet despite 100 years of extensive research. Cardiovascular risk factors such as high serum cholesterol, presence of the Apolipoprotein

    14. Recent developments in Alzheimer's disease therapeutics

      Directory of Open Access Journals (Sweden)

      Aisen Paul S

      2009-02-01

      Full Text Available Abstract Alzheimer's disease is a devastating neurological disorder that affects more than 37 million people worldwide. The economic burden of Alzheimer's disease is massive; in the United States alone, the estimated direct and indirect annual cost of patient care is at least $100 billion. Current FDA-approved drugs for Alzheimer's disease do not prevent or reverse the disease, and provide only modest symptomatic benefits. Driven by the clear unmet medical need and a growing understanding of the molecular pathophysiology of Alzheimer's disease, the number of agents in development has increased dramatically in recent years. Truly *disease-modifying' therapies that target the underlying mechanisms of Alzheimer's disease have now reached late stages of human clinical trials. Primary targets include beta-amyloid, whose presence and accumulation in the brain is thought to contribute to the development of Alzheimer's disease, and tau protein which, when hyperphosphorylated, results in the self-assembly of tangles of paired helical filaments also believed to be involved in the pathogenesis of Alzheimer's disease. In this review, we briefly discuss the current status of Alzheimer's disease therapies under study, as well the scientific context in which they have been developed.

    15. Validación de la prueba de dibujo del reloj - versión de Manos - como prueba de cribado para detectar demencia en una población adulta mayor de Lima, Perú Validation of the clock drawing test - Manos´ version - as a screening test for detection of dementia in older persons of Lima, Peru

      Directory of Open Access Journals (Sweden)

      Nilton Custodio

      2011-03-01

      Full Text Available Introducción. La prueba de dibujo del reloj versión de Manos (PDR-M es un instrumento de evaluación cognitiva breve para la detección de demencia. Objetivos. Evaluar la validez y confiabilidad de la PDR-M para discriminar entre pacientes con demencia y sujetos controles sanos. Materiales y métodos. Se evaluaron sujetos mayores de 65 años de edad, excluyendo los que presentaban enfermedades concomitantes graves y con dificultades auditivas o visuales. Se recogieron datos demográficos y se les realizó PDR-M y Mini Mental State Examination (MMSE. A los individuos del grupo de demencia se les realizó además evaluaciones clínicas, de laboratorio, neuropsicológicas y tomografía cerebral. Se calculó la sensibilidad y especificidad de la PDR-M así como el área bajo la curva ROC. Resultados. Se evaluó 210 individuos, 103 con diagnóstico confirmado de demencia y 107 controles sanos, con edad y sexo similares en ambos grupos; y mayor nivel educativo en el grupo control. Estableciendo un punto de corte de 7 se obtuvo una sensibilidad de 99,0% y una especificidad de 83,5%. Cuando se compararon las áreas bajo la curva ROC de la PDR-M y del MMSE no se encontraron diferencias significativas. Conclusiones. La PDR-M es un instrumento breve y confiable para la detección de demencia en la población urbana de Lima en el Perú.Introduction. The clock drawing test (PDR-M - Manos´ version - is a brief cognitive assessment tool for dementia detection. Objectives. To assess the validity and reliability of the PDR-M to discriminate between patients with dementia and healthy control subjects. Materials and methods. We evaluated subjects over 65 years of age, excluding those with severe concomitant diseases and those with hearing or visual impairment. We obtained demographic data and performed the PDR-M and Mini Mental State Examination (MMSE. Subjects of the dementia group were also submitted to clinical, laboratory and neuropsychological evaluations

    16. TREM2 Variants in Alzheimer's Disease

      Science.gov (United States)

      Guerreiro, Rita; Wojtas, Aleksandra; Bras, Jose; Carrasquillo, Minerva; Rogaeva, Ekaterina; Majounie, Elisa; Cruchaga, Carlos; Sassi, Celeste; Kauwe, John S.K.; Younkin, Steven; Hazrati, Lilinaz; Collinge, John; Pocock, Jennifer; Lashley, Tammaryn; Williams, Julie; Lambert, Jean-Charles; Amouyel, Philippe; Goate, Alison; Rademakers, Rosa; Morgan, Kevin; Powell, John; St. George-Hyslop, Peter; Singleton, Andrew; Hardy, John

      2013-01-01

      BACKGROUND Homozygous loss-of-function mutations in TREM2, encoding the triggering receptor expressed on myeloid cells 2 protein, have previously been associated with an autosomal recessive form of early-onset dementia. METHODS We used genome, exome, and Sanger sequencing to analyze the genetic variability in TREM2 in a series of 1092 patients with Alzheimer's disease and 1107 controls (the discovery set). We then performed a meta-analysis on imputed data for the TREM2 variant rs75932628 (predicted to cause a R47H substitution) from three genomewide association studies of Alzheimer's disease and tested for the association of the variant with disease. We genotyped the R47H variant in an additional 1887 cases and 4061 controls. We then assayed the expression of TREM2 across different regions of the human brain and identified genes that are differentially expressed in a mouse model of Alzheimer's disease and in control mice. RESULTS We found significantly more variants in exon 2 of TREM2 in patients with Alzheimer's disease than in controls in the discovery set (P = 0.02). There were 22 variant alleles in 1092 patients with Alzheimer's disease and 5 variant alleles in 1107 controls (P<0.001). The most commonly associated variant, rs75932628 (encoding R47H), showed highly significant association with Alzheimer's disease (P<0.001). Meta-analysis of rs75932628 genotypes imputed from genomewide association studies confirmed this association (P = 0.002), as did direct genotyping of an additional series of 1887 patients with Alzheimer's disease and 4061 controls (P<0.001). Trem2 expression differed between control mice and a mouse model of Alzheimer's disease. CONCLUSIONS Heterozygous rare variants in TREM2 are associated with a significant increase in the risk of Alzheimer's disease. (Funded by Alzheimer's Research UK and others.) PMID:23150934

    17. Microprobe PIXE analysis and EDX analysis on the brain of patients with Alzheimer`s disease

      Energy Technology Data Exchange (ETDEWEB)

      Yumoto, S. [Tokyo Univ. (Japan). Faculty of Medicine; Horino, Y.; Mokuno, Y.; Fujii, K.; Kakimi, S.; Mizutani, T.; Matsushima, H.; Ishikawa, A.

      1996-12-31

      To investigate the cause of Alzheimer`s disease (senile dementia of Alzheimer`s disease type), we examined aluminium (Al) in the brain (hippocampus) of patients with Alzheimer`s disease using heavy ion (5 MeV Si{sup 3+}) microprobe particle-induced X-ray emission (PIXE) analysis. Heavy ion microprobes (3 MeV Si{sup 2+}) have several times higher sensitivity for Al detection than 2 MeV proton microprobes. We also examined Al in the brain of these patients by energy dispersive X-ray spectroscopy (EDX). (1) Al was detected in the cell nuclei isolated from the brain of patients with Alzheimer`s disease using 5 MeV Si{sup 3+} microprobe PIXE analysis, and EDX analysis. (2) EDX analysis demonstrated high levels of Al in the nucleolus of nerve cells in frozen sections prepared from the brain of these patients. Our results support the theory that Alzheimer`s disease is caused by accumulation of Al in the nuclei of brain cells. (author)

    18. Riesgo de tipo de cambio: cobertura con instrumentos financieros

      OpenAIRE

      Gutiérrez Blanco, Vidal

      2017-01-01

      RESUMEN: En el siguiente trabajo se hace una pequeña aproximación al mercado de divisas, explicando qué es el tipo de cambio y cuál es el riesgo que conlleva operar con monedas de diferentes países. En primer lugar, se define el mercado de divisas, poniendo énfasis sobre el hecho de que es el mercado más grande y líquido del mundo, y se identifican cuáles son las principales operaciones llevadas a cabo en este mercado. Seguidamente, se ha explicado lo que es el tipo de cambio, cuáles son l...

    19. Self- Efficacy and Caregiver Strain in Alzheimer\\'s Caregivers

      Directory of Open Access Journals (Sweden)

      Farahnaz Mohamadi Shahbalaghi

      2006-10-01

      Full Text Available This study with a co relational design has conducted to determine relationship between caregiving strain and self-efficacy in family caregiver of patient with Alzheimer. Accessible sample of the study consisted of 81 family caregivers that all of them were member of Iranian Alzheimer Association. Data was gathered by demographic, self-efficacy and care giving strain questioners. Findings showed the most of the subjects were female (%60, spouse of care giving recipient (56%, married (64%, reside in same household (55%, 49% under high school education, 45% of them haven't taken formal courses about the care of the patients, 53% of them were satisfied about providing of care, 36% reported bad health status. The most important caring needs consisted education for better care providing. the Mean of self-efficacy was 66/96 (29-106 and strain 39/43 (17-65. There were not any relations between strain and self-efficacy with demographic variables. There was positive significant Pearson correlation (r=0/539, p=O/ 01 between self-efficacy and strain. Findings indicated that self-efficacy and care giving strain are subjective and individualized concepts. Care giving to elderly patients is a stressful event but moderate co-relationship shows that caregivers apprise the stress of care giving as a constructive and controllable manner.

    20. [Antibody therapy for Alzheimer's disease].

      Science.gov (United States)

      Tabira, Takeshi; Matsumoto, Shin-Ei; Jin, Haifeng

      2011-11-01

      In order to avoid Abeta-induced autoimmune encephalitis, several monoclonal and polyclonal antibodies are in clinical trials. These are bapineuzumab, solanezumab, ponezumab, gantenerumab, BAN2401, gammaguard and octagam. Since each antibody has a different antigen epitope of Abeta, anti-amyloid activities are different. It is unknown which antibody is effective for Alzheimer disease, and we must wait for the result of clinical trials. Some patients who developed tissue amyloid plaque immuno-reactive (TAPIR) antibody showed slower decline after AN-1792 vaccination. We developed TAPIR-like monoclonal antibody, which was found to react with Abeta oligomers preferentially.

    1. Mathematical model on Alzheimer's disease.

      Science.gov (United States)

      Hao, Wenrui; Friedman, Avner

      2016-11-18

      Alzheimer disease (AD) is a progressive neurodegenerative disease that destroys memory and cognitive skills. AD is characterized by the presence of two types of neuropathological hallmarks: extracellular plaques consisting of amyloid β-peptides and intracellular neurofibrillary tangles of hyperphosphorylated tau proteins. The disease affects 5 million people in the United States and 44 million world-wide. Currently there is no drug that can cure, stop or even slow the progression of the disease. If no cure is found, by 2050 the number of alzheimer's patients in the U.S. will reach 15 million and the cost of caring for them will exceed $ 1 trillion annually. The present paper develops a mathematical model of AD that includes neurons, astrocytes, microglias and peripheral macrophages, as well as amyloid β aggregation and hyperphosphorylated tau proteins. The model is represented by a system of partial differential equations. The model is used to simulate the effect of drugs that either failed in clinical trials, or are currently in clinical trials. Based on these simulations it is suggested that combined therapy with TNF- α inhibitor and anti amyloid β could yield significant efficacy in slowing the progression of AD.

    2. Concept Analysis: Alzheimer's Caregiver Stress.

      Science.gov (United States)

      Llanque, Sarah; Savage, Lynette; Rosenburg, Neal; Caserta, Michael

      2016-01-01

      The aim of this article was to analyze the concept of caregiver stress in the context of caring for a person with Alzheimer's disease and related dementias. Currently, there are more than 15 million unpaid caregivers for persons suffering from Alzheimer's disease and related dementias. This unpaid care can be stressful for caregivers due to the chronic nature of the disease process, as well as other factors. The paper incorporates the modified method of Wilson's concept analysis procedure to analyze the concept of caregiver stress. A review of the literature was undertaken using the Cumulative Index to Nursing and Allied Health Literature, Google Scholar, and PubMed. A theoretical definition of caregiver stress is provided, and the defining attributes, related concepts, antecedents, and consequences of caregiver stress are proposed, and case studies are presented. The analysis demonstrates that caregiver stress is the unequal exchange of assistance among people who stand in close relationship to one another, which results in emotional and physical stress on the caregiver. Implications for future nursing research and practice conclude the paper. © 2014 Wiley Periodicals, Inc.

    3. A IDENTIFICAÇÃO DE TIPOS DE LIDERANÇA A PARTIR DE ARQUÉTIPOS

      Directory of Open Access Journals (Sweden)

      Adriana Nunes Lacerda e Prestupa

      2009-09-01

      junguianos analisados por Moore e Gillette (1993 foram relacionados com características de líderes dentro do contexto organizacional. Desta forma foi possível apresentar uma tipologia rica e aplicável, onde o individuo pode se identificar e também entender o processo e a maturação das características dos arquétipos estudados para melhor desempenho dentro das organizações.

    4. Análisis estadístico exploratorio de dos tipos de secado de quinua

      OpenAIRE

      Mena Reinoso, Angel Patricio

      2015-01-01

      El presente trabajo “Análisis Estadístico Exploratorio de dos Tipos de Secado de Quinua” permite realizar una validación estadística del tipo de secador que posea una alta eficiencia, rendimiento en el secado de este tipo de cereal (Chenopodium quinoa Willd). Para el efecto se empleó el secador de bandejas y un secador solar tipo invernadero, el experimento se llevó a cabo con tres tipos de muestras, una con cascara y las otras escarificadas. La quinua fue sometida a un secado ...

    5. Fisher Center for Alzheimer's Research Foundation

      Science.gov (United States)

      ... Hear Kent Karosen, President and CEO of the Fisher Center, describe his new book and the power ... Signs of Alzheimer's Clinical Stages of Alzheimer’s About Fisher About Us Board of Trustees Financials Terms of ...

    6. Education and the risk for Alzheimers disease

      DEFF Research Database (Denmark)

      Letenneur, L; Launer, L J; Andersen, K

      2000-01-01

      The hypothesis that a low educational level increases the risk for Alzheimer's disease remains controversial. The authors studied the association of years of schooling with the risk for incident dementia and Alzheimer's disease by using pooled data from four European population-based follow......-up studies. Dementia cases were identified in a two-stage procedure that included a detailed diagnostic assessment of screen-positive subjects. Dementia and Alzheimer's disease were diagnosed by using international research criteria. Educational level was categorized by years of schooling as low (...), middle (8-11), or high (> or =12). Relative risks (95% confidence intervals) were estimated by using Poisson regression, adjusting for age, sex, study center, smoking status, and self-reported myocardial infarction and stroke. There were 493 (328) incident cases of dementia (Alzheimer's disease) and 28...

    7. 10 Early Signs and Symptoms of Alzheimer's

      Science.gov (United States)

      ... with Alzheimer's may start to remove themselves from hobbies, social activities, work projects or sports. They may ... team or remembering how to complete a favorite hobby. They may also avoid being social because of ...

    8. Alzheimer's disease: A review of recent developments

      African Journals Online (AJOL)

      2011-06-15

      Jun 15, 2011 ... Keywords:Advancing age, Alzheimer's disease, cognitive dysfunction, dementia, neuropsychological testing, primary ..... of associated behavioral and neurologic problems. ... whether to continue therapy with a particular drug.

    9. The Global Alzheimer's Association Interactive Network.

      Science.gov (United States)

      Toga, Arthur W; Neu, Scott C; Bhatt, Priya; Crawford, Karen L; Ashish, Naveen

      2016-01-01

      The Global Alzheimer's Association Interactive Network (GAAIN) is consolidating the efforts of independent Alzheimer's disease data repositories around the world with the goals of revealing more insights into the causes of Alzheimer's disease, improving treatments, and designing preventative measures that delay the onset of physical symptoms. We developed a system for federating these repositories that is reliant on the tenets that (1) its participants require incentives to join, (2) joining the network is not disruptive to existing repository systems, and (3) the data ownership rights of its members are protected. We are currently in various phases of recruitment with over 55 data repositories in North America, Europe, Asia, and Australia and can presently query >250,000 subjects using GAAIN's search interfaces. GAAIN's data sharing philosophy, which guided our architectural choices, is conducive to motivating membership in a voluntary data sharing network. Copyright © 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

    10. Synaptic changes in Alzheimer's disease in vivo

      International Nuclear Information System (INIS)

      Mueller-Gaertner, H.W.

      1994-01-01

      The article describes the current knowledge on biochemical changes in Alzheimer's disease. Following a summary on post mortem findings, results from positron emission tomography will be focused on. This synopsis shows that patients with Alzheimer's disease show very consistently changes in the cholinergic transmission. In addition to this, changes of the dopaminergic, noradrenergic and serotonergic system are observed. It is possible, that clinical, pathological and functional differences in Alzheimer's disease between different patients reflect variations of a single disease process. It is also thinkable, that there are subclassifications in Alzheimer's disease which are reflected in the above described biochemical abnormalities. In this case it is important in therapeutical terms to investigate these subtypes. (orig.) [de

    11. Caregiving for Alzheimer's Disease or Other Dementia

      Science.gov (United States)

      ... What's this? Submit Button Caregiving for Person with Alzheimer's Disease or a related Dementia Recommend on Facebook Tweet Share Compartir What is Alzheimer’s Disease? Alzheimer’s disease is the most common form ...

    12. Senile dementia of the Alzheimer type

      Energy Technology Data Exchange (ETDEWEB)

      Hutton, J.T.; Kenny, A.D.

      1985-01-01

      This book contains papers on Alzheimer's Disease. They are divided into several topics. The topic headings are: Clinical Evaluation, Management, and Treatment; Related Clinical Disorders; Epidemiology and Genetics; Basic Science; and National Perspectives and Future Directions.

    13. Síndrome de Waardenburg tipo I: relato de caso

      Directory of Open Access Journals (Sweden)

      Patricia Capua Vieira da Silva

      2011-06-01

      Full Text Available A síndrome de Waardenburg tipo I é uma desordem auditivo-pigmentária que inclui, entre outros, perda auditiva neurossensorial congênita não progressiva, telecanto, distúrbios pigmentares de íris, cabelo e pele. Indivíduos afetados podem ter maior risco de: defeitos no tubo neural, fendas labial e palatina, anormalidades nos membros e doença de Hirschsprung. O diagnóstico é clínico, sendo necessários dois critérios maiores ou um maior e dois menores. PAX3 é o único gene conhecido associado à síndrome, sendo, entretanto, mais usado no aconselhamento genético. Quanto ao diagnóstico diferencial, podemos citar: outras causas de perda auditiva neurossensorial congênita não progressiva, outros tipo de síndrome de Waardenburg, piebaldismo, albinismo, vitiligo e síndrome de Teitz. Neste trabalho, apresenta-se um paciente masculino de 11 anos com diagnóstico de síndrome de Waardenburg tipo I. Ressalta-se a importância do oftalmologista no auxílio do diagnóstico deste raro quadro sistêmico, uma vez que inclui algumas alterações oftalmológicas. O diagnóstico precoce da síndrome permite estimulação adequada para a perda auditiva, assim como medidas preventivas em caso de gestantes afetadas no aconselhamento genético.

    14. Tipos do Herbário Prisco Bezerra - EAC

      Directory of Open Access Journals (Sweden)

      Maria Stela Bezerra da Silva

      1990-01-01

      Full Text Available Com o presente trabalho pretende-se contribuir para a divulgação dos tipos do Herbário Prisco Bezerra - EAC. Um levantamento realizado no acervo do Herbário revelou o registro de dez tipos. Sete deles pertencentes à família Leguminosae distribuídas entre as subfamilias Caesalpinioideae: Peltogyne crenulata, Sentia dardanoi, Moldenhawera acuminata, Chamaecrista duckeana, Papilionoideae: Aeschynomene monteiroi, Cranocarpus gracilis e Mimosoideae: Mimosa niomarlei; dois, pertencentes à família Erythroxylaceae. As espécies Erythroxylum tianguanum e Erythroxylum bezerrae e um à família Euphorbiaceae: Dalechampia fernandesii recentemente descrita por G. Webster. Os tipos são apresentados na seqüência das indicações: nome das famílias, seguido do epíteto específico, habitat, com a transferência de todas as informações mencionadas na ficha de exsicata do material, bem como, a fotografia correspondente. Citam-se também alguns aspectos característicos das espécies, para melhor visualização dos detalhes fotográficos.The present paper repasts the type specimens in the Herbário Prisco Bezerra (University of Ceará. The Herbário has ten type, of which seven are Leguminosae: Peltoqyne crenulata, Senna dardanoi, Moldenhawera acuminata Chamaecrista duckeana, Aeschynomene monteiroi, Cranocarpus gracilis, Mimosa niomarlei, two the Erythroxylaceae: Erythroxylum tianquanum and Erythroxylum bezerrae and one Euphorbiaceae: Dalechampia fernandesii. Additional informations for these exsicata is presented.

    15. Estresse em mulheres com Diabetes mellitus tipo 2

      OpenAIRE

      Lessmann, Juliana Cristina; Silva, Denise Maria Guerreiro Vieira da; Nassar, Silvia Modesto

      2011-01-01

      OBJETIVO: O objetivo do estudo foi investigar a relação entre estresse e Diabetes Mellitus Tipo 2 em mulheres. MÉTODO: Estudo transversal prospectivo, desenvolvido com 147 mulheres, utilizando a Escala de Estresse Percebido (PSS). RESULTADOS: Houve associação entre as variáveis testadas, sendo possível inferir que as mulheres com estresse elevado são as que vivenciaram sofrimento e apresentam controle glicêmico alterado, ou seja, com valores superiores a 180 mg/dL. A maioria relatou sofriment...

    16. Diabetes tipo 2 y obesidad leve: tratamiento quirúrgico

      OpenAIRE

      Lanzaren S,Enrique

      2013-01-01

      Introducción: En la actualidad la diabetes mellitus tipo 2 (DM2) y la obesidad representan un serio problema de salud, comportándose como enfermedades epidémicas. Existe un gran interés en explorar distintas opciones de tratamiento de la DM2 en pacientes que no tienen obesidad mórbida. Objetivo: Reportar los parámetros de control glicémico en pacientes con DM2 y obesidad leve sometidos a bypass gástrico (BPG) a 3 años de seguimiento. Metodología: Estudio clínico prospectivo que incluye pacien...

    17. Tipos de Tiempo en el periodo de Semana Santa Vallisoletana.

      OpenAIRE

      Miranda Martín, Javier

      2017-01-01

      El propósito del proyecto es el análisis y la caracterización de ciertos tipos de tiempo a partir de los datos observados de la Base de Datos Climatológica del Observatorio de Valladolid. Los datos analizados corresponden a los ocho días de Semana Santa de un periodo de 37 años que comprenden entre los años 1981 y 2017. Grado en Geografía y Ordenación del Territorio

    18. Atrofia muscular espinal tipo 1: enfermedad de Werdnig-Hoffmann

      OpenAIRE

      Zárate-Aspiros, Romeo; Rosas-Sumano, Ana Beatriz; Paz-Pacheco, Alberto; Fenton-Navarro, Patricia; Chinas-López, Silvet; López-Ríos, José Antonio

      2013-01-01

      Introducción. Las atrofias musculares espinales de la infancia son enfermedades neuromusculares hereditarias, autosómicas, recesivas, caracterizadas por la degeneración de las neuronas motoras del asta anterior de la médula espinal. La atrofia muscular espinal tipo I (enfermedad de Werdnig-Hoffmann) es la forma más severa. Se inicia in útero o durante los primeros meses de vida. La muerte suele ocurrir antes de los dos años de edad. Caso clínico. Lactante de 6 meses de edad que ingresa al Ser...

    19. Fundamentos del Tipo de Cambio Real en Chile

      OpenAIRE

      Rodrigo Cerda; Alvaro Donoso; Aldo Lema

      2003-01-01

      Un modelo basado en la relación gasto-producto (efecto Salter-Swan) y los términos de intercambio, habría predicho un incremento más pronunciado del tipo de cambio real (TCR) en Chile durante la segunda mitad de los '80, una caída menos acentuada entre 1990 y 1997, y un aumento más fuerte a partir de 1998 cuando irrumpió la crisis financiera internacional. Este trabajo incorpora en forma exhaustiva otros factores en la determinación de largo plazo del TCR, tanto de oferta como de demanda. Usa...

    20. Propiedades y aplicaciones de piezocomposites tipo címbalo

      Directory of Open Access Journals (Sweden)

      Ochoa, P.

      2001-08-01

      Full Text Available The metal-ceramic composite actuators, moonies and cymbals consist in capped piezoceramic disks with metallic endcaps having cavities inside. These cavities favour the amplification of direct and reverse piezoelectric effects. These actuators fill the gap between high displacement low generative force bimorph actuators and low displacement high generative force multilayer ceramic actuators. The moonie actuator can give displacements greater than 100 mm, maximum generative force of 3N to several N´s, response time of 20 to 100 ms, and low fatigue test response for more than 107 cycles. Cymbals actuators shows twice as big as displacement than moonie for the studied size, much higher generative force and the possibility to avoid the temperature dependence of the displacement for selected materials. Properties of cymbal actuators can be tailored trough the selection of materials. Also, cymbal actuators can be tuned to adopt different resonance frequencies.

      Los composites metal-cerámica tipo luna y címbalo consisten en discos piezoeléctricos encapsulados con cápsulas metálicas que poseen una cavidad. Esta cavidad favorece la amplificación de los efectos piezoeléctricos directo e inverso. Estos actuadores llenan el escalón entre actuadores multicapa, con desplazamientos pequeños y fuerzas generativas elevadas, y actuadores bimorfos, con desplazamientos grandes y fuerzas generativas pequeñas. El actuador tipo luna alcanza desplazamientos de más de 100mm, fuerzas generativas máximas de hasta varios N´s, tiempos de respuesta desde 20 hasta 100ms, y baja respuesta en ensayos de fatiga a más de 107 ciclos. Los actuadores tipo címbalo muestran desplazamientos dos veces mayores que los obtenidos con actuadores tipo luna para el mismo tamaño, fuerzas generativas mucho mayores y la posibilidad de eliminar la dependencia del desplazamiento con la temperatura mediante selección de los materiales. Además poseen unas caracter

    1. The genetics of Alzheimer disease.

      Science.gov (United States)

      Tanzi, Rudolph E

      2012-10-01

      Family history is the second strongest risk factor for Alzheimer disease (AD) following advanced age. Twin and family studies indicate that genetic factors are estimated to play a role in at least 80% of AD cases. The inheritance of AD exhibits a dichotomous pattern. On one hand, rare mutations in APP, PSEN1, and PSEN2 virtually guarantee early-onset (<60 years) familial AD, which represents ∼5% of AD. On the other hand, common gene polymorphisms, such as the ε4 and ε2 variants of the APOE gene, can influence susceptibility for ∼50% of the common late-onset AD. These four genes account for 30%-50% of the inheritability of AD. Genome-wide association studies have recently led to the identification of 11 additional AD candidate genes. This paper reviews the past, present, and future attempts to elucidate the complex and heterogeneous genetic underpinnings of AD.

    2. Neuropathological Alterations in Alzheimer Disease

      Science.gov (United States)

      Serrano-Pozo, Alberto; Frosch, Matthew P.; Masliah, Eliezer; Hyman, Bradley T.

      2011-01-01

      The neuropathological hallmarks of Alzheimer disease (AD) include “positive” lesions such as amyloid plaques and cerebral amyloid angiopathy, neurofibrillary tangles, and glial responses, and “negative” lesions such as neuronal and synaptic loss. Despite their inherently cross-sectional nature, postmortem studies have enabled the staging of the progression of both amyloid and tangle pathologies, and, consequently, the development of diagnostic criteria that are now used worldwide. In addition, clinicopathological correlation studies have been crucial to generate hypotheses about the pathophysiology of the disease, by establishing that there is a continuum between “normal” aging and AD dementia, and that the amyloid plaque build-up occurs primarily before the onset of cognitive deficits, while neurofibrillary tangles, neuron loss, and particularly synaptic loss, parallel the progression of cognitive decline. Importantly, these cross-sectional neuropathological data have been largely validated by longitudinal in vivo studies using modern imaging biomarkers such as amyloid PET and volumetric MRI. PMID:22229116

    3. Brain Imaging in Alzheimer Disease

      Science.gov (United States)

      Johnson, Keith A.; Fox, Nick C.; Sperling, Reisa A.; Klunk, William E.

      2012-01-01

      Imaging has played a variety of roles in the study of Alzheimer disease (AD) over the past four decades. Initially, computed tomography (CT) and then magnetic resonance imaging (MRI) were used diagnostically to rule out other causes of dementia. More recently, a variety of imaging modalities including structural and functional MRI and positron emission tomography (PET) studies of cerebral metabolism with fluoro-deoxy-d-glucose (FDG) and amyloid tracers such as Pittsburgh Compound-B (PiB) have shown characteristic changes in the brains of patients with AD, and in prodromal and even presymptomatic states that can help rule-in the AD pathophysiological process. No one imaging modality can serve all purposes as each have unique strengths and weaknesses. These modalities and their particular utilities are discussed in this article. The challenge for the future will be to combine imaging biomarkers to most efficiently facilitate diagnosis, disease staging, and, most importantly, development of effective disease-modifying therapies. PMID:22474610

    4. [Alzheimer's disease: New therapeutic strategies].

      Science.gov (United States)

      Villegas, Sandra

      2015-07-20

      The rapid increase in prevalence rates of Alzheimer's disease means that treatments to prevent, stop or reverse this devastating disease are urgently needed. Despite advances in understanding its molecular pathology, there are no drugs that can halt its progression. This review takes a tour through phase 2, or higher studies, probing receptor agonist agents interfering with aggregation, inhibitors/modulators of secretases, lipid-lowering agents, and, finally and most extensively, immunotherapy. The fact that phase 3 studies with bapineuzumab and solaneuzumab have recently failed does not invalidate the potential of immunotherapy, as more information is available and new clinical trials are being initiated. Copyright © 2014 Elsevier España, S.L.U. All rights reserved.

    5. The genetics of Alzheimer's disease

      Directory of Open Access Journals (Sweden)

      Bagyinszky E

      2014-04-01

      Full Text Available Eva Bagyinszky,1 Young Chul Youn,2 Seong Soo A An,1,* SangYun Kim3,*1Department of BioNano Technology Gachon University, Gyeonggi-do, 2Department of Neurology, Chung-Ang University College of Medicine, Seoul, 3Department of Neurology, Seoul National University Budang Hospital, Gyeonggi-do, South Korea*These authors contributed equally to this workAbstract: Alzheimer's disease (AD is a complex and heterogeneous neurodegenerative disorder, classified as either early onset (under 65 years of age, or late onset (over 65 years of age. Three main genes are involved in early onset AD: amyloid precursor protein (APP, presenilin 1 (PSEN1, and presenilin 2 (PSEN2. The apolipoprotein E (APOE E4 allele has been found to be a main risk factor for late-onset Alzheimer's disease. Additionally, genome-wide association studies (GWASs have identified several genes that might be potential risk factors for AD, including clusterin (CLU, complement receptor 1 (CR1, phosphatidylinositol binding clathrin assembly protein (PICALM, and sortilin-related receptor (SORL1. Recent studies have discovered additional novel genes that might be involved in late-onset AD, such as triggering receptor expressed on myeloid cells 2 (TREM2 and cluster of differentiation 33 (CD33. Identification of new AD-related genes is important for better understanding of the pathomechanisms leading to neurodegeneration. Since the differential diagnoses of neurodegenerative disorders are difficult, especially in the early stages, genetic testing is essential for diagnostic processes. Next-generation sequencing studies have been successfully used for detecting mutations, monitoring the epigenetic changes, and analyzing transcriptomes. These studies may be a promising approach toward understanding the complete genetic mechanisms of diverse genetic disorders such as AD.Keywords: dementia, amyloid precursor protein, presenilin 1, presenilin 2, APOE, mutation, diagnosis, genetic testing

    6. Deconstructing Mitochondrial Dysfunction in Alzheimer Disease

      Directory of Open Access Journals (Sweden)

      Vega García-Escudero

      2013-01-01

      Full Text Available There is mounting evidence showing that mitochondrial damage plays an important role in Alzheimer disease. Increased oxygen species generation and deficient mitochondrial dynamic balance have been suggested to be the reason as well as the consequence of Alzheimer-related pathology. Mitochondrial damage has been related to amyloid-beta or tau pathology or to the presence of specific presenilin-1 mutations. The contribution of these factors to mitochondrial dysfunction is reviewed in this paper. Due to the relevance of mitochondrial alterations in Alzheimer disease, recent works have suggested the therapeutic potential of mitochondrial-targeted antioxidant. On the other hand, autophagy has been demonstrated to play a fundamental role in Alzheimer-related protein stress, and increasing data shows that this pathway is altered in the disease. Moreover, mitochondrial alterations have been related to an insufficient clearance of dysfunctional mitochondria by autophagy. Consequently, different approaches for the removal of damaged mitochondria or to decrease the related oxidative stress in Alzheimer disease have been described. To understand the role of mitochondrial function in Alzheimer disease it is necessary to generate human cellular models which involve living neurons. We have summarized the novel protocols for the generation of neurons by reprogramming or direct transdifferentiation, which offer useful tools to achieve this result.

    7. Periodontitis and Cognitive Decline in Alzheimer's Disease.

      Directory of Open Access Journals (Sweden)

      Mark Ide

      Full Text Available Periodontitis is common in the elderly and may become more common in Alzheimer's disease because of a reduced ability to take care of oral hygiene as the disease progresses. Elevated antibodies to periodontal bacteria are associated with an increased systemic pro-inflammatory state. Elsewhere raised serum pro-inflammatory cytokines have been associated with an increased rate of cognitive decline in Alzheimer's disease. We hypothesized that periodontitis would be associated with increased dementia severity and a more rapid cognitive decline in Alzheimer's disease. We aimed to determine if periodontitis in Alzheimer's disease is associated with both increased dementia severity and cognitive decline, and an increased systemic pro inflammatory state. In a six month observational cohort study 60 community dwelling participants with mild to moderate Alzheimer's Disease were cognitively assessed and a blood sample taken for systemic inflammatory markers. Dental health was assessed by a dental hygienist, blind to cognitive outcomes. All assessments were repeated at six months. The presence of periodontitis at baseline was not related to baseline cognitive state but was associated with a six fold increase in the rate of cognitive decline as assessed by the ADAS-cog over a six month follow up period. Periodontitis at baseline was associated with a relative increase in the pro-inflammatory state over the six month follow up period. Our data showed that periodontitis is associated with an increase in cognitive decline in Alzheimer's Disease, independent to baseline cognitive state, which may be mediated through effects on systemic inflammation.

    8. Active Vaccines for Alzheimer Disease Treatment.

      Science.gov (United States)

      Sterner, Rosalie M; Takahashi, Paul Y; Yu Ballard, Aimee C

      2016-09-01

      Vaccination against peptides specific to Alzheimer disease may generate an immune response that could help inhibit disease and symptom progression. PubMed and Scopus were searched for clinical trial articles, review articles, and preclinical studies relevant to the field of active Alzheimer disease vaccines and raw searches yielded articles ranging from 2016 to 1973. ClinicalTrials.gov was searched for active Alzheimer disease vaccine trials. Manual research and cross-referencing from reviews and original articles was performed. First generation Aβ42 phase 2a trial in patients with mild to moderate Alzheimer disease resulted in cases of meningoencephalitis in 6% of patients, so next generation vaccines are working to target more specific epitopes to induce a more controlled immune response. Difficulty in developing these vaccines resides in striking a balance between providing a vaccine that induces enough of an immune response to actually clear protein sustainably but not so much of a response that results in excess immune activation and possibly adverse effects such as meningoencephalitis. Although much work still needs to be done in the field to make this a practical possibility, the enticing allure of being able to treat or even prevent the extraordinarily impactful disease that is Alzheimer disease makes the idea of active vaccination for Alzheimer disease very appealing and something worth striving toward. Copyright © 2016 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

    9. Microsatellite D21D210 (GT-12) allele frequencies in sporadic Alzheimer`s disease

      Energy Technology Data Exchange (ETDEWEB)

      Lannfelt, L; Lilius, L; Viitanen, M; Winblad, B; Basun, H [Huddinge Hospital, Karolinska Institute, Dept. of Geriatric Medicine, (Sweden); Houlden, H; Rossor, M [St. Mary` s Hospital, Dept. of Neurology, Medical School, London (United Kingdom); Hardy, J [University of South Florida, Suncoast Alzheimer` s Disease Research Labs, Department of Psychiatry, Tampa (United States)

      1995-02-01

      Four disease-causing mutations have so far been described in the amyloid precursor protein gene on chromosome 21 in familial early-onset Alzheimer`s disease. Linkage analysis with a fourteen-allele microsatellite at D21S210 named GT-12 has proven useful in the elucidation of amyloid presursor protein gene involvement in Alzheimer`s disease families, as it is closely linked to the gene. Most cases of Alzheimer`s disease are thought to be sporadic and not familial. However, evidence from earlier studies suggests an important genetic contribution also in sporadic cases, where gene-environment interaction may contribute to the disease. We have determined frequencies of the GT-12 alleles in 78 Swedish and 49 British sporadic Alzheimer`s disease cases and 104 healthy elderly control subjects, to investigate if the disease associates with a particular genotype in GT-12. However, no differences in allele frequencies were observed between any of the groups. (au) (26 refs.).

    10. Diabetes mellitus tipo 2 y resistencia a la insulina

      Directory of Open Access Journals (Sweden)

      Enrique Cipriani-Thorne

      2010-07-01

      Full Text Available Se analizó la literatura de los últimos 15 años para poder objetivar los temas que son materia de esta comunicación. En primer lugar se analiza en qué consiste el llamado Síndrome Metabólico, sus características; a continuación se resume la historia natural de la Diabetes Mellitus tipo II y su patogenia. Se revisa la importancia de la resistencia a la insulina en el músculo estriado principal órgano de combustión de la glucosa y el factor mitocondrial de la resistencia a la insulina. Se analiza además la importancia de resistencia a la insulina con respecto al metabolismo del hígado y en particular a las alteraciones del metabolismo del colesterol y de los triglicéridos. Se hace un comentario extenso de cómo así la Diabetes Mellitus Tipo II es considerada en la actualidad como una enfermedad de origen inflamatorio y por último se discuten las consecuencias de la hiperinsulinemia, dado que el exceso de insulina es producido por el bloqueo en la línea metabólica de su acción más no en su línea de producir proliferación tisular.(Rev Med Hered 2010;21:160-170.

    11. Is MTHFR polymorphism a risk factor for Alzheimer's disease like APOE? Polimorfismo da MTHFR é um fator de risco para demência de Alzheimer como APOE?

      Directory of Open Access Journals (Sweden)

      Liana Lisboa Fernandez

      2005-03-01

      Full Text Available BACKGROUND: The role of methylenetetrahydrofolate reductase (MTHFR gene polymorphisms as risk factors for the occurence of Alzheimer's disease (AD is still controversial: OBJECTIVE: To verify the association between MTHFR and apolipoprotein E (APOE polymorphisms and Alzheimer's disease. METHOD: This work was conducted as a case-control study. Cases included thirty patients with probable AD. Controls were constituted by 29 individuals without dementia according to neuropsychological tests paired to age, sex, race and educational level. DNA was isolated from peripheral leukocytes of anticoagulated venous blood. Genotyping of APOE and MTHFR were performed by DNA amplification and digestion. The frequences of APOE and MTHFR genotypes were submitted by chi-square test corrected by Fisher test; the APOE genotypes, to chi-square linear tendency test and the frequences of MTHFR mutant and AD, by stratificated anlysis adjust by Mantel-Haenszel method. RESULTS: There was significant difference about APOE4 and APOE2 in the groups. (p=0.002 The odds ratio increased exponentially with the increased number of E4 allele (chi2 linear tendency test. No significant difference was detected on MTHFR genotypes in both case and control groups. CONCLUSION: The APOE4 is a risk factor and demonstrated a dose-depenent effect while APOE2 allele conferred a protection to AD. The MTHFR mutation had no correlation with AD.INTRODUÇÃO: O papel do polimorfismo do gene da metilenotetrahidrofolato redutase (MTHFR como um fator de risco para demência de Alzheimer (DA é controverso ainda. OBJETIVO: Verificar a associação entre os polimorfismos da MTHFR e apolipoproteína E (APOE e DA. MÉTODO: O trabalho foi conduzido como um estudo caso-controle. Trinta pacientes com DA provável foram incluídos no grupo caso. Vinte e nove indivíduos sem demência comprovadas por testes neuropsicológicos, emparelhados pela idade, sexo, cor e nível educacional constituíram o grupo

    12. FKBP immunophilins and Alzheimer's disease: A chaperoned affair

      Indian Academy of Sciences (India)

      2011-07-08

      Jul 8, 2011 ... FKBP immunophilins and Alzheimer's disease: A chaperoned affair. Weihuan Cao Mary ... Keywords. Alzheimer's disease; amyloid precursor protein; beta amyloid; FKBP; FK506; immunophilins; tau ... 43 | Issue 1. March 2018.

    13. Complement C4 phenotypes in dementia of the Alzheimer type

      NARCIS (Netherlands)

      Eikelenboom, P.; Goetz, J.; Pronk, J. C.; Hauptmann, G.

      1988-01-01

      Complement C4 phenotype distribution was studied in 64 patients with dementia of the Alzheimer type. In contrast to reported findings we failed to find a significant association between C4B2 gene frequency and Alzheimer's dementia

    14. Medical foods for Alzheimer's disease.

      Science.gov (United States)

      Shah, Raj C

      2011-06-01

      Alzheimer's disease (AD) is a neurodegenerative condition associated with cognitive loss, behavioural changes, functional ability decline and caregiver burden. Given the worldwide public health impact of AD, novel interventions to reduce suffering experienced by AD patients need to be developed. Foods may offer a mechanism for intervention complementary to drugs, devices, biologicals and vaccines. Apart from foods with health claims (including dietary supplements), medical foods are also being explored as an intervention option. The purpose of this article is to describe how medical foods may complement other interventions for AD patients by: (i) defining what a medical food is; (ii) discussing whether AD is a condition amenable to medical food intervention; (iii) reviewing current clinical trial data on medical foods used in participants with AD; and (iv) highlighting steps needed to establish a more comprehensive framework for developing medical foods for AD. While medical foods may be defined differently in other countries, the US Orphan Drug Act of 1998 defined a medical food as a food formulated for enteral intake, taken under physician supervision, and intended to meet the distinctive nutritional requirements identified for a disease or condition. For AD to be amenable to medical food intervention, it must: (i) result in limited or impaired capacity to ingest, digest, absorb or metabolize ordinary foodstuff or certain nutrients; or (ii) have unique, medically determined nutrient requirements; and (iii) require dietary management that cannot be achieved by modification of the normal diet alone. While these criteria are most likely met in advanced AD, identifying unique nutritional requirements in early AD that cannot be met by normal diet modification requires a better understanding of AD pathophysiology. A PubMed search using the terms 'medical food' and 'Alzheimer', limited to clinical trials published in English with human participants with AD aged >65

    15. Precision pharmacology for Alzheimer's disease.

      Science.gov (United States)

      Hampel, Harald; Vergallo, Andrea; Aguilar, Lisi Flores; Benda, Norbert; Broich, Karl; Cuello, A Claudio; Cummings, Jeffrey; Dubois, Bruno; Federoff, Howard J; Fiandaca, Massimo; Genthon, Remy; Haberkamp, Marion; Karran, Eric; Mapstone, Mark; Perry, George; Schneider, Lon S; Welikovitch, Lindsay A; Woodcock, Janet; Baldacci, Filippo; Lista, Simone

      2018-04-01

      The complex multifactorial nature of polygenic Alzheimer's disease (AD) presents significant challenges for drug development. AD pathophysiology is progressing in a non-linear dynamic fashion across multiple systems levels - from molecules to organ systems - and through adaptation, to compensation, and decompensation to systems failure. Adaptation and compensation maintain homeostasis: a dynamic equilibrium resulting from the dynamic non-linear interaction between genome, epigenome, and environment. An individual vulnerability to stressors exists on the basis of individual triggers, drivers, and thresholds accounting for the initiation and failure of adaptive and compensatory responses. Consequently, the distinct pattern of AD pathophysiology in space and time must be investigated on the basis of the individual biological makeup. This requires the implementation of systems biology and neurophysiology to facilitate Precision Medicine (PM) and Precision Pharmacology (PP). The regulation of several processes at multiple levels of complexity from gene expression to cellular cycle to tissue repair and system-wide network activation has different time delays (temporal scale) according to the affected systems (spatial scale). The initial failure might originate and occur at every level potentially affecting the whole dynamic interrelated systems within an organism. Unraveling the spatial and temporal dynamics of non-linear pathophysiological mechanisms across the continuum of hierarchical self-organized systems levels and from systems homeostasis to systems failure is key to understand AD. Measuring and, possibly, controlling space- and time-scaled adaptive and compensatory responses occurring during AD will represent a crucial step to achieve the capacity to substantially modify the disease course and progression at the best suitable timepoints, thus counteracting disrupting critical pathophysiological inputs. This approach will provide the conceptual basis for effective

    16. formales o categorías tipo interfase?

      Directory of Open Access Journals (Sweden)

      Julio Alfonso Piña López

      2011-01-01

      Full Text Available Se analiza la relación entre los fenómenos básicos y los fenómenos del desarrollo y la personalidad, en términos de si los primeros deberían concebirse como condición de existencia necesaria y suficiente de los segundos, y, a su vez, si los unos y los otros lo son de los últimos. Se concluye que dependiendo de cómo se plantee dicha relación, es que eventualmente tendrá sentido la construcción de teorías formales sobre el desarrollo y la personalidad, o bien caracterizar ambos fenómenos como categorías tipo interfase con fines de predicción.

    17. Terapêutica da diabetes mellitus tipo 1

      OpenAIRE

      Antunes, Ana Luisa Lopes

      2009-01-01

      Introdução: Diabetes Mellitus (DM) é uma doença metabólica de etiologia múltipla caracterizada por hiperglicemia crónica com distúrbios no metabolismo dos hidratos de carbono, lípidos e proteínas, por deficiências na secreção e/ou acção da insulina. A descoberta da insulina em 1921, foi um grande marco na sua terapêutica, aumentando a esperança e qualidade de vida dos doentes, nomeadamente na DM tipo 1. Tornou-se um fármaco salvador de vidas (life saving). A primeira a ser comercializad...

    18. Tipo abstracto de datos "Biblioteca" Library Abstract data type

      Directory of Open Access Journals (Sweden)

      Silvana Temesio Vizoso

      2010-12-01

      Full Text Available Análisis de la descripción bibliográfica desde un punto de vista conceptual a partir de la especificación formal: tipo abstracto de datos "biblioteca". Se detallan otros abordajes usando el modelo entidad-relación y el lenguaje XML. Se concluye la relevancia del enfoque abstracto y su aplicabilidad genérica en un sujeto de cambio permanente.Analysis of bibliographic description from a conceptual point of view from the formal specification: "library" abstract data type. Other approaches are detailed using the entity-relationship model and XML language. We conclude the relevance of abstract approach and its general applicability in a subject of constant change.

    19. Tipos de socialización y desesperanza aprendida

      Directory of Open Access Journals (Sweden)

      Sandro Macassi

      1988-12-01

      Full Text Available Las nociones de alienación, falta de poder y desesperanza aprendida son revisadas. Sesenta obreros de una empresa limeña fueron evaluados en términos del tipo de socialización dominante (SD y desesperanza aprendida (DA en sus tres áreas: falta de motivación, falta de control y expectativas de no-control en el futuro. Las escalas SD y DA resultaron consistentes. El análisis de regresión múltiple con las variables grado de división del trabajo, el grado de instrucción y –en migrantes- edad de arribo y permanencia en la capital, evidenció que el único predictor de DA es el grado de instrucción, correlacionándose negativamente. Los resultados se discuten a la luz de la realidad peruana.

    20. Uso de la metformina en la diabetes mellitus tipo II

      Directory of Open Access Journals (Sweden)

      Yohana Salazar ÁLvarez

      2011-03-01

      Full Text Available Metformina es una biguanida eficaz en el control metabólico de la diabetes mellitus tipo II, no insulinodependiente cuando el control dietético falla. Dada su probada eficacia y actual accesibilidad en el mercado de medicamentos en Cuba, para ser utilizada a nivel primario de atención no solo en pacientes sintomáticos sino en la población en riesgo, se presenta este artículo cuyo propósito es actualizar a los especialistas de Medicina General Integral y Medicina Interna acerca de aspectos de interés relacionados con este medicamento, como: interacciones medicamentosas, enfermedades concomitantes, la biotransformación de la droga y los posibles efectos adversos que se pueden asociar a su uso. Se presentan consideraciones finales acerca del uso de esta droga.

    1. Compatibilidad sexual entre dos tipos de Hylocerus (Cactaceae

      Directory of Open Access Journals (Sweden)

      Roberta Castillo M

      2003-09-01

      Full Text Available Dos de los tipos de pitahaya mas cultivados en la Península de Yucatán, México, difieren principalmente por el color de su cáscara, el primero es de color rojo (Uqroo1, perteneciente a Hylocereus undatus, mientras que en el segundo es color amarillo claro (Uqroo2, hasta el momento también identificado como H. undatus; este último es mas dulce. En ambos tipos de pitahayas, se realizaron autopolinizaciones y polinizaciones cruzadas directas y recíprocas, con el propósito de evaluar el efecto en la cantidad de frutos que lograron su desarrollo. Se midieron algunas variables para detectar la influencia del progenitor paterno en algunas características del fruto. Los testigos se obtuvieron de flores polinizadas libremente. El diseño experimental utilizado fue completamente al azar, con 15 repeticiones por tratamiento. Se encontró que Uqroo1 es autocompatible, mientras que Uqroo2 es autoincompatible. Los testigos de ambos tipos alcanzaron el mismo peso, y los frutos de Uqroo2 logrados por polinización cruzada tuvieron un peso similar al de los testigos o fueron significativamente mas pesados. Algunas variables resultaron positivamente correlacionados; el coeficiente entre el número de semillas y el peso total del fruto fue de r = 0.84. La correlación mas alta (r = 0.97 resultó entre el peso total y el peso de la pulpa. En los frutos obtenidos por polinización cruzada prevalecieron las características del progenitor materno. Se recomienda cultivar la Pitahaya blanca con otro tipo de pitahaya, además de Uqroo1There are two types of pitahaya that are cultivated in Yucatan Peninsula of Mexico. They differ mainly in the skin color of the fruit, one of them has a red skin (Uqroo1, while the other has a light yellow skin (Uqroo2 both belong to Hylocereus undatus (Haworth Britt. & Rose. The yellow skin pitahaya is the sweetest. The studies were conducted using the methods of self pollination and cross pollination, with direct crosses and

    2. [Anesthesia and Alzheimer disease - Current perceptions].

      Science.gov (United States)

      Marques, Ana Filipa Vieira da Silva Ferreira; Lapa, Teresa Alexandra Santos Carvalho

      It has been speculated that the use of anesthetic agents may be a risk factor for the development of Alzheimer disease. The objective of this review is to describe and discuss pre-clinical and clinical data related to anesthesia and this disease. Alzheimer disease affects about 5% of the population over 65 years old, with age being the main risk factor and being associated with a high morbidity. Current evidence questions a possible association between anesthesia, surgery, and long-term cognitive effects, including Alzheimer disease. Although data from some animal studies suggest an association between anesthesia and neurotoxicity, this link remains inconclusive in humans. We performed a review of the literature in which we selected scientific articles in the PubMed database, published between 2005 and 2016 (one article from 1998 due to its historical relevance), in English, which address the possible relationship between anesthesia and Alzheimer disease. 49 articles were selected. The possible relationship between anesthetic agents, cognitive dysfunction, and Alzheimer disease remains to be clarified. Prospective cohort studies or randomized clinical trials for a better understanding of this association will be required. Copyright © 2017 Sociedade Brasileira de Anestesiologia. Publicado por Elsevier Editora Ltda. All rights reserved.

    3. Scintigraphic appearance of Alzheimer diesase

      International Nuclear Information System (INIS)

      Holman, B.L.; Johnson, K.A.

      1991-01-01

      Alzheimer disease (AD) is a devastating affliction of the elderly that has reached epidemic proportions. It produces regional abnormalities of brain blood flow and metabolism that may have diagnostic utility. In this paper the author determine the predictive value of Tc-99m HMPAO SPECT for detecting AD based on the prospective study of 132 consecutive patients coming to their nuclear medicine clinical unit for evaluation of memory loss or cognitive abnormalities. The final diagnosis was determined during clinical follow-up of 10.1 months ± 10.8. A final diagnosis was established in 113 patients, 52 of whom had AD. The probability of AD was 0.19 for normal perfusion 0.82 for bilateral posterotemporal and/or parietal defects, 0.77 for bilateral posterotemporal and/or parietal defects with additional defects, 0.57 for unilateral posterotemporal and/or parietal defects with or without additional defects, 0.25 for defects not involving the posterotemporal and/or parietal cortex, and 0.0 for small cortical defects. Of nine patients with bilateral posterotemporal and/or parietal defects with AD, six had Parkinson disease dementia

    4. Insulin Resistance in Alzheimer's Disease

      Science.gov (United States)

      Dineley, Kelly T; Jahrling, Jordan B; Denner, Larry

      2014-01-01

      Insulin is a key hormone regulating metabolism. Insulin binding to cell surface insulin receptors engages many signaling intermediates operating in parallel and in series to control glucose, energy, and lipids while also regulating mitogenesis and development. Perturbations in the function of any of these intermediates, which occur in a variety of diseases, cause reduced sensitivity to insulin and insulin resistance with consequent metabolic dysfunction. Chronic inflammation ensues which exacerbates compromised metabolic homeostasis. Since insulin has a key role in learning and memory as well as directly regulating ERK, a kinase required for the type of learning and memory compromised in early Alzheimer's disease (AD), insulin resistance has been identified as a major risk factor for the onset of AD. Animal models of AD or insulin resistance or both demonstrate that AD pathology and impaired insulin signaling form a reciprocal relationship. Of note are human and animal model studies geared toward improving insulin resistance that have led to the identification of the nuclear receptor and transcription factor, peroxisome proliferator-activated receptor gamma (PPARγ) as an intervention tool for early AD. Strategic targeting of alternate nodes within the insulin signaling network has revealed disease-stage therapeutic windows in animal models that coalesce with previous and ongoing clinical trial approaches. Thus, exploiting the connection between insulin resistance and AD provides powerful opportunities to delineate therapeutic interventions that slow or block the pathogenesis of AD. PMID:25237037

    5. The genetics of Alzheimer's disease.

      Science.gov (United States)

      Bertram, Lars; Tanzi, Rudolph E

      2012-01-01

      Genetic factors play a major role in determining a person's risk to develop Alzheimer's disease (AD). Rare mutations transmitted in a Mendelian fashion within affected families, for example, APP, PSEN1, and PSEN2, cause AD. In the absence of mutations in these genes, disease risk is largely determined by common polymorphisms that, in concert with each other and nongenetic risk factors, modestly impact risk for AD (e.g., the ε4-allele in APOE). Recent genome-wide screening approaches have revealed several additional AD susceptibility loci and more are likely to be discovered over the coming years. In this chapter, we review the current state of AD genetics research with a particular focus on loci that now can be considered established disease genes. In addition to reviewing the potential pathogenic relevance of these genes, we provide an outlook into the future of AD genetics research based on recent advances in high-throughput sequencing technologies. Copyright © 2012 Elsevier Inc. All rights reserved.

    6. Mitochondrial Drugs for Alzheimer Disease

      Directory of Open Access Journals (Sweden)

      Xiongwei Zhu

      2009-12-01

      Full Text Available Therapeutic strategies for Alzheimer disease (AD have yet to offer a diseasemodifying effect to stop the debilitating progression of neurodegeneration and cognitive decline. Rather, treatments thus far are limited to agents that slow disease progression without halting it, and although much work towards a cure is underway, a greater understanding of disease etiology is certainly necessary for any such achievement. Mitochondria, as the centers of cellular metabolic activity and the primary generators of reactive oxidative species in the cell, received particular attention especially given that mitochondrial defects are known to contribute to cellular damage. Furthermore, as oxidative stress has come to the forefront of AD as a causal theory, and as mitochondrial damage is known to precede much of the hallmark pathologies of AD, it seems increasingly apparent that this metabolic organelle is ultimately responsible for much, if not all of disease pathogenesis. In this review, we review the role of neuronal mitochondria in the pathogenesis of AD and critically assess treatment strategies that utilize this upstream access point as a method for disease prevention. We suspect that, with a revived focus on mitochondrial repair and protection, an effective and realistic therapeutic agent can be successfully developed.

    7. Epigenetic Alterations in Alzheimer's Disease.

      Science.gov (United States)

      Sanchez-Mut, Jose V; Gräff, Johannes

      2015-01-01

      Alzheimer's disease (AD) is the major cause of dementia in Western societies. It progresses asymptomatically during decades before being belatedly diagnosed when therapeutic strategies have become unviable. Although several genetic alterations have been associated with AD, the vast majority of AD cases do not show strong genetic underpinnings and are thus considered a consequence of non-genetic factors. Epigenetic mechanisms allow for the integration of long-lasting non-genetic inputs on specific genetic backgrounds, and recently, a growing number of epigenetic alterations in AD have been described. For instance, an accumulation of dysregulated epigenetic mechanisms in aging, the predominant risk factor of AD, might facilitate the onset of the disease. Likewise, mutations in several enzymes of the epigenetic machinery have been associated with neurodegenerative processes that are altered in AD such as impaired learning and memory formation. Genome-wide and locus-specific epigenetic alterations have also been reported, and several epigenetically dysregulated genes validated by independent groups. From these studies, a picture emerges of AD as being associated with DNA hypermethylation and histone deacetylation, suggesting a general repressed chromatin state and epigenetically reduced plasticity in AD. Here we review these recent findings and discuss several technical and methodological considerations that are imperative for their correct interpretation. We also pay particular focus on potential implementations and theoretical frameworks that we expect will help to better direct future studies aimed to unravel the epigenetic participation in AD.

    8. Ayurvedic Profiling of Alzheimer's Disease.

      Science.gov (United States)

      Bredesen, Dale E; Rao, Rammohan V

      2017-05-01

      Alzheimer's disease (AD) is an age-associated, progressive neurodegenerative disease that is characterized by severe memory loss, personality changes, and an overall decline in cognitive function. The cause of AD is not yet completely defined and efforts to find a cure for it have so far been disappointing. AD is one of the most significant health care problems nationally and globally. Recently, we described a personalized therapeutic approach called metabolic enhancement for neurodegeneration (MEND) that successfully reversed the cognitive decline in patients with early AD. The magnitude of the improvement was exceptional, providing testimony to the fact that a personalized and programmatic approach to cognitive decline is highly effective. Ayurveda is a personalized system of traditional medicine native to India and the Indian subcontinent. Although a direct reference to AD in the ancient Ayurvedic literature is missing, concepts including forgetfulness, memory loss, and brain cell loss have been described. Using the clinical information and the metabolic profiling of AD individuals we recently reported using the MEND program, we now describe in this commentary, 3 subtypes of AD based on the Ayurvedic interpretation. Ayurvedic profiling of patients with AD reveals 3 readily distinguishable subtypes, namely Vata, Pitta, and Krimi, which will prove useful in patients with cognitive decline and those at risk for such decline from the standpoint of specific subtype-based Ayurvedic intervention.

    9. Molecular subtypes of Alzheimer's disease.

      Science.gov (United States)

      Di Fede, Giuseppe; Catania, Marcella; Maderna, Emanuela; Ghidoni, Roberta; Benussi, Luisa; Tonoli, Elisa; Giaccone, Giorgio; Moda, Fabio; Paterlini, Anna; Campagnani, Ilaria; Sorrentino, Stefano; Colombo, Laura; Kubis, Adriana; Bistaffa, Edoardo; Ghetti, Bernardino; Tagliavini, Fabrizio

      2018-02-19

      Protein misfolding and aggregation is a central feature of several neurodegenerative disorders including Alzheimer's disease (AD), in which assemblies of amyloid β (Aβ) peptides accumulate in the brain in the form of parenchymal and/or vascular amyloid. A widely accepted concept is that AD is characterized by distinct clinical and neuropathological phenotypes. Recent studies revealed that Aβ assemblies might have structural differences among AD brains and that such pleomorphic assemblies can correlate with distinct disease phenotypes. We found that in both sporadic and inherited forms of AD, amyloid aggregates differ in the biochemical composition of Aβ species. These differences affect the physicochemical properties of Aβ assemblies including aggregation kinetics, resistance to degradation by proteases and seeding ability. Aβ-amyloidosis can be induced and propagated in animal models by inoculation of brain extracts containing aggregated Aβ. We found that brain homogenates from AD patients with different molecular profiles of Aβ are able to induce distinct patterns of Aβ-amyloidosis when injected into mice. Overall these data suggest that the assembly of mixtures of Aβ peptides into different Aβ seeds leads to the formation of distinct subtypes of amyloid having distinctive physicochemical and biological properties which result in the generation of distinct AD molecular subgroups.

    10. Functional neuroimaging in Alzheimer's disease

      International Nuclear Information System (INIS)

      Matsuda, Hiroshi

      2006-01-01

      Recent progress in the title is reviewed often referring to authors' investigations. The method eZIS developed by them is for automated diagnosis of brain perfusion SPECT, where voxel-based analysis can be done using a Z-score map calculable from patient's data and standard database with 3D-stereotactic surface projection. Decreases of regional cerebral blood flow (rCBF) and of glucose metabolism detectable in specified brain regions by PET or SPECT in patients with mild cognitive impairment (MCI), are found useful for predicting the stage progression of MCI to Alzheimer disease (AD) in future. Partial volume correction method, essentially the division of images of a gray matter SPECT by MR, has elevated the precision of cerebral image analysis. Differential diagnosis of AD and dementia with Lewy bodies, the second most common form of dementia, is possible by the difference of occipital perfusion or glucose metabolism. Evidences by rCBF SPECT as well as by symptomatic ones have been accumulated recently for the therapeutic effect of donepezil, an inhibitor of acetylcholine esterase used for AD treatment. PET and SPECT imaging for the assessment of rCBF and metabolism has thus played very important roles in AD diagnosis, staging, differentiation, prediction and drug effect assessment. Recent advance in voxel-based statistical analysis of PET and SPECT images has raised the value of neuroimaging in dementia. (T.I.)

    11. Genetic Aspects of Alzheimer Disease

      Science.gov (United States)

      Williamson, Jennifer; Goldman, Jill; Marder, Karen S.

      2011-01-01

      Background Alzheimer disease (AD) is a genetically complex disorder. Mutations in 3 genes, presenilin 1, amyloid precursor protein, and presenilin 2, lead to early-onset familial AD in rare families with onset of disease occurring prior to age 65. Specific polymorphisms in apolipoprotein E are associated with the more common, late-onset AD occurring after age 65. In this review, we discuss current advances in AD genetics, the implications of the known AD genes, presenilin 1, presenilin 2, amyloid precursor protein, and apolipoprotein E, and other possible genes on the clinical diagnosis, treatment, and genetic counseling of patients and families with early- and late-onset AD. Review Summary In addition to the mutations in 4 known genes associated with AD, mutations in other genes may be implicated in the pathogenesis of the disease. Most recently, 2 different research groups have reported genetic association between 2 genes, sortilin-related receptor and GAB2, and AD. These associations have not changed the diagnostic and medical management of AD. Conclusions New research in the genetics of AD have implicated novel genes as having a role in the disease, but these findings have not been replicated nor have specific disease causing mutations been identified. To date, clinical genetic testing is limited to familial early-onset disease for symptomatic individuals and asymptomatic relatives and, although not recommended, amyloid precursor protein apolipoprotein E testing as an adjunct to diagnosis of symptomatic individuals. PMID:19276785

    12. The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium

      DEFF Research Database (Denmark)

      Frisoni, G.B.; Henneman, W.J.; Weiner, M.W.

      2008-01-01

      BACKGROUND: In North America, the Alzheimer's Disease Neuroimaging Initiative (ADNI) has established a platform to track the brain changes of Alzheimer's disease. A pilot study has been carried out in Europe to test the feasibility of the adoption of the ADNI platform (pilot E-ADNI). METHODS: Seven...... academic sites of the European Alzheimer's Disease Consortium (EADC) enrolled 19 patients with mild cognitive impairment (MCI), 22 with AD, and 18 older healthy persons by using the ADNI clinical and neuropsychological battery. ADNI compliant magnetic resonance imaging (MRI) scans, cerebrospinal fluid...

    13. Lexical priming in Alzheimer's disease and aphasia.

      Science.gov (United States)

      Arroyo-Anlló, Eva Maria; Beauchamps, Mireille; Ingrand, Pierre; Neau, Jean Philippe; Gil, Roger

      2013-01-01

      Lexical priming was examined in patients with Alzheimer's disease and in aphasic patients. Control participants were divided into young and elderly [cf. Arroyo-Anlló et al.: Eur J Cogn Psychol 2004;16:535-553]. For lexical priming, a word-stem completion task was used. Normal elderly participants had lexical priming scores that were significantly lower than those of young individuals. Analysis of covariance with age and educational level as covariates showed that the control participants, aphasic and Alzheimer patients did not differ significantly on the lexical priming task. Our results suggest that performance in the lexical priming task diminishes with physiological aging, but is not significantly affected by mild or moderate Alzheimer's disease or by fluent or non-fluent aphasia. Copyright © 2013 S. Karger AG, Basel.

    14. Current treatments for patients with Alzheimer disease.

      Science.gov (United States)

      Osborn, Gerald G; Saunders, Amanda Vaughn

      2010-09-01

      There is neither proven effective prevention for Alzheimer disease nor a cure for patients with this disorder. Nevertheless, a spectrum of biopsychosocial therapeutic measures is available for slowing progression of the illness and enhancing quality of life for patients. These measures include a range of educational, psychological, social, and behavioral interventions that remain fundamental to effective care. Also available are a number of pharmacologic treatments, including prescription medications approved by the US Food and Drug Administration for Alzheimer disease, "off-label" uses of medications to manage target symptoms, and controversial complementary therapies. Physicians must make the earliest possible diagnosis to use these treatments most effectively. Physicians' goals should be to educate patients and their caregivers, to plan long-term care options, to maximally manage concurrent illnesses, to slow and ameliorate the most disabling symptoms, and to preserve effective functioning for as long as possible. The authors review the various current treatments for patients with Alzheimer disease.

    15. Computed tomography study of Alzheimer's disease

      Energy Technology Data Exchange (ETDEWEB)

      Arai, H; Kobayashi, K; Ikeda, Y; Nagao, Y; Ogihara, R; Kosaka, K

      1983-01-01

      Computed tomography (CT) was used to study cerebral atrophy in 18 patients with clinically diagnosed Alzheimer's disease of presenile type and in 14 healthy age-matched subjects as controls. Using the computerized planimetric method, Subarachnoid Space Volume Index and Ventricle Volume Index were calculated as the measure of cortical atrophy and ventricular dilatation respectively. From the results the following conclusions were drawn: 1. The cerebral atrophy in Alzheimer patients could be attributable to the disease processes rather than to physiological aging of the brain. 2. The degree of atrophy increases in parallel with the progress of the clinical stage, and the cortical atrophy is already apparent at an early stage, whereas the ventricular dilatation becomes pronounced at later stages. 3. CT could be one of the most useful clinical tests available for the diagnosis of Alzheimer's disease.

    16. A computed tomography study of Alzheimer's disease

      International Nuclear Information System (INIS)

      Arai, H.; Kobayashi, K.; Juntendo Univ. School of Medicine, Tokyo; Ikeda, Y.; Nagao, Y.; Ogihara, R.; Kosaka, K.; Psychiatric Research Inst. of Tokyo

      1983-01-01

      Computed tomography (CT) was used to study cerebral atrophy in 18 patients with clinically diagnosed Alzheimer's disease of presenile type and in 14 healthy age-matched subjects as controls. Using the computerized planimetric method, Subarachnoid Space Volume Index and Ventricle Volume Index were calculated as the measure of cortical atrophy and ventricular dilatation respectively. From the results the following conclusions were drawn: 1. The cerebral atrophy in Alzheimer patients could be attributable to the disease processes rather than to physiological aging of the brain. 2. The degree of atrophy increases in parallel with the progress of the clinical stage, and the cortical atrophy is already apparent at an early stage, whereas the ventricular dilatation becomes pronounced at later stages. 3. CT could be one of the most useful clinical tests available for the diagnosis of Alzheimer's disease. (orig.) [de

    17. [Anti-ageing therapies in Alzheimer's disease].

      Science.gov (United States)

      Alonso Abreu, Gara S; Brito Armas, José M; Castro Fuentes, Rafael

      Alzheimer's disease is the most common cause of dementia in the elderly population. Currently, there are no effective treatments to prevent or delay the natural course of the disease. Numerous studies have provided information about the molecular processes underlying biological ageing and, perhaps more importantly, potential interventions to slow ageing and promote healthy longevity in laboratory model systems. The main issue addressed in this review is whether an intervention that has anti-ageing properties can alter the appearance and/or progression of Alzheimer's disease, a disease in which age is the biggest risk factor. Different anti-ageing interventions have been shown to prevent (and in some cases possibly restore) several parameters recognised as central symptoms to the development of Alzheimer's disease. In addition, they are taking the first steps towards translating these laboratory discoveries into clinical applications. Copyright © 2017 SEGG. Publicado por Elsevier España, S.L.U. All rights reserved.

    18. A Critical Assessment of Research on Neurotransmitters in Alzheimer's Disease.

      Science.gov (United States)

      Reddy, P Hemachandra

      2017-01-01

      The purpose of this mini-forum, "Neurotransmitters and Alzheimer's Disease", is to critically assess the current status of neurotransmitters in Alzheimer's disease. Neurotransmitters are essential neurochemicals that maintain synaptic and cognitive functions in mammals, including humans, by sending signals across pre- to post-synaptic neurons. Authorities in the fields of synapses and neurotransmitters of Alzheimer's disease summarize the current status of basic biology of synapses and neurotransmitters, and also update the current status of clinical trials of neurotransmitters in Alzheimer's disease. This article discusses the prevalence, economic impact, and stages of Alzheimer's dementia in humans.

    19. Diagnosis and treatment of Alzheimer's disease

      International Nuclear Information System (INIS)

      Hampel, H.; Padberg, F.; Koetter, H.U.; Teipel, S.J.; Ehrhardt, T.; Hegerl, U.; Stuebner, S.; Moeller, H.J.

      1997-01-01

      Alzheimer's disease is often diagnosed too late. Its etiology is still largely unknown and remains one of the big challenges in neurobiological fundamental research. Optimized early and differential diagnosis can be ensured by a dynamic concept of multidisciplinary diagnosis in cooperation between practitioners specializing in brain disorders, clinical psychogeriatric deprtments, and general practitioners. This, in turn, will enable individualized planning of further living conditions and care of Alzheimer patients and their relations as well as efficient and early pharmacotherapy and psychological intervention. (orig) [de

    20. [Aβ immunotherapy for Alzheimer's disease].

      Science.gov (United States)

      Sakai, Kenji; Yamada, Masahito

      2013-04-01

      Alzheimer's disease (AD) is one of the neurodegenerative diseases characterized by the deposition of amyloid-β-protein (Aβ) as senile plaques in the brain parenchyma and phosphorylated-tau accumulation as neurofibrillary tangles in the neurons. Although details of the disease pathomechanisms remain unclear, Aβ likely acts as a key protein for AD initiation and progression, followed by abnormal tau phosphorylation and neuronal death (amyloid-cascade hypothesis). According to this hypothesis, Aβ immunization therapies are created to eliminate Aβ from the brain, and to prevent the neurons from damage by these pathogenic proteins. There are two methods for Aβ immunotherapies: active and passive immunization. Previous studies have shown Aβ removal and improved cognitive function in animal models of AD. Clinical trials on various drugs, including AN1792, bapineuzumab, and solanezumab, have been carried out; however, all trials have failed to demonstrate apparent clinical benefits. On the contrary, side effects emerged, such as meningoencephalitis, vasogenic edema, which are currently called amyloid related imaging abnormalities (ARIA)-E and microhemorrhage (ARIA-H). In neuropathological studies of immunized cases, Aβ was removed from the brain parenchyma and phosphorylated-tau was reduced in the neuronal processes. Moreover, deterioration of the cerebral amyloid angiopathy (CAA) and an increase of microhemorrhages and microinfarcts were described. Aβ is cleared from the brain mainly via the lymphatic drainage pathway. ARIA could stem from severe CAA due to dysfunction of the drainage pathway after immunotherapy. Aβ immunization has a potential of cure for AD patients, although the above-described problems must be overcome before applying this therapy in clinical treatment.

    1. Effect Size Analyses of Souvenaid in Patients with Alzheimer?s Disease

      OpenAIRE

      Cummings, Jeffrey; Scheltens, Philip; McKeith, Ian; Blesa, Rafael; Harrison, John E.; Bertolucci, Paulo H.F.; Rockwood, Kenneth; Wilkinson, David; Wijker, Wouter; Bennett, David A.; Shah, Raj C.

      2016-01-01

      Background: Souvenaid? (uridine monophosphate, docosahexaenoic acid, eicosapentaenoic acid, choline, phospholipids, folic acid, vitamins B12, B6, C, and E, and selenium), was developed to support the formation and function of neuronal membranes. Objective: To determine effect sizes observed in clinical trials of Souvenaid and to calculate the number needed to treat to show benefit or harm. Methods: Data from all three reported randomized controlled trials of Souvenaid in Alzheimer?s disease (...

    2. Computed tomography of the temporal horns at Alzheimer's disease. Computertomographie der Temporalhoerner bei Morbus Alzheimer

      Energy Technology Data Exchange (ETDEWEB)

      Gerber, U; Vogel, [Allgemeines Krankenhaus Ochsenzoll, Hamburg (Germany, F.R.). Abt. Roentgendiagnostik

      1989-06-01

      In the literature there are different opinions referring to the involvement of the temporal lobes or horns at Alzheimer's disease. Conventionally computed tomogram of the head does not include the temporal horn in its full length. A simple method to demonstrate the temporal horns after cranial computer tomography is described. It allows the evaluation of temporal lobe and temporal horn if questionable alterations at Alzheimer's disease are to be discussed. (orig.).

    3. Early neurovascular dysfunction in a transgenic rat model of Alzheimer?s disease

      OpenAIRE

      Joo, Illsung L.; Lai, Aaron Y.; Bazzigaluppi, Paolo; Koletar, Margaret M.; Dorr, Adrienne; Brown, Mary E.; Thomason, Lynsie A. M.; Sled, John G.; McLaurin, JoAnne; Stefanovic, Bojana

      2017-01-01

      Alzheimer?s disease (AD), pathologically characterized by amyloid-? peptide (A?) accumulation, neurofibrillary tangle formation, and neurodegeneration, is thought to involve early-onset neurovascular abnormalities. Hitherto studies on AD-associated neurovascular injury have used animal models that exhibit only a subset of AD-like pathologies and demonstrated some A?-dependent vascular dysfunction and destabilization of neuronal network. The present work focuses on the early stage of disease p...

    4. Association of apolipoprotein E allele {epsilon}4 with late-onset sporadic Alzheimer`s disease

      Energy Technology Data Exchange (ETDEWEB)

      Lucotte, G.; David, F.; Berriche, S. [Regional Center of Neurogenetics, Reims (France)] [and others

      1994-09-15

      Apolipoprotein E, type {epsilon}4 allele (ApoE {epsilon}4), is associated with late-onset sporadic Alzheimer`s disease (AD) in French patients. The association is highly significant (0.45 AD versus 0.12 controls for {epsilon}4 allele frequencies). These data support the involvement of ApoE {epsilon}4 allele as a very important risk factor for the clinical expression of AD. 22 refs., 1 fig., 3 tabs.

    5. The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer?s disease

      OpenAIRE

      Yang, Shuang-shuang; Zhang, Rui; Wang, Gang; Zhang, Yong-fang

      2017-01-01

      Alzheimer?s disease (AD) is a chronic neurodegenerative disease, which is associated with learning and memory impairment in the elderly. Recent studies have found that treating AD in the way of chromatin remodeling via histone acetylation is a promising therapeutic regimen. In a number of recent studies, inhibitors of histone deacetylase (HDACs) have been found to be a novel promising therapeutic?agents for neurological disorders, particularly for AD and other neurodegenerative diseases. Alth...

    6. Qualidade de vida e sobrecarga: perfil dos cuidadores de idosos com doença de Alzheimer

      Directory of Open Access Journals (Sweden)

      Emilene da silva Araujo

      2016-07-01

      Full Text Available Objetivo: buscou-se, através de uma análise do perfil do cuidador de pessoas com Doença de Alzheimer, fatores que possam influenciar na sobrecarga e em sua qualidade de vida. Método: trata-se de um estudo transversal, do tipo quantitativo, composto por doze cuidadores de pessoas com diagnóstico da Doença de Alzheimer, os quais foram recrutados através do cadastrado no grupo Assistência Multidisciplinar Integrada aos Cuidadores dos Portadores da Doença de Alzheimer (AMICA, de Santa Maria, Rio Grande do Sul. O estudo utilizou três instrumentos para coleta de dados baseados numa entrevista estruturada, que foi executada pela pesquisadora, sendo uma ficha de caracterização do cuidador, a entrevista de Zarit de sobrecarga do cuidador e o questionário de qualidade de vida (versão cuidador. Resultados: dos doze cuidadores entrevistados, observou-se que 10 eram do sexo feminino, sendo 6 filhas e 10 residiam juntamente com os idosos. Verificou-se que, em relação à qualidade de vida, 9 dos cuidadores relataram que a vida, em geral, estava boa e 9 apresentaram sobrecarga moderada. Considerações finais: através do estudo, é perceptível a importância de políticas públicas aos cuidadores de pessoas com diagnóstico da Doença de Alzheimer, para que os mesmos possam exercer suas funções com menos sobrecarga e com qualidade de vida.

    7. Efectos del tipo de diabetes, estrategias de afrontamiento, sexo y optimismo en el apoyo social

      OpenAIRE

      Rondón, José E.; Lugli, Zoraide

      2013-01-01

      Se desea conocer el efecto del tipo de diabetes, las estrategias de afrontamiento, el sexo, y el optimismo sobre las redes sociales y el apoyo social percibido por sujetos con diabetes. Participaron 103 hombres y 197 mujeres divididos en diabéticos tipo

    8. DESENVOLVIMENTO DE MUDAS DE REPOLHO EM DIFERENTES TIPOS SUBSTRATOS

      Directory of Open Access Journals (Sweden)

      Rebyson Bissaco Guidinelle

      2017-05-01

      Full Text Available Resumo: O objetivo deste trabalho foi avaliar o crescimento vegetativo de mudas de repolho, em diferentes tipos de substrato orgânicos. O experimento foi conduzido em uma casa de vegetação utilizando três substratos, S1 - Comercial; S2 - Vermicomposto; S3 - Serapilheira. Os parâmetros morfoagronômicos avaliados foram o comprimento das mudas, sendo: altura parte aérea (APA, comprimento da maior raiz (CMR e altura total das plântulas (AT que é o somatório da APA e CMR. Os substratos apresentaram diferenças significativas entre si, sendo que a Serapilheira apresentou os melhores resultados de desenvolvimento vegetativo juntamente com o vermicomposto. Concluindo-se que a produção de mudas de repolho pode ser feita a partir de substratos orgânicos alternativos, recomendando a substituição total dos substratos comerciais, visando menor custo na produção das mudas, garantindo boa produtividade e qualidade das mudas de repolho das cultivares estudadas.

    9. Estresse em mulheres com Diabetes mellitus tipo 2

      Directory of Open Access Journals (Sweden)

      Juliana Cristina Lessmann

      2011-06-01

      Full Text Available OBJETIVO: O objetivo do estudo foi investigar a relação entre estresse e Diabetes Mellitus Tipo 2 em mulheres. MÉTODO: Estudo transversal prospectivo, desenvolvido com 147 mulheres, utilizando a Escala de Estresse Percebido (PSS. RESULTADOS: Houve associação entre as variáveis testadas, sendo possível inferir que as mulheres com estresse elevado são as que vivenciaram sofrimento e apresentam controle glicêmico alterado, ou seja, com valores superiores a 180 mg/dL. A maioria relatou sofrimento decorrente de problemas nas relações interpessoais, óbito, doença de familiares e solidão. CONCLUSÃO: Mulheres com DM2 que convivem com estresse e/ou sofrimento constituem grupo vulnerável ao desenvolvimento de agravos à saúde demandando aos serviços de saúde o desenvolvimento de estratégias que modifiquem esta situação.

    10. 78 FR 46590 - Office of the Assistant Secretary for Planning and Evaluation; Advisory Council on Alzheimer's...

      Science.gov (United States)

      2013-08-01

      ... Evaluation; Advisory Council on Alzheimer's Research, Care, and Services AGENCY: Office of the Assistant... Alzheimer's Research, Care, and Services. The six positions are for each of the following categories, as specified in the National Alzheimer's Project Act: Alzheimer's patient advocate, Alzheimer's caregiver...

    11. Differing astrocytic cytoskeleton alterations in alzheimer's disease

      Czech Academy of Sciences Publication Activity Database

      Olabarria, M.; Noristani, H.; Chvátal, Alexandr; Verkhratsky, Alexei; Rodríguez Arellano, Jose Julio

      2009-01-01

      Roč. 57, č. 13 (2009), S103-S104 ISSN 0894-1491. [European Meeting on Glial Cells in Health and Disease /9./. 09.09.2009-12.09.2009, Paris] Institutional research plan: CEZ:AV0Z50390703 Keywords : Alzheimer ´s disease Subject RIV: FH - Neurology

    12. [Medical nutrition in Alzheimer's: the trials].

      Science.gov (United States)

      Scheltens, Philip; Twisk, Jos W R

      2013-01-01

      We describe the small but statistically significant effects of the medical nutrition diet 'Souvenaid' on memory in early Alzheimer's disease in two published randomised clinical trials. We specifically discuss the design and statistical approach, which were predefined and meet current standards in the field. Further research is needed to substantiate the long term effects and learn more about the mode of action of Souvenaid.

    13. What Are the Signs of Alzheimer's Disease?

      Science.gov (United States)

      ... changes in behavior and personality Conduct tests of memory, problem solving, attention, counting, and language Carry out standard medical tests, ... or her to check for changes in your memory and thinking. Read More "Living with Alzheimer's Disease" Articles ... Information | Contact Us | Viewers & Players Friends of the National ...

    14. Het immuunsysteem en de ziekte van Alzheimer

      NARCIS (Netherlands)

      van Exel, E.; Eikelenboom, P.; Comijs, H. C.; Kurniawan, C.; Frölich, M.; Smit, J. H.; Stek, M. L.; Scheltens, P.; Eefsting, J. E.; Westendorp, R. G. J.

      2011-01-01

      It has still not been established unequivocally whether vascular risk factors and inflammatory reactions, determined by heredity, are a cause or a result of Alzheimer's disease If the offspring of parents with AD have more risk factors and more frequent and severe inflammatory reactions than the

    15. Hypocretin (orexin) loss in Alzheimer's disease.

      NARCIS (Netherlands)

      Fronczek, R.; Geest, S. de; Frolich, M.; Overeem, S.; Roelandse, F.W.; Lammers, G.J.; Swaab, D.F.

      2012-01-01

      Sleep disturbances in Alzheimer's disease (AD) patients are associated with the severity of dementia and are often the primary reason for institutionalization. These sleep problems partly resemble core symptoms of narcolepsy, a sleep disorder caused by a general loss of the neurotransmitter

    16. Hypocretin (orexin) loss in Alzheimer's disease

      NARCIS (Netherlands)

      Fronczek, Rolf; van Geest, Sarita; Frölich, Marijke; Overeem, Sebastiaan; Roelandse, Freek W. C.; Lammers, Gert Jan; Swaab, Dick F.

      2012-01-01

      Sleep disturbances in Alzheimer's disease (AD) patients are associated with the severity of dementia and are often the primary reason for institutionalization. These sleep problems partly resemble core symptoms of narcolepsy, a sleep disorder caused by a general loss of the neurotransmitter

    17. Neuroinflammation in Alzheimer's disease and prion disease

      NARCIS (Netherlands)

      Eikelenboom, P.; Bate, C.; van Gool, W. A.; Hoozemans, J. J. M.; Rozemuller, J. M.; Veerhuis, R.; Williams, A.

      2002-01-01

      Alzheimer's disease (AD) and prion disease are characterized neuropathologically by extracellular deposits of Abeta and PrP amyloid fibrils, respectively. In both disorders, these cerebral amyloid deposits are co-localized with a broad variety of inflammation-related proteins (complement factors,

    18. A light therapy for treating Alzheimer's disease

      Science.gov (United States)

      Wang, Xue; Han, Mengmeng; Wang, Qiyan; Zeng, Yuhui; Meng, Qingqiang; Zhang, Jun; Wei, Xunbin

      2017-02-01

      It is generally believed that there are some connections between Alzheimer's disease and amyloid protein plaques in the brain. The typical symptoms of Alzheimer's disease are memory loss, language disorders, mood swings, loss of motivation and behavioral issues. Currently, the main therapeutic method is pharmacotherapy, which may temporarily reduce symptoms, but has many side effects. Infrared light therapy has been studied in a range of single and multiple irradiation protocols in previous studies and was found beneficial for neuropathology. In our research we have studied the effect of infrared light on Alzheimer's disease through transgenic mouse model. We designed an experimental apparatus for treating mice, which primarily included a therapeutic box and a LED array, which emitted infrared light. After the treatment, we assessed the effects of infrared light by performing two tests: cognitive performance of mice in Morris water maze, and plaque load by immunofluorescence analysis. Immunofluorescence analysis was based on measuring the quantity of plaques in mouse brain slices. Our results show that infrared therapy is able to improve cognitive performance in the mouse model. It might provide a novel and safe way to treat Alzheimer's disease.

    19. Normal tension glaucoma and Alzheimer disease

      DEFF Research Database (Denmark)

      Bach-Holm, Daniella; Kessing, Svend Vedel; Mogensen, Ulla Brasch

      2012-01-01

      Purpose: To investigate whether normal tension glaucoma (NTG) is associated with increased risk of developing dementia/Alzheimer disease (AD). Methods: A total of 69 patients with NTG were identified in the case note files in the Glaucoma Clinic, University Hospital of Copenhagen (Rigshospitalet...

    20. Alzheimer disease : presenilin springs a leak

      NARCIS (Netherlands)

      Gandy, S.; Doeven, M.K.; Poolman, B.

      2006-01-01

      Presenilins are thought to contribute to Alzheimer disease through a protein cleavage reaction that produces neurotoxic amyloid-beta peptides. A new function for presenilins now comes to light - controlling the leakage of calcium out of the endoplasmic reticulum. Is this a serious challenge to the

    1. Progression of Alzheimer Disease in Europe

      DEFF Research Database (Denmark)

      Vellas, B; Hausner, L; Frolich, L

      2012-01-01

      The clinical progression of Alzheimer disease (AD) was studied in European subjects under treatment with AChE inhibitors (AChE-I) in relation to geographical location over a 2-years period. One thousand three hundred and six subjects from 11 European countries were clustered into 3 regions (North...

    2. Verbal Repetitions and Echolalia in Alzheimer's Discourse

      Science.gov (United States)

      Da Cruz, Fernanda Miranda

      2010-01-01

      This article reports on an investigation of echolalic repetition in Alzheimer's disease (AD). A qualitative analysis of data from spontaneous conversations with MHI, a woman with AD, is presented. The data come from the DALI Corpus, a corpus of spontaneous conversations involving subjects with AD. This study argues that echolalic effects can be…

    3. Alzheimer's disease and other neurological disorders.

      Science.gov (United States)

      Henderson, V W

      2007-10-01

      Menopausal status and estrogen-containing hormone therapy may influence several neurological disorders, including Alzheimer's disease, epilepsy, migraine headache, multiple sclerosis, Parkinson's disease, sleep disorders, and stroke. For most of these illnesses, evidence on hormone therapy is insufficient to guide practice decisions. For stroke, clinical trial evidence indicates that hormone therapy increases risk of cerebral infarction. For women with Alzheimer's disease, estrogen treatment trials have tended to be small and of short duration. Most suggest that estrogen started after the onset of dementia symptoms does not meaningfully improve cognition or slow disease progression. Hormone therapy initiated after age 64 increased all-cause dementia in the Women's Health Initiative Memory Study. Many observational studies, however, report protective associations between hormone use and Alzheimer risk. Apparent risk reduction may represent a bias toward hormone therapy, since hormones are more often prescribed to healthier women. However, when compared to the Women's Health Initiative Memory Study, estrogen exposures in many observational studies reflect hormone initiation at a younger age, closer to the time of menopause. One intriguing hypothesis is that hormone therapy initiated or used during an early critical window may reduce later Alzheimer incidence. Public health implications of this hypothesis are important, but current data are inadequate to decide the issue.

    4. Retrograde amnesia in patients with Alzheimer's disease

      NARCIS (Netherlands)

      Meeter, M.; Eijsackers, E; Mulder, J

      2006-01-01

      Patients with mild to moderate Alzheimer's disease and normal controls were tested on two retrograde memory tests, one based on public events, and the other querying autobiographical memory. On both tests, patients showed strong decrements as compared to normal controls, pointing to retrograde

    5. Llama VHH as immunotherapeutics in Alzheimer's disease

      NARCIS (Netherlands)

      Dorresteijn, B.|info:eu-repo/dai/nl/31401635X

      2013-01-01

      Alzheimer's Disease (AD) is the most common form of dementia among elderly in the Western world. AD is a devastating neurodegenerative disease where patients starting with episodic memory problems end up completely bedridden and care dependent. At present there is no real therapy stopping or

    6. Nanodeeltjes in de strijd tegen Alzheimer

      NARCIS (Netherlands)

      Paulusse, Jos Marie Johannes

      2015-01-01

      Medicatie bij de ziekte van Alzheimer is vooral gericht op symptoombestrijding. Kan dat niet anders, vroegen wetenschappers van de Universiteit Twente zich af. De komende vier jaar gaan zij proberen een cocktail van medicijnen met behulp van nanodeeltjes gericht in de hersenen te brengen.

    7. Aripiprazole in the treatment of Alzheimer's disease

      NARCIS (Netherlands)

      De Deyn, P.P.; Drenth, Annemieke F. J.; Kremer, B.P.; Oude Voshaar, R.C.; Van Dam, D.

      Introduction: Psychosis is a common and difficult to treat symptom in Alzheimer's disease (AD). It is a cause of diminished quality of life and care-giver distress. Atypical antipsychotics are frequently used for the treatment of dementia-related psychosis, despite FDA warnings because of increased

    8. Alzheimer's disease therapies: Selected advances and future ...

      African Journals Online (AJOL)

      Among the neurodegenerative diseases, Alzheimer's disease (AD) represents one of the biggest challenges that the modern health care system has to deal with. The lack of data about the etiology and the complexity of the underlying pathogenesis constitute the biggest struggle facing the development of new therapeutical ...

    9. Alzheimer Café : Prima Praktijken

      NARCIS (Netherlands)

      Frans Nauta; Marica Crombach

      2010-01-01

      In Nederland lijden zo’n 230.000 mensen aan een vorm van dementie. Door de vergrijzing en veroudering van de bevolking zal dit aantal de komende decennia alleen maar toenemen. Psychogerontoloog Bère Miesen heeft voor deze doelgroep het Alzheimer Café opgericht: een maandelijkse bijeenkomst in de

    10. Imaging epigenetics in Alzheimer's disease.

      Science.gov (United States)

      Lista, Simone; Garaci, Francesco G; Toschi, Nicola; Hampel, Harald

      2013-01-01

      Sporadic Alzheimer's disease (AD) is a prevalent, complex and chronically progressive brain disease. Its course is non-linear, dynamic, adaptive to maladaptive, and compensatory to decompensatory, affecting large-scale neural networks through a plethora of mechanistic and signaling pathway alterations that converge into regional and cell type-specific neurodegeneration and, finally, into clinically overt cognitive and behavioral decline. This decline includes reductions in the activities of daily living, quality of life, independence, and life expectancy. Evolving lines of research suggest that epigenetic mechanisms may play a crucial role during AD development and progression. Epigenetics designates molecular mechanisms that alter gene expression without modifications of the genetic code. This topic includes modifications on DNA and histone proteins, the primary elements of chromatin structure. Accumulating evidence has revealed the relevant processes that mediate epigenetic modifications and has begun to elucidate how these processes are apparently dysregulated in AD. This evidence has led to the clarification of the roles of specific classes of therapeutic compounds that affect epigenetic pathways and characteristics of the epigenome. This insight is accompanied by the development of new methods for studying the global patterns of DNA methylation and chromatin alterations. In particular, high-throughput sequencing approaches, such as next-generation DNA sequencing techniques, are beginning to drive the field into the next stage of development. In parallel, genetic imaging is beginning to answer additional questions through its ability to uncover genetic variants, with or without genome-wide significance, that are related to brain structure, function and metabolism, which impact disease risk and fundamental network-based cognitive processes. Neuroimaging measures can further be used to define AD systems and endophenotypes. The integration of genetic neuroimaging

    11. Funcionamiento psicofisiológico y susceptibilidad a la sintomatología premenstrual en mujeres Tipo A y Tipo B

      Directory of Open Access Journals (Sweden)

      Francesc Palmero

      2002-01-01

      Full Text Available El presente trabajo se centra en explorar el papel que juega el componente emocional del Patrón de Conducta Tipo A (PCTA en diversas áreas relacionadas con la salud. En este contexto nuestra investigación desarrolla dos objetivos diferenciados. El primero trata de constatar la relación entre determinadas características del PCTA y el mecanismo psicofisiológico en una tarea experimental de estrés real (situación de examen, considerando si existen diferencias entre los dos grupos de personas, Tipo A y Tipo B, tanto en la dimensión tónica como en la dimensión fásica de la tasa cardiaca. El segundo de nuestros objetivos trata de establecer la relación existente entre determinadas características del PCTA y la experiencia de sintomatología relacionada con el ciclo menstrual, considerando tanto la sintomatología premenstrual global, como la sintomatología premenstrual específica, diferenciando tres grandes grupos de síntomas: fisiológicos, psicológicos y conductuales. La muestra final estuvo conformada por 28 mujeres Tipo A y 29 mujeres Tipo B. Los instrumentos utilizados fueron el inventario de Actividad de Jenkins (JAS, el calendario menstrual de síntomas de registro diario (CMSRD y un polígrafo que permitió registrar la tasa cardiaca. En cuanto a nuestro primer objetivo, los datos hacen pensar en la existencia de distintos perfiles psicofisiológicos en ambos grupos de mujeres; en el segundo objetivo, parece que las mujeres Tipo A experimentan de forma clara más síntomas psicológicos que las mujeres Tipo B.

    12. O uso de politetrafluoroetileno expandido em tireoplastia tipo I

      Directory of Open Access Journals (Sweden)

      Mello-Filho Francisco Veríssimo de

      2003-01-01

      Full Text Available A paralisia unilateral de prega vocal (PUPV em abdução é uma alteração que produz grande desconforto ao paciente, principalmente pelos distúrbios fonatórios causados. Atualmente dispomos de uma variedade de métodos para seu tratamento. OBJETIVO: Verificar a eficiência, vantagens e desvantagens do uso da fita de politetrafluoretileno expandido (PTFE-e, na medialização de prega vocal (PV paralisada, em abdução. FORMA DE ESTUDO: Coorte Longitudinal. MATERIAL E MÉTODOS: Foram estudados quatro pacientes com diagnóstico clínico-laringoscópico de disfonia por PPVU, em abdução há pelo menos um ano. Os pacientes foram submetidos a avaliação fonoaudiológica e a tireoplastia tipo I para medialização da PV com fita de PTFE-e. Durante o seguimento pós-operatório procedeu-se videolaringoscopia, tomografia computadorizada e fonoterapia. RESULTADOS: Todos os pacientes estão satisfeitos com a qualidade vocal, apresentam medialização estável da PV com a fonocirurgia e bons resultados à avaliação fonoaudiológica. Um paciente apresentou extrusão intra-operatória da fita de PTFE-e, sendo feito um segundo procedimento, sem complicações, seis meses depois. CONCLUSÃO: Na opinião dos autores a fita de PTFE-e se presta com eficiência ao tratamento da PUPV, sem apresentar riscos importantes.

    13. Intervenciones Farmaceuticas en pacientes con Diabetes Mellitus Tipo 2

      Directory of Open Access Journals (Sweden)

      Gladys Mabel Maidana

      Full Text Available Resumen Introducción: La Atención Farmacêutica es la provision responsable de la farmacoterapia con el propósito de alcanzar resultados concretos que mejoren la calidad de vida de los pacientes. Objetivo: Evaluar el impacto de las intervenciones farmacéuticas en pacientes con Diabetes Mellitus Tipo 2. Metodologia: Ensayo Clínico Aleatorizado, con medición de variables antes y después. No probabilísti-co. De conveniencia. Participaron 32 pacientes del grupo intervenido y 32 en grupo control. Se realizaron entrevistas mensuales en un periodo de intervención farmacéutica de 6 meses (desde octubre 2011 hasta junio 2012. Se registraron solo 3 abandonos. Resultados: La edad de los pacientes fue 55,6±10,6 anos. Los pacientes del grupo intervenido mejoraron la glicemia en 34%, donde 24 pacientes tenian el valor (< 130 mg/dL; la hemoglobina glicosilada mejoró 1,9%, donde 15 pacientes lograron los parámetros deseados (< 6,5%. La calidad de vida del grupo inter-venido aumentó de (56,3 a 71,3 % y fue medido con el cuestionario SF-36. En el grupo intervenido se encontraron 80 problemas relacionados con medicamentos, en 27 pacientes, se resolvieron 59; al final del estudio 12 pacientes resolvieron todos los problemas relacionados con medicamentos; se realizaron 254 intervenciones farmacêuticas, el nivel de conocimiento de los pacientes sobre la enfermedad mejoró en 41%, el conocimiento sobre sus medicamentos mejoró en 53%. Conclusión: Las intervenciones farmacêuticas mejoraron los parámetros clínicos de glicemia, hemoglobina glicosilada, optimizaron el uso de medicamentos, disminuyeron los problemas relacionados con medicamentos, mejoraron la calidad de vida de los pacientes.

    14. 78 FR 36192 - Agency Information Collection Activities: Submission for OMB Review; Comment Request; Alzheimer's...

      Science.gov (United States)

      2013-06-17

      ... Collection Activities: Submission for OMB Review; Comment Request; Alzheimer's Disease Supportive Services... collection for the Alzheimer's Disease Supportive Services Program. DATES: Submit written comments on the... SUPPLEMENTARY INFORMATION: The Alzheimer's Disease Supportive Services Program (ADSSP) is authorized through...

    15. 75 FR 12241 - Agency Information Collection Activities; Proposed Collection; Comment Request; Alzheimer's...

      Science.gov (United States)

      2010-03-15

      ... Activities; Proposed Collection; Comment Request; Alzheimer's Disease Supportive Services Program... requirements relating to the Alzheimer's Disease Supportive Services Program. DATES: Submit written or... other forms of information technology. The Alzheimer's Disease Supportive Services Program (ADSSP) is...

    16. Reconocimiento facial de emociones básicas y complejas en una población de pacientes con demencia frontotemporal variante frontal Facial recognition of basic and complex emotions in a population of patients with frontal variant of frontotemporal dementia

      Directory of Open Access Journals (Sweden)

      María Eugenia Tabernero

      2011-12-01

      Full Text Available La variante frontal de la Demencia Frontotemporal (DFTvf se caracteriza por un severo trastorno de la conducta y la personalidad, explicado por alteraciones en el procesamiento emocional y/o en la Teoría de la Mente (TdM. Objetivo: Evaluar los procesos cognitivos involucrados en a resolución del Test de Caras (Baron-Cohen et al., 1997 en comparación con el test Lectura de la Mente en los Ojos (LMO (Baron-Cohen et al., 2001 y la utilidad de ambos para el diagnóstico de alteraciones en la TdM en pacientes con DFTvf. Población: 20 pacientes con diagnóstico de DFTvf, media de edad 66,9 años y escolaridad 6,25 años. Resultados: Correlación significativa entre LMO y el Test de Caras. Doble disociación entre ambas pruebas. Conclusión: La presencia de correlaciones indica que ambas pruebas se afectan en esta demencia, resultando herramientas de igual valor clínico. El hallazgo de disociaciones indica que cada una de ellas evalúa procesos cognitivos parcialmente independientesThe frontal variant of frontotemporal dementia (FTDfv is characterized by a severe behavioural and personality impairment, explained by alterations in the emotional process and/or in Theory of Mind (ToM. Objective: To assess the cognitive processes involved in performing the Faces Test (Baron-Cohen et al., 1997 in comparison with Reading de Mind in the Eyes Test (RME (Baron-Cohen et al., 2001, and the utility of both in the diagnosis of ToM alterations in FTDfv patients. Subjects: 20 patients diagnosed with FTDfv, mean age 66,9 years and mean education 6,25 years. Results: Significative correlation between RME and Faces Test. Double dissociation between these tests. Conclusion: The presence of correlations indicates that both tests are affected in this dementia, being both useful as clinical tools. The dissociations founded indicates that each one assesses partially-independent cognitive processes.

    17. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

      NARCIS (Netherlands)

      McKhann, G.M.; Knopman, D.S.; Chertkow, H.; Hyman, B.T.; Jack, C.R.; Kawas, C.H.; Klunk, W.E.; Koroshetz, W.J.; Manly, J.J.; Mayeux, R.; Mohs, R.C.; Morris, J.C.; Rossor, M.N.; Scheltens, P.; Carrillo, M.C.; Thies, B.; Weintraub, S.; Phelps, C.H.

      2011-01-01

      The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers

    18. Effectiveness of Music Therapy in Alzheimer Patients: Systematic Review

      Directory of Open Access Journals (Sweden)

      Neslihan Lok

      Full Text Available The incidence of Alzheimers disease increases with advancing age. This increase cause significant economic and emotional burden on family and national health care system which makes Alzheimers disease a national issue to be considered. Music therapy could be an alternative treatment approach in Alzheimer's disease. Especially in the second stage of Alzheimers disease, growth and expansion of amyloid plaques results in anger and aggression among patients. Calming effects of music might be beneficial in management of patients during this period. This study is a systematic review of researches conducted to determine the effects of music therapy in Alzheimer's diseases. In sum results have supported possible positive effects of music therapy on Alzheimer patients. [Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry 2016; 8(3.000: 266-274

    19. Diseño de antenas tipo DRA (Dielectric Resonator Antennas)

      OpenAIRE

      Soria Gallego, Juan

      2013-01-01

      En este trabajo se va a estudiar un tipo de antenas conocidas como antenas resonantes dieléctricas (DRA) desde el punto de vista de diseño y características radiantes, así como de sus posibles aplicaciones. Las DRAs son un tipo de antenas cada vez más usadas ya que presentan numerosas ventajas respecto a otro tipo de antenas, entre ellas que son fáciles de diseñar, baratas y muy eficientes. Por ello, cada vez aparecen nuevos diseños y nuevas aplicaciones. Entre ellas se ha extendido el uso...

    20. Influencia del contacto precoz, nacionalidad, tipo de parto y prematuridad en la lactancia materna

      OpenAIRE

      Ana Belén Laviña Castan

      2015-01-01

      Conocer si en el HUMS existe asociación entre lactancia materna y nacionalidad, prematuridad, tipo de parto, contacto precoz piel con piel. Estudio de cohortes, en una muestra de 541 puérperas del HUMS en octubre-noviembre 2011. Las variables: nacionalidad, tipo de parto, contacto precoz, parto prematuro e inicio lactancia materna se recogieron antes del alta hospitalaria mediante cuestionario. A los dos meses postparto se contactó telefónicamente con las madres para conocer el tipo de lactan...

    1. Short-term memory binding deficits in Alzheimer's disease.

      Science.gov (United States)

      Parra, Mario A; Abrahams, Sharon; Fabi, Katia; Logie, Robert; Luzzi, Simona; Della Sala, Sergio

      2009-04-01

      Alzheimer's disease impairs long term memories for related events (e.g. faces with names) more than for single events (e.g. list of faces or names). Whether or not this associative or 'binding' deficit is also found in short-term memory has not yet been explored. In two experiments we investigated binding deficits in verbal short-term memory in Alzheimer's disease. Experiment 1: 23 patients with Alzheimer's disease and 23 age and education matched healthy elderly were recruited. Participants studied visual arrays of objects (six for healthy elderly and four for Alzheimer's disease patients), colours (six for healthy elderly and four for Alzheimer's disease patients), unbound objects and colours (three for healthy elderly and two for Alzheimer's disease patients in each of the two categories), or objects bound with colours (three for healthy elderly and two for Alzheimer's disease patients). They were then asked to recall the items verbally. The memory of patients with Alzheimer's disease for objects bound with colours was significantly worse than for single or unbound features whereas healthy elderly's memory for bound and unbound features did not differ. Experiment 2: 21 Alzheimer's disease patients and 20 matched healthy elderly were recruited. Memory load was increased for the healthy elderly group to eight items in the conditions assessing memory for single or unbound features and to four items in the condition assessing memory for the binding of these features. For Alzheimer's disease patients the task remained the same. This manipulation permitted the performance to be equated across groups in the conditions assessing memory for single or unbound features. The impairment in Alzheimer's disease patients in recalling bound objects reported in Experiment 1 was replicated. The binding cost was greater than that observed in the healthy elderly group, who did not differ in their performance for bound and unbound features. Alzheimer's disease grossly impairs the

    2. Manifestações da apraxia de fala na doença de Alzheimer Manifestations of apraxia of speech in Alzheimer's disease

      Directory of Open Access Journals (Sweden)

      Maysa Luchesi Cera

      2011-09-01

      Full Text Available OBJETIVO: Identificar as manifestações práxicas de pacientes com doença de Alzheimer em diferentes estágios da doença e verificar as similaridades entre as suas ocorrências. MÉTODOS: Foram avaliados noventa pacientes com doença de Alzheimer, 30 em cada fase da doença (leve, moderada e grave, por meio dos instrumentos: Escala de Avaliação Clínica da Demência (CDR, Mini-Exame do Estado Mental (MEEM, Avaliação das Atividades Instrumentais de Vida Diária (Índice Lawton e Protocolo de Avaliação da Apraxia Verbal e Não-verbal. Foram avaliados 66 pacientes do gênero feminino e 24 do masculino, a média da idade foi 80,2±7,2 e da escolaridade foi 4,2±3,5 anos. RESULTADOS: Na fase leve, as proporções de ensaio, repetição e adição foram semelhantes, assim como omissão, substituição e autocorreção. Na fase moderada foram semelhantes: ensaio e repetição, substituição, omissão e adição, e autocorreção. Na fase grave, todas as manifestações se assemelharam, exceto a adição. O erro do tipo adição diferenciou os pacientes em relação às fases da doença. CONCLUSÃO: Os pacientes dos três estágios da doença apresentam diferentes padrões de manifestações práxicas verbais.PURPOSE: To identify praxic speech manifestations in patients diagnosed with different stages of Alzheimer's disease, and to verify similarities among their occurrences. METHODS: Participants were 90 patients with Alzheimer's, 30 in each stage of the disease (mild, moderate and severe, who were assessed using the following instruments: Clinical Dementia Rating (CDR, Mini-Mental State Examination (MMSE, Lawton Instrumental Activities of Daily Living, and the Assessment Protocol of Verbal and Orofacial Apraxia. Sixty six female subjects and 24 male subjects were assessed; mean age was 80.2±7.2 years, and mean level of education was 4.2±3.5 years. RESULTS: In the mild stage, the proportions of trial-and-error, repetition and addition were

    3. Prevention of Alzheimer disease: The roles of nutrition and primary care.

      Science.gov (United States)

      Bane, Tabitha J; Cole, Connie

      2015-05-15

      Risk factors for developing Alzheimer disease include hypercholesterolemia, hypertension, obesity, and diabetes. Due to lack of effective treatments for Alzheimer disease, nutrition and primary prevention becomes important.

    4. Actividad hidráulica de un cemento belítico obtenido a partir de cenizas volantes tipo C: influencia del aditivo y tipo de curado

      OpenAIRE

      Goñi, S.; Guerrero, A.

      2006-01-01

      En este trabajo se discute la influencia del tipo de curado y de un aditivo reductor de la demanda de agua en la actividad hidráulica de un cemento belítico de cenizas volantes de alto contenido en cal denominado (CBCV-2-A). Este cemento ha sido sintetizado por una ruta húmeda hidrotermal con posterior calcinación, empleando ceniza volante de alto contenido en cal (ASTM tipo C) como materia prima. La actividad hidráulica se ha estudiado en la pasta de cemento, durante un periodo de 180 días, ...

    5. Actividad hidráulica de un cemento belítico obtenido a partir de cenizas volantes tipo C: influencia del aditivo y tipo de curado

      OpenAIRE

      Goñi Elizalde, Sara; Guerrero Bustos, Ana María

      2006-01-01

      En este trabajo se discute la influencia del tipo de curado y de un aditivo reductor de la demanda de agua en la actividad hidráulica de un cemento belítico de cenizas volantes de alto contenido en cal denominado (CBCV-2-A). Este cemento ha sido sintetizado por una ruta húmeda hidrotermal con posterior calcinación, empleando ceniza volante de alto contenido en cal (ASTM tipo C) como materia prima. La actividad hidráulica se ha estudiado en la pasta de cemento, durante un periodo de 180 ...

    6. Modern approach in the therapy of Alzheimer's disease

      Directory of Open Access Journals (Sweden)

      D. I. Rodin

      2014-01-01

      Full Text Available Alzheimer's disease is a well-known neurodegenerative disorder. One of its main risk factors is age. Due to a worldwide increase of human longevity Alzheimer's disease became the most common form of dementia. The disease has been studied in different countries for many decades but still its etiology remains unclear. By now there is no cure for Alzheimer's, moreover there are no that can at least slow down the disease progression. In this review we made an attempt to summarize all current studies of the most advanced drugs for Alzheimer's.

    7. Developing novel blood-based biomarkers for Alzheimer's disease

      DEFF Research Database (Denmark)

      Snyder, Heather M; Carrillo, Maria C; Grodstein, Francine

      2014-01-01

      Alzheimer's disease is the public health crisis of the 21st century. There is a clear need for a widely available, inexpensive and reliable method to diagnosis Alzheimer's disease in the earliest stages, track disease progression, and accelerate clinical development of new therapeutics. One avenue...... of research being explored is blood based biomarkers. In April 2012, the Alzheimer's Association and the Alzheimer's Drug Discovery Foundation convened top scientists from around the world to discuss the state of blood based biomarker development. This manuscript summarizes the meeting and the resultant...

    8. Does prevention for Alzheimer's disease exist?

      Directory of Open Access Journals (Sweden)

      Sonia Maria Dozzi Brucki

      Full Text Available Abstract The prevention of Alzheimer's disease is a growing public health concern amidst an ageing population. Meanwhile, there is no effective or curative treatment available where prevention could greatly reduce health costs. This review was based on reports of potential preventive factors, including modifiable lifestyle factors, as well as preventive pharmacological strategies. Although the present review was not systematic, the reports selected from PubMed using "Alzheimer's disease" and "prevention" as key-words, allow us to affirm that pursuing a healthy lifestyle; physical, cognitive, leisure activities; good social engagement; a high consumption of fish, low consumption of dietary fat and moderate consumption of wine, and control of vascular risk factors appear to be potential factors for delaying dementia.

    9. Alzheimer's disease: synaptic dysfunction and Abeta

      LENUS (Irish Health Repository)

      Shankar, Ganesh M

      2009-11-23

      Abstract Synapse loss is an early and invariant feature of Alzheimer\\'s disease (AD) and there is a strong correlation between the extent of synapse loss and the severity of dementia. Accordingly, it has been proposed that synapse loss underlies the memory impairment evident in the early phase of AD and that since plasticity is important for neuronal viability, persistent disruption of plasticity may account for the frank cell loss typical of later phases of the disease. Extensive multi-disciplinary research has implicated the amyloid β-protein (Aβ) in the aetiology of AD and here we review the evidence that non-fibrillar soluble forms of Aβ are mediators of synaptic compromise. We also discuss the possible mechanisms of Aβ synaptotoxicity and potential targets for therapeutic intervention.

    10. Alzheimer's Disease: Aging, Insomnia and Epigenetics

      Directory of Open Access Journals (Sweden)

      Tzong Yuan Wu

      2010-12-01

      Full Text Available Alzheimer's disease (AD is the most common form of dementia. Severe memory loss, confusion, and impaired cognitive abilities characterize AD. It was only a century after Alzheimer's discovery that scientists were able to shed light on the mystery of its cause, but AD has also become a globally important health issue and the treatment of AD is a challenge for modern medicine. At present, there are five drugs approved in the United States for the treatment of AD, namely, donepezil, galantamine, rivastigmine, and tacrine (which are all cholinesterase inhibitors; and memantine (which is a glutamate receptor antagonist. However, these drugs show only modest effects on AD patients. Thus, new investigations are necessary for pharmacological development in AD. This brief review focuses on new studies that demonstrate the link between epigenetics and AD, and explores the possibility that insomnia may be one factor that effects AD.

    11. Neurogenesis in Alzheimer´s disease

      Czech Academy of Sciences Publication Activity Database

      Rodríguez Arellano, Jose Julio; Verkhratsky, Alexei

      2011-01-01

      Roč. 219, č. 1 (2011), s. 78-89 ISSN 0021-8782 R&D Projects: GA ČR GA309/09/1696; GA ČR(CZ) GAP304/11/0184; GA ČR GA309/08/1381; GA ČR GA305/08/1384 Institutional research plan: CEZ:AV0Z50390703 Keywords : Alzheimer 's disease * hippocampus * neurodegeneration Subject RIV: FH - Neurology Impact factor: 2.370, year: 2011

    12. Alzheimer's Disease and Stem Cell Therapy

      OpenAIRE

      Choi, Sung S.; Lee, Sang-Rae; Kim, Seung U.; Lee, Hong J.

      2014-01-01

      The loss of neuronal cells in the central nervous system may occur in many neurodegenerative diseases. Alzheimer's disease is a common senile disease in people over 65 years, and it causes impairment characterized by the decline of mental function, including memory loss and cognitive impairment, and affects the quality of life of patients. However, the current therapeutic strategies against AD are only to relieve symptoms, but not to cure it. Because there are only a few therapeutic strategie...

    13. Feelings Without Memory in Alzheimer Disease

      OpenAIRE

      Guzmán-Vélez, Edmarie; Feinstein, Justin S.; Tranel, Daniel

      2014-01-01

      Background: Patients with Alzheimer disease (AD) typically have impaired declarative memory as a result of hippocampal damage early in the disease. Far less is understood about AD’s effect on emotion. Objective: We investigated whether feelings of emotion can persist in patients with AD, even after their declarative memory for what caused the feelings has faded. Methods: A sample of 17 patients with probable AD and 17 healthy comparison participants (case-matched for age, sex, and education) ...

    14. Application of PET in Alzheimer's disease

      International Nuclear Information System (INIS)

      Zhang Chun

      2003-01-01

      Alzheimer's disease (AD) is a neurodegenerative disease of central nervous system that causes progressive cognitive and memory deterioration in the elderly people. Affected brains of AD patients are characterized by the presence of senile plaques (SP) and neurofilbrillary tangles (NFT). The review will focus on the application of positron emission tomography (PET) in the diagnosis, progression prediction, treatment and evaluation of neurotransmission activity of AD

    15. Bilingualism delays clinical manifestation of Alzheimer's disease

      OpenAIRE

      Woumans, Evy; Santens, Patrick; Sieben, Anne; Versijpt, Jan; Stevens, Michaël; Duyck, Wouter

      2015-01-01

      The current study investigated the effects of bilingualism on the clinical manifestation of Alzheimer's disease (AD) in a European sample of patients. We assessed all incoming AD patients in two university hospitals within a specified timeframe. Sixty-nine monolinguals and 65 bilinguals diagnosed with probable AD were compared for time of clinical AD manifestation and diagnosis. The influence of other potentially interacting variables was also examined. Results indicated a significant delay f...

    16. Proverb and idiom comprehension in Alzheimer disease.

      Science.gov (United States)

      Kempler, D; Van Lancker, D; Read, S

      1988-01-01

      Twenty-nine patients diagnosed with Probable Alzheimer Disease were administered tests of word, familiar phrases (idioms and proverbs), and novel phrase comprehension. From the early stage of the disease, patients performed worse at understanding familiar phrases than single words or novel phrases. The results uphold common observations that AD patients have difficulty interpreting abstract meanings. Cognitive variables responsible for poor idiom/proverb comprehension and the clinical implications of this new protocol are discussed.

    17. ¿Existe el deterioro de categorías específicas en la enfermedad de Alzheimer?

      Directory of Open Access Journals (Sweden)

      Iván Moratilla Pérez

      2012-10-01

      Full Text Available Diversos estudios con pacientes con lesiones neuronales bien localizadas, como las asociadas a la encefalitis herpética, han revelado que el procesamiento de distintas categorías o dominios semánticos puede verse diferencialmente afectado. De este modo, mientras algunos pacientes muestran déficits selectivos en el procesamiento de ítems del dominio de los seres vivos, otros muestran déficits selectivos en el procesamiento del dominio de los seres no vivos. Sin embargo, en lo que respecta a patologías que provocan un daño difuso, como la enfermedad de Alzheimer, este tipo de hallazgos no se ha confirmado de manera concluyente.

    18. Tratamento da doença de Alzheimer: avaliação crítica sobre o uso de anticolinesterásicos Update on anticholinesterase treatment of Alzheimer's disease

      Directory of Open Access Journals (Sweden)

      OSVALDO P. ALMEIDA

      1998-09-01

      Full Text Available A demência do tipo Alzheimer (DA é uma doença degenerativa que há até pouco tempo não tinha nenhum tratamento eficaz. Pesquisas realizadas a partir da década de 70 revelaram que os sistemas cerebrais que utilizam acetilcolina encontram-se gravemente comprometidos nesses pacientes, o que serviu de base para a introdução da terapêutica de base colinérgica da doença. Os inibidores da acetilcolinesterase foram os primeiros medicamentos que demonstraram ser úteis para o tratamento da DA em ensaios clínicos controlados contra placebo. Este artigo revê os principais estudos desenhados para investigar a eficácia e efeitos adversos da tacrina, donepezil, rivastigmina, e metrifonato em pacientes com DA. Discutem-se, ainda, os fatores que podem interferir na resposta do paciente ao tratamento com anticolinesterásicos, bem como as limitações inerentes a esse tipo de abordagem terapêutica.Alzheimer's disease (AD is a neurogenerative disorder that had no effective treatment until a few years ago. Many studies published during the past 20 years showed that the disease is associated with the disruption of brain systems that use acetilcholine. These findings shaped the development of the cholinergic treatment strategies for AD. The cholinesterase inhibitors were the first class of drugs to show positive results in double-blind placebo controlled studies for the treatment of AD. This paper reviews efficacy and safety studies of tacrine, donepezil, rivastigmine, and metrifonate in patients with AD. Factors that may interfere with patients' response to treatment are also discussed, as well as the limitations associated with the use of this class of drugs.

    19. Anti-amyloid treatments in Alzheimer's disease.

      Science.gov (United States)

      Sapra, Mamta; Kim, Kye Y

      2009-06-01

      Alzheimer's disease is one of the most challenging threats to the healthcare system in society. One of the main characteristic of Alzheimer's disease (AD) pathology is formation of amyloid plaques from accumulation of amyloid beta peptide. The therapeutic agents that are currently available for AD including acetylcholinesterase inhibitors (AchEIs) and the N-methyl-D-aspartate (NMDA) antagonist are focused on improving the symptoms and do not revert the progression of the disease. This limitation coupled with the burgeoning increase in the prevalence of AD and resultant impact on healthcare economics calls for more substantial treatments for AD. According to the leading amyloid hypothesis, cleavage of amyloid precursor protein to release amyloid beta peptide is the critical event in pathogenesis of Alzheimer's disease. Recently treatment strategies have been focused on modifying the formation, clearance and accumulation of neurotoxic amyloid beta peptide. This article reviews different therapeutic approaches that have been investigated to target amyloid beta ranging from secretase modulators, antiaggregation agents to amyloid immunotherapy. Authors review the different novel drugs which are in clinical trials.

    20. Personalized medicine in Alzheimer's disease and depression.

      Science.gov (United States)

      Souslova, Tatiana; Marple, Teresa C; Spiekerman, A Michael; Mohammad, Amin A

      2013-11-01

      Latest research in the mental health field brings new hope to patients and promises to revolutionize the field of psychiatry. Personalized pharmacogenetic tests that aid in diagnosis and treatment choice are now becoming available for clinical practice. Amyloid beta peptide biomarkers in the cerebrospinal fluid of patients with Alzheimer's disease are now available. For the first time, radiologists are able to visualize amyloid plaques specific to Alzheimer's disease in live patients using Positron Emission Tomography-based tests approved by the FDA. A novel blood-based assay has been developed to aid in the diagnosis of depression based on activation of the HPA axis, metabolic, inflammatory and neurochemical pathways. Serotonin reuptake inhibitors have shown increased remission rates in specific ethnic subgroups and Cytochrome P450 gene polymorphisms can predict antidepressant tolerability. The latest research will help to eradicate "trial and error" prescription, ushering in the most personalized medicine to date. Like all major medical breakthroughs, integration of new algorithms and technologies requires sound science and time. But for many mentally ill patients, diagnosis and effective therapy cannot happen fast enough. This review will describe the newest diagnostic tests, treatments and clinical studies for the diagnosis and treatment of Alzheimer's disease and unipolar, major depressive disorder. © 2013 Elsevier Inc. All rights reserved.

    1. Accelerating stem cell trials for Alzheimer's disease.

      Science.gov (United States)

      Hunsberger, Joshua G; Rao, Mahendra; Kurtzberg, Joanne; Bulte, Jeff W M; Atala, Anthony; LaFerla, Frank M; Greely, Henry T; Sawa, Akira; Gandy, Sam; Schneider, Lon S; Doraiswamy, P Murali

      2016-02-01

      At present, no effective cure or prophylaxis exists for Alzheimer's disease. Symptomatic treatments are modestly effective and offer only temporary benefit. Advances in induced pluripotent stem cell (iPSC) technology have the potential to enable development of so-called disease-in-a-dish personalised models to study disease mechanisms and reveal new therapeutic approaches, and large panels of iPSCs enable rapid screening of potential drug candidates. Different cell types can also be produced for therapeutic use. In 2015, the US Food and Drug Administration granted investigational new drug approval for the first phase 2A clinical trial of ischaemia-tolerant mesenchymal stem cells to treat Alzheimer's disease in the USA. Similar trials are either underway or being planned in Europe and Asia. Although safety and ethical concerns remain, we call for the acceleration of human stem cell-based translational research into the causes and potential treatments of Alzheimer's disease. Copyright © 2016 Elsevier Ltd. All rights reserved.

    2. Pituitary gland levels of mercury, selenium, iron, and zinc in an Alzheimer`s disease study

      Energy Technology Data Exchange (ETDEWEB)

      Cornett, C.R.; Markesbery, W.R.; Wekstein, D.R.; Ehmann, W.D. [Univ. of Kentucky, Lexington, KY (United States)

      1996-12-31

      Mercury, iron, selenium, and zinc imbalances have been observed in comparisons between Alzheimer`s disease (AD) and control subject brains. Analyses of the pituitary gland have demonstrated that this organ retains relatively high concentrations of trace elements, including mercury, iron, and zinc. Our previous work has shown that the pituitary glands of AD and control subjects are typically higher in these trace elements than brain samples from the same subject. Instrumental neutron activation analysis (INAA) was used to compare the pituitary trace element levels of AD and control subjects. This study also describes the intrasubject relationships of brain trace element levels to those in the pituitary gland of AD and control subjects.

    3. Genótipos de haptoglobina e hipertensão refratária em pacientes com diabete melito tipo 2

      Directory of Open Access Journals (Sweden)

      Vânia Pereira Albuquerque Wobeto

      2011-10-01

      Full Text Available FUNDAMENTO: Tem sido sugerido que o polimorfismo da haptoglobina pode influenciar na patogênese das complicações microvasculares e macrovasculares em pacientes diabéticos. OBJETIVO: O objetivo principal deste estudo transversal foi de realizar uma investigação da existência ou não de uma associação entre os genótipos de haptoglobina e a prevalência de eventos isquêmicos cardiovasculares (angina estável, angina instável e infarto agudo do miocárdio, hipertensão arterial sistêmica, hipertensão refratária, obesidade e dislipidemia em 120 pacientes com diabete melito tipo 2, seguidos no Hospital Universitário da Unicamp, em Campinas, Estado de São Paulo. MÉTODOS: A genotipagem da haptoglobina foi realizada por reações em cadeia da polimerase alelo-específicas. As frequências dos genótipos de haptoglobina foram comparadas com a presença/ausência de doença cardiovascular, hipertensão arterial sistêmica, hipertensão refratária, obesidade e dislipidemia; medições de pressão arterial sistólica e diastólica; glicemia, colesterol (total, lipoproteínas de alta densidade - HDL e lipoproteínas de baixa densidade - LDL e triglicerídeos; assim como níveis de creatinina sérica. RESULTADOS: Embora nenhuma associação entre o genótipo de haptoglobina e a presença de doença cardiovascular tenha sido identificada, encontramos um excesso significativo de pacientes com o genótipo Hp2-1 entre as pessoas com hipertensão refratária, que também apresentavam uma maior pressão arterial sistólica e diastólica e níveis de colesterol total e LDL. CONCLUSÃO: Nossos resultados sugerem que os pacientes com diabete melito tipo 2 com o genótipo Hp2-1 podem apresentar uma maior chance de desenvolver hipertensão refratária. Estudos adicionais em populações diabéticas são necessários para confirmar esses achados.

    4. Telomere shortening reduces Alzheimer's disease amyloid pathology in mice

      NARCIS (Netherlands)

      Rolyan, Harshvardhan; Scheffold, Annika; Heinrich, Annette; Begus-Nahrmann, Yvonne; Langkopf, Britta Heike; Hoelter, Sabine M.; Vogt-Weisenhorn, Daniela M.; Liss, Birgit; Wurst, Wolfgang; Lie, Dieter Chichung; Thal, Dietmar Rudolf; Biber, Knut; Rudolph, Karl Lenhard

      Alzheimer's disease is a neurodegenerative disorder of the elderly and advancing age is the major risk factor for Alzheimer's disease development. Telomere shortening represents one of the molecular causes of ageing that limits the proliferative capacity of cells, including neural stem cells.

    5. Risk factors for Alzheimer's disease : a genetic-epidemiologic study

      NARCIS (Netherlands)

      C.M. van Duijn (Cornelia)

      1992-01-01

      textabstractThe work presented in this thesis has been motivated by the Jack of knowledge of risk factors for Alzheimer's disease. It has been long recognised that genetic factors are implicated, in particular in early-onset Alzheimer's disease.4 But to what extent are genetic factors involved?

    6. Aging and Alzheimer's Disease: Lessons from the Nun Study.

      Science.gov (United States)

      Snowdon, David A.

      1997-01-01

      Describes a woman who maintained high cognitive test scores until her death at 101 years of age despite anatomical evidence of Alzheimer's disease. The woman was part of a larger "Nun Study" in which 678 sisters donated their brains to teach others about the etiology of aging and Alzheimer's disease. Findings are discussed. (RJM)

    7. The role of Lipocalin 2 in Alzheimer's disease and depression

      NARCIS (Netherlands)

      Naudé, Petrus Johan Wichardt

      2012-01-01

      De meeste mensen, zo niet alle mensen die deze samenvatting lezen, hebbcn persoonlijk iemand onrmoet of weten van iemand die gediagnosticeerd is met de ziekte van Alzheimer. De ziekte van Alzheimer is een neurodegeneratieve ziekte die voornamelijk voorkomt bij oudere mensen. De eerste tekenen van de

    8. Neuroinflammation and Alzheimer disease: clinical and therapeutic implications

      NARCIS (Netherlands)

      Eikelenboom, P.; Rozemuller, A. J.; Hoozemans, J. J.; Veerhuis, R.; van Gool, W. A.

      2000-01-01

      In Alzheimer disease brains, the amyloid plaques are closely associated with a locally induced, nonimmune-mediated, chronic inflammatory response without any apparent influx of leukocytes from the blood. The present findings indicate that in cerebral A beta diseases (Alzheimer disease, Down

    9. Software tool for improved prediction of Alzheimer's disease

      DEFF Research Database (Denmark)

      Soininen, Hilkka; Mattila, Jussi; Koikkalainen, Juha

      2012-01-01

      Diagnostic criteria of Alzheimer's disease (AD) emphasize the integration of clinical data and biomarkers. In practice, collection and analysis of patient data vary greatly across different countries and clinics.......Diagnostic criteria of Alzheimer's disease (AD) emphasize the integration of clinical data and biomarkers. In practice, collection and analysis of patient data vary greatly across different countries and clinics....

    10. Alcohol consumption and mortality in patients with mild Alzheimer's disease

      DEFF Research Database (Denmark)

      Berntsen, Sine; Kragstrup, Jakob; Siersma, Volkert

      2015-01-01

      OBJECTIVE: To investigate the association between alcohol consumption and mortality in patients recently diagnosed with mild Alzheimer's disease (AD). DESIGN: A post hoc analysis study based on a clinical trial population. SETTING: The data reported were collected as part of the Danish Alzheimer...

    11. Efficacy of psychosocial intervention in patients with mild Alzheimer's disease

      DEFF Research Database (Denmark)

      Waldorff, F B; Buss, D V; Eckermann, A

      2012-01-01

      To assess the efficacy at 12 months of an early psychosocial counselling and support programme for outpatients with mild Alzheimer's disease and their primary care givers.......To assess the efficacy at 12 months of an early psychosocial counselling and support programme for outpatients with mild Alzheimer's disease and their primary care givers....

    12. The clinical use of structural MRI in Alzheimer disease

      NARCIS (Netherlands)

      Frisoni, G.B.; Fox, N.C.; Jack, C.R.; Scheltens, P.; Thompson, P.M.

      2010-01-01

      Structural imaging based on magnetic resonance is an integral part of the clinical assessment of patients with suspected Alzheimer dementia. Prospective data on the natural history of change in structural markers from preclinical to overt stages of Alzheimer disease are radically changing how the

    13. Aluminium and Alzheimer's disease: the science that describes the link

      National Research Council Canada - National Science Library

      Exley, Christopher

      2001-01-01

      ... that has been encircled is the gene for the amyloid precursor protein. (Thanks to Walter Lukiw for supplying this information.) Aluminium and Alzheimer's Disease: The Science that Describes the LinkAluminium and Alzheimer's Disease The Science that Describes the Link Edited by Christopher Exley Birchall Centre for Inorganic Chemistry and Materials Scienc...

    14. The Alzheimer myth and biomarker research in dementia

      NARCIS (Netherlands)

      Richard, E.; Schmand, B.; Eikelenboom, P.; Westendorp, R.G.; van Gool, W.A.

      2012-01-01

      The focus of most of the research on Alzheimer's disease in the last decades has been on senile plaques and neurofibrillary tangles. The vast majority of patients with Alzheimer's disease are over 75 years of age, whereas most of the research focuses on younger subjects. To consider old-age dementia

    15. The Alzheimer Myth and Biomarker Research in Dementia

      NARCIS (Netherlands)

      Richard, Edo; Schmand, Ben; Eikelenboom, Piet; Westendorp, Rudi G.; van Gool, Willem A.

      2012-01-01

      The focus of most of the research on Alzheimer's disease in the last decades has been on senile plaques and neurofibrillary tangles. The vast majority of patients with Alzheimer's disease are over 75 years of age, whereas most of the research focuses on younger subjects. To consider old-age dementia

    16. International Work Group Criteria for the Diagnosis of Alzheimer Disease

      NARCIS (Netherlands)

      Cummings, J.L.; Dubois, B; Molinuevo, J.L.; Scheltens, P.

      2013-01-01

      Alzheimer-type biomarker changes are identifiable in asymptomatic and mildly symptomatic predementia phases of Alzheimer disease (AD) and AD dementia. The International Work Group (IWG) guidelines for diagnosis identify a unified spectrum of 3 phases. The classic clinical feature that indicates AD

    17. Developing injectable immunoglobulins to treat cognitive impairment in Alzheimer's disease.

      Science.gov (United States)

      Steinitz, Michael

      2008-05-01

      Alzheimer's disease is a devastating disorder, clinically characterized by a comprehensive cognitive decline. The novel strategy of anti-amyloid-beta immunotherapy has been suggested following encouraging results obtained in murine models of Alzheimer's disease, in non-human primates, and in small-scale clinical trials. To examine the choice between active or passive anti-amyloid-beta immunization and the choice of the molecule to which the immune machinery should be targeted, which are central issues in future immune therapy of Alzheimer's disease. Research into the new area of Alzheimer's disease immune therapy is primarily based on in vivo and in vitro studies of murine models of Alzheimer's disease. The studies are hence limited to defined genetic deficiencies. In humans, infusion of anti-amyloid-beta antibodies is considered a safer approach than active anti-amyloid-beta vaccination. Alzheimer's-disease-protective anti-amyloid-beta monoclonal antibodies should target specific epitopes within the amyloid beta(1 42) peptide, avoiding possibly harmful binding to the ubiquitous normal amyloid precursor protein. Since Alzheimer's disease immunotherapy requires repeated infusion of antibodies over a prolonged period of time, Alzheimer's disease patients will tolerate such antibodies provided the latter are exclusively of human origin. Human monoclonal antibodies that correspond to ubiquitous anti-amyloid-beta, present in all healthy humans, might bear important protective characteristics.

    18. The Alzheimer's Disease Knowledge Scale: Development and Psychometric Properties

      Science.gov (United States)

      Carpenter, Brian D.; Balsis, Steve; Otilingam, Poorni G.; Hanson, Priya K.; Gatz, Margaret

      2009-01-01

      Purpose: This study provides preliminary evidence for the acceptability, reliability, and validity of the new Alzheimer's Disease Knowledge Scale (ADKS), a content and psychometric update to the Alzheimer's Disease Knowledge Test. Design and Methods: Traditional scale development methods were used to generate items and evaluate their psychometric…

    19. Predicting cognitive decline in Alzheimer's disease: an integrated analysis

      DEFF Research Database (Denmark)

      Lopez, Oscar L; Schwam, Elias; Cummings, Jeffrey

      2010-01-01

      Numerous patient- and disease-related factors increase the risk of rapid cognitive decline in patients with Alzheimer's disease (AD). The ability of pharmacological treatment to attenuate this risk remains undefined.......Numerous patient- and disease-related factors increase the risk of rapid cognitive decline in patients with Alzheimer's disease (AD). The ability of pharmacological treatment to attenuate this risk remains undefined....

    20. Are Judgments of Semantic Relatedness Systematically Impaired in Alzheimer's Disease?

      Science.gov (United States)

      Hornberger, M.; Bell, B.; Graham, K. S.; Rogers, T. T.

      2009-01-01

      We employed a triadic comparison task in patients with Alzheimer's disease (AD) and healthy controls to contrast (a) multidimensional scaling (MDS) and accuracy-based assessments of semantic memory, and (b) degraded-store versus degraded-access accounts of semantic impairment in Alzheimer's disease (AD). Similar to other studies using triadic…

    1. [Nutritional approaches to modulate oxidative stress that induce Alzheimer's disease. Nutritional approaches to prevent Alzheimer's disease].

      Science.gov (United States)

      Lara, Humberto Herman; Alanís-Garza, Eduardo Javier; Estrada Puente, María Fernanda; Mureyko, Lucía Liliana; Alarcón Torres, David Alejandro; Ixtepan Turrent, Liliana

      2015-01-01

      Alzheimer's disease is the most common cause of dementia in the world; symptoms first appear after age 65 and have a progressive evolution. Expecting an increase on its incidence and knowing there is currently no cure for Alzheimer's disease, it is a necessity to prevent progression. The change in diet due to globalization may explain the growth of the incidence in places such as Japan and Mediterranean countries, which used to have fewer incidences. There is a direct correlation between disease progression and the increased intake of alcohol, saturated fats, and red meat. Therefore, we find obesity and higher serum levels in cholesterol due to saturated fat as a result. A way to decrease the progression of Alzheimer's is through a diet rich in polipheno/es (potent antioxidants), unsaturated fats (monounsaturated and polyunsaturated), fish, vegetable fa t, fruits with low glycemic index, and a moderate consumption of red wine. Through this potent antioxidant diet we accomplish the prevention of dementia and the progression of Alzheimer's disease. This article emphasizes the food and other components that have been demonstrated to decrease the oxidative stress related to these progressive diseases.

    2. The Potential role of marine derived food products on Alzheimer\\'s disese and cognitive decline

      Directory of Open Access Journals (Sweden)

      Mahsan Assadi

      2011-11-01

      Full Text Available Background: Alzheimer's disese is the most frequent cause of dementia and is one of important cause of mortality and morbidity in the world. Although, there are different therapeutic options for its treatment , the results of these therapies are disappointing. Omega-3 fatty acids in marine- derived food products, affect on different mechanisms, improve cognitive function, memory.in this study, effect Omega-3 fatty acids in marine- derived food products of cognitive disorders and Alzheimer's are reviewed. Methods: The method employed in this research was a systematic bibiliographic review,in which only the double-blind placebo-controlled studies or the clinically detailed enough open-labeled studies using validated scales were retained. Results: Many studies have shown that Omega-3 fatty acids in marine- derived food products, affect by different mechanisms include decrease inflammation and oxidative stress, synaptogenesis, synaptic plasticity, and neurogenesis promotion in neuroprotection and improvement cognitive function and memory, also omega3 fatty acid could lead to a decrease in risk of Alzheimer's diseas and the other cognitive impairements. Conclusion: However, more and large clinical trials are needed to confirm the beneficial effects of omega 3 fatty acid supplementation on the management of Alzheimer's disease and cognitive decline.

    3. Toward better Alzheimer's research information sources for the public.

      Science.gov (United States)

      Payne, Perry W

      2013-03-01

      The National Plan to Address Alzheimer's Disease calls for a new relationship between researchers and members of the public. This relationship is one that provides research information to patients and allows patients to provide ideas to researchers. One way to describe it is a "bidirectional translational relationship." Despite the numerous sources of online and offline information about Alzheimer's disease, there is no information source which currently provides this interaction. This article proposes the creation an Alzheimer's research information source dedicated to monitoring Alzheimer's research literature and providing user friendly, publicly accessible summaries of data written specifically for a lay audience. This information source should contain comprehensive, updated, user friendly, publicly available, reviews of Alzheimer's research and utilize existing online multimedia/social networking tools to provide information in useful formats that help patients, caregivers, and researchers learn rapidly from one another.

    4. Resgate vegetativo por alporquia de genótipos adultos de urucum (Bixa orellana L.

      Directory of Open Access Journals (Sweden)

      Nilton César Mantovani

      2010-09-01

      Full Text Available Este trabalho teve por objetivos avaliar a técnica de alporquia visando ao resgate vegetativo de genótipos de urucum (Bixa orellana L. e a obtenção de plantas fornecedoras de propágulos para processos de propagação clonal. Foram utilizadas dez plantas matrizes de urucum, com 12 anos de idade, obtidas partindo do cruzamento artificial entre os genótipos "Fruto Verde Piloso" X "Fruto Vermelho Liso". Os alporques foram realizados em ramos de 1 a 2 cm de diâmetro, utilizando-se como substrato uma mistura de vermiculita e musgo. Foi avaliado o efeito (1 do tipo de anelamento da casca dos ramos (total ou parcial, com 1 cm de comprimento, (2 do AIB (ácido indol-3-butírico a 0 e 4,92 mM aplicado em papel filtro e (3 do tipo de proteção dos alporques (filmes plásticos transparente ou preto ou tecido tencel, no enraizamento de alporque dos dez genótipos. A técnica de alporquia proporcionou o enraizamento de ramos dos dez genótipos avaliados, com eficiência variável de 20 a 100%, havendo efeito do genótipo sobre a frequência de enraizamento. A sobrevivência desses alporques foi de 100% após o plantio quando estes foram produzidos com anelamento total, tratados com AIB e protegidos com plástico transparente. Em casa de vegetação os alporques desenvolveram ramos partindo da brotação de gemas caulinares constituindo estoques de explantes apropriados para serem utilizados como estacas ou como fontes de segmentos nodais para a propagação in vitro desta espécie.

    5. Diabetes tipo 2 en niños: Serie de casos

      Directory of Open Access Journals (Sweden)

      Helard Manrique-Hurtado

      2015-01-01

      Full Text Available Objetivos: Describir las características clínicas y bioquímicas de un grupo de niños y adolescentes con diagnóstico reciente de diabetes tipo 2. Material y métodos: Estudio descriptivo, retrospectivo, tipo de serie de casos. Se definió caso al niño o adolescente con glucosa plasmática en ayunas mayor a 126 mg/dl, ausencia de antiGAD y péptido C mayor a 1,5 ng/dl. Se excluyeron a los pacientes con diagnóstico previo de diabetes mellitus tipo 1, diabetes tipo MODY o diabetes secundaria a uso de fármacos. Resultados: La edad media fue 14,3 años, 59% fueron mujeres y 43% tenía por lo menos un padre con diabetes tipo 2. Al momento del diagnóstico, el índice de masa corporal fue 32,8 kg/m2, 85% tenía acantosis nigricans y 68% estaba en estadio Tanner IV y V. El tratamiento inicial incluyó el uso de hipoglicemiantes orales en 75% de los casos, siendo más frecuente el uso de metformina (64,3%. Solamente el 41% de los pacientes recibía algún tipo de insulina. Conclusiones: Los niños y adolescentes con diabetes tipo 2, tienen una frecuencia aumentada de obesidad/sobrepeso, acantosis nigricans y antecedente familiar de DM2. En general, tienen mal control metabólico y reciben metformina como tratamiento inicial.

    6. Clinical utility of color-form naming in Alzheimer's disease: preliminary evidence

      DEFF Research Database (Denmark)

      Nielsen, Niels Peter; Wiig, Elisabeth H; Warkentin, Siegbert

      2004-01-01

      Performances on Alzheimer's Quick Test color-form naming and Mini-Mental State Examination were compared for 38 adults with Alzheimer's disease and 38 age- and sex-matched normal controls. Group means differed significantly and indicated longer naming times by adults with Alzheimer's disease...... associated with Alzheimer's disease, are preliminary given the relatively small sample....

    7. Effects of nutrition on cognitive decline in Alzheimer's disease : Dietary intervention affects relevant parameters in Alzheimer models

      NARCIS (Netherlands)

      de Wilde, Mattheus Cornelis

      2013-01-01

      Voedingssupplementen en de ziekte van Alzheimer Het verband tussen de ziekte van Alzheimer (AD) en voeding wordt sinds ongeveer 25 jaar herkend. De laatste paar jaar wordt steeds duidelijker dat vooral combinaties van voedingsstoffen potentie hebben voor behandelingsdoeleinden. Het onderzoek van

    8. Efficacy of psychosocial intervention in patients with mild Alzheimer's disease: the multicentre, rater blinded, randomised Danish Alzheimer Intervention Study (DAISY)

      DEFF Research Database (Denmark)

      Waldorff, F.B.; Buss, D.V.; Eckermann, A.

      2012-01-01

      To assess the efficacy at 12 months of an early psychosocial counselling and support programme for outpatients with mild Alzheimer's disease and their primary care givers.......To assess the efficacy at 12 months of an early psychosocial counselling and support programme for outpatients with mild Alzheimer's disease and their primary care givers....

    9. Anti-Alzheimer Properties of Probiotic, Lactobacillus plantarum MTCC 1325 in Alzheimer's Disease induced Albino Rats.

      Science.gov (United States)

      Nimgampalle, Mallikarjuna; Kuna, Yellamma

      2017-08-01

      Alzheimer's disease is a type of dementia, and till now there is no suitable drug available for the complete cure of this disease. Now-a-days Probiotics, Lactobacillus strains play a therapeutic role in cognitive disorders through Gut-Brain Axis communication. The present study was aimed to evaluate the anti-Alzheimer properties of Lactobacillus plantarum MTCC1325 against D-Galactose-induced Alzheimer's disease in albino rats. Healthy rats (48) of wistar strain were divided into four groups viz., Group-I: control rats received saline, Group-II: rats received intraperitoneal injection of D-Galactose (120 mg/kg body weight) throughout experiment, Group-III: initially animals were subjected to D-Galactose injection for six weeks, then followed by simultaneously received both D-Galactose and L. plantarum MTCC1325 (12×10 8 CFU/ml; 10 ml/kg body weight) for 60 days and Group-IV: rats which were orally administered only with Lactobacillus plantarum MTCC1325 for 60 days. During the experimentation, both morphometric and behavioural aspects were studied. Later we have examined histopathological changes and estimated cholinergic levels in selected brain regions of all experimental groups of rats including control on selected days. Morphometric, behavioural changes, ACh levels were significantly decreased and pathological hallmarks such as amyloid plaques and tangles were also observed in AD model group. Treatment of AD-group with L. plantarum MTCC1325 for 60 days, not only ameliorated cognition deficits but also restored ACh and the histopathological features to control group. However, no significant effects have been observed in the group treated with L. plantarum alone. The study revealed that, L. plantarum MTCC1325 might have anti-Alzheimer properties against D-Galactose induced Alzheimer's disease.

    10. Altered levels of acetylcholinesterase in Alzheimer plasma.

      Directory of Open Access Journals (Sweden)

      María-Salud García-Ayllón

      Full Text Available BACKGROUND: Many studies have been conducted in an extensive effort to identify alterations in blood cholinesterase levels as a consequence of disease, including the analysis of acetylcholinesterase (AChE in plasma. Conventional assays using selective cholinesterase inhibitors have not been particularly successful as excess amounts of butyrylcholinesterase (BuChE pose a major problem. PRINCIPAL FINDINGS: Here we have estimated the levels of AChE activity in human plasma by first immunoprecipitating BuChE and measuring AChE activity in the immunodepleted plasma. Human plasma AChE activity levels were approximately 20 nmol/min/mL, about 160 times lower than BuChE. The majority of AChE species are the light G(1+G(2 forms and not G(4 tetramers. The levels and pattern of the molecular forms are similar to that observed in individuals with silent BuChE. We have also compared plasma AChE with the enzyme pattern obtained from human liver, red blood cells, cerebrospinal fluid (CSF and brain, by sedimentation analysis, Western blotting and lectin-binding analysis. Finally, a selective increase of AChE activity was detected in plasma from Alzheimer's disease (AD patients compared to age and gender-matched controls. This increase correlates with an increase in the G(1+G(2 forms, the subset of AChE species which are increased in Alzheimer's brain. Western blot analysis demonstrated that a 78 kDa immunoreactive AChE protein band was also increased in Alzheimer's plasma, attributed in part to AChE-T subunits common in brain and CSF. CONCLUSION: Plasma AChE might have potential as an indicator of disease progress and prognosis in AD and warrants further investigation.

    11. Alzheimer's disease camouflaged by histrionic personality disorder.

      Science.gov (United States)

      Hellwig, Sabine; Dykierek, Petra; Hellwig, Bernhard; Zwernemann, Stefan; Meyer, Philipp T

      2012-02-01

      A common condition in Alzheimer's disease (AD) is unawareness of deficits. Different concepts try to elucidate the nature of this symptom. An essential question relates to the interaction of organic and psychogenic factors. Here we present a patient who displayed her cognitive deficits as attention-seeking behaviour. There was a history of histrionic personality disorder according to ICD-10 criteria. Unexpectedly, the final diagnosis after extensive diagnostic work-up was AD. The unusual coincidence of AD and a histrionic personality disorder hampered the clinical process of diagnosing dementia. We discuss unawareness as a complex concept incorporating neuroanatomical, psychiatric, and psychosocial aspects.

    12. A current view of Alzheimer's disease.

      Science.gov (United States)

      Hooli, Basavaraj V; Tanzi, Rudolph E

      2009-07-08

      Several genes that influence susceptibility to Alzheimer's disease (AD) have been known for over two decades. Recent advances have elucidated novel candidate genes and the pathogenetic mechanisms underlying neurodegeneration in AD. Here, we summarize what we have learned from studies of the known AD genes with regard to the causes of AD and emerging therapies. We also review key recent discoveries that have enhanced our understanding of the etiology and pathogenesis of this devastating disease, based on new investigations into the genes and molecular mechanisms underlying AD.

    13. Therapeutic role of rifampicin in Alzheimer's disease.

      Science.gov (United States)

      Yulug, Burak; Hanoglu, Lütfü; Ozansoy, Mehmet; Isık, Dogan; Kilic, Ulkan; Kilic, Ertugrul; Schabitz, Wolf Rüdiger

      2018-03-01

      Rifampicin exerts significant brain protective functions in multiple experimental models. Here we summarize the underlying mechanisms of the neuroprotective and pro-cognitive effects of rifampicin that are mediated by its anti-inflammatory, anti-tau, anti-amyloid, and cholinergic effects. Beyond suggesting that rifampicin shows strong brain protective effects in preclinical models of Alzheimer's disease, we also provide substantial clinical evidence for the neuroprotective and pro-cognitive effects of rifampicin. Future neuroimaging studies combined with clinical assessment scores are the following steps to be taken in this field of research. © 2018 The Authors. Psychiatry and Clinical Neurosciences © 2018 Japanese Society of Psychiatry and Neurology.

    14. Alzheimer's disease due to loss of function

      DEFF Research Database (Denmark)

      Kepp, Kasper Planeta

      2016-01-01

      Alzheimer's Disease (AD) is a highly complex disease involving a broad range of clinical, cellular, and biochemical manifestations that are currently not understood in combination. This has led to many views of AD, e.g. the amyloid, tau, presenilin, oxidative stress, and metal hypotheses....... The amyloid hypothesis has dominated the field with its assumption that buildup of pathogenic β-amyloid (Aβ) peptide causes disease. This paradigm has been criticized, yet most data suggest that Aβ plays a key role in the disease. Here, a new loss-of-function hypothesis is synthesized that accounts...

    15. Exploring Symmetry to Assist Alzheimer's Disease Diagnosis

      Science.gov (United States)

      Illán, I. A.; Górriz, J. M.; Ramírez, J.; Salas-Gonzalez, D.; López, M.; Padilla, P.; Chaves, R.; Segovia, F.; Puntonet, C. G.

      Alzheimer's disease (AD) is a progressive neurodegenerative disorder first affecting memory functions and then gradually affecting all cognitive functions with behavioral impairments and eventually causing death. Functional brain imaging as Single-Photon Emission Computed Tomography (SPECT) is commonly used to guide the clinician's diagnosis. The essential left-right symmetry of human brains is shown to play a key role in coding and recognition. In the present work we explore the implications of this symmetry in AD diagnosis, showing that recognition may be enhanced when considering this latent symmetry.

    16. Computed tomography in dementia of Alzheimer type

      International Nuclear Information System (INIS)

      Tsunoda, Masahiko; Fujii, Tsutomu; Tanii, Yasuyuki

      1990-01-01

      Computed tomography (CT) examinations of 7 patients with dementia of Alzheimer type were reviewed and correlated with clinical stages. The findings of CT were also compared with those of single photon emission computed tomography (SPECT). There was no positive correlation between the degree of cerebral atrophy on CT and clinical stage. Cerebral atrophy seemed to be influenced by aging, ill duration, and the degree of dementia. The cerebral/cerebellar uptake ratio of RI on SPECT was significantly decreased with the progression of clinical stage. SPECT seemed to reflect the degree of dementia, irrespective of ages and ill duration. (N.K.)

    17. Why Do We Get Alzheimer's Disease?

      International Nuclear Information System (INIS)

      Wyss-Coray, Tony

      2006-01-01

      Neurodegenerative diseases and Alzheimer's disease (AD) in particular, are among the major health concerns of the elderly in industrialized societies. The cause of AD is unknown and no disease-modifying treatments are available. The disease is characterized clinically by a progressive dementia and pathologically by the accumulation of protein aggregates in the brain and a profound loss of nerve cells. It has also become clear recently that local immune responses are activated in the AD brain and may have a role in the disease. Our laboratory uses genetic mouse models to understand the disease process and to identify potential therapeutic targets.

    18. Evolución de la categorización semántica en adultos mayores con diagnóstico de DCL-A y DTA y sin patología neurológica

      OpenAIRE

      Comesaña, Ana; Vivas, Jorge

      2015-01-01

      Tradicionalmente la memoria semántica ha sido definida como un tesoro mental que almacena información sobre las palabras, su significado, como así también la relación entre ellas, los hechos y los conceptos. Una de las vías principales para explicar cómo se organiza la información en la memoria semántica (MS) es a través de categorías. La demencia tipo Alzheimer (DTA) suele estar caracterizada por un deterioro en la memoria episódica. Sin embargo, se debate en torno al deterioro de la misma, ...

    19. Apolipoprotein E4 and Alzheimer's disease in São Paulo - Brazil Apolipoproteina E 4 e doença de Alzheimer em São Paulo - Brasil

      Directory of Open Access Journals (Sweden)

      Osvaldo P. Almeida

      1997-01-01

      em países do hemisfério norte. Este estudo investigou a associação entre a presença do alelo ε4 da apolipoproteina E e a doença de Alzheimer em amostra de pacientes brasileiros atendidos em um serviço público de saúde. Foram investigados 55 pacientes com diagnóstico de AD possível ou provável e 56 controles idosos atendidos em serviços ambulatoriais do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo e do Centro de Saúde Escola da Faculdade de Saúde Pública da Universidade de São Paulo. A determinação do tipo de alelo foi feita através de tipagem genética. Do total de alelos investigados (n=222 observou-se um excesso de ε4 entre os pacientes (20,9% vs 8,9%, p=0,038, com 36,4% deles exibindo ao menos 1 alelo ε4 (vs 17,9% dos controles, p=0,027. O risco de indivíduos com ao menos 1 alelo ε4 serem diagnosticados como sofrendo de AD foi 2,63 vezes maior que para aqueles sem este alelo. Três pacientes apresentaram o genótipo ε4ε4, sendo todos homens com início pré-senil da doença. Não se observou diferença na freqüência de ao menos 1 alelo ε4 entre pacientes com demência senil e pré-senil (41,9% vs 29,2%, p=0,326 ou entre homens e mulheres (36,0% vs 36,7%, p=0,959. Não havia diferença significativa quanto à idade de início dos sintomas entre grupos de pacientes com diferentes genótipos, embora indivíduos com genótipo ε4ε4 revelassem tendência a desenvolver a doença mais precocemente. Quando apenas pacientes com diagnóstico de AD provável foram incluídos na análise (n=43, verificou-se que 22,1% dos alelos eram ε4, uma taxa significativamente maior que os 8,9% dos controles (p=0,024. Os resultados deste estudo confirmam a associação entre ε4 e AD e estendem este achado para uma amostra de pacientes brasileiros. Entretanto, a presença desse alelo não é necessária nem suficiente para o desenvolvimento da doença e é possível que sua contribuição varie de acordo com o grupamento

    20. Recruitment of subjects into clinical trials for Alzheimer disease.

      Science.gov (United States)

      Knebl, Janice A; Patki, Deepti

      2010-09-01

      Alzheimer disease is a devastating neurodegenerative disorder affecting millions of Americans. It reduces the ability of the individual to remain independent, places a burden on caregivers, and substantially increases healthcare costs. New treatments are being tested in numerous clinical trials with the goal of preventing or delaying the onset of Alzheimer disease, slowing or modifying the disease's course, or finding a cure for patients with the disease. Alzheimer disease research can successfully proceed only if individuals who have this illness are willing to participate in clinical trials. However, recruitment and retention of subjects in clinical trials for Alzheimer disease is a challenging task. Furthermore, because of reductions in decision-making capacities of individuals with Alzheimer disease, clinical trials also need to involve caregivers. The present article delineates unique hurdles encountered in the recruitment process for Alzheimer disease clinical trials. The article also identifies strategies for effective recruitment of subjects in Alzheimer disease clinical trials, including guidelines to help principal investigators and clinical research coordinators reach recruitment goals.